incivo acts against the virus that causes hepatitis c infection and is used to treat chronic hepatitis c infection in adult patients ( aged 1865 years ) in combination with peginterferon alfa and ribavirin . incivo contains a substance called telaprevir and belongs to a group of medicines called ' ns3 - 4a protease inhibitors '. the ns3 - 4a protease inhibitor reduces the amount of hepatitis c virus in your body . incivo must not be taken alone and must be taken in combination with peginterferon alfa and ribavirin to be sure your treatment works . incivo can be used for patients with chronic hepatitis c infection who have never been treated before or can be used in patients with chronic hepatitis c infection who have been treated previously with an interferon - based regimen .
do not take incivo if you are allergic to telaprevir or any of the other ingredients of this medicine ( listed in section 6 ). see the package leaflets for peginterferon alfa and ribavirin for a list of their contraindications ( e. g. pregnancy precautions for men and women ) since incivo must be used in combination with peginterferon alfa and ribavirin. ask your doctor if you are unsure about any contraindications mentioned in the package leaflets. do not use incivo in combination with any of the following medicines as they may increase the risk of severe side effects, and / or affect the way incivo or the other medicine works : 56 medicine ( name of the active substance ) purpose of the medicine alfuzosin to treat symptoms of an enlarged prostate ( alpha - 1 - adrenoreceptor antagonists ) amiodarone, bepridil, quinidine, other class ia or iii antiarrhythmics to treat certain heart disorders such as irregular heart beat ( antiarrhythmics ) astemizole, terfenadine to treat allergy symptoms ( antihistamines ) rifampicin to treat some infections like tuberculosis ( antimycobacterial ) dihydroergotamine, ergonovine, ergotamine, methylergonovine to treat migraine and headaches ( ergot derivatives ) cisapride to treat some stomach conditions ( gastrointestinal motility agents ) st john's wort ( hypericum perforatum ) an herbal product to relieve anxiety atorvastatin, lovastatin, simvastatin to lower cholesterol levels ( hmg coa reductase inhibitors ) pimozide to treat psychiatric conditions ( neuroleptics ) sildenafil, tadalafil sildenafil or tadalafil must not be used to treat a heart and lung disorder called pulmonary arterial hypertension
always take this medicine exactly as your doctor or pharmacist has told you. check with your doctor or pharmacist if you are not sure. instructions for proper use your doctor will decide on the appropriate dose regimen for you. the recommended dose regimen is : - 3 tablets of incivo twice daily ( morning and evening ) with food. the total dose is 6 tablets per day, or - 2 tablets of incivo every 8 hours with food. the total dose is 6 tablets per day. if you have both hepatitis c virus infection and human immunodeficiency virus infection, and are taking efavirenz, the recommended dose regimen is 3 tablets of incivo every 8 hours with food. you must always take incivo with food as this is important to get the right levels of medicine in your body. you must not reduce your dose of incivo. swallow the tablets whole. do not chew, 60 break, or dissolve the tablets before you swallow them. tell your health care provider if you have problems swallowing whole tablets. since incivo treatment always needs to be used together with peginterferon alfa and ribavirin, please also check the package leaflets for the dosage instructions of these medicines. if you need help, ask your doctor or pharmacist. take incivo with peginterferon alfa and ribavirin for 12 weeks. the total duration of treatment of peginterferon alfa and ribavirin varies from 24 to 48 weeks depending on treatment response and whether you have been treated before. your doctor will measure blood levels of your virus at weeks 4 and 12 to determine your treatment duration. the recommended total duration of treatment for patients who have received a liver transplant is 48 weeks. please check with your doctor and follow the recommended duration of treatment. if your doctor stops incivo because of side effects or because your treatment is not working, incivo should not be restarted. removing the child resistant cap the plastic bottle comes with a child resistant cap and should be opened as follows : - push the plastic screw cap down while turning it counter clockwise. - remove the unscrewed cap. if you take more incivo than you should contact
like all medicines, this medicine can cause side effects, although not everybody gets them. rash patients taking incivo frequently get an itchy skin rash. usually the rash is mild or moderate, but the rash may be, or may become, severe and / or life - threatening. rarely patients may have other symptoms with the rash that may be a sign of a severe skin reaction. contact your doctor immediately if you get a skin rash. also contact your doctor immediately : - if your rash worsens, or - if you develop other symptoms with a rash such as : - fever - tiredness - swelling of the face - swelling of lymph glands, or - if you have a wide - spread rash with peeling skin which may be accompanied by fever, flu - like symptoms, painful skin blisters, and blisters in the mouth, eyes, and / or genitals. your doctor should check your rash to determine how to manage it. your doctor may stop your treatment. incivo must not be restarted if discontinued by your doctor. contact your doctor immediately also if you develop any of the following symptoms : - tiredness, weakness, shortness of breath, light - headedness, and / or feeling of heart racing. these may be symptoms of anaemia ( decrease in your red blood cells ); - fainting ; - painful inflammation of the joints most commonly in the foot ( gout ); - problems with your eyesight ; - bleeding from the anus ; - swelling of the face. the frequency rate of the side effects associated with incivo is given below. very common side effects ( affects more than 1 in 10 people ): - low red blood cell count ( anaemia ); - nausea, diarrhoea, vomiting ; - swollen veins in the rectum or anus ( haemorrhoids ), pain in the anus or rectum ; - skin rash and itching of the skin. common side effects ( affects less than 1 in 10 people
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the label after exp . the expiry date refers to the last day of that month . incivo tablets should be stored in the original bottle . keep the bottle tightly closed in order to protect from moisture . each bottle contains one pouch or two pouches of desiccant to keep the tablets dry . do not remove this desiccant from the bottle . do not eat the desiccant . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what incivo contains the active substance is telaprevir . each tablet of incivo contains 375 mg of telaprevir . the other ingredients are : tablet core hypromellose acetate succinate , calcium hydrogen phosphate ( anhydrous ), microcrystalline cellulose , silica colloidal anhydrous , sodium lauryl sulphate , croscarmellose sodium , sodium stearyl fumarate tablet film - coat polyvinyl alcohol , macrogol , talc , titanium dioxide ( e171 ), iron oxide yellow ( e172 ) what incivo looks like and contents of the pack film - coated tablet . yellow caplet - shaped tablets of approximately 20 mm in length , marked with ' t375 ' on one side . incivo is available in packs containing one bottle or 4 bottles per carton . each bottle contains one pouch or two pouches to keep the tablets dry ( desiccant ). not all pack - sizes may be marketed .
the active substance in zinbryta is daclizumab beta . this is a type of medicine called a monoclonal antibody . what zinbryta is used for zinbryta is used to treat relapsing forms of multiple sclerosis ( ms ) in adults who have failed to respond despite therapy with at least two ms treatment and who cannot be given other treatments . in ms , the body ' s immune system causes inflammation which damages the protective sheath ( called myelin ) around the nerves in the central nervous system ( including the brain and spinal cord ). this loss of myelin is called demyelination . this stops nerves from working properly . people with relapsing ms have repeated attacks ( relapses ) of symptoms caused by their nerves not working properly . these symptoms vary from patient to patient but usually involve problems such as difficulty with walking , vision and balance . symptoms may disappear completely after the relapse is over but , over time , some problems may remain between relapses and interfere with daily activities . how zinbryta works zinbryta works by stopping the body ' s immune system from damaging your brain and spinal cord . this can help to reduce the number of relapses that you have and slow down the disabling effects of ms . treatment with zinbryta can help to prevent you from getting worse , although it will not cure ms . your doctor will decide whether zinbryta is the right medicine for you .
do not use zinbryta - if you have previously had a serious allergic reaction to any form of daclizumab, or any of the other ingredients of this medicine listed in section 6. - if you have liver problems. warnings and precautions talk to your doctor before using zinbryta : - if you have any other autoimmune disorders in addition to ms - if you are taking, have recently taken or might take any other medicines and herbal supplements. your doctor will evaluate if any medicines or supplements you are taking have liver side effects and whether you should continue these medicines while taking zinbryta - if you have depression or have had it in the past. - if you have a serious infection, such as pneumonia. - if you have ever had tuberculosis ( also called tb ) or live in a region where tb infections are common, you may be at greater risk of tb. you may be tested for tb before starting zinbryta and monitored during treatment. possible liver problems zinbryta may cause serious liver problems that may be life - threatening or result in death. serious liver problems can occur both early after starting treatment with zinbryta, any time during treatment and several months after discontinuing treatment. even if you have had no previous liver problems, your doctor will carry out blood tests to test your liver function. you will need : - a blood test before starting treatment to check your liver function and if you have hepatitis b and c. if your blood test shows that you have some liver problems, your doctor will decide whether to start zinbryta - at least monthly blood tests during treatment, as close as possible before each dose of zinbryta, and more often if your doctor decides this is necessary - tests for up to 6 months after stopping treatment. side effects may occur even after stopping treatment ( see serious side effects in section 4 ). it is very important that you have these regular blood tests. if you do not not undergo your scheduled blood tests your doctor may decide to stop treatment with zinbryta.
zinbryta will be prescribed to you by a doctor experienced in the treatment of ms. always use this medicine exactly as your doctor has told you. check with your doctor if you are not sure. recommended dose the dose of zinbryta is 150 mg every month. try to do your injection on the same day each month, to help you remember it. for example, inject on the first day of each month. you will also have a blood test to check your liver every month, as close as possible before each dose of zinbryta, and more often if your doctor decides this is necessary. it is very important that you do 40 not miss this blood test. try to keep to a set day for it each month. contact your doctor if you think you may have missed a blood test. injecting yourself zinbryta is injected under the skin ( subcutaneously ) into your thigh, stomach or back of your upper arm. detailed instructions for injecting zinbryta are given in section 7, instructions for injecting zinbryta. your doctor or nurse should train you to give yourself the injections. read and follow the advice given in section 7. if you have trouble handling the syringe / pen, tell your doctor or nurse who may be able to help. how long to use zinbryta your doctor will tell you how long you need to keep using zinbryta. do not make changes unless your doctor tells you to. if your doctor has told you to stop using your medicine, do not restart unless your doctor tells you to. if your ms does not respond to zinbryta, your doctor may decide to stop your treatment with zinbryta. if you use more zinbryta than you should if you have injected more than your usual dose, and you notice any side effects, or are concerned, speak with your doctor or nurse. patients have received double the recommended dose of zinbryta with no serious extra side effects. if you forget to take zinbryta zinbryta
like all medicines, this medicine can cause side effects, although not everybody gets them. do not try to treat any side effects yourself, but contact your doctor or nurse. some side effects may require your doctor to interrupt your treatment and refer you to a specialist. serious side effects : liver problems : ( common - may affect up to 1 in 10 people ) unexplained nausea ( feeling sick ) vomiting ( being sick ) stomach pain increased tiredness loss of appetite ( anorexia ) your skin or the whites of your eyes turn yellow dark ( tea - coloured ) urine 41 ( uncommon may affect up to 1 in 100 people ) severe inflammation of the liver which might be life - threatening or result in death contact your doctor immediately. these may be signs of a serious liver problem. your patient card has more information about these side effects. skin reactions : ( common - may affect up to 1 in 10 people ) severe wide - spread rash. depression : ( uncommon may affect up to 1 in 100 people ) feeling unusually sad, hopeless or bad about yourself irritability, getting upset easily nervousness, anxiety thoughts of hurting yourself or suicide lung infections : ( common - may affect up to 1 in 10 people ) lung infection ( e. g. pneumonia, bronchitis ) low red blood cell counts ( autoimmune haemolytic anaemia ): ( uncommon may affect up to 1 in 100 people ) paleness increased tiredness dark urine shortness of breath your skin or the whites of the eyes turn yellow increased tiredness, dark urine and skin or whites of the eyes turning yellow also may be symptoms of liver problems, see section above on liver problems. inflammation of the bowel ( colitis ): ( common may affect up to 1 in 10 people ) diarrhoea that does not go away stomach pain fever blood in your stools stomach pain may also be a symptom of liver problems, see section above on liver problems. low level of a type of white blood cells ( called lymphocytes ): zinbryta could reduce your level of these white blood cells so you will have a blood test every 3 months. contact your doctor immediately
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the carton and the label after ' exp '. the expiry date refers to the last day of that month . keep the zinbryta pre - filled syringe / pen in its original package to protect from light . keep the pack closed until you need to use a new syringe / pen . store in a refrigerator ( 2oc to 8oc ). o do not freeze . throw away any zinbryta that is accidentally frozen . if a refrigerator is not available , zinbryta syringes / pens can be stored at room temperature ( up to 30oc ) in the original pack for up to 30 days . o make sure zinbryta is out of the refrigerator for no longer than 30 days . o if zinbryta has been outside of the refrigerator for more than a total of 30 days or if you are not sure how long zinbryta has been at room temperature , throw the syringe / pen away ( see section 7 , instructions for injecting zinbryta ). do not place zinbryta back into the refrigerator after warming to room temperature . additional information do not use this medicine if you notice that : the syringe / pen is cracked or broken . the solution is cloudy or you can see particles floating in it . the solution is any other colour than colourless to slightly yellow . the pen has been dropped or is visibly damaged . disposal do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what zinbryta contains the active substance is daclizumab beta . each pre - filled syringe contains 150 mg of daclizumab beta in 1 ml solution for injection . each pre - filled pen contains 150 mg of daclizumab beta in 1 ml solution for injection . the other ingredients are sodium succinate , succinic acid , sodium chloride , polysorbate 80 , water for injections ( see section 2 ' zinbryta contains a small amount of sodium '). what zinbryta looks like and contents of the pack zinbryta is a colourless to slightly yellow , clear to opalescent liquid contained within a syringe / pen . pack sizes : each pack contains one pre - filled glass syringe / pre - filled pen with an attached needle , ready to inject . a multipack of three packs of one syringe / pen is also available . not all pack sizes may be marketed .
wilzin belongs to a group of medicines called various alimentary tract and metabolism products . wilzin is indicated in the treatment of wilson ' s disease , which is a rare inherited defect in copper excretion . dietary copper , which cannot be properly eliminated , accumulates first in the liver , then in other organs such as the eyes and the brain . this potentially leads to liver damage and neurological disorders . wilzin blocks the absorption of copper from the intestine thereby preventing its transfer into the blood and its further accumulation in the body . unabsorbed copper is then eliminated in the stool . wilson ' s disease will persist during the entire lifetime of the patient and therefore the need for this treatment is life - long .
do not take wilzin if you are allergic ( hypersensitive ) to zinc or any of the other ingredients of wilzin. take special care with wilzin wilzin is usually not recommended for initial therapy of patients with signs and symptoms of wilson's disease because of its slow onset of action. if you are currently treated with another anti - copper agent, for example, penicillamine, your doctor may add wilzin before stopping the initial treatment. as with other anti - copper agents such as penicillamine, your symptoms may get worse after starting the treatment. in this case, you must inform your doctor. in order to follow up your condition and treatment your doctor will check your blood and urine on a regular basis. this is to ensure that you receive sufficient treatment. monitoring may detect evidence 25 of insufficient treatment ( copper excess ) or excessive treatment ( copper deficiency ), both of which can be harmful, particularly to growing children and pregnant women. you should tell your doctor if you experience unusual muscle weakness or abnormal feeling in your limbs as this may indicate excessive treatment. taking other medicines please tell your doctor or your pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. please consult your doctor before taking any other medicines which may reduce the effectiveness of wilzin, such as iron, calcium supplements, tetracyclines ( antibiotics ) or phosphorus. conversely, the effectiveness of some medicines, such as iron, tetracyclines or fluoroquinolones ( antibiotics ), may be reduced by wilzin. taking wilzin with food and drink wilzin should be taken on an empty stomach, separated from mealtimes. dietary fibres and some dairy products, in particular, delay the absorption of zinc salts. some patients experience stomach upset after the morning dose. please discuss the matter with your wilson's disease doctor if this affects you. this side effect may be reduced by postponing the first dose of the day until mid - morning ( between breakfast and the midday meal ). it may also be minimised
always take wilzin exactly as your doctor has told you . you should check with your doctor or pharmacist if you are not sure . for the different dose regimens wilzin is available in hard capsules of 25 mg or 50 mg . for adults : the usual dose is 1 hard capsule of wilzin 50 mg ( or 2 hard capsules of wilzin 25 mg ) three times daily with a maximum dose of 1 hard capsule of wilzin 50 mg ( or 2 hard capsules of wilzin 25 mg ) five times daily . for children and adolescents : the usual dose is : - from 1 to 6 years : 1 hard capsule of wilzin 25 mg twice daily - from 6 to 16 years if bodyweight under 57 kg : 1 hard capsule of wilzin 25 mg three times daily - from 16 years or if bodyweight above 57 kg : 2 hard capsules of wilzin 25 mg or 1 hard capsule of wilzin 50 mg three times daily . always take wilzin on an empty stomach , at least one hour before or 2 - 3 hours after meals . if the morning dose is not well tolerated ( see section 4 ) it is possible to delay it to mid - morning , between breakfast and lunch . it is also possible to take wilzin with a little protein , such as meat . if you have been prescribed wilzin with another anti - copper agent , such as penicillamine , keep an interval of at least 1 hour between the two medicines . to administer wilzin to children who are unable to swallow capsules , open the capsule and mix the powder with a little water ( possibly flavoured with sugar or syrup ). if you take more wilzin than you should : if you take more wilzin than prescribed , you may experience nausea , vomiting and dizziness . in this case you must ask your doctor for advice . if you forget to take wilzin : do not take a double dose to make up for a forgotten individual dose . if you have any further questions on the use of this medicine , ask your doctor .
like all medicines , wilzin can cause side effects , although not everybody gets them .. these side effects may occur with certain frequencies , which are defined as follows : very common : affects more than 1 user in 10 common : affects 1 to 10 users in 100 uncommon : affects 1 to 10 users in 1 , 000 rare : affects 1 to 10 users in 10 , 000 very rare : affects less than 1 user in 10 , 000 not known : frequency cannot be estimated from the available data . common : after wilzin intake , gastric irritation may occur , especially at the beginning of treatment . changes in blood tests have been reported , including an increase in some liver and pancreatic enzymes . uncommon : a decrease in blood red and white cells may occur . reporting of side effects if you get any side effects , talk to your doctor or pharmacist . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
keep out of the reach and sight of children . do not use wilzin after the expiry date stated on the bottle and the carton , after exp . the expiry date refers to the last day of that month . do not store above 25 . medicines should not be disposed of via wastewater or household waste . ask your pharmacist how to dispose of medicines no longer required . these measures will help to protect the environment .
what wilzin contains the active substance is zinc . each hard capsule contains 25 mg of zinc ( corresponding to 83 . 92 mg of zinc acetate dihydrate ) or 50 mg of zinc ( corresponding to 167 . 84 mg of zinc acetate dihydrate ). the other ingredients are maize starch and magnesium stearate . the capsule shell contains gelatin , titanium dioxide ( e171 ) and either brilliant blue fcf ( e133 ) for wilzin 25 mg , or sunset yellow fcf ( e110 ) for wilzin 50 mg . the printing ink contains black iron oxide ( e172 ) and shellac . what wilzin looks like and contents of the pack wilzin 25 mg is an aqua blue hard capsule imprinted " 93 - 376 ". wilzin 50 mg is an orange opaque hard capsule imprinted " 93 - 377 ". it is available in packs of 250 hard capsules in a polyethylene bottle closed by a polypropylene and polyethylene closure . the bottle also contains a cotton filler .
biktarvy contains three active substances : bictegravir , an antiretroviral medicine known as an integrase strand transfer inhibitor ( insti ) emtricitabine , an antiretroviral medicine of a type known as a nucleoside reverse transcriptase inhibitor ( nrti ) tenofovir alafenamide , an antiretroviral medicine of a type known as a nucleotide reverse transcriptase inhibitor ( ntrti ) biktarvy is a single tablet for the treatment of human immunodeficiency virus 1 ( hiv - 1 ) infection in adults . biktarvy reduces the amount of hiv in your body . this will improve your immune system and reduce the risk of developing illnesses linked to hiv infection .
do not take biktarvy if you are allergic to bictegravir, emtricitabine, tenofovir alafenamide or any of the other ingredients of this medicine ( listed in section 6 ). if you are currently taking any of the following medicines : - rifampicin used to treat some bacterial infections such as tuberculosis - st. john's wort ( hypericum perforatum ), a herbal remedy used for depression and anxiety, or products that contain it. if any of these apply to you, do not take biktarvy and tell your doctor immediately. warnings and precautions talk to your doctor before taking biktarvy : if you have liver problems or a history of liver disease, including hepatitis. patients with liver disease including chronic hepatitis b or c, who are treated with antiretrovirals, have a higher risk of severe and potentially fatal liver complications. if you have hepatitis b infection, your doctor will carefully consider the best treatment regimen for you. if you have hepatitis b infection. liver problems may become worse after you stop taking biktarvy. do not stop taking biktarvy if you have hepatitis b. talk to your doctor first. for more details, see section 3, do not stop taking biktarvy. while you are taking biktarvy once you start taking biktarvy, look out for : signs of inflammation or infection joint pain, stiffness or bone problems if you notice any of these symptoms, tell your doctor immediately. for more information see section 4, possible side effects. although kidney problems have not been observed with biktarvy, there is a possibility that you may experience kidney problems when taking biktarvy over a long period of time. you can still pass on hiv when taking this medicine, although the risk is lowered by effective antiretroviral therapy. discuss with your doctor the precautions needed to avoid infecting other people. this medicine is not
always take this medicine exactly as your doctor has told you. check with your doctor or pharmacist if you are not sure. the recommended dose is : adults : one tablet each day with or without food do not chew, crush or split the tablet. get advice from a doctor or pharmacist if you are taking : antacids to treat stomach ulcers, heartburn, or acid reflux, containing aluminium and / or magnesium hydroxide mineral supplements or vitamins containing magnesium or iron see section 2 for more information on taking these medicines with biktarvy. if you are on dialysis, take your daily dose of biktarvy following completion of dialysis. if you take more biktarvy than you should if you take more than the recommended dose of biktarvy you may be at higher risk of side effects of this medicine ( see section 4, possible side effects ). contact your doctor or nearest emergency department immediately for advice. keep or take the tablet bottle with you so that you can easily describe what you have taken. if you forget to take biktarvy it is important not to miss a dose of biktarvy. if you do miss a dose : if you notice within 18 hours of the time you usually take biktarvy, you must take the tablet as soon as possible. then take the next dose as usual. if you notice 18 hours or more after the time you usually take biktarvy, then do not take the missed dose. wait and take the next dose at your usual time. if you vomit less than 1 hour after taking biktarvy, take another tablet. if you vomit more than 1 hour after taking biktarvy you do not need to take another tablet until your next regularly scheduled tablet. do not stop taking biktarvy do not stop taking biktarvy without talking to your doctor. stopping biktarvy can seriously affect how future treatment works. if biktarvy is stopped for any reason, speak to your doctor before you restart taking biktarvy tablets. when your supply of biktarvy starts to run low, get more from your doctor or pharmacist. this
like all medicines, this medicine can cause side effects, although not everybody gets them. possible side effects : tell a doctor immediately any signs of inflammation or infection. in some patients with advanced hiv infection ( aids ) and a history of opportunistic infections ( infections that occur in people with a weak immune system ), signs and symptoms of inflammation from previous infections may occur soon after hiv treatment is started. it is thought that these symptoms are due to an improvement in the body's immune response, enabling the body to fight infections that may have been present with no obvious symptoms. autoimmune disorders, when the immune system attacks healthy body tissue, may also occur after you start taking medicines for hiv infection. autoimmune disorders may occur many months after the start of treatment. look out for any symptoms of infection or other symptoms such as : - muscle weakness - weakness beginning in the hands and feet and moving up towards the trunk of the body - palpitations, tremor or hyperactivity if you notice these or any symptoms of inflammation or infection, tell your doctor immediately. common side effects ( may affect up to 1 in 10 people ) depression abnormal dreams headache dizziness diarrhoea feeling sick ( nausea ) tiredness ( fatigue ) uncommon side effects ( may affect up to 1 in 100 people ) anaemia vomiting stomach pain problems with digestion resulting in discomfort after meals ( dyspepsia ) wind ( flatulence ) swelling of the face, lips, tongue or throat ( angioedema ) itching ( pruritus ) rash hives ( urticaria ) joint pain ( arthralgia ) suicidal behaviour anxiety sleep disorders 37 rare side effects ( may affect up to 1 in 1000 people ) stevens - johnson syndrome ( sjs ) is a serious life - threatening condition which usually starts with flu - like symptoms. a few days later other symptoms appear including : - painful red or purple skin that looks burned and peels off - blisters on your skin, mouth, nose, and genitals - red, painful, watery eyes if you have any of these symptoms,
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the carton and bottle after { exp }. the expiry date refers to the last day of that month . store in the original package in order to protect from moisture . keep the bottle tightly closed . do not use if the seal over the bottle opening is broken or missing . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what biktarvy contains the active substances are bictegravir , emtricitabine and tenofovir alafenamide . each biktarvy tablet contains bictegravir sodium equivalent to 50 mg of bictegravir , 200 mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 25 mg of tenofovir alafenamide . the other ingredients are tablet core microcrystalline cellulose , croscarmellose sodium , magnesium stearate . film - coating polyvinyl alcohol , titanium dioxide ( e171 ), macrogol , talc , iron oxide red ( e172 ), iron oxide black ( e172 ). what biktarvy looks like and contents of the pack biktarvy film - coated tablets are purplish - brown , capsule - shaped , film - coated tablets debossed on one side with " gsi " and " 9883 " on the other side . biktarvy comes in bottles of 30 tablets and in packs made up of 3 bottles , each containing 30 tablets . each bottle contains a silica gel desiccant that must be kept in the bottle to help protect your tablets . the silica gel desiccant is contained in a separate sachet or canister and should not be swallowed . not all pack sizes may be marketed .
novonorm is an oral antidiabetic medicine containing repaglinide which helps your pancreas produce more insulin and thereby lower your blood sugar ( glucose ). type 2 diabetes is a disease in which your pancreas does not make enough insulin to control the sugar in your blood or where your body does not respond normally to the insulin it produces . novonorm is used to control type 2 diabetes in adults as an add - on to diet and exercise : treatment is usually started if diet , exercise and weight reduction alone have not been able to control ( or lower ) your blood sugar . novonorm can also be given with metformin , another medicine for diabetes . novonorm has been shown to lower the blood sugar , which helps to prevent complications from your diabetes .
do not take novonorm if you are allergic to repaglinide or any of the other ingredients in this medicine ( listed in section 6 ). if you have type 1 diabetes. if the acid level in your blood is raised ( diabetic ketoacidosis ). if you have a severe liver disease. if you take gemfibrozil ( a medicine used to lower increased fat levels in the blood ). warnings and precautions talk to your doctor before taking novonorm : 47 if you have liver problems. novonorm is not recommended in patients with moderate liver disease. novonorm should not be taken if you have a severe liver disease ( see do not take novonorm ). if you have kidney problems. novonorm should be taken with caution. if you are about to have major surgery or you have recently suffered a severe illness or infection. at such times diabetic control may be lost. if you are under 18 or over 75 years of age. novonorm is not recommended. it has not been studied in these age groups. talk to your doctor if any of the above applies to you. novonorm may not be suitable for you. your doctor will advise you. children and adolescents do not take this medicine if you are under 18 years of age. if you get a hypo ( low blood sugar ) you may get a hypo ( short for hypoglycaemia ) if your blood sugar gets too low. this may happen : if you take too much novonorm if you exercise more than usual if you take other medicines or suffer from liver or kidney problems ( see other sections of 2. what you need to know before you take novonorm ). the warning signs of a hypo may come on suddenly and can include : cold sweat ; cool pale skin ; headache ; rapid heart beat ; feeling sick ; feeling very hungry ; temporary changes in vision ; drowsiness ; unusual tiredness and weakness ; nervousness or tremor ; feeling anxious ; feeling confused ; difficulty in concentrating. if your blood sugar is low or you feel a hypo coming on : eat glucose tablets or a high sugar snack
always take this medicine exactly as your doctor has told you . check with your doctor if you are not sure . your doctor will work out your dose . the normal starting dose is 0 . 5 mg before each main meal . swallow the tablets with a glass of water immediately before or up to 30 minutes before each main meal . the dose may be adjusted by your doctor by up to 4 mg to be taken immediately before or up to 30 minutes before each main meal . the maximum recommended daily dose is 16 mg . do not take more novonorm than your doctor has recommended . if you take more novonorm than you should if you take too many tablets , your blood sugar may become too low , leading to a hypo . please see if you get a hypo on what a hypo is and how to treat it . if you forget to take novonorm if you miss a dose , take the next dose as usual - do not double the dose . if you stop taking novonorm be aware that the desired effect is not achieved if you stop taking novonorm . your diabetes may get worse . if any change of your treatment is necessary contact your doctor first . if you have any further questions on the use of this medicine , ask your doctor or pharmacist .
like all medicines , this medicine can cause side effects , although not everybody gets them . hypoglycaemia the most frequent side effect is hypoglycaemia which may affect up to 1 in 10 patients ( see if you get a hypo in section 2 ). hypoglycaemic reactions are generally mild / moderate but may occasionally develop into hypoglycaemic unconsciousness or coma . if this happens , medical assistance is needed immediately . allergy allergy is very rare ( may affect up to 1 in 10 , 000 patients ). symptoms such as swelling , difficulty in breathing , rapid heartbeat , feeling dizzy and sweating could be signs of anaphylactic reaction . contact a doctor immediately . other side effects common ( may affect up to 1 in 10 patients ) stomach pain diarrhoea . rare ( may affect up to 1 in 1 , 000 patients ) acute coronary syndrome ( but it may not be due to the medicine ). very rare ( may affect up to 1 in 10 , 000 patients ) vomiting constipation visual disturbances severe liver problems , abnormal liver function such as increased liver enzymes in your blood . frequency not known hypersensitivity ( such as rash , itchy skin , redening of the skin , swelling of the skin ) feeling sick ( nausea ). reporting of side effects if you get any side effects , talk to your doctor or pharmacist . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
what novonorm contains the active substance is repaglinide . the other ingredients are microcrystalline cellulose ( e460 ), calcium hydrogen phosphate anhydrous , maize starch , polacrilin potassium , povidone ( polyvidone ), glycerol 85 %, magnesium stearate , meglumine , poloxamer , iron oxide yellow ( e172 ) only in the 1 mg tablets and iron oxide red ( e172 ) only in the 2 mg tablets . what novonorm looks like and contents of the pack novonorm tablets are round and convex and engraved with the novo nordisk logo ( apis bull ). the strengths are 0 . 5 mg , 1 mg and 2 mg . 0 . 5 mg tablets are white , 1 mg tablets are yellow and 2 mg tablets are peach - coloured . four blister pack sizes are available . each pack contains 30 , 90 , 120 or 270 tablets . not all pack sizes may be marketed .
what pumarix is and what it is used for pumarix is a vaccine for use in adults from 18 years old to prevent pandemic flu ( influenza ). pandemic flu is a type of influenza that happens at intervals that vary from less than 10 years to many decades . it spreads rapidly around the world . the signs of pandemic flu are similar to those of ordinary flu but may be more serious . how pumarix works when a person is given the vaccine , the body ' s natural defence system ( immune system ) produces its own protection ( antibodies ) against the disease . none of the ingredients in the vaccine can cause flu . as with all vaccines , pumarix may not fully protect all persons who are vaccinated .
pumarix should not be given : if you have previously had a sudden life - threatening allergic reaction to any ingredient of this vaccine ( listed in section 6 ) or to anything else that may be present in very small amounts, such as : egg and chicken protein, ovalbumin, formaldehyde or sodium deoxycholate. - signs of an allergic reaction may include itchy skin rash, shortness of breath and swelling of the face or tongue. - however, in a pandemic situation, you may still be given the vaccine. this is as long as medical treatment is available straight away, in case you have an allergic reaction. do not have pumarix if any of the above apply to you. if you are not sure, talk to your doctor or nurse before having this vaccine. warnings and precautions 33 talk to your doctor or nurse before you are given pumarix : if you have had any allergic reaction other than a sudden life - threatening allergic reaction to any ingredient contained in this vaccine ( listed in section 6 ) or to thiomersal, to egg and chicken protein, ovalbumin, formaldehyde or to sodium deoxycholate. if you have a serious infection with a high temperature ( over 38 ). if this applies to you then your vaccination will usually be postponed until you are feeling better. a minor infection such as a cold should not be a problem, but your doctor will advise whether you could still be vaccinated with pumarix. if you have problems with your immune system, since your response to the vaccine may then be poor. if you are having a blood test to look for evidence of infection with certain viruses. in the first few weeks after vaccination with pumarix the results of these tests may not be correct. tell the doctor requesting these tests that you have recently been given pumarix. if you have a bleeding problem or you bruise easily. if any of the above apply to you ( or you are not sure ), talk to your doctor or nurse before having pumarix. this is because the vaccination may not be recommended, or may need to be delayed. fainting can occur following,
adults from 18 years onwards : you will receive two doses of pumarix . the second dose should be given after an interval of at least three weeks after the first dose . if you have previously received one or two doses of a similar h5n1 as03 - containing vaccine adults from 18 years onwards : you will receive one dose of pumarix . use in children there is limited information available on the use of vaccine very similar to pumarix ( but manufactured in a different facility ) to children aged from 3 - 9 years who received either two adult doses or two half adult doses given three weeks apart . there is no information available on use in children aged less than 3 years or aged from 10 - 17 years . your doctor or nurse will give you pumarix . they will give pumarix as an injection into a muscle this will usually be in the upper arm . if you have any further questions on the use of this vaccine , ask your doctor or nurse .
like all medicines, this vaccine can cause side effects, although not everybody gets them. allergic reactions allergic reactions which may cause you to have dangerously low blood pressure. if this is not treated it may lead to shock. your doctors know that this might happen and will have emergency treatment ready to use. other side effects : very common : may affect more than 1 in 10 people pain where the injection was given headache feeling tired aching muscles, joint pain common : may affect up to 1 in 10 people redness and swelling where the injection was given fever sweating shivering diarrhoea, feeling sick uncommon : may affect up to 1 in 100 people reactions where the injection was given such as bruising, a hard lump, itching, warmth swollen glands in your neck feeling dizzy generally feeling unwell unusual weakness 35 being sick, stomach pain, acid indigestion not being able to sleep tingling or numbness of the hands or feet shortness of breath pain in the chest itching, rash pain in the back or neck, stiff muscles, muscle spasms, pain in your leg or hand additional side effects in children when a dose of 0. 5 ml of a similar vaccine was given to children aged 3 - 9 years, fever occurred more often than when half of this dose ( 0. 25 ml of vaccine ) was given. also fever occurred more often in children aged 6 - 9 years compared to the children aged 3 - 5 years. there was no increase after the second dose whether the children received half of the adult or the adult dose, except for some side effects which were higher after the second dose, particularly for rates of fever in <unk> 6 years old children. in other clinical studies where children 6 months to 17 years received a similar vaccine containing a / indonesia / 05 / 2005, increases in the frequency of some side effects ( including injection site pain, redness and fever ) were seen after the second dose in children aged less than 6 years. the side effects listed below have happened with h1n1 as03 - containing vaccines. they may also happen with pumarix. if any of the side
keep this vaccine out of the sight and reach of children . before the vaccine is mixed : do not use the suspension and the emulsion after the expiry date which is stated on the carton . the expiry date refers to the last day of that month . store in a refrigerator ( 2 to 8 ). store in the original package in order to protect from light . do not freeze . after the vaccine is mixed : after mixing , use the vaccine within 24 hours and do not store above 30 . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what pumarix contains active substance : split influenza virus , inactivated , containing antigen * equivalent to : a / h5n1 / indonesia / 5 / 2005 like strain used ( pr8 - ibcdc - rg2 ) 3 . 75 micrograms ** per 0 . 5 ml dose * propagated in eggs ** expressed in microgram haemagglutinin this vaccine complies with the who recommendation and eu decision for the pandemic . adjuvant : the vaccine contains an ' adjuvant ' as03 . this adjuvant contains squalene ( 10 . 69 milligrams ), dl - Î± - tocopherol ( 11 . 86 milligrams ) and polysorbate 80 ( 4 . 86 milligrams ). adjuvants are used to improve the body ' s response to the vaccine . other ingredients : the other ingredients are : thiomersal , sodium chloride , disodium hydrogen phosphate , potassium dihydrogen phosphate , potassium chloride , water for injections what pumarix looks like and contents of the pack the suspension is a translucent to off white opalescent suspension , which may sediment slightly . the emulsion is a whitish homogeneous liquid . before the vaccine is given , the two parts will be mixed together . the mixed vaccine is a whitish emulsion . one pack of pumarix consists of : one pack containing 50 vials of 2 . 5 ml suspension ( antigen ) two packs containing 25 vials of 2 . 5 ml emulsion ( adjuvant )
this medicine is a radiopharmaceutical product for diagnostic use only . it contains the active substance edotreotide . before it can be used , the powder in the vial is mixed with a radioactive substance called gallium ( 68ga ) chloride to make gallium ( 68ga ) edotreotide ( this procedure is called radiolabelling ). gallium ( 68ga ) edotreotide contains a small amount of radioactivity . after injection into a vein , it can make parts of the body areas visible to doctors during a medical imaging procedure called positron emission tomography ( pet ). this medical procedure obtains images of your organs , to help locate the abnormal cells or tumours giving valuable information about your disease . the use of somakit toc involves exposure to small amounts of radioactivity . your doctor and the nuclear medicine doctor have considered that the clinical benefit from the procedure with the radiopharmaceutical outweighs the risk due to radiation .
somakit toc must not be used - if you are allergic to edotreotide or any of the other ingredients of this medicine ( listed in section 6 ). warnings and precautions talk to your nuclear medicine specialist before you are given somakit toc : - if you experience any signs of allergic reaction ( listed in section 4 ) after previous administration of somakit toc ; - if you have kidney or liver problems ( renal or hepatic disease ); - if you are under 18 years of age ; - if you have signs of dehydration before and after the examination ; 28 - if you have others medical conditions, such as high level of cortisol in the body ( cushing syndrome ), inflammation, thyroid disease, other type of tumour ( of pituitary gland, lung, brain, breast, immune system, thyroid, adrenal gland or others ) or disease of spleen that may affect the interpretation of the images ; - if you have been taking other medicines, such as somatostatin analogues and glucocorticoids, which may interact with somakit toc ; - if you are pregnant or believe you may be pregnant ; - if you are breast - feeding. your nuclear medicine doctor will inform you if you need to take any other special precaution before or after using somakit toc. before administration of somakit toc you should drink plenty of water before the start of the examination in order to urinate as often as possible during the first hours after the procedure to ensure that somakit toc is removed as quickly as possible from the body. children and adolescents this medicine is not recommended in patients under 18 years of age because its safety and efficacy have not been established in this patient population. other medicines and somakit toc tell your nuclear medicine doctor if you are taking, have recently taken or might take any other medicines, including somatostatin analogues, glucocorticoids ( also called corticosteroids ), since they may interfere with the interpretation of the images. if you are taking somatostatin analogues you
there are strict laws on the use , handling and disposal of radiopharmaceutical products . somakit toc will only be used in special controlled areas . this product will only be handled and given to you by 29 people who are trained and qualified to use it safely . these persons will take special care for the safe use of this product and will keep you informed of their actions . the nuclear medicine doctor supervising the procedure will decide on the quantity of somakit toc to be used in your case . it will be the smallest quantity necessary to get the desired information . the quantity to be administered usually recommended for an adult ranges from 100 mbq to 200 mbq ( megabecquerel , the unit used to express radioactivity ). administration of somakit toc and conduct of the procedure after radiolabelling , somakit toc is administered by intravenous injection . a single injection is sufficient to conduct the test that your doctor needs . after injection , you will be offered something to drink and asked to urinate immediately preceding the test . duration of the procedure your nuclear medicine doctor will inform you about the usual duration of the procedure . after administration of somakit toc , you should : - avoid any close contact with young children and pregnant women for 8 hours after the injection - urinate frequently in order to eliminate the product from your body . the nuclear medicine doctor will inform you if you need to take any special precautions after receiving this medicine . contact your nuclear medicine doctor if you have any questions . if you have been given more somakit toc than you should an overdose is unlikely because you will only receive a single dose under controlled conditions by the nuclear medicine doctor supervising the procedure . however , in the case of an overdose , you will receive the appropriate treatment . drinking and emptying your bladder frequently will help remove the radioactive substance from your body more quickly . should you have any further questions on the use of somakit toc , please ask the nuclear medicine doctor who supervises the procedure .
like all medicines , this medicine can cause side effects , although not everybody gets them . although no side effects have been reported , a potential risk of allergic reactions ( hypersensitivity ) exists with somakit toc . symptoms may include : warm flush , redness of the skin , swelling , itching , nausea and difficulty breathing . in case of allergic reactions you will receive the appropriate treatment from your medical staff . not known ( frequency cannot be estimated from the available data ): - stinging near the injection site this radiopharmaceutical will deliver low amounts of ionising radiation associated with the least risk of cancer and hereditary abnormalities . reporting of side effects if you get any side effects talk to your nuclear medicine doctor . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
you will not have to store this medicine . this medicine is stored under the responsibility of the specialist in appropriate premises . storage of radiopharmaceuticals will be in accordance with national regulation on radioactive materials . the following information is intended for the specialist only . keep this medicine out of the sight and reach of children . somakit toc must not be used after the expiry date which is stated on the carton . the expiry date refers to the last day of that month . store in a refrigerator ( 2 to 8 ). store in the original package in order to protect from light . after radiolabelling , somakit toc should be used within 4 hours . do not store above 25 after radiolabelling . somakit toc must not be used if there are visible signs of deterioration . do not throw away any medicines via wastewater or household waste . wait for the level of radioactivity to decay adequately before throwing away radioactive products . these measures will help protect the environment .
what somakit toc contains - the active substance is edotreotide . one vial of powder contains 40 Âµg of edotreotide . - the other ingredients are : 1 , 10 - phenanthroline , gentisic acid , mannitol , formic acid , sodium hydroxide , water for injections . somakit toc contains sodium ( see section 2 ). after radiolabelling , the solution obtained also contains hydrochloric acid . what somakit toc looks like and contents of the pack somakit toc is a kit for radiopharmaceutical preparation containing : - a glass vial with black flip - off cap containing a white powder . - a glass vial with yellow flip - off cap containing a clear and colourless solution . the radioactive substance is not part of the kit and should be added during the preparation steps before injection .
afinitor is an anticancer medicine containing the active substance everolimus . everolimus reduces the blood supply to the tumour and slows down the growth and spread of cancer cells . afinitor is used to treat adult patients with : hormone receptor - positive advanced breast cancer in postmenopausal women , in whom other treatments ( so called " non - steroidal aromatase inhibitors ") no longer keep the disease under control . it is given together with a medicine called exemestane , a steroidal aromatase inhibitor , which is used for hormonal anticancer therapy . advanced tumours called neuroendocrine tumours that originate from the stomach , bowels , lung or pancreas . it is given if the tumours are inoperable and do not overproduce specific hormones or other related natural substances . advanced kidney cancer ( advanced renal cell carcinoma ), where other treatments ( so - called " vegf - targeted therapy ") have not helped stop your disease .
afinitor will only be prescribed for you by a doctor with experience in cancer treatment. follow all the doctor's instructions carefully. they may differ from the general information contained in this leaflet. if you have any questions about afinitor or why it has been prescribed for you, ask your doctor. do not take afinitor if you are allergic to everolimus, to related substances such as sirolimus or temsirolimus, or to any of the other ingredients of this medicine ( listed in section 6 ). if you think you may be allergic, ask your doctor for advice. warnings and precautions talk to your doctor before taking afinitor : if you have any problems with your liver or if you have ever had any disease which may have affected your liver. if this is the case, your doctor may need to prescribe a different dose of afinitor. if you have diabetes ( high level of sugar in your blood ). afinitor may increase blood sugar levels and worsen diabetes mellitus. this may result in the need for insulin and / or oral antidiabetic agent therapy. tell your doctor if you experience any excessive thirst or increased frequency of urination. if you need to receive a vaccine while taking afinitor. if you have high cholesterol. afinitor may elevate cholesterol and / or other blood fats. if you have had recent major surgery, or if you still have an unhealed wound following surgery. afinitor may increase the risk of problems with wound healing. if you have an infection. it may be necessary to treat your infection before starting afinitor. if you have previously had hepatitis b, because this may be reactivated during treatment with afinitor ( see section 4'possible side effects '). afinitor may also : weaken your immune system. therefore, you may be at risk of getting an infection while you are taking afinitor. if you have fever or other signs of an infection, consult with your doctor. some infections may be severe and may have fatal consequences. impact your kidney function. therefore, your doctor will monitor your kidney function while you are taking
always take this medicine exactly as your doctor or pharmacist has told you . check with your doctor or pharmacist if you are not sure . the recommended dose is 10 mg , taken once a day . your doctor will tell you how many tablets of afinitor to take . if you have liver problems , your doctor may start you on a lower dose of afinitor ( 2 . 5 , 5 or 7 . 5 mg per day ). if you experience certain side effects while you are taking afinitor ( see section 4 ), your doctor may lower your dose or stop treatment , either for a short time or permanently . take afinitor once a day , at about the same time every day , consistently either with or without food . swallow the tablet ( s ) whole with a glass of water . do not chew or crush the tablets . if you take more afinitor than you should if you have taken too much afinitor , or if someone else accidentally takes your tablets , see a doctor or go to a hospital immediately . urgent treatment may be necessary . take the carton and this leaflet , so that the doctor knows what has been taken . if you forget to take afinitor if you miss a dose , take your next dose as scheduled . do not take a double dose to make up for the forgotten tablets . if you stop taking afinitor do not stop taking afinitor unless your doctor tells you to . if you have any further questions on the use of this medicine , ask your doctor or pharmacist .
like all medicines, this medicine can cause side effects, although not everybody gets them. stop taking afinitor and seek medical help immediately if you experience any of the following signs of an allergic reaction : difficulty breathing or swallowing swelling of the face, lips, tongue or throat severe itching of the skin, with a red rash or raised bumps serious side effects of afinitor include : very common ( may affect more than 1 in 10 people ) increased temperature, chills ( signs of infection ) fever, coughing, difficulty breathing, wheezing ( signs of inflammation of the lung, also known as pneumonitis ) 46 common ( may affect up to 1 in 10 people ) excessive thirst, high urine output, increased appetite with weight loss, tiredness ( signs of diabetes ) bleeding ( haemorrhage ), for example in the gut wall severely decreased urine output ( sign of kidney failure ) uncommon ( may affect up to 1 in 100 people ) fever, skin rash, joint pain and inflammation, as well as tiredness, loss of appetite, nausea, jaundice ( yellowing of the skin ), pain in the upper right abdomen, pale stools, dark urine ( may be signs of hepatitis b reactivation ) breathlessness, difficulty breathing when lying down, swelling of the feet or legs ( signs of heart failure ) swelling and / or pain in one of the legs, usually in the calf, redness or warm skin in the affected area ( signs of blockade of a blood vessel ( vein ) in the legs caused by blood clotting ) sudden onset of shortness of breath, chest pain or coughing up blood ( potential signs of pulmonary embolism, a condition that occurs when one or more arteries in your lungs become blocked ) severely decreased urine output, swelling in the legs, feeling confused, pain in the back ( signs of sudden kidney failure ) rash, itching, hives, difficulty breathing or swallowing, dizziness ( signs of serious allergic reaction, also known as hypersensitivity ) rare ( may affect up to 1 in 1, 000 people ) shortness of breath or rapid breath
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the carton and blister foil . the expiry date refers to the last day of that month . do not store above 25 . store in the original package in order to protect from light and moisture . open the blister just before taking the tablets . do not use this medicine if any pack is damaged or shows signs of tampering . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help to protect the environment .
what afinitor contains the active substance is everolimus . each tablet of afinitor 2 . 5 mg contains 2 . 5 mg everolimus . each tablet of afinitor 5 mg contains 5 mg everolimus . each tablet of afinitor 10 mg contains 10 mg everolimus . the other ingredients are butylhydroxytoluene , magnesium stearate , lactose monohydrate , hypromellose , crospovidone type a and lactose anhydrous . what afinitor looks like and contents of the pack afinitor 2 . 5 mg tablets are white to slightly yellowish , elongated tablets . they are engraved with " lcl " on one side and " nvr " on the other . afinitor 5 mg tablets are white to slightly yellowish , elongated tablets . they are engraved with " 5 " on one side and " nvr " on the other . afinitor 10 mg tablets are white to slightly yellowish , elongated tablets . they are engraved with " uhe " on one side and " nvr " on the other . afinitor 2 . 5 mg is available in blister packs containing 30 or 90 tablets . afinitor 5 mg and afinitor 10 mg are available in blister packs containing 10 , 30 or 90 tablets . not all pack sizes or strengths may be marketed in your country .
what laventair ellipta is laventair ellipta contains two active substances umeclidinium bromide and vilanterol . these belong to a group of medicines called bronchodilators . what laventair ellipta is used for laventair ellipta is used to treat chronic obstructive pulmonary disease ( copd ) in adults . copd is a long - term condition characterised by breathing difficulties that slowly get worse . in copd the muscles around the airways tighten . this medicine blocks the tightening of these muscles in the lungs , making it easier for air to get in and out of the lungs . when used regularly , it can help to control your breathing difficulties and reduce the effects of copd on your everyday life . laventair ellipta should not be used to relieve a sudden attack of breathlessness or wheezing . if you get this sort of attack you must use a quick - acting reliever inhaler ( such as salbutamol ). if you do not have a quick - acting inhaler contact your doctor .
do not use laventair ellipta : 31 - if you are allergic to umeclidinium, vilanterol or any of the other ingredients of this medicine ( listed in section 6 ). if you think this applies to you, don't use this medicine until you have checked with your doctor. warnings and precautions talk to your doctor before using this medicine : - if you have asthma ( don't use laventair ellipta to treat asthma ) - if you have heart problems or high blood pressure - if you have an eye problem called narrow - angle glaucoma - if you have an enlarged prostate, difficulty passing urine or a blockage in your bladder - if you suffer from epilepsy - if you have thyroid gland problems - if you have diabetes - if you have severe liver problems check with your doctor if you think any of these may apply to you. immediate breathing difficulties if you get tightness of the chest, coughing, wheezing or breathlessness immediately after using your laventair ellipta inhaler : stop using this medicine and seek medical help immediately, as you may have a serious condition called paradoxical bronchospasm. eye problems during treatment with laventair ellipta if you get eye pain or discomfort, temporary blurring of vision, visual halos or coloured images in association with red eyes during treatment with laventair ellipta : stop using this medicine and seek medical help immediately, these may be signs of an acute attack of narrow - angle glaucoma. children and adolescents do not give this medicine to children or adolescents below the age of 18 years. other medicines and laventair ellipta tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. if you are not sure what your medicine contains talk to your doctor or pharmacist. some medicines may affect how this medicine works, or make it more likely that you'll have side effects. these include : - medicines called beta blockers ( such as propranolol ), to treat high blood pressure or other heart problems
always use this medicine exactly as your doctor has told you. check with your doctor or pharmacist if you are not sure. the recommended dose is one inhalation every day at the same time of day. you only need to inhale once a day because the effect of this medicine lasts for 24 hours. don't use more than your doctor tells you to use. use laventair ellipta regularly it is very important that you use laventair ellipta every day, as instructed by your doctor. this will help to keep you free of symptoms throughout the day and night. laventair ellipta should not be used to relieve a sudden attack of breathlessness or wheezing. if you get this sort of attack you must use a quick - acting reliever inhaler ( such as salbutamol ). how to use the inhaler see'step - by - step instructions'in this leaflet for full information. laventair ellipta is for inhalation use. to use laventair ellipta, you breathe it into your lungs through your mouth using the ellipta inhaler. if your symptoms do not improve if your copd symptoms ( breathlessness, wheezing, cough ) do not improve or get worse, or if you are using your quick - acting inhaler more often : contact your doctor as soon as possible. if you use more laventair ellipta than you should if you accidentally use too much of this medicine, contact your doctor or pharmacist for advice immediately as you may need medical attention. if possible, show them the inhaler, the package or this leaflet. you may notice that your heart is beating faster than usual, you feel shaky, you have visual disturbances, have a dry mouth, or have a headache. if you forget to use laventair ellipta don't inhale an extra dose to make up for a forgotten dose. just inhale your next dose at the usual time. if you become wheezy or breathless, use your quick - acting reliever
like all medicines, this medicine can cause side effects, although not everybody gets them. allergic reactions if you have any of the following symptoms after taking laventair ellipta stop using this medicine and tell your doctor immediately. uncommon side effects ( may affect up to 1 in 100 people ): skin rash ( hives ) or redness rare side effects ( may affect up to 1 in 1, 000 people ): swelling, sometimes of the face or mouth ( angioedema ) becoming very wheezy, coughing or having difficulty in breathing suddenly feeling weak or light headed ( which may lead to collapse or loss of consciousness ) immediate breathing difficulties immediate breathing difficulties after using laventair ellipta are rare. if you get tightness of the chest, coughing, wheezing or breathlessness immediately after using this medicine : stop using this medicine and seek medical help immediately, as you may have a serious condition called paradoxical bronchospasm. common side effects these may affect up to 1 in 10 people : painful and frequent urination ( may be signs of a urinary tract infection ) combination of sore throat and runny nose sore throat feeling of pressure or pain in the cheeks and forehead ( may be signs of inflammation of the sinuses called sinusitis ) headache cough pain and irritation in the back of the mouth and throat constipation dry mouth infection of the upper airways. uncommon side effects these may affect up to 1 in 100 people : irregular heart beat faster heart beat awareness of heart beat ( palpitations ) rash tremor taste disturbance hoarseness. rare side effects these may affect up to 1 in 1, 000 people : blurred vision increase of the measured eye pressure decrease in vision or pain in your eyes due to high pressure ( possible signs of glaucoma ). difficulty and pain when passing urine these may be signs of a bladder obstruction or urinary retention. frequency not known frequency cannot be estimated from the available data : dizziness. reporting of side effects if you get any side effects, talk to your doctor, pharmacist or nurse. this includes any possible side effects not listed in this leaflet. you can also report side effects directly via the national reporting system listed in appendix
what laventair ellipta contains the active substances are umeclidinium bromide and vilanterol . each single inhalation provides a delivered dose ( the dose leaving the mouthpiece ) of 55 micrograms umeclidinium ( equivalent to 65 micrograms of umeclidinium bromide ) and 22 micrograms of vilanterol ( as trifenatate ). the other ingredients are lactose monohydrate ( see section 2 under ' laventair ellipta contains lactose ') and magnesium stearate . what laventair ellipta looks like and contents of the pack laventair ellipta is an inhalation powder , pre - dispensed . the ellipta inhaler consists of a light grey plastic body , a red mouthpiece cover and a dose counter . it is packaged in a foil laminate tray with a peelable foil lid . the tray contains a desiccant packet , to reduce moisture in the packaging . the active substances are present as a white powder in separate blisters inside the inhaler . each inhaler contains either 7 or 30 doses . multipacks containing 90 ( 3 inhalers of 30 ) doses are also available . not all pack sizes may be marketed .
tremfya contains the active substance guselkumab which is a type of protein called a monoclonal antibody . this medicine works by blocking the activity of a protein called il - 23 , which is present at increased levels in people with psoriasis . tremfya is used to treat adults with moderate to severe " plaque psoriasis ", an inflammatory condition affecting the skin and nails . tremfya can improve the condition of the skin and appearance of nails and reduce symptoms , such as scaling , shedding , flaking , itching , pain and burning .
do not use tremfya if you are allergic to guselkumab or any of the other ingredients of this medicine ( listed in section 6 ). if you think you may be allergic, ask your doctor for advice before using tremfya if you have an active infection, including active tuberculosis warnings and precautions talk to your doctor, pharmacist or nurse before using tremfya : if you are being treated for an infection if you have an infection that does not go away or that keeps coming back if you have tuberculosis or have been in close contact with someone with tuberculosis 36 if you think you have an infection or have symptoms of an infection ( see below under'look out for infections and allergic reactions ') if you have recently had a vaccination or if you are due to have a vaccination during treatment with tremfya. if you are not sure if any of the above applies to you, talk to your doctor, pharmacist or nurse before using tremfya. look out for infections and allergic reactions tremfya can potentially cause serious side effects, including allergic reactions and infections. you must look out for signs of these conditions while you are taking tremfya. stop using tremfya and tell your doctor or seek medical help immediately if you notice any signs indicating a possible serious allergic reaction or an infection. signs of infections may include fever or flu like symptoms ; muscle aches ; cough ; shortness of breath ; burning when you urinate or urinating more often than usual ; blood in your phlegm ( mucus ); weight loss ; diarrhoea or stomach pain ; warm, red, or painful skin or sores on your body which are different from your psoriasis. serious allergic reactions, which can include symptoms of hives and shortness of breath, have occurred with tremfya ( see " serious side effects " in section 4 ). children and adolescents tremfya is not recommended for children and adolescents under 18 years of age because it has not been studied in this age group
always use this medicine exactly as your doctor or nurse has told you . check with your doctor , nurse or pharmacist if you are not sure . how much tremfya is given and for how long your doctor will decide for how long you need to use tremfya . the dose is 100 mg ( the content of 1 pre - filled syringe ) given by injection under the skin ( subcutaneous injection ). this may be given by your doctor or nurse . after the first dose , you will have the next dose 4 weeks later , and then every 8 weeks . at the start , your doctor or nurse will inject tremfya . however , you may decide together with your doctor to give tremfya yourself in which case you will get the appropriate training on how to inject tremfya . talk to your doctor or nurse if you have any questions about giving yourself an injection . it is important not to try to inject yourself until you have been trained by your doctor or nurse . for detailed instructions on how to use tremfya , carefully read the ' instructions for use ' leaflet before use , which is included in the carton . if you use more tremfya than you should if you have received more tremfya than you should or the dose has been given sooner than prescribed , inform your doctor . if you forget to use tremfya if you have forgotten to inject a dose of tremfya , inform your doctor . if you stop using tremfya you should not stop using tremfya without speaking to your doctor first . if you stop treatment , symptoms of psoriasis may come back .
like all medicines , this medicine can cause side effects , although not everybody gets them . serious side effects tell your doctor or seek medical help immediately if you get any of the following side effects : possible serious allergic reaction - the signs may include : - difficulty breathing or swallowing - swelling of the face , lips , tongue or throat - severe itching of the skin , with a red rash or raised bumps other side effects the following side effects are all mild to moderate . if any of these side effects becomes severe , tell your doctor , pharmacist or nurse immediately . some side effects are very common ( may affect more than 1 in 10 people ): - upper respiratory infections some side effects are common ( may affect up to 1 in 10 people ): - headache - joint pain ( arthralgia ) - diarrhoea - stomach flu ( gastroenteritis ) - redness at the injection site - hives - fungal infection of the skin , for instance between the toes ( e . g ., athlete ' s foot ) - herpes simplex infections some side effects are uncommon ( may affect up to 1 in 100 people ): - pain at the injection site - allergic reaction - skin rash reporting of side effects if you get any side effects , talk to your doctor , pharmacist or nurse . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting 38 system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the syringe label and on the outer carton after " exp ". the expiry date refers to the last day of that month . keep the pre - filled syringe in the outer carton in order to protect it from light . store in a refrigerator ( 28 ). do not freeze . do not shake . do not use this medicine if you notice that the medicine is cloudy or discoloured , or contains large particles . before use , remove the carton from the refrigerator and keep the pre - filled syringe inside the carton and allow to reach room temperature by waiting for 30 minutes . this medicine is for single use only . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what tremfya contains - the active substance is guselkumab . each pre - filled syringe contains 100 mg of guselkumab in 1 ml solution . - the other ingredients are histidine , histidine monohydrochloride monohydrate , polysorbate 80 , sucrose and water for injections . what tremfya looks like and contents of the pack solution for injection ( injection ). tremfya is a clear , colourless to light yellow solution . it is supplied as a carton pack containing one single - dose glass syringe and as a multipack containing 2 ( 2 packs of 1 ) single - dose pre - filled syringes . not all pack sizes may be marketed .
what trepulmix is the active ingredient of trepulmix is treprostinil . treprostinil belongs to a group of medicines which work in a similar way to the naturally occurring prostacyclins . prostacyclins are hormone - like substances which reduce blood pressure by relaxing blood vessels , causing them to widen , which allows the blood to flow more easily . prostacyclins can also have an influence in preventing blood from clotting . what trepulmix is used to treat trepulmix is used for the treatment of adult patients with inoperable chronic thromboembolic pulmonary hypertension ( cteph ), or persistent or recurrent cteph after surgical treatment ( severity classified who functional class ( fc ) iii or iv ), to improve exercise capacity and symptoms of the disease . chronic thromboembolic pulmonary hypertension is a condition where your blood pressure is too high in the blood vessels between the heart and the lungs causing shortness of breath , dizziness , tiredness , fainting , palpitations or abnormal heartbeat , dry cough , chest pain and swollen ankles or legs . how trepulmix works trepulmix lowers blood pressure within the pulmonary artery by improving blood flow and reducing the amount of work for the heart . improved blood flow leads to an increased supply of oxygen to the body and reduced strain on the heart , causing it to function more effectively . trepulmix improves the symptoms associated with cteph and the ability to exercise in patients who are limited in terms of activity .
do not use trepulmix : - if you are allergic to treprostinil or any of the other ingredients of this medicine ( listed in section 6 ). - if you have been diagnosed with a disease called " pulmonary veno - occlusive disease ". this is a disease in which the blood vessels that carry blood through your lungs become swollen and clogged resulting in a higher pressure in the blood vessels between the heart and the lungs. - if you have severe liver disease - if you have a heart problem, for example : a heart attack ( myocardial infarction ) within the last six months severe changes in heart rate severe coronary heart disease or unstable angina a heart defect has been diagnosed, such as a faulty heart valve that causes the heart to work poorly any disease of the heart which is not being treated or not under close medical observation - if you are at a specific high risk of bleeding for example active stomach ulcers, injuries or other bleeding conditions - if you have had a stroke within the last 3 months, or any other interruption of blood supply to the brain warnings and precautions talk to your doctor before using trepulmix if you : - suffer from any liver disease - suffer from kidney disease - have been advised that you are medically obese ( bmi greater than 30 kg / m2 ) - are on a low sodium diet during your treatment with trepulmix, tell your doctor : - if your blood pressure decreases ( hypotension ) - if you experience a rapid increase in breathing difficulties or persistent cough ( this can be related to congestion in the lungs or asthma or other condition ), consult your doctor immediately. - if you have excessive bleeding as treprostinil may increase the risk, by preventing your blood from clotting children and adolescents trepulmix must not be used in children and adolescents. other medicines and trepulmix tell your doctor if you are taking / using, have recently taken / used or might take / use any other medicines. please tell your doctor if you are taking : - medicines used to treat high blood pressure ( antihyp
always use this medicine exactly as your doctor has told you. check with your doctor if you are not sure. trepulmix is administered undiluted as a continuous subcutaneous infusion ( under the skin ) via a small tube ( cannula ) which is located in your abdomen or thigh ; trepulmix is pushed through the tubing by a portable pump. before you leave the hospital or clinic, your doctor will tell you how to prepare trepulmix and at what rate the pump should deliver your treprostinil. information on how to use the pump correctly and what to do if it stops working should also be given to you. the information should also tell you who to contact in an emergency. flushing of the infusion line whilst connected may cause accidental overdose. adult patients trepulmix is available as 1 mg / ml, 2. 5 mg / ml, 5 mg / ml or 10 mg / ml solution for infusion. your doctor will determine the infusion rate and dose appropriate for your condition. elderly patients no special dose adjustments are necessary for these patients. patients with liver or kidney disease your doctor will determine the infusion rate and dose appropriate for your condition. infusion rate the infusion rate can be reduced or increased on an individual basis under medical supervision only. the aim of adjusting the infusion rate is to establish an effective maintenance rate which improves symptoms of cteph while minimising any undesirable effects. if your symptoms increase or if you need complete rest, or are confined to your bed or chair, or if any physical activity brings on discomfort and your symptoms occur at rest, do not increase your dose without medical advice. trepulmix may no longer be sufficient to treat your disease and another treatment may be required. if you use more trepulmix than you should if you accidentally overdose trepulmix, you may experience nausea, vomiting, diarrhoea, low blood pressure ( dizziness, light - headedness or fainting ), skin flushes and / or headaches. if any of these effects become severe you should contact your doctor or hospital immediately. your doctor may reduce
like all medicines , this medicine can cause side effects , although not everybody gets them . very common ( may affect more than 1 in 10 people ) widening of blood vessels pain around the infusion site reaction around the infusion site bleeding or bruising around the infusion site headaches nausea diarrhoea jaw pain common ( may affect up to 1 in 10 people ) dizziness light - headedness or fainting due to low blood pressure skin rashes muscle pain ( myalgia ) joint pain ( arthralgia ) swelling of feet , ankles , legs or fluid retention hot flush pain in arms and / or legs 36 uncommon ( may affect up to 1 in 100 people ) swollen eyelids ( eyelid oedema ) indigestions vomiting skin itches exanthema back pain decreased appetite tiredness other possible side effects observed in pulmonary arterial hypertension ( pah ) patients : bleeding episodes such as : as nose bleeds , coughing up blood , blood in the urine , bleeding from the gums , blood in the faeces other possible side effects observed during clinical practice : infection at the infusion site abscess at the infusion site a decrease of blood clotting cells ( platelets ) in the blood ( thrombocytopenia ) bone pain skin rashes with discolouration or raised bumps tissue infection under the skin ( cellulitis ) reporting of side effects if you get any side effects , talk to your doctor . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v .* by reporting side effects you can help provide more information on the safety of this medicine .
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date that is stated on the carton and vial after " exp ". the expiry date refers to the last day of that month . this medicinal product does not require any special storage conditions . a trepulmix vial must be used or discarded within 30 days after first opening . during continuous subcutaneous infusion , a single reservoir ( syringe ) of undiluted trepulmix must be used within 72 hours . do not use this medicine if you notice any damage to the vial , discolouration or other signs of deterioration . do not throw away any medicines via waste water or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what trepulmix contains the active substance is treprostinil. trepulmix 1 mg / ml solution for infusion each ml of solution contains 1 mg treprostinil ( as sodium salt ). each 10 ml vial of solution contains 10 mg treprostinil ( as sodium salt ). trepulmix 2. 5 mg / ml solution for infusion each ml of solution contains 2. 5 mg treprostinil ( as sodium salt ) each 10 ml vial of solution contains 25 mg treprostinil ( as sodium salt ). trepulmix 5 mg / ml solution for infusion each ml of solution contains 5 mg treprostinil ( as sodium salt ). each 10 ml vial of solution contains 50 mg treprostinil ( as sodium salt ). trepulmix 10 mg / ml solution for infusion each ml of solution contains 10 mg treprostinil ( as sodium salt ). each 10 ml vial of solution contains 100 mg treprostinil ( as sodium salt ). the other ingredients are : sodium citrate, sodium chloride, sodium hydroxide, hydrochloric acid, metacresol and water for injections. see section 2, " trepulmix contains sodium ". what trepulmix looks like and the contents of the pack trepulmix is a clear colourless to slightly yellow solution, available in a 10 ml clear glass vial sealed with a rubber stopper and a colour coded cap : trepulmix 1 mg / ml solution for infusion trepulmix 1 mg / ml solution for infusion has a yellow rubber cap. trepulmix 2. 5 mg / ml solution for infusion trepulmix 2. 5 mg / ml solution for infusion has a blue rubber cap. trepulmix 5 mg / ml solution for infusion trepulmix 5 mg / ml solution for infusion has a green rubber cap. trepulmix 10 mg /
thorinane contains the active substance called enoxaparin sodium that is a low molecular weight heparin ( lmwh ). thorinane works in two ways . 1 ) stopping existing blood clots from getting any bigger . this helps your body to break them down and stops them from causing you harm . 2 ) stopping blood clots from forming in your blood . thorinane can be used to : treat blood clots that are in your blood stop blood clots from forming in your blood in the following situations : o before and after an operation o when you have an acute illness and face period of limited mobility o when you have unstable angina ( a condition when not enough blood gets to your heart ) o after a heart attack stop blood clots forming in the tubes of your dialysis machine ( used for people with severe kidney problems ).
do not use thorinane if you are allergic to enoxaparin sodium or any of the other ingredients of this medicine ( listed in section 6 ). signs of an allergic reaction include : rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue. if you are allergic to heparin or other low molecular weight heparins such as nadroparin, tinzaparin or dalteparin. if you have had a reaction to heparin that caused a severe drop in the number of your clotting cells ( platelets ) - this reaction is called heparin - induced thrombocytopenia - within the last 100 days or if you have antibodies against enoxaparin in your blood. if you are bleeding heavily or have a condition with a high risk of bleeding ( such as stomach ulcer, recent surgery of the brain or eyes ), including recent bleeding stroke. if you are using thorinane to treat blood clots in your body and going to receive spinal or epidural anaesthesia or lumbar puncture within 24 hours. warnings and precautions thorinane should not be used interchangeably with other medicines belonging to the group of low molecular weight heparins. this is because they are not exactly the same and do not have the same activity and instructions for use. talk to your doctor or pharmacist before using thorinane if : you have ever had a reaction to heparin that caused a severe drop in the number of your platelets you are going to receive spinal or epidural anesthesia or lumbar puncture ( see operations and anaesthetics ): a delay should be respected between thorinane use and this procedure you have had a heart valve fitted you have endocarditis ( an infection of the inner lining of the heart ) you have history of gastric ulcer you have had a recent stroke you have high blood pressure you have diabetes or problems with blood vessels in the eye caused by diabetes ( called diabetic retinopathy ) you have had an operation recently on your eyes or brain
like other similar medicines ( medicines to reduce blood clotting ), thorinane may cause bleeding which may potentially be life - threatening. in some cases the bleeding may not be obvious. if you experience any bleeding event that does not stop by itself or if you experience signs of excessive bleeding ( exceptional weakness, tiredness, paleness, dizziness, headache or unexplained swelling ), consult your doctor immediately. your doctor may decide to keep you under closer observation or change your medicine. stop using thorinane and talk to a doctor or nurse at once if you get any signs of a severe allergic reaction ( such as difficulty breathing, swelling of the lips, mouth, throat or eyes ). you should tell your doctor straight away if you have any sign of blockage of a blood vessel by a blood clot such as : - cramping pain, redness, warmth, or swelling in one of your legs these are symptoms of deep vein thrombosis - breathlessness, chest pain, fainting or coughing up blood these are symptoms of a pulmonary embolism if you have a painful rash of dark red spots under the skin which do not go away when you put pressure on them. your doctor may request you perform a blood test to check your platelet count. overall list of possible side effects : very common ( may affect more than 1 in 10 people ) bleeding. increases in liver enzymes. common ( may affect up to 1 in 10 people ) you bruise more easily than usual. this could be because of a blood problem with low platelet counts. pink patches on your skin. these are more likely to appear in the area you have been injected with thorinane. skin rash ( hives, urticaria ). itchy red skin. bruising or pain at the injection site. decreased red blood cell count. high platelet counts in the blood. headache. uncommon ( may affect up to 1 in 100 people ) sudden severe headache. this could be a sign of bleeding in the brain. a feeling of tenderness and swelling in your stomach. you may have bleeding in your stomach. large red irregularly
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the label and carton . the expiry date refers to the last day of that month . store below 25 . do not freeze . after dilution the solution should be used within 8 hours . do not use this medicine if you notice any visible change in the appearance of the solution . the thorinane pre - filled syringes are for single dose use only . discard any unused medicine . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what thorinane contains - the active substance is enoxaparin sodium . each ml contains 100 mg enoxaparin sodium . each pre - filled syringe of 0 . 2 ml contains 2 , 000 iu ( 20 mg ) of enoxaparin sodium . - the other ingredient is water for injections . what thorinane looks like and contents of the pack 0 . 2 ml of solution in a clear , colourless type i neutral glass syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a blue polypropylene plunger rod . supplied in packs of 2 or 10 pre - filled syringes . not all pack sizes may be marketed .
senstend is a combination of two medicines : lidocaine and prilocaine . these belong to a group of medicines called local anaesthetics . senstend is indicated for the treatment of lifelong premature ejaculation in adult men . it works by decreasing the sensitivity of the head of the penis to increase time before ejaculation .
do not use senstend - if you or your sexual partner are allergic to lidocaine or prilocaine or any of the other ingredients of this medicine ( listed in section 6 ); - if you or your sexual partner have a history of allergy or sensitivity to other local anaesthetics with a similar structure ( known as amide - type local anaesthetics ). warnings and precautions talk to your doctor or pharmacist before using senstend - if you, or your sexual partner, have been diagnosed with a genetic disease or other condition affecting your red blood cells ( glucose - 6 - phosphate deficiency, anaemia or methaemoglobinaemia ); - if you have a history of medicine sensitivities, especially if you are not certain which medicine causes sensitivity ; - if you suffer from severe liver problems. when you use this medicine, particularly during priming of the container, aim the container away from the face to avoid accidental contact with ears, eyes, nose and mouth. if some medicine accidentally gets into your eyes or your partner's eyes, rinse them immediately with cold water or saline solution and cover them gently until any effects, such as numbness, wear off. be aware that normal protective mechanisms, such as blinking, or sensation of a foreign body in the eye, may not occur until the numbness has worn off. senstend may also come into contact with other mucous membranes such as your, or your partner's, mouth, nose and throat, causing them to feel slightly numb for a short while. as this will reduce the ability to feel pain in these areas, extra care should be taken not to injure them until the numbness has worn off. during sexual intercourse, a small amount of this medicine may be transferred e. g. to the vagina or the anus. therefore, both partners may feel slight numbness for a short while and should take care not to injure themselves, particularly during sexual activity. senstend should not come into contact with
always use this medicine exactly as your doctor has told you . check with your doctor or pharmacist if you are not sure . the recommended dose of senstend is 3 sprays ( 3 sprays = 1 dose ) on the head of the penis before sexual intercourse . a maximum of 3 doses can be used within 24 hours with at least 4 hours between doses . instructions for use before initial use , briefly shake the spray container and then prime the pump mechanism by spraying the valve three times into the air . aim the container away from faces to avoid contact with eyes , nose , mouth and ears . before each subsequent dose , briefly shake the spray container and then re - prime the pump by spraying 1 time into the air . retract any foreskin from the head of the penis . holding the can upright ( valve up ), apply 1 dose ( 3 sprays ) of senstend to the entire head of the penis , by covering one third with each spray . wait 5 minutes then wipe off any excess spray prior to having sexual intercourse . if you use more senstend than you should as this medicine is applied to the surface of the head of the penis the risk of overdose is low . if you do apply too much , wipe it off . symptoms of using too much senstend are listed below . contact your doctor or pharmacist if you experience any of these . they are very unlikely to happen if it is used as instructed : feeling light - headed or dizzy tingling of the skin around the mouth and numbness of the tongue abnormal taste blurred vision ringing in the ears there is also a risk of a disorder reducing the amount of oxygen in the blood ( methaemoglobinaemia ). this is more likely when certain medicines have been taken at the same time . if this happens , the skin becomes bluish - grey due to a lack of oxygen . in serious cases of overdose , symptoms may include fits , low blood pressure , slowed breathing , stopped breathing and altered heart beat . these effects may be life - threatening . if you have any further questions on the use of this medicine , ask your doctor or pharmacist .
like all medicines , this medicine can cause side effects , although not everybody gets them . the following side effects have been reported with senstend in male patients : common ( may affect up to 1 in 10 people ) inability to develop or maintain an erection reduced feeling in and around the penis feeling of burning in and around the penis uncommon ( may affect up to 1 in 100 people ) headache local irritation of the throat ( if inhaled ) irritation of the skin redness on and around the penis failure to ejaculate during sexual intercourse abnormal orgasm tingling in and around the penis pain or discomfort in and around the penis itching in and around the penis a high temperature the following side effects have been reported with senstend in female partners : common : ( may affect up to 1 in 10 people ) feeling of burning in and around the vagina reduced feeling in and around the vagina uncommon ( may affect up to 1 in 100 people ) headache local irritation of the throat ( if inhaled ) vaginal thrush ( candida ) infection discomfort in the anus and rectum loss of feeling in the mouth difficulty or pain passing urine pain in the vagina discomfort or itching in the vulva and vagina reporting of side effects if you or your sexual partner get any side effects , talk to your doctor or pharmacist . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the spray container label and the carton after " exp ". the expiry date refers to the last day of that month . store below 25 . do not freeze . you must throw away the container 12 weeks after you first use it . the metal container is pressurised . do not puncture , break or burn it even when apparently empty . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help to protect the environment .
what senstend contains - the active substances are lidocaine and prilocaine . - each ml of solution contains 150 mg lidocaine and 50 mg prilocaine - each spray delivers 50 microlitres which contains 7 . 5 mg lidocaine and 2 . 5 mg prilocaine . - each spray container of 6 . 5 ml delivers a minimum of 20 doses . - each spray container of 5 ml delivers a minimum of 12 doses . - the other ingredient is norflurane what senstend looks like and contents of the pack senstend is a colourless to light yellow cutaneous spray , solution in an aluminium spray container with metering valve . each pack contains 1 spray container with 6 . 5 ml or 5 ml of solution .
opdivo is a medicine used to treat : advanced melanoma ( a type of skin cancer ) in adults melanoma after complete resection in adults ( treatment after surgery is called adjuvant therapy ) advanced non - small cell lung cancer ( a type of lung cancer ) in adults advanced renal cell carcinoma ( advanced kidney cancer ) in adults classical hodgkin lymphoma that has come back after or has not responded to previous therapies , including an autologous stem - cell transplant ( a transplant of your own blood - producing cells ) in adults advanced cancer of the head and neck in adults advanced urothelial carcinoma ( bladder and urinary tract cancer ) in adults . it contains the active substance nivolumab , which is a monoclonal antibody , a type of protein designed to recognise and attach to a specific target substance in the body . nivolumab attaches to a target protein called programmed death - 1 receptor ( pd - 1 ) that can switch off the activity of t cells ( a type of white blood cell that forms part of the immune system , the body ' s natural defences ). by attaching to pd - 1 , nivolumab blocks its action and prevents it from switching off your t cells . this helps increase their activity against the melanoma , lung , kidney , lymphoid , head and neck or bladder cancer cells . opdivo may be given in combination with other anti - cancer medicines . it is important that you also read the package leaflet for these other medicines . if you have any questions about these medicines , please ask your doctor .
you should not be given opdivo if you are allergic to nivolumab or any of the other ingredients of this medicine ( listed in section 6 " contents of the pack and other information "). talk to your doctor if you are not sure. warnings and precautions talk to your doctor before using opdivo as it may cause : problems with your heart such as a change in the rhythm or rate of the heartbeat or an abnormal heart rhythm. problems with your lungs such as breathing difficulties or cough. these may be signs of inflammation of the lungs ( pneumonitis or interstitial lung disease ). diarrhoea ( watery, loose or soft stools ) or any symptoms of inflammation of the intestines ( colitis ), such as stomach pain and mucus or blood in stool. inflammation of the liver ( hepatitis ). signs and symptoms of hepatitis may include abnormal liver function tests, eye or skin yellowing ( jaundice ), pain on the right side of your stomach area, or tiredness. inflammation or problems with your kidneys. signs and symptoms may include abnormal kidney function tests, or decreased volume of urine. problems with your hormone producing glands ( including the pituitary, the thyroid, the parathyroid and adrenal glands ) that may affect how these glands work. signs and symptoms that these glands are not working properly may include fatigue ( extreme tiredness ), weight change or headache, decreased blood levels of calcium and visual disturbances. diabetes ( symptoms include excessive thirst, the passing of a greatly increased amount of urine, increase in appetite with a loss of weight, feeling tired, drowsy, weak, depressed, irritable and generally unwell ) or diabetic ketoacidosis ( acid in the blood produced from diabetes ). inflammation of the skin that can lead to severe skin reaction ( known as toxic epidermal necrolysis and stevens - johnson syndrome ). signs and symptoms of severe skin reaction may include rash, itching, and peeling of the skin ( possibly fatal ). inflammation of the muscles such as myocarditis ( inflammation of the heart muscle ), myo
how much opdivo is given when opdivo is given on its own, the recommended dose is either 240 mg given every 2 weeks or 480 mg given every 4 weeks depending on indication. when opdivo is given in combination with ipilimumab for the treatment of skin cancer, the recommended dose of opdivo is 1 mg of nivolumab per kilogram of your body weight for the first 4 doses ( combination phase ). thereafter the recommended dose of opdivo is 240 mg given every 2 weeks or 480 mg given every 4 weeks ( single - agent phase ). when opdivo is given in combination with ipilimumab for the treatment of advanced kidney cancer, the recommended dose of opdivo is 3 mg of nivolumab per kilogram of your body weight for the 93 first 4 doses ( combination phase ). thereafter, the recommended dose of opdivo is 240 mg given every 2 weeks or 480 mg given every 4 weeks ( single - agent phase ). when opdivo is given in combination with ipilimumab and chemotherapy for the treatment of advanced non - small cell lung cancer, the recommended dose of opdivo is 360 mg every 3 weeks. after completion of 2 cycles of chemotherapy, opdivo is given in combination with ipilimumab, the recommended dose of opdivo is 360 mg every 3 weeks. depending on your dose, the appropriate amount of opdivo will be diluted with sodium chloride 9 mg / ml ( 0. 9 %) solution for injection or glucose 50 mg / ml ( 5 %) solution for injection before use. more than one vial of opdivo may be necessary to obtain the required dose. how opdivo is given you will receive treatment with opdivo in a hospital or clinic, under the supervision of an experienced doctor. opdivo will be given to you as an infusion ( a drip ) into a vein ( intravenously ) over a period of 30 or 60 minutes, every 2 weeks or 4 weeks,
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the carton and the vial label after exp . the expiry date refers to the last day of that month . store in a refrigerator ( 2 to 8 ). do not freeze . store in the original package in order to protect from light . the unopened vial can be stored at controlled room temperature up to 25 with room light for up to 48 hours . do not store any unused portion of the infusion solution for reuse . any unused medicine or waste material should be disposed of in accordance with local requirements .
what opdivo contains the active substance is nivolumab . each ml of concentrate for solution for infusion contains 10 mg of nivolumab . each vial contains either 40 mg ( in 4 ml ), 100 mg ( in 10 ml ) or 240 mg ( in 24 ml ) of nivolumab . the other ingredients are sodium citrate dihydrate , sodium chloride ( see section 2 " opdivo contains sodium "), mannitol ( e421 ), pentetic acid , polysorbate 80 ( e433 ), sodium hydroxide , hydrochloric acid and water for injections . what opdivo looks like and contents of the pack opdivo concentrate for solution for infusion ( sterile concentrate ) is a clear to opalescent , colourless to pale yellow liquid that may contain few light particles . it is available in packs containing either 1 vial of 4 ml , 1 vial of 10 ml or 1 vial of 24 ml . not all pack sizes may be marketed .
clopidogrel tad contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products. platelets are very small structures in the blood, which clump together during blood clotting. by preventing this clumping, antiplatelet medicinal products reduce the chances of blood clots forming ( a process called thrombosis ). clopidogrel tad is taken by adults to prevent blood clots ( thrombi ) forming in hardened blood vessels ( arteries ), a process known as atherothrombosis, which can lead to atherothrombotic events ( such as stroke, heart attack, or death ). you have been prescribed clopidogrel tad to help prevent blood clots and reduce the risk of these severe events because : - you have a condition of hardening of arteries ( also known as atherosclerosis ), and - you have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease, or - you have experienced a severe type of chest pain known as'unstable angina'or'myocardial infarction'( heart attack ). for the treatment of this condition your doctor may have placed a stent in the blocked or narrowed artery to restore effective blood flow. you should also be given acetylsalicylic acid ( a substance present in many medicines used to relieve pain and lower fever as well as to prevent blood clotting ) by your doctor. - you have an irregular heartbeat, a condition called'atrial fibrillation ', and you cannot take medicines known as'oral anticoagulants'( vitamin k antagonists ) which prevent new clots from forming and prevent existing clots from growing. you should have been told that'oral anticoagulants'are more effective than acetylsalicylic acid or the combined use of clopidogrel tad and acetylsalicylic acid for this condition. your doctor should have prescribed clopidogrel t
do not take clopidogrel tad confidential 30 - if you are allergic to clopidogrel or any of the other ingredients of this medicine ( listed in section 6 ). - if you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain. - if you suffer from severe liver disease. if you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking clopidogrel tad. warnings and precautions if any of the situations mentioned below apply to you, you should tell your doctor before taking clopidogrel tad : - if you have a risk of bleeding such as - a medical condition that puts you at risk of internal bleeding ( such as a stomach ulcer ) - a blood disorder that makes you prone to internal bleeding ( bleeding inside any tissues, organs or joints of your body ). - a recent serious injury - a recent surgery ( including dental ) - a planned surgery ( including dental ) in the next seven days - if you have had a clot in an artery of your brain ( ischaemic stroke ) which occurred within the last seven days - if you have kidney or liver disease - if you have had an allergy or reaction to any medicine used to treat your disease. while you are taking clopidogrel tad : - you should tell your doctor if a surgery ( including dental ) is planned. - you should also tell your doctor immediately if you develop a medical condition ( also known as thrombotic thrombocytopenic purpura or ttp ) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes ( jaundice ) ( see section 4'possible side effects '). - if you cut or injure yourself, it may take longer than usual for bleeding to stop. this is linked to the way your medicine works as it prevents the ability of blood clot
always take this medicine exactly as your doctor or pharmacist has told you . check with your doctor or pharmacist if you are not sure . the recommended dose , including for patients with a condition called ' atrial fibrillation ' ( an irregular heartbeat ), is one 75 mg tablet of clopidogrel tad per day to be taken orally with or without food , and at the same time each day . if you have experienced severe chest pain ( unstable angina or heart attack ), your doctor may give you 300 mg of clopidogrel tad ( 4 tablets of 75 mg ) once at the start of treatment . then , the recommended dose is one 75 mg tablet of clopidogrel tad per day as described above . you should take clopidogrel tad for as long as your doctor continues to prescribe it . if you take more clopidogrel tad than you should contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding . if you forget to take clopidogrel tad if you forget to take a dose of clopidogrel tad , but remember within 12 hours of your usual time , take your tablet straightaway and then take your next tablet at the usual time . if you forget for more than 12 hours , simply take the next single dose at the usual time . do not take a double dose to make up for a forgotten tablet . confidential 32 if you stop taking clopidogrel tad do not stop the treatment unless your doctor tells you so . contact your doctor or pharmacist before stopping . if you have any further questions on the use of this medicine , ask your doctor or pharmacist .
like all medicines, this medicine can cause side effects, although not everybody gets them. contact your doctor immediately if you experience : - fever, signs of infection or extreme tiredness. these may be due to rare decrease of some blood cells. - signs of liver problems such as yellowing of the skin and / or the eyes ( jaundice ), whether or not associated with bleeding which appears under the skin as red pinpoint dots and / or confusion ( see section 2'warnings and precautions '). - swelling in the mouth or skin disorders such as rashes and itching, blisters of the skin. these may be the signs of an allergic reaction. the most common side effect is bleeding. bleeding may occur as bleeding in the stomach or bowels, bruising, haematoma ( unusual bleeding or bruising under the skin ), nose bleed, blood in the urine. in a small number of cases, bleeding in the eye, inside the head, the lung or the joints has also been reported. if you experience prolonged bleeding when taking clopidogrel tad if you cut or injure yourself, it may take longer than usual for bleeding to stop. this is linked to the way your medicine works as it prevents the ability of blood clots to form. for minor cuts and injuries e. g., cutting yourself, shaving, this is usually of no concern. however, if you are concerned by your bleeding, you should contact your doctor straightaway ( see section 2'warnings and precautions '). other side effects include : common side effects ( may affect up to 1 in 10 people ): diarrhoea, abdominal pain, indigestion or heartburn. uncommon side effects ( may affect up to 1 in 100 people ): headache, stomach ulcer, vomiting, nausea, constipation, excessive gas in stomach or intestines, rashes, itching, dizziness, sensation of tingling and numbness. rare side effects ( may affect up to 1 in 1000 people ): vertigo, enlarged breasts in males. very rare
what clopidogrel tad contains - the active substance is clopidogrel . each film - coated tablet contains 75 mg of clopidogrel ( as hydrochloride ). - the other ingredients are microcrystalline cellulose , colloidal anhydrous silica , crospovidone ( type a ), macrogol 6000 and hydrogenated castor oil in the tablet core and polyvinyl alcohol , titanium dioxide ( e171 ), red iron oxide ( e172 ), yellow iron oxide ( e172 ), talc and macrogol 3000 in the film - coating . what clopidogrel tad looks like and contents of the pack the film - coated tablets are pink , round and slightly convex . boxes of 7 , 14 , 28 , 30 , 50 , 56 , 84 , 90 and 100 film - coated tablets in blisters are available . not all pack sizes may be marketed .
tacforius contains the active substance tacrolimus . it is an immunosuppressant . following your organ transplant ( liver , kidney ), your body ' s immune system will try to reject the new organ . tacforius is used to control your body ' s immune response , enabling your body to accept the transplanted organ . you may also be given tacforius for an ongoing rejection of your transplanted liver , kidney , heart or other organ when any previous treatment you were taking was unable to control this immune response after your transplantation . tacforius is used in adults .
do not take tacforius - if you are allergic to tacrolimus or any of the other ingredients of this medicine ( listed in section 6 ). - if you are allergic to sirolimus or to any macrolide - antibiotic ( e. g. erythromycin, clarithromycin, josamycin ). warnings and precautions tacrolimus immediate release capsules ( e. g, tacni ) and tacforius prolonged - release capsules both contain the active substance, tacrolimus. however, tacforius prolonged - release capsules are taken once daily, whereas the immediate release capsules are taken twice daily. this is because tacforius capsules allow for a prolonged - release ( more slow release over a longer period ) of tacrolimus. tacforius prolonged - release capsules and tacrolimus immediate release capsules are not interchangeable. tell your doctor if any of the following apply to you : - if you are taking any medicines mentioned below under " other medicines and tacforius ". - if you have or have had liver problems - if you have diarrhoea for more than one day - if you feel strong abdominal pain accompanied or not with other symptoms, such as chills, fever, nausea or vomiting - if you have an alteration of the electrical activity of your heart called " qt prolongation ". tell your doctor immediately if during treatment you suffer from : - problems with your vision such as blurred vision, changes in colour vision, difficulty in seeing detail or if your field of vision becomes restricted. your doctor may need to adjust your dose of tacforius. you should keep in regular contact with your doctor. from time to time, your doctor may need to do blood, urine, heart, eye tests, to set the right dose of tacforius. you should limit your exposure to the sun and uv ( ultraviolet ) light whilst taking tacforius. this is because immunosuppressants could increase the risk of skin cancer. wear appropriate protective clothing and use a sunscreen with a high
always take this medicine exactly as your doctor has told you. you should check with your doctor or pharmacist if you are not sure. this medicine should only be prescribed to you by a doctor with experience in the treatment of transplant patients. make sure that you receive the same tacrolimus medicine every time you collect your prescription, unless your transplant specialist has agreed to change to a different tacrolimus medicine. this medicine should be taken once a day. if the appearance of this medicine is not the same as usual, or if dosage instructions have changed, speak to your doctor or pharmacist as soon as possible to make sure that you have the right medicine. the starting dose to prevent the rejection of your transplanted organ will be determined by your doctor calculated according to your body weight. initial daily doses just after transplantation will generally be in the range of 0. 10 - 0. 30 mg per kg body weight per day 35 depending on the transplanted organ. when treating rejection, these same doses may be used. your dose depends on your general condition and on which other immunosuppressive medication you are taking. following the initiation of your treatment with tacforius, frequent blood tests will be taken by your doctor to define the correct dose. afterwards regular blood tests by your doctor will be required to define the correct dose and to adjust the dose from time to time. your doctor will usually reduce your tacforius dose once your condition has stabilised. your doctor will tell you exactly how many capsules to take. you will need to take tacforius every day as long as you need immunosuppression to prevent rejection of your transplanted organ. you should keep in regular contact with your doctor. tacforius is taken orally once daily in the morning. take tacforius on an empty stomach or 2 to 3 hours after a meal. wait at least 1 hour until the next meal. take the capsules immediately following removal from the blister. the capsules should be swallowed whole with a glass of water. do not swallow the desiccant contained in the foil pouch. if you take more tacforius than you should if you have accidentally taken too many capsules, contact your doctor or nearest hospital emergency department immediately. if you
like all medicines, this medicine can cause side effects, although not everybody gets them. tacforius reduces your body's defence mechanism ( immune system ), which will not be as good at fighting infections. therefore, you may be more prone to infections while you are taking tacforius. severe effects may occur, including allergic and anaphylactic reactions. benign and malignant tumours have been reported following tacforius treatment. cases of pure red cell aplasia ( a very severe reduction in red blood cell counts ), agranulocytosis ( a severely lowered number of white blood cells ), haemolytic anaemia ( decreased number of red blood cells due to abnormal breakdown ) and febrile neutropenia ( a decrease in the type of white blood cells which fight infection, accompanied by fever ) have been reported. it is not known exactly how often these side effects occur. very common side effects ( may affect more than 1 in 10 people ) - increased blood sugar, diabetes mellitus, increased potassium in the blood - difficulty in sleeping - trembling, headache - increased blood pressure - liver function tests abnormal 36 - diarrhoea, nausea - kidney problems common side effects ( may affect up to 1 in 10 people ) - reduction in blood cell counts ( platelets, red or white blood cells ), increase in white blood cell counts, changes in red blood cell counts ( seen in blood tests ) - reduced magnesium, phosphate, potassium, calcium or sodium in the blood, fluid overload, increased uric acid or lipids in the blood, decreased appetite, increased acidity of the blood, other changes in the blood salts ( seen in blood tests ) - anxiety symptoms, confusion and disorientation, depression, mood changes, nightmare, hallucination, mental disorders - fits, disturbances in consciousness, tingling and numbness ( sometimes painful ) in the hands and feet, dizziness, impaired writing ability, nervous system disorders - blurred vision, increased sensitivity to light, eye disorders - ringing sound in your ears
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the carton and blister after " exp ". the expiry date refers to the last day of that month . store in the original package in order to protect from light and moisture . this medicinal product does not require any special temperature storage conditions . use all the prolonged - release hard capsules within 1 year of opening the aluminium wrapping . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what tacforius contains - the active substance is tacrolimus. each capsule of tacforius 0. 5 mg contains 0. 5 mg of tacrolimus ( as monohydrate ). each capsule of tacforius 1 mg contains 1 mg of tacrolimus ( as monohydrate ). each capsule of tacforius 3 mg contains 3 mg of tacrolimus ( as monohydrate ). each capsule of tacforius 5 mg contains 5 mg of tacrolimus ( as monohydrate ). - the other ingredients are : capsule content hypromellose 2910, ethylcellulose, lactose, magnesium stearate. capsule shell tacforius 0. 5 mg / 1 mg / 3 mg prolonged - release hard capsules : red iron oxide ( e172 ), yellow iron oxide ( e172 ), titanium dioxide ( e171 ), gelatin. tacforius 5 mg prolonged - release hard capsules : red iron oxide ( e172 ), yellow iron oxide ( e172 ), titanium dioxide ( e171 ), black iron oxide ( e172 ), ponceau 4r ( e124 ), gelatin. printing ink shellac, propylene glycol, black iron oxide ( e172 ), potassium hydroxide. what tacforius looks like and contents of the pack tacforius 0. 5 mg prolonged - release hard capsules hard gelatin capsules imprinted with " tr " on the light yellow capsule cap and " 0. 5 mg " on the light orange capsule body. tacforius 1 mg prolonged - release hard capsules hard gelatin capsules imprinted with " tr " on the white capsule cap and " 1 mg " on the light orange capsule body. tacforius 3 mg prolonged - release hard capsules hard gelatin capsules imprinted with " tr " on the light orange capsule cap and " 3 mg " on the light orange capsule body. tacforius 5 mg prolonged - release hard capsules hard gelatin capsules imprinted with " tr " on the greyish red capsule cap and " 5 mg " on the light orange capsule body
clopidogrel zentiva contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products. platelets are very small structures in the blood which clump together during blood clotting. by preventing this clumping, antiplatelet medicinal products reduce the chances of blood clots forming ( a process called thrombosis ). clopidogrel zentiva is taken by adults to prevent blood clots ( thrombi ) forming in hardened blood vessels ( arteries ), a process known as atherothrombosis, which can lead to atherothrombotic events ( such as stroke, heart attack, or death ). you have been prescribed clopidogrel zentiva to help prevent blood clots and reduce the risk of these severe events because : - you have a condition of hardening of arteries ( also known as atherosclerosis ), and - you have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease, or - you have experienced a severe type of chest pain known as'unstable angina'or'myocardial infarction'( heart attack ). for the treatment of this condition your doctor may have placed a stent in the blocked or narrowed artery to restore effective blood flow. you should also be given acetylsalicylic acid ( a substance present in many medicines used to relieve pain and lower fever as well as to prevent blood clotting ) by your doctor. - you have an irregular heartbeat, a condition called'atrial fibrillation ', and you cannot take medicines known as'oral anticoagulants'( vitamin k antagonists ) which prevent new clots from forming and prevent existing clots from growing. you should have been told that'oral anticoagulants'are more effective than acetylsalicylic acid or the combined use of clopidogrel zentiva and acetylsalicylic acid for this condition. your doctor should have prescribed clopidogrel zentiva
do not take clopidogrel zentiva : - if you are allergic ( hypersensitive ) to clopidogrel or any of the other ingredients of this medicine ( listed in section 6 ). - if you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain. - if you suffer from severe liver disease. if you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking clopidogrel zentiva. warnings and precautions if any of the situations mentioned below apply to you, you should tell your doctor before taking clopidogrel zentiva : if you have a risk of bleeding such as - a medical condition that puts you at risk of internal bleeding ( such as a stomach ulcer ). - a blood disorder that makes you prone to internal bleeding ( bleeding inside any tissues, organs or joints of your body ). - a recent serious injury. - a recent surgery ( including dental ). - a planned surgery ( including dental ) in the next seven days. if you have had a clot in an artery of your brain ( ischaemic stroke ) which occurred within the last seven days. if you have kidney or liver disease. if you have had an allergy or reaction to any medicine used to treat your disease. while you are taking clopidogrel zentiva : you should tell your doctor if a surgery ( including dental ) is planned. you should also tell your doctor immediately if you develop a medical condition ( also known as thrombotic thrombocytopenic purpura or ttp ) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes ( jaundice ) ( see section 4'possible side effects '). if you cut or injure yourself, it may take longer than usual for bleeding to stop. this is linked to the way your medicine works as it prevents the ability of blood clots
always take this medicine exactly as your doctor or pharmacist has told you . check with your doctor or pharmacist if you are not sure . the recommended dose , including for patients with a condition called ' atrial fibrillation ' ( an irregular heartbeat ), is one 75 mg tablet of clopidogrel zentiva per day to be taken orally with or without food , and at the same time each day . if you have experienced severe chest pain ( unstable angina or heart attack ), your doctor may give you 300 mg of clopidogrel zentiva ( 1 tablet of 300 mg or 4 tablets of 75 mg ) once at the start of treatment . then , the recommended dose is one 75 - mg tablet of clopidogrel zentiva per day as described above . you should take clopidogrel zentiva for as long as your doctor continues to prescribe it . if you take more clopidogrel zentiva than you should contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding . if you forget to take clopidogrel zentiva if you forget to take a dose of clopidogrel zentiva , but remember within 12 hours of your usual time , take your tablet straightaway and then take your next tablet at the usual time . if you forget for more than 12 hours , simply take the next single dose at the usual time . do not take a double dose to make up for a forgotten tablet . for the 7 , 14 , 28 and 84 tablets pack sizes , you can check the day on which you last took a tablet of clopidogrel zentiva by referring to the calendar printed on the blister . if you stop taking clopidogrel zentiva do not stop the treatment unless your doctor tells you so . contact your doctor or pharmacist before stopping . if you have any further questions on the use of this medicine , ask your doctor or pharmacist .
like all medicines, this medicine can cause side effects, although not everybody gets them. contact your doctor immediately if you experience : - fever, signs of infection or extreme tiredness. these may be due to rare decrease of some blood cells. - signs of liver problems such as yellowing of the skin and / or the eyes ( jaundice ), whether or not associated with bleeding which appears under the skin as red pinpoint dots and / or confusion ( see section 2'warnings and precautions '). - swelling in the mouth or skin disorders such as rashes and itching, blisters of the skin. these may be the signs of an allergic reaction. the most common side effect reported with clopidogrel zentiva is bleeding. bleeding may occur as bleeding in the stomach or bowels, bruising, haematoma ( unusual bleeding or bruising under the skin ), nose bleed, blood in the urine. in a small number of cases, bleeding in the eye, inside the head, the lung or the joints has also been reported. if you experience prolonged bleeding when taking clopidogrel zentiva if you cut or injure yourself, it may take longer than usual for bleeding to stop. this is linked to the way your medicine works as it prevents the ability of blood clots to form. for minor cuts and injuries e. g., cutting yourself, shaving, this is usually of no concern. however, if you are concerned by your bleeding, you should contact your doctor straightaway ( see section 2'warnings and precautions '). other side effects include : common side effects ( may affect up to 1 in 10 people ): diarrhoea, abdominal pain, indigestion or heartburn. uncommon side effects ( may affect up to 1 in 100 people ): headache, stomach ulcer, vomiting, nausea, constipation, excessive gas in stomach or intestines, rashes, itching, dizziness, sensation of tingling and numbness. rare side effect ( may affect up to 1 in 1000 people ): vertigo
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the carton and on the blister , after exp . the expiry date refers to the last day of that month . refer to the storage conditions on the carton . if clopidogrel zentiva is supplied in pvc / pvdc / aluminium blisters , store below 30 . if clopidogrel zentiva is supplied in all aluminium blisters , it does not require any special storage conditions . do not use this medicine if you notice any visible sign of deterioration . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help to protect the environment .
what clopidogrel zentiva contains the active substance is clopidogrel . each tablet contains 75 mg of clopidogrel ( as hydrogen sulphate ). the other ingredients are ( see section 2 ' clopidogrel zentiva contains lactose ' and ' clopidogrel zentiva contains hydrogenated castor oil '): - tablet core : mannitol ( e421 ), hydrogenated castor oil , microcrystalline cellulose , macrogol 6000 and low - substituted hydroxypropylcellulose , - tablet coating : lactose monohydrate ( milk sugar ), hypromellose ( e464 ), triacetin ( e1518 ), red iron oxide ( e172 ) and titanium dioxide ( e171 ), - polishing agent : carnauba wax . what clopidogrel zentiva looks like and contents of the pack clopidogrel zentiva 75 - mg film - coated tablets ( tablets ) are round , biconvex , pink , engraved on one side with the number ' 75 ' and on the other side with the number ' 1171 '. clopidogrel zentiva is supplied in cardboard cartons containing : - 7 , 14 , 28 , 30 , 50 , 84 , 90 and 100 tablets in pvc / pvdc / aluminium blisters or in all aluminium blisters 41 - 50x1 tablets in pvc / pvdc / aluminium blisters or in all aluminium perforated unit - dose blisters . not all pack sizes may be marketed .
yttriga is a radioactive medicine used in combination with another medicine which targets specific body cells . when the target is reached , yttriga gives tiny radiation doses to these specific sites . for further information regarding the treatment and possible effects caused by the radiolabelled medicinal product , please refer to the package leaflet of the medicinal product used as combination partner .
do not use yttriga : - if you are allergic ( hypersensitive ) to yttrium ( 90y ) chloride or any of the other ingredients of yttriga . - if you are pregnant or if there is a possibility that you may be pregnant ( see below ). take special care with yttriga - yttriga is a radioactive medicine and is only used in combination with another medicinal product . it is not intended for direct use in patients . - because there are strict laws covering the use , handling and disposal of radiopharmaceuticals , yttriga will always be used in a hospital or a similar setting . it will only be handled and administered by people who are trained and qualified in the safe handling of radioactive material . particular care should be taken when administering radioactive medicinal products to children and adolescents ( from 2 to 16 years old ). taking other medicines please tell your doctor or pharmacist , if you are taking or have recently taken any other medicines , including medicines obtained without a prescription . no interactions of yttrium ( 90y ) chloride with other medicines are known as no clinical studies are available . pregnancy yttriga is contraindicated in pregnancy . please tell your doctor if there is any possibility that you are pregnant . if you have missed a period , you should assume to be pregnant until a pregnancy test conducted is negative . your doctor will consider alternative techniques which do not involve ionising radiation . women of childbearing potential should use effective contraception during and after treatment . breast - feeding your doctor will ask you to stop breast - feeding . ask your doctor or pharmacist for advice before taking any medicine .
your doctor will not administer yttriga directly . dose your physician will decide on the amount of yttriga , which you will receive for the treatment . method of administration yttriga is intended for radiolabelling of medicinal products to treat specific diseases , which are subsequently administered by approved route . if yttriga is administered inadvertently yttriga is administered after being combined with another medicine by your doctor under strictly controlled conditions . the risk to receive a possible overdose is small . however , should this occur , you will receive appropriate treatment from your doctor .
like all medicines , yttriga can cause side effects , although not everybody gets them . for more information , refer to the package leaflet of the particular medicinal product to be radiolabelled . if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist . reporting of side effects if you get any side effects , talk to your doctor or pharmacist . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
keep out of the reach and sight of children . do not use yttriga after the expiry date and time which is stated on the label after exp . store in accordance with local regulations for radioactive substances . any unused product or waste material should be disposed of in accordance with local requirements .
what yttriga contains - the active substance is yttrium ( 90y ) chloride . - 1 ml sterile solution contains 0 . 1 - 300 gbq yttrium ( 90y ) on the reference date and time ( corresponding to 0 . 005 - 15 micrograms of yttrium [ 90y ]) ( as yttrium [ 90y ] chloride ). - the other ingredient is hydrochloric acid ( 0 . 04 m ). what yttriga looks like and contents of the pack colourless type i glass vial of 3 ml with a v - shapped bottom or a colourless type i glass vial of 10 ml with a flat bottom with a silicon stopper , closed with an aluminium seal . radiopharmaceutical precursor , solution . colourless clear sterile solution .
ciambra is a medicine used in the treatment of cancer . ciambra is given in combination with cisplatin , another anti - cancer medicine , as treatment for malignant pleural mesothelioma , a form of cancer that affects the lining of the lung , to patients who have not received prior chemotherapy . ciambra is also given in combination with cisplatin for the initial treatment of patients with advanced stage of lung cancer . ciambra can be prescribed to you if you have lung cancer at an advanced stage if your disease has responded to treatment or it remains largely unchanged after initial chemotherapy . ciambra is also a treatment for patients with advanced stage of lung cancer whose disease has progressed after other initial chemotherapy has been used .
do not use ciambra - if you are allergic ( hypersensitive ) to pemetrexed or any of the other ingredients of ciambra ( listed in section 6 ). - if you are breast - feeding ; you must discontinue breast - feeding during treatment with ciambra. - if you have recently received or are about to receive a vaccine against yellow fever. warnings and precautions talk to your doctor or pharmacist before receiving ciambra. if you currently have or have previously had problems with your kidneys, talk to your doctor or hospital pharmacist as you may not be able to receive ciambra. before each infusion you will have samples of your blood taken to evaluate if you have sufficient kidney and liver function and to check that you have enough blood cells to receive ciambra. your doctor may decide to change the dose or delay treating you depending on your general condition and if your blood cell counts are too low. if you are also receiving cisplatin, your doctor will make sure that you are properly hydrated and receive appropriate treatment before and after receiving cisplatin to prevent vomiting. if you have had or are going to have radiation therapy, please tell your doctor, as there may be an early or late radiation reaction with ciambra. if you have been recently vaccinated, please tell your doctor, as this can possibly cause bad effects with ciambra. if you have heart disease or a history of heart disease, please tell your doctor. if you have an accumulation of fluid around your lungs, your doctor may decide to remove the fluid before giving you ciambra. children and adolescents ciambra is not to be given to children and adolescents because no studies were performed in these groups. other medicines and ciambra please tell your doctor if you are taking any medicine for pain or inflammation ( swelling ), such as medicines called " nonsteroidal anti - inflammatory drugs " ( nsaids ), including medicines purchased without a doctor's prescription ( such as ibuprofen ). there are many sorts of nsaids with different durations of activity. based on the planned date of your infusion of ciambr
the dose of ciambra is 500 mg for every square metre of your body's surface area. your height and weight are measured to work out the surface area of your body. your doctor will use this body surface area to work out the right dose for you. this dose may be adjusted, or treatment may be delayed depending on your blood cell counts and on your general condition. a hospital pharmacist, nurse or doctor will have mixed the ciambra powder with 9 mg / ml ( 0. 9 %) sodium chloride solution for injection before it is given to you. you will always receive ciambra by infusion into one of your veins. the infusion will last approximately 10 minutes. when using ciambra in combination with cisplatin : the doctor or hospital pharmacist will work out the dose you need based on your height and weight. cisplatin is also given by infusion into one of your veins, and is given approximately 30 minutes after the infusion of ciambra has finished. the infusion of cisplatin will last approximately 2 hours. you should usually receive your infusion once every 3 weeks. additional medicines : corticosteroids : your doctor will prescribe you steroid tablets ( equivalent to 4 mg of dexamethasone twice a day ) that you will need to take on the day before, on the day of, and the day after ciambra treatment. this medicine is given to you to reduce the frequency and severity of skin reactions that you may experience during your anticancer treatment. vitamin supplementation : your doctor will prescribe you oral folic acid ( vitamin ) or a multivitamin containing folic acid ( 350 to 1000 micrograms ) that you must take once a day while you are taking ciambra. you must take at least 5 doses during the seven days before the first dose of ciambra. you must continue taking the folic acid for 21 days after the last dose of ciambra. you will also receive an injection of vitamin b12 ( 1000 micrograms ) in the week before administration of ciambra and then approximately every 9 weeks ( corresponding to 3 courses of ciambra treatment
like all medicines, this medicine can cause side effects, although not everybody gets them. you must contact your doctor immediately if you notice any of the following : 52 fever or infection : if you have a temperature of 38oc or greater, sweating or other signs of infection ( since you might have less white blood cells than normal ). infection ( sepsis ) may be severe and could lead to death. if you start feeling chest pain or having a fast heart rate. if you have pain, redness, swelling or sores in your mouth. allergic reaction : if you develop skin rash / burning or prickling sensation, or fever. rarely, skin reactions may be severe and could lead to death. contact your doctor if you get a severe rash, or itching, or blistering ( stevens - johnson syndrome or toxic epidermal necrolysis ). if you experience tiredness, feeling faint, becoming easily breathless or if you look pale ( since you might have less haemoglobin than normal ). if you experience bleeding from the gums, nose or mouth or any bleeding that would not stop, reddish or pinkish urine, unexpected bruising ( since you might have less platelets than normal ). if you experience sudden breathlessness, intense chest pain or cough with bloody sputum ( may indicate a blood clot in the blood vessels of the lungs ) side effects with ciambra may include : very common ( may affect more than 1 in 10 people ) infection pharyngitis ( a sore throat ) low number of neutrophil granulocytes ( a type of white blood cell ) low white blood cells low haemoglobin level pain, redness, swelling or sores in your mouth loss of appetite vomiting diarrhoea nausea skin rash flaking skin abnormal blood tests showing reduced functionality of kidneys fatigue ( tiredness ) common ( may affect up to 1 in 10 people ) blood infection fever with low number of neutrophil granulocytes ( a type of white blood cell ) low platelet count allergic reaction loss of body fluids taste change
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the carton and vial label after exp . the expiry date refers to the last day of that month . this medicine does not require any special storage conditions . chemical and physical in - use stability of the infusion solution of pemetrexed was demonstrated for 24 hours at 2 - 8 or 15 - 25 . the reconstituted solution should be used immediately to prepare the infusion solution . from a microbiological point of view , the infusion solution should be used immediately . if not used immediately , in - use storage times and conditions prior to use are the responsibility of the user and should not be longer than 24 hours at 2 to 8 or 15 to 25 . this medicine is for single use only ; any unused solution must be disposed of in accordance with local requirement . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what ciambra contains - the active substance is pemetrexed . ciambra 100 mg : one vial of powder contains 100 mg of pemetrexed ( as pemetrexed disodium hemipentahydrate ). ciambra 500 mg : each vial contains 500 mg of pemetrexed ( as pemetrexed disodium hemipentahydrate ). after reconstitution , the solution contains 25 mg / ml of pemetrexed . further dilution by a healthcare provider is required prior to administration . - the other ingredients are mannitol ( e 421 ), hydrochloric acid ( for ph adjustment ) and sodium hydroxide ( for ph adjustment ) ( see section 2 , " ciambra contains sodium "). what ciambra looks like and contents of the pack ciambra is a powder for concentrate for solution for infusion in a vial . it is a white to almost white lyophilised powder . each pack of ciambra consists of one glass vial with rubber stopper and an aluminium seal with flip off cap , and it is covered with a shrink - wrapped plastic sleeve . the vial contains 100 mg or 500 mg of pemetrexed ( as pemetrexed disodium hemipentahydrate ). each pack contains 1 vial .
what immunogam is immunogam belongs to a group of medicines containing immunoglobulins ( antibodies which can protect against certain infections ), which are present in your blood . immunogam contains increased levels of human hepatitis b immunoglobulins mainly immunoglobulin g ( igg ) and is obtained from blood plasma of screened donors from the usa . what immunogam is used for immunogam provides protection against hepatitis b virus for a short period of time and it is used to treat the following : - accidental exposure in non - immunised subjects ( including persons whose vaccination is incomplete or status unknown ). - haemodialysed patients , until vaccination has become effective . - newborn of a hepatitis b virus carrier - mother . - subjects who did not show an immune response ( no measurable hepatitis b antibodies ) after vaccination and for whom a continuous prevention is necessary due to the continuous risk of being infected with hepatitis b .
you should not be given immunogam - if you have previously developed an allergic reaction to human immunoglobulins, to other blood products or to any of the other ingredients of immunogam. - if you have an iga deficiency such that you have developed an allergic reaction to iga containing products 18 take special care with immunogam general warnings related to immunogam : immunoglobulins in general may cause adverse reactions such as chills, headache, fever, vomiting, allergic reactions, nausea, arthralgia ( joint pain ), low blood pressure and moderate low back pain. patients should be monitored for antibodies against human hepatitis b immunoglobulin regularly. human hepatitis b immunoglobulin injections can induce a drop in blood pressure with an allergic reaction, even in patients who have tolerated previous treatments with immunoglobulin. suspicion of allergic or anaphylactic type reactions requires immediate discontinuation of the injection. in case of shock, standard medical treatments for shock should be administered. immunoglobulin a : please tell your doctor if your blood does not have immunoglobulin a ( iga ). immunogam contains small amounts of iga. patients who have an iga deficiency may develop an allergic reaction to this medicine. immunogam contains maltose ( 10 % w / w ). serological testing immunogam may cause a rise of various transferred antibodies which may result in misleading positive results of certain blood serum tests. also transmission of antibodies to blood group antigens may interfere with some blood tests for red cell allo - antibodies ( e. g. coombs'test ). blood glucose testing blood glucose testing : when administering immunogam, the measurement of blood glucose must be done with a glucose - specific method. this is because some types of blood glucose testing systems falsely interpret the maltose contained in immunogam as glucose. this may result in falsely elevated glucose readings and consequently in the inappropriate administration of insulin which may result in hypoglycemia. also cases of true hypoglycemia may go untreated if the hypoglycemic state is masked by falsely elevated glucose readings
the quantity of immunogam you will need will be determined by your doctor or nurse . the table below provides a recommended dose . vaccination against hepatitis b virus is highly recommended . the first vaccine dose can be injected on the same day as human hepatitis b immunoglobulin , however in different sites . indication dose frequency of administration prevention of hepatitis b in case of accidental exposure in non - immunised subjects at least 500 iu depending on the intensity of exposure , as soon as possible after exposure , and preferably within 24 - 72 hours immunoprophylaxis of hepatitis b in haemodialysed patients 8 - 12 iu / kg with a maximum of 500 iu every 2 months until seroconversion following vaccination . prevention of hepatitis b in the newborn , of a hepatitis b virus carrier - mother , at birth or as soon as possible after birth 30 - 100 iu / kg the hepatitis b immunoglobulin administration may need to be repeated until seroconversion following vaccination instructions for use immunogam should be brought to room temperature ( approximately 20 to 25 ) before use . the solution should be clear to slightly opalescent and colourless or pale yellow essentially free of foreign particles . do not use solutions that are cloudy or have deposits . for intramuscular administration , immunogam should be injected into the upper part of the shoulder ( deltoid muscle ), or into the right part of the thigh in the front ( anteriolateral thigh ) in newborn children . if a large volume ( greater than 2 ml for children or greater than 5 ml for adults ) is required , it is recommended that the administration of immunogam be divided doses at different sites . when simultaneous vaccination is necessary , the immunoglobulin and the vaccine should be administered at two different sites . if more immunogam is used than recommended no data is available in the event of an overdose . for intramuscular administration of immunogam , the only manifestations of overdose would be pain and tenderness at the injection site .
like all medicines, immunogam can cause side effects, although not everybody gets them. the frequency of possible side effects listed below is defined using the following convension : - very common ( affects more than 1 user in 10 ) - common ( affects 1 to 10 users in 100 ) - uncommon ( affects 1 to 10 users in 1, 000 ) - rare ( affects 1 to 10 users in 10, 000 ) - very rare ( affects less than 1 user in 10, 000 ) - not known ( frequency cannot be estimated from the available data ) undesirable effects reported during clinical trials with immunogam, that was administered intramuscularly ( injected into a muscle ), were uncommon ( affects 1 to 10 users in 1, 000 ). these undesirable effects were reported within the first 7 days after receiving immunogam : nausea, fatigue, induration ( swelling and firmness ) at the injection site, feeling unwell, pain, fever, joint pain, back pain, muscle pain, headache and dizziness. the following side effect can be serious and has been observed occasionally. allergic reaction : there is a chance that you may experience an allergic reaction after administration of this medicine. please tell your doctor immediately if you experience any of the following symptoms after receiving immunogam : o hives, flushed skin or rash, swelling of a specific area such as the injection site or face o chest tightness, shortness of breath, wheezing o rapid increase in heart beat, sudden drop in blood pressure and / or shock these symptoms may be early signs of an allergic reaction. depending on the nature and severity of the allergic reaction, your doctor may give you an additional treatment or your doctor may decide to stop the injection immediately. in case of intramuscular administration, some discomfort may occur occasionally at the site of injection such as local pain or tenderness. in patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, immunogam should be given only if the expected benefits outweigh the potential risks. if any of the side effects mentioned in this leaflet gets serious, or if you notice any side effects not listed
keep out of the reach and sight of children . do not use immunogam after the expiry date which is stated on the label and carton . the expiry date refers to the last day of that month . store in a refrigerator ( 2 to 8 ). do not freeze . keep the vial in the outer carton in order to protect from light . do not use immunogam if the solution appears cloudy or has deposits . medicines should not be disposed via wastewater or household waste . any unused product should be disposed of in accordance with local requirements . these measures will help to protect the environment .
what immunogam contains - the active substance is human hepatitis b immunoglobulin . immunogam comes in a 1 ml or 5 ml vial containing 30 - 70 mg / ml of human plasma protein of which 96 % ( 312 iu / ml ) is immunoglobulin g ( igg ). - the other ingredients are maltose and polysorbate 80 . what immunogam looks like and contents of the pack immunogam is presented as a solution for injection in a glass vial . it is clear to slightly opalescent and colourless or pale yellow liquid . pack size of 1 vial .
remicade contains the active substance infliximab. infliximab is a monoclonal antibody a type of protein that attaches to a specific target in the body called tnf ( tumour necrosis factor ) alpha. remicade belongs to a group of medicines called'tnf blockers '. it is used in adults for the following inflammatory diseases : rheumatoid arthritis psoriatic arthritis ankylosing spondylitis ( bechterew's disease ) psoriasis. remicade is also used in adults and children 6 years of age or older for : crohn's disease ulcerative colitis. remicade works by selectively attaching to tnf alpha and blocking its action. tnf alpha is involved in inflammatory processes of the body so blocking it can reduce the inflammation in your body. rheumatoid arthritis rheumatoid arthritis is an inflammatory disease of the joints. if you have active rheumatoid arthritis you will first be given other medicines. if these medicines do not work well enough, you will be given remicade which you will take in combination with another medicine called methotrexate to : reduce the signs and symptoms of your disease slow down the damage in your joints improve your physical function. psoriatic arthritis psoriatic arthritis is an inflammatory disease of the joints, usually accompanied by psoriasis. if you have active psoriatic arthritis you will first be given other medicines. if these medicines do not work well enough, you will be given remicade to : reduce the signs and symptoms of your disease slow down the damage in your joints improve your physical function. ankylosing spondylitis ( bechterew's disease ) ankylosing spondylitis is an inflammatory disease of the spine. if you have ankylosing spondylitis you will first be given other medicines. if these medicines do not work well enough
you should not be given remicade if : you are allergic to infliximab or to any of the other ingredients in remicade ( listed in section 6 ). you are allergic ( hypersensitive ) to proteins that come from mice. you have tuberculosis ( tb ) or another serious infection such as pneumonia or sepsis. you have heart failure that is moderate or severe. do not use remicade if any of the above applies to you. if you are not sure, talk to your doctor before you are given remicade. warnings and precautions talk to your doctor before or during treatment with remicade if you have : had treatment with remicade before tell your doctor if you have had treatment with remicade in the past and are now starting remicade treatment again. if you have had a break in your remicade treatment of more than 16 weeks, there is a higher risk for allergic reactions when you start the treatment again. infections tell your doctor before you are given remicade if you have an infection even if it is a very minor one. tell your doctor before you are given remicade if you have ever lived in or travelled to an area where infections called histoplasmosis, coccidioidomycosis, or blastomycosis are common. these infections are caused by specific types of fungi that can affect the lungs or other parts of your body. you may get infections more easily when you are being treated with remicade. if you are 65 or older, you have a greater risk. these infections may be serious and include tuberculosis, infections caused by viruses, fungi, bacteria, or other organisms in the environment and sepsis that may be life - threatening. tell your doctor straight away if you get signs of infection during treatment with remicade. signs include fever, cough, flu - like signs, feeling unwell, red or hot skin, wounds or dental problems. your doctor may recommend temporarily stopping remic
rheumatoid arthritis the usual dose is 3 mg for every kg of body weight . psoriatic arthritis , ankylosing spondylitis ( bechterew ' s disease ), psoriasis , ulcerative colitis and crohn ' s disease the usual dose is 5 mg for every kg of body weight . how remicade is given remicade will be given to you by your doctor or nurse . your doctor or nurse will prepare the medicine for infusion . the medicine will be given as an infusion ( drip ) ( over 2 hours ) into one of your veins , usually in your arm . after the third treatment , your doctor may decide to give your dose of remicade over 1 hour . you will be monitored while you are given remicade and also for 1 to 2 hours afterwards . how much remicade is given the doctor will decide your dose and how often you will be given remicade . this will depend on your disease , weight and how well you respond to remicade . the table below shows how often you will usually have this medicine after your first dose . 2nd dose 2 weeks after your 1st dose 3rd dose 6 weeks after your 1st dose further doses every 6 to 8 weeks depending on your disease use in children and adolescents remicade should only be used in children if they are being treated for crohn ' s disease or ulcerative colitis . these children must be 6 years of age or older . if you are given too much remicade as this medicine is being given by your doctor or nurse , it is unlikely that you will be given too much . there are no known side effects of having too much of remicade . if you forget or miss your remicade infusion if you forget or miss an appointment to receive remicade , make another appointment as soon as possible . if you have any further questions on the use of this medicine , ask your doctor .
like all medicines, this medicine can cause side effects, although not everybody gets them. most side effects are mild to moderate. however some patients may experience serious side effects and may require treatment. side effects may also occur after your treatment with remicade has stopped. tell your doctor straight away if you notice any of the following : signs of an allergic reaction such as swelling of your face, lips, mouth or throat which may cause difficulty in swallowing or breathing, skin rash, hives, swelling of the hands, feet or ankles. some of these reactions may be serious or life - threatening. an allergic reaction could happen within 2 hours of your injection or later. more signs of allergic side effects that may happen up to 12 days after your injection include pain in the muscles, fever, joint or jaw pain, sore throat or headache. signs of a heart problem such as chest discomfort or pain, arm pain, stomach pain, shortness of breath, anxiety, lightheadedness, dizziness, fainting, sweating, nausea ( feeling sick ), vomiting, fluttering or pounding in your chest, a fast or a slow heartbeat, and swelling of your feet. signs of infection ( including tb ) such as fever, feeling tired, cough which may be persistent, shortness of breath, flu - like symptoms, weight loss, night sweats, diarrhoea, wounds, collection of pus in the gut or around the anus ( abscess ), dental problems or burning sensation when urinating. possible signs of cancer including but not limited to swelling of lymph nodes, weight loss, fever, unusual skin nodules, changes in moles or skin colouring, or unusual vaginal bleeding. signs of a lung problem such as coughing, breathing difficulties or tightness in the chest. signs of a nervous system problem ( including eye problems ) such as signs of a stroke ( sudden numbness or weakness of your face, arm or leg, especially on one side of your body ; sudden confusion, trouble speaking or understanding ; trouble seeing in one or both eyes
remicade will generally be stored by the health professionals . the storage details should you need them are as follows : keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the label and the carton after " exp ". the expiry date refers to the last day of that month . store in a refrigerator ( 2 - 8 ). this medicine can also be stored in the original carton outside of refrigerated storage up to a maximum of 25 for a single period of up to six months , but not beyond the original expiry date . in this situation , do not return to refrigerated storage again . write the new expiry date on the carton including day / month / year . discard this medicine if not used by the new expiry date or the expiry date printed on the carton , whichever is earlier . it is recommended that when remicade is prepared for infusion , it is used as soon as possible ( within 3 hours ). however , if the solution is prepared in germ - free conditions , it can be stored in a refrigerator at 2 to 8 up to 28 days and for an additional 24 hours at 25 after removal from the refrigerator . do not use this medicine if it is discoloured or if there are particles present .
what remicade contains the active substance is infliximab . each vial contains 100 mg of infliximab . after preparation each ml contains 10 mg of infliximab the other ingredients are sucrose , polysorbate 80 , monobasic sodium phosphate and dibasic sodium phosphate . what remicade looks like and contents of the pack remicade is supplied as a glass vial containing a powder for concentrate for solution for infusion . the powder is a freeze - dried white pellet . remicade is produced in packs of 1 , 2 , 3 , 4 or 5 vials . not all pack sizes may be marketed .
rasagiline mylan is used for the treatment of parkinson ' s disease . it can be used together with or without levodopa ( another medicine that is used to treat parkinson ' s disease ). with parkinson ' s disease , there is a loss of cells that produce dopamine in the brain . dopamine is a chemical in the brain involved in movement control . rasagiline mylan helps to increase and sustain levels of dopamine in the brain .
do not take rasagiline mylan : - if you are allergic to rasagiline or any of the other ingredients of this medicine ( listed in section 6 ). - if you have severe liver problems. do not take the following medicines while taking rasagaline mylan : - monoamine oxidase ( mao ) inhibitors ( e. g. for treatment of depression or parkinson's disease, or used for any other indication ), including medicinal and natural products without prescription e. g. st. john's wort. - pethidine ( a strong pain killer ). you must wait at least 14 days after stopping rasagiline mylan treatment and starting treatment with mao inhibitors or pethidine. warnings and precautions talk to your doctor before taking rasagiline mylan. - if you have mild to moderate liver problems - if you have any suspicious skin changes. children and adolescents rasagiline mylan is not recommended for use under the age of 18. other medicines and rasagiline mylan tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without prescription or if you are smoking or intend to stop smoking. ask your doctor for advice before taking any of the following medicines together with rasagiline mylan : certain antidepressants ( selective serotonin reuptake inhibitors, selective serotonin - norepinephrine reuptake inhibitors, tricyclic or tetracyclic antidepressants ) the antibiotic ciprofloxacin used against infections the cough suppressant dextromethorphan sympathomimetics such as those present in eye drops, nasal and oral decongestants and cold medicine containing ephedrine or pseudoephedrine the use of rasagiline mylan together with the antidepressants containing fluoxetine or fluvoxamine should be avoided. if you are starting treatment with rasagiline mylan, you should wait at least 5 weeks after stopping fluoxetine treatment. if you are starting treatment with fluoxetine or fluvo
always take this medicine exactly as your doctor has told you . check with your doctor or pharmacist if you are not sure . the recommended dose is 1 tablet of 1 mg taken by mouth once daily . rasagiline mylan may be taken with or without food . if you take more rasagiline mylan than you should if you think that you may have taken too many rasagiline mylan tablets , contact your doctor or pharmacist immediately . take the rasagiline mylan carton with you to show the doctor or pharmacist . if you forget to take rasagiline mylan 23 do not take a double dose to make up for a forgotten dose . take the next dose normally , when it is time to take it . if you stop taking rasagiline mylan do not stop taking rasagiline mylan without first talking to your doctor . if you have any further questions on the use of this medicine , ask your doctor or pharmacist .
like all medicines, this medicine can cause side effects, although not everybody gets them. the following side effects have been reported in placebo controlled clinical trials : the frequency of possible side effects listed below is defined using the following convention : very common ( may affect more than 1 in 10 people ) common ( may affect up to 1 in 10 people ) uncommon ( may affect up to 1 in 100 people ) rare ( may affect up to 1 in 1, 000 people ) very rare ( may affect up to 1 in 10, 000 people ) not known ( frequency cannot be estimated from the available data ) very common abnormal movements ( dyskinesia ) headache common abdominal pain fall allergy fever flu ( influenza ) general feeling of being unwell ( malaise ) neck pain chest pain ( angina pectoris ) low blood pressure when rising to a standing position with symptoms like dizziness / light headedness ( orthostatic hypotension ) decreased appetite constipation dry mouth nausea and vomiting flatulence abnormal results of blood tests ( leucopenia ) joint pain ( arthralgia ) musculoskeletal pain joint inflammation ( arthritis ) numbness and muscle weakness of the hand ( carpal tunnel syndrome ) decreased weight abnormal dreams difficulty in muscular coordination ( balance disorder ) depression dizziness ( vertigo ) prolonged muscle contractions ( dystonia ) runny nose ( rhinitis ) irritation of the skin ( dermatitis ) rash bloodshot eyes ( conjunctivitis ) 24 urinary urgency uncommon stroke ( cerebrovascular accident ) heart attack ( myocardial infarction ) blistering rash ( vesiculobullous rash ) in addition, skin cancer was reported in around 1 % of patients in the placebo controlled clinical trials. nevertheless, scientific evidence suggests that parkinson's disease, and not any medicine in particular, is associated with a higher risk of skin cancer ( not exclusively melanoma ). you should speak with your doctor about any suspicious skin changes. parkinson's disease is associated with symptoms of hallucinations and confusion. in post - marketing experience these symptoms have also been observed in parkinson's disease patients treated with rasagiline
what rasagiline mylan contains - the active substance is rasagiline . each tablet contains rasagiline tartrate corresponding to 1 mg rasagiline . - the other ingredients are microcrystalline cellulose , tartric acid , maize starch , pregelatinized maize starch , talc , stearic acid . what rasagiline mylan looks like and contents of the pack rasagiline tablets are presented as white to off - white , oblong ( approximately 11 . 5 mm x 6 mm ) biconvex tablets , debossed with ' r9se ' on one side and ' 1 ' on the other side . the tablets are available in blister packs of 7 , 10 , 28 , 30 , 100 and 112 tablets and in perforated blister packs containing 7 x 1 , 10 x 1 , 28 x 1 , 30 x 1 , 100 x 1 and 112 x 1 tablets . not all pack sizes may be marketed .
do not give hulio - if your child is allergic to adalimumab or any of the other ingredients of this medicine ( listed in section 6 ). - if your child has a severe infection, including tuberculosis ( see " warnings and precautions "). it is important that you tell your doctor if your child has symptoms of infections, e. g. fever, wounds, feeling tired, dental problems. if your child has moderate or severe heart failure. it is important to tell your doctor if your child has had or have a serious heart condition ( see " warnings and precautions "). warnings and precautions talk to your doctor or pharmacist before using hulio. allergic reaction if your child has allergic reactions with symptoms such as chest tightness, wheezing, dizziness, swelling or a rash do not inject them more hulio and contact their doctor immediately since, in rare cases, these reactions can be life - threatening. infections if your child have an infection, including long - term or localised infection ( for example, leg ulcer ) consult your child's doctor before starting hulio. if you are unsure, contact your child's doctor. your child might get infections more easily while he / she is receiving hulio treatment. this risk may increase if your child lung function is reduced. these infections may be serious and include tuberculosis, infections caused by viruses, fungi, parasites or bacteria, or other unusual infectious organisms and sepsis ( blood poisoning ). in rare cases, these infections may be life - threatening. it is important to tell your child's doctor if your child gets symptoms such as fever, wounds, feeling tired or dental problems. your child's doctor may recommend temporarily stopping hulio. tuberculosis ( tb ) as cases of tuberculosis have been reported in patients treated with adalimumab, your child's doctor will check your child for signs
always use this medicine exactly as your child's doctor or pharmacist has instructed. check with your child's doctor or pharmacist if you are not sure about any of the instructions or if you have any questions. your doctor may prescribe another strength of hulio if your child needs a different dose. children and adolescents with polyarticular juvenile idiopathic arthritis children and adolescents from 2 to 17 years of age weighing 10 kg to less than 30 kg : the recommended dose of hulio is 20 mg every other week. children and adolescents from 2 to 17 years of age weighing 30 kg or more : the recommended dose of hulio is 40 mg every other weeks. children and adolescents with enthesitis - related arthritis children and adolescents from 6 to 17 years of age weighing 15 kg to less than 30 kg : the recommended dose of hulio is 20 mg every other week. children and adolescents from 6 to 17 years of age weighing 30 kg or more : the recommended dose of hulio is 40 mg every other week. children and adolescents with crohn's disease children and adolescents from 6 to 17 years of age weighing less than 40 kg : the usual dose regimen is 40 mg initially, followed by 20 mg two weeks later. if a faster response is required, your child's doctor may prescribe an initial dose of 80 mg ( as two 40 mg injections in one day ) followed by 40 mg two weeks later. thereafter, the usual dose is 20 mg every other week. if this dose does not work well enough, your child's doctor may increase the dose frequency to 20 mg every week. children and adolescents from 6 to 17 years of age weighing 40 kg or more : the usual dose regimen is 80 mg initially ( as two 40 mg injections in one day ), followed by 40 mg two weeks later. if a faster response is required, your child's doctor may prescribe an initial dose of 160 mg initially ( as four 40 mg injections in one day or two 40 mg injections per day for two consecutive days ) followed by 80 mg ( as two 40 mg injections in one day ) two weeks later. thereafter, the usual dose is 40 mg
like all medicines, this medicine can cause side effects, although not everybody gets them. most side effects are mild to moderate. however, some may be serious and require urgent medical treatment. side effects may occur up to 4 months or more after the last hulio injection. seek medical attention urgently if your child develops any of the following signs of allergic reaction or heart failure : severe rash, hives swollen face, hands or feet ; trouble breathing or swallowing ; pale complexion, dizziness, persistent fever, bruising or bleeding very easily. tell your doctor as soon as possible, if you notice any of the following : signs and symptoms of infection such as fever, feeling sick, wounds, dental problems, burning on urination, feeling weak or tired or coughing ; symptoms of nerve problems such as tingling, numbness, double vision or arm or leg weakness ; signs of skin cancer such as a bump or open sore that doesn't heal ; signs and symptoms suggestive of blood disorders such as persistent fever, bruising, bleeding, paleness. the following side effects have been observed with adalimumab : very common ( may affect more than 1 in 10 people ): injection site reactions ( including pain, swelling, redness or itching ); respiratory tract infections ( including cold, runny nose, sinus infection, throat infection, pneumonia ); abnormal blood results ; headache ; abdominal ( belly ) pain ; nausea and vomiting ; pain in bone and muscles. common ( may affect up to 1 in 10 people ): any infection ( including tuberculosis, blood poisoning, influenza, cellulitis, shingles, ear infections, tooth infections, cold sores, reproductive tract infections, urinary tract infection, fungal infections, joint infections ); benign tumours ; skin cancer ; mild allergic reactions ( including seasonal allergy ); dehydration ; mood swings ( including depression ); anxiety ; difficulty sleeping ; sensation disorders such as tingling, prickling or numbness ; migraine ; neck or
what hulio contains - the active substance is adalimumab - the other ingredients are monosodium glutumate , sorbitol , methionine , polysorbate 80 , hydrochloric acid and water for injections . what hulio looks like and contents of the pack hulio 40 mg solution for injection ( injection ) in vials is supplied as a sterile solution of 40 mg adalimumab dissolved in 0 . 8 ml clear or slightly opalescent , colourless to pale brownish - yellow solution . the hulio vial is a glass vial with a rubber stopper . hulio is supplied as packs containing 1 or 2 boxes . each box contains 1 vial , 1 sterile injection syringe , 1 sterile needle , 1 sterile vial adapter and 2 alcohol pads . hulio is also available as a pre - filled syringe or a pre - filled pen .
yellox contains bromfenac and belongs to a group of medicines called non - steroidal anti - inflammatory drugs ( nsaids ). it works by blocking certain substances involved in causing inflammation . yellox is used to reduce eye inflammation following cataract surgery in adults .
do not use yellox - if you are allergic to bromfenac or to any of the other ingredients of this medicine ( listed in section 6 ). - if you have experienced asthma, skin allergy or intense inflammation in your nose when using other nsaids. examples of nsaids are : acetylsalicylic acid, ibuprofen, ketoprofen, diclofenac. warning and precautions talk to your doctor or pharmacist before using this medicine - if you are using topical steroids ( e. g. cortisone ), as this may cause unwanted side effects. - if you have bleeding problems ( e. g. haemophilia ) or have had them in the past, or you are taking other medicines which may prolong bleeding time ( e. g. warfarin, clopidogrel, acetylsalicylic acid ). - if you have eye problems ( e. g. dry eye syndrome, corneal problems ). - if you have diabetes. - if you have rheumatoid arthritis. - if you had repeated eye surgery within a short period of time. wearing contact lenses is not recommended after cataract surgery. therefore, do not wear contact lenses whilst using yellox. children and adolescents yellox should not be used in children and adolescents. other medicines and yellox tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. pregnancy, breastfeeding and fertility if you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before you use yellox. yellox should not be used during the last three months of pregnancy. the doctor may prescribe this medicine during pregnancy if expected benefit to mother outweigh possible risk to baby. yellox may be prescribed to breast - feeding woman and have no important influence on fertility. driving and using machines your vision may be blurred for a short time after using this eye drops. if
always use this medicine exactly as your doctor has told you. check with your doctor or pharmacist if you are not sure. dose the recommended dose is one drop of yellox in the affected eye ( s ) twice daily ( morning and evening ). do not use more than one drop in the affected eye ( s ) 2 times daily. start using the drops the next day after your cataract surgery. method of administration yellox is for ocular use. - wash your hands before using the eye drops. - put yourself in a comfortable and stable position. - twist off the bottle cap. - hold the bottle, pointing down, between your thumb and fingers. - tilt your head back. - pull down your lower eyelid with a clean finger. - bring the bottle tip close to the eye. - do not touch your eye or eyelid, surrounding areas or other surfaces with the dropper. - gently squeeze the bottle to release one drop of yellox. - close the bottle cap firmly immediately after use. - keep the bottle tightly closed when not in use. if you use any other eye drops, wait at least five minutes between using yellox and the other drops. duration of treatment continue the drops through the first 2 weeks after your surgery. do not use yellox longer than 2weeks. if you use more yellox than you should rinse out your eye with warm water. do not put in any more drops until it is time for your next regular dose. if yellox is accidentally swallowed, a glass of water or other fluid should be taken to water down the medicine. if you forget to use yellox use a single dose as soon as you remember. if it is almost time for the next dose, leave out the missed dose. continue with the next regularly scheduled dose. do not use a double dose to make up for a forgotten dose. if you stop using yellox do not stop using yellox without speaking to your doctor. in rare cases upon withdrawal of yellox, a flare - up of the inflammatory response, e. g. in the
what yellox contains - the active substance is bromfenac . one ml of solution contains 0 . 9 Â° mg bromfenac ( as sodium sesquihydrate ). one drop contains approximately 33 micrograms bromfenac . - the other ingredients are : boric acid , borax , sodium sulphite anhydrous ( e221 ), benzalkonium chloride ( see section 2 ), tyloxapol , povidone ( k30 ), disodium edetate , water for injection , sodium hydroxide ( to keep acidity levels normal ). what yellox looks like and contents of the pack yellox is a clear yellow liquid ( solution ) supplied in a pack containing one 5 ml plastic bottle with a screw cap .
the active substance of dzuveo is sufentanil , which belongs to a group of strong painkillers called opioids . sufentanil is used to treat sudden moderate - to - severe pain in adults in medically monitored settings such as a hospital .
do not use dzuveo : - if you are allergic to sufentanil or any of the other ingredients of this medicine ( listed in section 6 ). - if you have a serious lung or breathing problem warnings and precautions talk to your doctor or nurse before using dzuveo. tell your doctor or nurse before treatment if you : - are suffering from any condition that affects your breathing ( such as asthma, wheezing, or shortness of breath ). as dzuveo may affect your breathing, your doctor or nurse will check your breathing during treatment ; - have a head injury or brain tumour ; - have problems with your heart and circulation, especially slow heart rate, irregular heartbeat, low blood volume or low blood pressure ; - have moderate to severe liver problems or severe kidney problems, as these organs have an effect on the way in which your body breaks down and eliminates the medicine ; have abnormally slow bowel movements ; - have a disease of the gall bladder or pancreas ; - have a history of medicine or alcohol abuse ; children and adolescents dzuveo should not be used in children and adolescents below 18 years. other medicines and dzuveo tell your doctor if you are taking, have recently taken or might take any other medicines. in particular, 28 tell your doctor if you are taking any of the following : - ketoconazole, which is used for the treatment of fungal infections this medicine may have an effect on the way in which your body breaks down sufentanil. - any medicines which might make you sleepy ( have a sedative effect ), such as sleeping pills, medicines to treat anxiety ( e. g. benzodiazipines ), tranquillisers or other opioid medicines, as they can increase the risk of severe breathing problems, coma and may be life - threatening. - - medicines for the treatment of depression known as monoamine oxidase inhibitors ( maois ). these medicines must not be taken in the 2 weeks before or at the same time as dzuveo is given. - medicines for the treatment of depression known as selective
this medicine must be given to you by a doctor or a nurse using the single - dose administration device . you will not give yourself this medicine . dzuveo is only used in a medically monitored setting , such as a hospital . it is only prescribed by a doctor who is experienced in the use of strong painkillers like sufentanil and knows the effects it may have on you , in particular on your breathing ( see ' warnings and precautions ' above ). the recommended dose is a maximum of one 30 microgram sublingual tablet per hour . the sublingual tablet will be given to you by a healthcare professional using the disposable single - dose applicator . the applicator will help your healthcare provider place one tablet under your tongue . the tablets dissolve under your tongue and should not be chewed , or swallowed because the tablet is not effective for pain relief unless it is allowed to dissolve under your tongue . you should not eat or drink and should talk as little as possible for 10 minutes after each dose . after receiving a dose you will not be given another dose for at least one hour . the maximum daily dose is 720 micrograms ( 24 tablets per day ). dzuveo should not be used beyond 48 hours . after your treatment the medical staff will dispose of the applicator accordingly . if you use more dzuveo than you should the symptoms of overdose include severe breathing problems like slow and shallow breathing , loss of consciousness , extremely low blood pressure , collapse and muscle rigidity . if these start to develop , tell a doctor or nurse immediately . if you have any further questions on the use of this medicine , ask your doctor or nurse .
like all medicines, this medicine can cause side effects, although not everybody gets them. serious side effects the most serious side effects are severe breathing problems, like slow and shallow breathing, which may even lead to you stopping breathing. if you experience any of the above mentioned side effects, tell your doctor or nurse immediately. very common side effects ( may affect more than 1 in 10 people ): nausea or feeling sick, vomiting or being sick and generally feeling hot. common side effects ( may affect up to 1 in 10 people ): - inability or difficulty sleeping, feeling anxious or confused, dizziness. - headache, drowsiness, feeling sleepy. - increased heart rate, high blood pressure, low blood pressure. - low levels of oxygen in your blood, feeling pain in the lower throat, slow shallow breathing. - dry mouth, flatulence ( passing wind ), constipation, indigestion or reflux. - allergic reactions, itching of the skin. - muscle twitching and spasms. - inability to pass urine. - this medicine may also cause changes in levels of red blood cells, white blood cells, calcium, albumin, potassium and sodium in your blood which can only be identified through a blood test. if you are having a blood test ensure your doctor knows you are taking this medicine. uncommon side effects ( may affect up to 1 in 100 people ): - inflammation of the lungs, eye redness and inflammation, inflammation of the throat. - fatty lumps underneath skin. - inability to manage blood sugar ( diabetes ), increased cholesterol. - feeling agitated, lack of interest or emotion, lack of energy, disorientation, feeling elated, hallucinating or seeing things that are not there, nervousness. - problems coordinating muscle movements, muscle contractions, tremors or excessive shaking, exaggeration of reflex responses, burning sensation, feeling faint, abnormal sensation of the skin ( tingling, skin crawling ), numbness in general, tiredness, forgetfulness, migraine,
keep this medicine out of the sight and reach of children . your doctor or nurse will ensure that : - this medicine is not used after the expiry date which is stated on the label and carton after exp . the expiry date refers to the last day of that month . - is stored in the original package in order to protect from light and oxygen . - this medicine is not used if there are signs of deterioration . medicines should not be thrown away via wastewater or household waste . your healthcare provider will dispose of any waste according to hospital policies . these measures will help protect the environment .
what dzuveo contains - the active substance is sufentanil . each sublingual tablet contains 30 micrograms of sufentanil ( as citrate ). - the other ingredient ( s ) are mannitol ( e421 ), dicalcium phosphate , hypromellose , croscarmellose sodium , indigo carmine ( e132 ), stearic acid , and magnesium stearate . what dzuveo looks like and contents of the pack dzuveo is a blue - coloured , flat - faced sublingual tablet with round edges . it measures 3 mm in diameter and is enclosed within a single - dose applicator ( labelled [ sublingual tablet ]). the applicator , with the tablet inside , is enclosed within a pouch . each pouch contains one applicator and one sufentanil 30 micrograms tablet . each pack contains either 5 or 10 pouches . not all pack sizes may be marketed .
erleada is a cancer medicine that contains the active substance apalutamide . it is used to treat adult men with prostate cancer that : has metastasised to other parts of the body and still responds to medical or surgical treatments that lower testosterone ( also called hormone - sensitive prostate cancer ). has not metastasised to other parts of the body and no longer responds to medical or surgical treatment that lowers testosterone ( also called castration - resistant prostate cancer ). erleada works by blocking the activity of hormones called androgens ( such as testosterone ). androgens can cause the cancer to grow . by blocking the effect of androgens , apalutamide stops prostate cancer cells from growing and dividing .
do not take erleada if : you are allergic to apalutamide or any of the other ingredients of this medicine ( listed in section 6 ). you are a woman who is pregnant or may become pregnant ( see the pregnancy and contraception section below for more information ). do not take this medicine if any of the above apply to you. if you are not sure, talk to your doctor or pharmacist before taking this medicine. warnings and precautions talk to your doctor or pharmacist before taking this medicine if : you have ever had fits or seizures you are taking any medicines to prevent blood clots ( e. g. warfarin, acenocoumarol ) you have any heart or blood vessel conditions, including heart rhythm problems ( arrhythmia ). falls have been observed in patients taking erleada. take extra care to reduce your risk of a fall. broken bones have been observed in patients taking erleada. blockage of the arteries in the heart that can lead to death has happened in some people during treatment with erleada. your healthcare provider will monitor you for signs and symptoms of heart problems during your treatment with erleada. call your healthcare provider or go to the nearest emergency room right away if you get chest pain or discomfort at rest or with activity or shortness of breath during your treatment with erleada. if you are taking any medicines, talk to your doctor or pharmacist to see if they are associated with an increased risk of seizure, bleeding or heart condition. if any of the above apply to you ( or you are not sure ), talk to your doctor or pharmacist before taking erleada. children and adolescents this medicine is not for use in children and adolescents under 18 years of age. if a child or young person accidentally takes erleada : go to the hospital straight away take this package leaflet with you to show to the emergency doctor. other medicines and erleada tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. this is because erleada can affect the way some other medicines work. also, some other medicines
always take this medicine exactly as your doctor has told you . check with your doctor or pharmacist if you are not sure . how much to take the recommended dose is 240 mg ( four 60 mg tablets ) once a day . taking erleada take this medicine by mouth . you can take erleada with food or between meals . swallow the tablets whole . your doctor may also prescribe other medicines while you are taking erleada . if you take more erleada than you should if you take more than you should , stop taking erleada and contact your doctor . you may have an increased risk of side effects . if you forget to take erleada if you forget to take erleada , take your usual dose as soon as you remember . if you forget to take erleada for the whole day - take your usual dose the following day . if you forget to take erleada for more than one day - talk to your doctor straight away . do not take a double dose to make up for a forgotten dose . if you stop taking erleada do not stop taking erleada without checking with your doctor first . if you have any further questions on the use of this medicine , ask your doctor or pharmacist .
like all medicines, this medicine can cause side effects, although not everybody gets them. stop using erleada and seek medical attention immediately if you notice any of the following symptoms : reddish non - elevated, target - like or circular patches on the trunk, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes. these serious skin rashes can be preceded by fever and flu - like symptoms ( toxic epidermal necrolysis ). serious side effects tell your doctor straight away if you notice any of the following serious side effects your doctor may stop treatment : fit or seizure this is uncommon ( may affect up to 1 in 100 people ). your healthcare provider will stop erleada if you have a seizure during treatment. falls or fractures ( broken bones ) these are very common ( may affect more than 1 in 10 people ). your healthcare provider may monitor you more closely if you are at risk for fractures. heart disease this is common ( may affect up to 1 in 10 people ). your healthcare provider will monitor you for signs and symptoms of heart problems during your treatment. call your healthcare provider or go to the nearest emergency room right away if you get chest pain or discomfort at rest or with activity or shortness of breath during your treatment with erleada. tell your healthcare provider right away if you notice any of the serious side effects above. other side effects include very common ( may affect more than 1 in 10 people ): feeling very tired joint pain skin rash decreased appetite high blood pressure hot flush diarrhoea broken bones falls weight loss. common ( may affect up to 1 in 10 people ): muscle spasms itching change in sense of taste blood test showing high level of cholesterol in the blood blood test showing high level of a type of fat called " triglycerides " in the blood heart disease under - active thyroid which can make you feel more tired and have difficulty getting started in the morning, and blood tests may also show an under - active thyroid. not known ( frequency cannot be estimated from the available data ): abnormal heart tracing on an ecg ( electrocardiogram ) 43 life
what erleada contains the active substance is apalutamide . each film - coated tablet contains 60 mg of apalutamide . the other ingredients of the tablet core are colloidal anhydrous silica , croscarmellose sodium , hypromellose acetate succinate , magnesium stearate , microcrystalline cellulose , and silicified microcrystalline cellulose . the film - coating contains iron oxide black ( e172 ), iron oxide yellow ( e172 ), macrogol , polyvinyl alcohol ( partially hydrolysed ), talc , and titanium dioxide ( e171 ). what erleada looks like and contents of the pack erleada film - coated tablets are slightly yellowish to greyish green , oblong - shaped , film - coated tablets ( 16 . 7 mm long x 8 . 7 mm wide ), with " ar 60 " written on one side . the tablets may be supplied either in a bottle or in a wallet pack . not all pack sizes may be marketed . bottle the tablets are supplied in a plastic bottle with a child - resistant closure . each bottle contains 120 tablets and a total of 6 g of desiccant . each carton contains one bottle . store in the original package . do not swallow or discard desiccant . 28 - day carton each 28 - day carton contains 112 film - coated tablets in 4 cardboard wallet packs of 28 film - coated tablets each . 30 - day carton each 30 - day carton contains 120 film - coated tablets in 5 cardboard wallet packs of 24 film - coated tablets each .
this medicine is a radiopharmaceutical product for diagnostic use only . axumin contains the active ingredient fluciclovine ( 18f ) and is given so that doctors can perform a special type of scan called a pet scan . if you have previously had treatment for prostate cancer and information from other tests ( e . g . prostate specific antigen , psa ) indicates that the cancer may have returned , an axumin pet scan can help your doctor find the locations where the cancer has come back . you should discuss the results of the test with the doctor that requested the scan . the use of axumin does involve exposure to small amounts of radioactivity . your doctor and the nuclear medicine doctor have considered that the benefit of this procedure with the radiopharmaceutical outweighs the risk of being exposed to radiation .
axumin must not be used : - if you are allergic to fluciclovine ( 18f ) or any of the other ingredients of this medicine ( listed in section 6 ). warnings and precautions talk to your nuclear medicine doctor before you are given axumin if you : - have kidney problems - are on a low sodium diet ( see section " axumin contains sodium "). before administration of axumin you : - should avoid exercise for at least a day before the axumin scan . - should not eat or drink for at least 4 hours before the scan ( you can take your usual medicines with small amounts of water ). - may urinate at the latest 60 minutes before the axumin injection and you should avoid urination until after the scan has been completed . children and adolescents talk to your nuclear medicine doctor if you are under 18 years old . axumin is not intended for use in children and adolescents aged under 18 years . other medicines and axumin tell your nuclear medicine doctor if you are taking , have recently taken or might take any other medicines since they may interfere with the interpretation of the images . pregnancy and breast - feeding this medicine is not indicated for use in women . driving and using machines it is considered unlikely that axumin will affect your ability to drive or to use machines . axumin contains sodium this medicine contains up to 39 mg sodium per dose . this should be taken into consideration if you are on a controlled sodium diet .
there are strict laws on the use , handling and disposal of radiopharmaceutical products . axumin will only be used in specially controlled areas . this medicine will only be handled and given to you by people who are trained and qualified to use it safely . these persons will take special care for the safe use of this medicine and will keep you informed of their actions . the nuclear medicine doctor supervising the procedure will decide on the quantity of axumin to be used in your case . it will be the smallest quantity necessary to get the desired information . the quantity to be administered usually recommended for an adult is 370 mbq ( megabecquerel , the unit used to express radioactivity ). administration of axumin and conduct of the procedure axumin is administered intravenously as an injection into your vein followed by a flush of sodium chloride solution to ensure that you receive the full dose . one injection is usually sufficient to conduct the test that your doctor needs . duration of the procedure your nuclear medicine doctor will inform you about the usual duration of the procedure . the scan will usually start approximately 5 minutes after the axumin injection is given . after administration of axumin you should : - avoid any close contact with young children and pregnant women for the 12 hours following the injection - urinate frequently in order to eliminate the product from your body . the nuclear medicine doctor will inform you if you need to take any other special precautions after receiving this medicine . contact your nuclear medicine doctor if you have any questions . if you have been given more axumin than you should an overdose is unlikely because you will only receive a single dose of axumin precisely controlled by the nuclear medicine doctor supervising the procedure . however , in the case of an overdose , you will receive the appropriate treatment . in particular , the nuclear medicine doctor in charge of the procedure may provide ways to increase the passing of urine and stools in order to facilitate the removal of radioactivity from your body . should you have any further question on the use of axumin , please ask your nuclear medicine doctor who supervises the procedure .
like all medicines , this medicine can cause side effects , although not everybody gets them . in clinical studies side effects were reported by less than 1 in 100 patients given the medicine . the following side effects of axumin are common ( may affect up to 1 in 100 people ). - pain or rash at the site of injection , altered taste in the mouth , altered sense of smell . this radiopharmaceutical will deliver low amounts of ionising radiation associated with the least risk of cancer and hereditary abnormalities . reporting of side effects if you get any side effects talk to your nuclear medicine doctor . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
you will not have to store this medicine . this medicine is stored under the responsibility of the specialist in appropriate premises . storage of radiopharmaceuticals will be in accordance with national regulation on radioactive materials . the following information is intended for the specialist only . axumin must not be used after the expiry date which is stated on the shield label after exp .
what axumin contains - the active substance is fluciclovine ( 18f ). axumin 1600 mbq / ml solution for injection each ml of solution contains 1600 mbq fluciclovine ( 18f ) at date and time of calibration ( toc ). the activity per vial ranges from 1600 mbq to 16000 mbq at the date and time of calibration . axumin 3200 mbq / ml solution for injection each ml of solution contains 3200 mbq fluciclovine ( 18f ) at date and time of calibration ( toc ). the activity per vial ranges from 3200 mbq to 32000 mbq at the date and time of calibration . - the other ingredients are sodium citrate , concentrated hydrochloric acid , sodium hydroxide , water for injections ( see section 2 " axumin contains sodium ") what axumin looks like and contents of the pack axumin is a clear , colourless solution stored in a glass vial . axumin 1600 mbq / ml solution for injection each multidose vial contains 1 to 10 ml of solution , corresponding to 1600 to 16000 mbq at the date and time of calibration ( toc ). axumin 3200 mbq / ml solution for injection each multidose vial contains 1 to 10 ml of solution , corresponding to 3200 to 32000 mbq at the date and time of calibration ( toc ). pack size : 1 vial .
azopt contains brinzolamide which belongs to a group of medicines called carbonic anhydrase inhibitors . it reduces pressure within the eye . azopt eye drops are used to treat high pressure in the eye . this pressure can lead to an illness called glaucoma . if the pressure in the eye is too high , it can damage your sight .
do not use azopt - if you have severe kidney problems. - if you are allergic to brinzolamide or any of the other ingredients of this medicine ( listed in section 6 ). - if you are allergic to medicines called sulphonamides. examples include medicines used to treat diabetes and infections and also diuretics ( water tablets ). azopt may cause the same allergy. - if you have too much acidity in your blood ( a condition called hyperchloraemic acidosis ). if you have further questions, ask your doctor for advice. warnings and precautions talk to your doctor or pharmacist before using azopt : - if you have kidney or liver problems. - if you have dry eyes or cornea problems. - if you are taking other sulphonamide medicines - if you have a specific form of glaucoma in which the pressure inside the eye rises due to deposits that block fluid draining out ( pseudoexfoliative glaucoma or pigmentary glaucoma ) or a specific form of glaucoma in which the pressure inside the eye ( sometimes rapidly ) rises because the eye bulges forward and blocks fluid draining out ( narrow - angle glaucoma ) 22 children and adolescents azopt is not to be used by infants, children or adolescents under 18 years of age unless advised by your doctor. other medicines and azopt tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription. if you are taking another carbonic anhydrase inhibitor ( acetazolamide or dorzolamide, see section 1 what azopt is and what it is used for ), talk to your doctor. pregnancy and breast - feeding if you are pregnant or breast - feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. women who may become pregnant are advised to use effective contraception during azopt treatment. the use of azopt is not recommended during pregnancy or breast - feeding. do not use
always use this medicine exactly as your doctor or pharmacist has told you. check with your doctor or pharmacist if you are not sure. only use azopt for your eyes. do not swallow or inject. the recommended dose is 1 drop in the affected eye or eyes twice a day - morning and night. use this much unless your doctor told you to do something different. only use azopt in both eyes if your doctor told you to. take it for as long as your doctor told you to. how to use 1 2 3 get the azopt bottle and a mirror wash your hands shake the bottle and twist off the cap. after the cap is removed, if the tamper evident snap collar is loose, remove before using product. hold the bottle, pointing down, between your thumb and middle finger tilt your head back. pull down your eyelid with a clean finger, until there is a'pocket'between the eyelid and your eye. the drop will go in here ( picture 1 ) bring the bottle tip close to the eye. use the mirror if it helps do not touch your eye or eyelid, surrounding areas or other surfaces with the dropper. it could infect the drops gently press on the base of the bottle to release one drop of azopt at a time. do not squeeze the bottle : it is designed so that a gentle press on the bottom is all that it needs ( picture 2 ) after using azopt, press a finger to the corner of your eye, by the nose ( picture 3 ) for at least 1 minute. this helps to stop azopt getting into the rest of the body. if you take drops in both eyes, repeat the steps for your other eye. put the bottle cap back on firmly immediately after use use up one bottle before opening the next bottle. if a drop misses your eye, try again. if you are using other eye drops, leave at least 5 minutes between putting in azopt and the other drops. eye ointments should be administered last. if you use more azopt than you should if you get too much in your eyes, rinse it all out with warm
like all medicines, this medicine can cause side effects, although not everyone gets them. the following side effects have been seen with azopt. common side effects ( may affect up to 1 in 10 people ) - effects in the eye : blurred vision, eye irritation, eye pain, eye discharge, itchy eye, dry eye, abnormal eye sensation, redness of the eye. - general side effects : bad taste. uncommon side effects ( may affect up to 1 in 100 people ) - effects in the eye : sensitivity to light, inflammation or infection of the conjunctiva, eye swelling, eyelid itching, redness or swelling, deposits in eye, glare, burning sensation, growth on surface of eye, increased pigmentation of the eye, tired eyes, eyelid crusting, or increased tear production. - general side effects : decreased or reduced heart function, a forceful heartbeat that may be rapid or irregular, decreased heart rate, difficulty breathing, shortness of breath, cough, decreased red blood cell count in blood, increased chlorine level in blood, dizziness, difficulty with memory, depression, nervousness, decreased emotional interest, nightmare, generalized weakness, fatigue, feeling abnormal, pain, movement problems, decreased sex drive, male sexual difficulty, cold symptoms, chest congestion, sinus infection, throat irritation, throat pain, abnormal or decreased sensation in mouth, inflammation of the lining of the oesophagus, abdominal pain, nausea, vomiting, upset stomach, frequent bowel movements, diarrhoea, intestinal gas, digestive disorder, kidney pain, muscle pain, muscle spasms, back pain, nose bleeds, runny nose, stuffy nose, sneezing, rash, abnormal skin sensation, itching, smooth skin rash or redness covered by elevated bumps, skin tightness, headache, dry mouth, debris in eye. rare side effects ( may affect up to 1 in 1, 000 people ) -
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the bottle and box after " exp ". the expiry date refers to the last day of the month . this medicine does not require any special storage conditions . you must throw away a bottle four weeks after you first opened it , to prevent infections . write down the date you opened each bottle in the space below and in the space on the bottle label and box . for a pack containing a single bottle , write only one date . opened ( 1 ): opened ( 2 ): opened ( 3 ): do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what azopt contains - the active substance is brinzolamide . each millilitre contains 10 mg of brinzolamide . - the other ingredients are benzalkonium chloride , carbomer 974p , edetate disodium , mannitol ( e421 ), purified water , sodium chloride , tyloxapol . tiny amounts of hydrochloric acid or sodium hydroxide are added to keep acidity levels ( ph levels ) normal . what azopt looks like and contents of the pack azopt is a milky liquid ( a suspension ) supplied in a pack containing a 5 ml or a 10 ml plastic ( droptainer ) bottle with a screw cap , or in a pack containing three 5 ml plastic ( droptainer ) bottles with screw caps . not all pack sizes may be marketed .
what forxiga is forxiga contains the active substance dapagliflozin . it belongs to a group of medicines called " oral anti - diabetics ". these are medicines taken by mouth for diabetes . they work by lowering the amount of sugar ( glucose ) in your blood . forxiga is used in adult patients ( aged 18 years and older ). what forxiga is used for forxiga is used for the types of diabetes called : type 1 diabetes where your body hardly produces any insulin . forxiga should only be used in type 1 diabetes patients who are overweight or obese . type 2 diabetes where your body does not make enough insulin or is not able to use the insulin it produces properly . in both types of diabetes , this leads to a high level of sugar in your blood . forxiga works by removing excess sugar from your body via your urine . if you have type 2 diabetes , it can also help prevent heart disease . forxiga and other diabetes medicines type 1 diabetes : forxiga is used if your type 1 diabetes cannot be controlled with insulin alone . forxiga is used together with insulin . type 2 diabetes : forxiga is used if your type 2 diabetes cannot be controlled with diet and exercise . your doctor may ask you to take forxiga : - on its own if you cannot tolerate metformin . - together with other medicines to treat diabetes . it is important to continue to follow the advice on diet and exercise given to you by your doctor , pharmacist or nurse .
do not take forxiga : if you are allergic to dapagliflozin or any of the other ingredients of this medicine ( listed in section 6 ). warnings and precautions contact a doctor or the nearest hospital straight away : if you experience feeling sick or being sick, stomach pain, excessive thirst, fast and deep breathing, confusion, unusual sleepiness or tiredness, a sweet smell to your breath, a sweet or metallic taste in your mouth, or a different odour to your urine or sweat or rapid weight loss. the above symptoms could be a sign of " diabetic ketoacidosis " a serious, sometimes life - threatening problem you can get with diabetes because of increased levels of " ketone bodies " in your urine or blood, seen in tests. the risk of developing diabetic ketoacidosis may be increased with prolonged fasting, excessive alcohol consumption, dehydration, sudden reductions in insulin dose, or a higher need of insulin due to major surgery or serious illness. when you are treated with forxiga, diabetic ketoacidosis can occur even if your blood sugar is normal. the risk of getting diabetic ketoacidosis is different in the two types diabetes : - in type 2 diabetes it is rare. - in type 1 diabetes the risk is higher - this is because your body hardly produces any insulin, and diabetic ketoacidosis may occur at sudden decreases in insulin dose ( such as missed insulin injections, or issues with your insulin pen or pump ). if you have type 1 diabetes : talk with your doctor about the risk of diabetic ketoacidosis before you start to take forxiga. your doctor will tell you when you may need to measure ketones in your blood or urine and what you need to do when your ketone levels are raised : - at blood ketone readings from 0. 6 to 1. 5 mmol / l ( or urine ketones reading +) you may need to take extra insulin, drink water, and if your blood glucose is normal or low, you may need to eat carbohydrates. measure your ketone levels again in 2 hours. seek medical
always take this medicine exactly as your doctor has told you . check with your doctor , pharmacist or nurse if you are not sure . how much to take if you are taking forxiga for type 2 diabetes : the recommended dose is one 10 mg tablet each day . your doctor may start you on a 5 mg dose if you have a liver problem . your doctor will prescribe the strength that is right for you . if you are taking forxiga for type 1 diabetes : the recommended dose is one 5 mg tablet each day . taking this medicine swallow the tablet whole with half a glass of water . you can take your tablet with or without food . you can take the tablet at any time of the day . however , try to take it at the same time each day . this will help you to remember to take it . your doctor may prescribe forxiga together with other medicine ( s ) to lower the amount of sugar in your blood . remember to take these other medicine ( s ) as your doctor has told you . this will help get the best results for your health . diet and exercise can help your body use its blood sugar better . it is important to stay on any diet and exercise program recommended by your doctor while taking forxiga . if you take more forxiga than you should if you take more forxiga tablets than you should , talk to a doctor or go to a hospital immediately . take the medicine pack with you . if you forget to take forxiga what to do if you forget to take a tablet depends on how long it is until your next dose . if it is 12 hours or more until your next dose , take a dose of forxiga as soon as you remember . then take your next dose at the usual time . if it is less than 12 hours until your next dose , skip the missed dose . then take your next dose at the usual time . do not take a double dose of forxiga to make up for a forgotten dose . if you stop taking forxiga do not stop taking forxiga without talking to your doctor first . your blood sugar may increase without this medicine . if you have any further questions on the use of this medicine , ask your doctor , pharmacist or nurse .
like all medicines, this medicine can cause side effects, although not everybody gets them. contact a doctor or the nearest hospital straight away if you have any of the following side effects : angioedema, seen very rarely ( may affect up to 1 in 10, 000 people ). these are signs of angioedema : - swelling of the face, tongue or throat - difficulties swallowing - hives and breathing problems diabetic ketoacidosis - this is common in patients with type 1 diabetes ( may affect up to 1 in 10 people ) and rare in patients with type 2 diabetes ( may affect up to 1 in 1, 000 people ). these are the signs of diabetic ketoacidosis ( see also section 2 warnings and precautions ): - increased levels of " ketone bodies " in your urine or blood - feeling sick or being sick - stomach pain - excessive thirst - fast and deep breathing - confusion - unusual sleepiness or tiredness - a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat - rapid weight loss. this may occur regardless of blood sugar level. your doctor may decide to temporarily or permanently stop your treatment with forxiga. necrotising fasciitis of the perineum or fournier's gangrene, a serious soft tissue infection of the genitals or the area between the genitals and the anus, seen very rarely. stop taking forxiga and see a doctor as soon as possible if you notice any of the following serious side effects : loss of too much fluid from your body ( dehydration ), seen uncommonly ( may affect up to 1 in 100 people ). these are signs of dehydration : - very dry or sticky mouth, feeling very thirsty - feeling very sleepy or tired - passing little or no water ( urine ) - fast heartbeat. urinary tract infection, seen commonly ( may affect up to 1 in 10 people ). these are signs of a severe infection of the urinary tract : - fever and / or chills - burning sensation when passing water ( urinating ) - pain in
what forxiga contains the active substance is dapagliflozin . each forxiga 5 mg film - coated tablet ( tablet ) contains dapagliflozin propanediol monohydrate equivalent to 5 mg dapagliflozin . the other ingredients are : tablet core : microcrystalline cellulose ( e460i ), lactose ( see section 2 ' forxiga contains lactose '), crospovidone ( e1202 ), silicon dioxide ( e551 ), magnesium stearate ( e470b ). film - coating : polyvinyl alcohol ( e1203 ), titanium dioxide ( e171 ), macrogol 3350 , talc ( e553b ), yellow iron oxide ( e172 ). what forxiga looks like and contents of the pack forxiga 5 mg film - coated tablets are yellow and round with diameter of 0 . 7 cm . they have " 5 " on one side and " 1427 " on the other side . forxiga 5 mg tablets are available in aluminium blisters in pack sizes of 14 , 28 or 98 film - coated tablets in non - perforated calendar blisters and 30x1 or 90x1 film - coated tablets in perforated unit dose blisters . not all pack sizes may be marketed in your country .
mepact contains the active substance mifamurtide , similar to a component of the cell wall of certain bacteria . it stimulates your immune system to help your body kill tumour cells . mepact is used to treat osteosarcoma ( bone cancer ) in children , adolescents and young adults ( between 2 and 30 years ). it is used after you have had surgery to remove the tumour and together with chemotherapy to kill remaining cancer cells to reduce the risk of cancer coming back .
do not use mepact : - if you are allergic to mifamurtide or any of the other ingredients of this medicine ( listed in section 6 ). - if you are taking medicines containing ciclosporin or other calcineurin inhibitors or high doses of non - steroidal - anti - inflammatory drugs ( nsaids ) ( see " using other medicines " below ). warnings and precautions talk to your doctor before using mepact : - if you have or have had problems with your heart or blood vessels, like blood clots ( thrombosis ), bleeding ( haemorrhage ) or inflammation of the veins ( vasculitis ). you should be more closely monitored while receiving mepact treatment. if you have long - lasting or worsening symptoms, you should contact your doctor, as mepact treatment may need to be delayed or discontinued. - if you have a history of asthma or other breathing disorders. before using mepact, you should discuss with your doctor whether you should take medicine for your asthma when using mepact. - if you have a history of inflammatory or autoimmune disease or have been treated with corticosteroids or other medicines that may affect your immune system. - if you have any allergic reactions to any medicines such as rash, breathlessness and high blood pressure. if you have worsening symptoms, you should contact your doctor, as these may have been caused by mepact. - if you have stomach problems such as nausea, vomiting and lack of appetite. if your problems increase, you should contact your doctor, as these may have been caused by mepact when used with chemotherapy. - if you develop chills or shivering, or feel warm. you should take your temperature as you may have a fever. a fever with a low white blood cell count ( neutropenia ) may be a sign of serious infection. detailed information on warnings and precautions relating to side effects that could occur while you are taking the medicine is presented in section 4. children it is not recommended to give this medicine to children below the age
dose and duration of treatment mepact will be administered only under the supervision of a specialist physician . always use this medicine exactly as your doctor has told you . check with your doctor if you are not sure . the recommended dose of mepact is 2 mg mifamurtide / m2 body surface area . it will be given to you twice a week ( at least three days apart ) for the first 12 weeks , then once a week for 24 more weeks . the schedule of your mepact treatments can be adjusted to fit with your chemotherapy schedule . it is not necessary to interrupt your schedule of mepact if your chemotherapy is delayed ; you should complete 36 weeks ( 9 months ) of treatment with mepact without an interruption . how mepact is given the freeze - dried powder has to be reconstituted into a liquid suspension , filtered using the filter provided and further diluted before use . mepact is then infused directly into your vein ( intravenous ) over about 1 hour . this is done by your doctor or a nurse , who will also monitor you during that time . you do not need to be hospitalised to receive mepact . it can also be administered as an outpatient . if you use more mepact than you should you may experience more severe side effects , including fever , chills , fatigue , nausea , vomiting , headache and high blood pressure or low blood pressure . in the event of such an overdose , contact your doctor or nearest hospital . if you stop using mepact you should not stop treatment with mepact before finishing the course of treatment without discussing with your doctor first . if you have any further questions on the use of this medicine , ask your doctor .
like all medicines, mepact can cause side effects, although not everybody gets them. the majority of patients experience chills, fever and fatigue especially during the first administration of mepact. these are typically mild to moderate and transient and can usually be treated by your doctor, e. g. with paracetamol for fever. treatment with mepact can often cause stomach problems such as nausea, vomiting and loss of appetite when used with chemotherapy. contact your doctor immediately : - if you have continuing fever or chills more than 8 hours after your dose of mepact, because this may be a sign of an infection, or - if you experience rash or have any problems breathing ( wheezing ), or - if you experience any stomach problems. very common side effects ( may affect more than 1 in 10 people ): - fever, shaking / shivering, weakness, tiredness or general discomfort - nausea and / or vomiting, diarrhoea or constipation - headache or dizziness - rapid beating of the heart - high blood pressure or low blood pressure - no appetite for food - sweating - pain, including general pain, pain in your muscles and / or joints and pain in back, chest, abdomen, arm or leg - cough, trouble breathing or rapid breathing - low body temperature - low number of red blood cells 28 common side effects ( may affect up to 1 in 10 people ): - blue colour of tissues such as the skin or gums caused by too little oxygen - perceptible increase in frequency or force of heartbeat - swelling in arms or legs or other swelling - chest discomfort - upset stomach, decreased appetite or weight loss - injection site or catheter site redness, swelling, infection or other local reaction - rash or redness, inflammation of the skin, itching, dry skin, pale or transient red appearance - inflammation of skin, tendons, muscles or similar tissues that support body structure - inflammation of a vein - upper abdominal or chest wall pain ; abdominal bloating or pain ; indigestion or pain in your liver - other pain, including neck,
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the vial label and the carton after " exp ". the expiry date refers to the last day of that month . unopened vial store in a refrigerator ( 2 c - 8 ). do not freeze . keep the vial in outer carton in order to protect from light . reconstituted suspension once reconstituted in sodium chloride 9 mg / ml ( 0 . 9 %) solution , store at room temperature ( approximately 20Âºc - 25Âºc ) and use within 6 hours . do not use this medicine if you notice any visible signs of deterioration . do not throw away any medicines via wastewater . these measures will help protect the environment .
what mepact contains - the active substance is mifamurtide . each vial contains 4 mg of mifamurtide . after reconstitution , each ml of suspension contains 0 . 08 mg of mifamurtide . - the other ingredients are 1 - palmitoyl - 2 - oleoyl - sn - glycero - 3 - phosphocholine ( popc ) and 1 , 2 - dioleoyl - sn - glycero - 3 - phospho - l - serine monosodium salt ( oops ). see section 2 " mepact contains sodium " what mepact looks like and contents of the pack mepact is a white to off - white homogeneous cake or powder for concentrate for dispersion for infusion . mepact is supplied in a carton that contains - one 50 ml vial with a grey butyl stopper , aluminium seal and plastic flip - off cap . - one sterile filter for mepact supplied in a blister .
mirvaso contains the active substance brimonidine which belongs to a group of medicines commonly referred to as " alpha agonists ". it is applied to the skin of the face to treat redness due to rosacea in adult patients . redness of the face due to rosacea is caused by high levels of blood flow in the facial skin , which is the result of enlargement ( dilation ) of the small blood vessels of the skin . when applied , mirvaso acts to narrow these blood vessels again which reduces the excess blood flow and redness .
do not use mirvaso : - if you are allergic to brimonidine or any of the other ingredients of this medicine ( listed in section 6 ). - in children below 2 years of age, as they may be at greater risk of side effects from any of the medicine absorbed through the skin. - if you are taking certain medicines used for depression or parkinson's disease including so - called monoamine oxidase ( mao ) inhibitors ( for example selegiline or moclobemide ) or tricyclic antidepressants ( such as imipramine ) or tetracyclic antidepressants ( such as maprotiline, mianserin or mirtazapin ). use of mirvaso when taking these medicines may result in a fall in blood pressure. warnings and precautions talk to your doctor or pharmacist, before using mirvaso especially if : - the skin of your face is irritated or has open wounds. - you have problems with your heart or your blood circulation. - you have depression, decreased blood flow to the brain or the heart, fall in blood pressure on standing up, decreased blood flow to the hands, feet or skin, or sjÃ¶gren's syndrome ( a chronic disease in which the body's natural defence - the immune system - attacks the moisture - producing glands ). - you have kidney or liver problems or have had them in the past. - you have had, or plan to have any laser procedure on the skin of your face. it is important to start treatment with a small amount of gel, increase the dose gradually but do not exceed the maximum dose of 1 gram ( approximately 5 pea sized amounts ). see also instructions'how to use mirvaso '. do not apply mirvaso more than once a day and do not exceed the maximum daily dose of 1gram ( approximately 5 pea sized amounts ). see also instructions'how to use mirvaso '. worsening of skin redness, flushing or burning feeling of the skin up to 1 in 6 patients experience the return of their redness worse than it was initially. such worsening of red
always use this medicine exactly as your doctor has told you. check with your doctor or pharmacist if you are not sure. important : mirvaso is intended for adults and only for use on the skin of the face. do not use this medicine on other parts of your body, especially moist body surfaces, e. g. your eyes, mouth, nose or vagina. do not swallow. keep mirvaso gel away from children. how to use mirvaso mirvaso is recommended to be applied to the face once a day only. during the first week, start the treatment with a small amount of gel ( a pea - sized amount ) as explained by your doctor or nurse. if your symptoms remain the same or improve only slightly, you may then gradually increase the amount of gel. spread it smoothly and evenly as a very thin layer as directed by your doctor or nurse. it is important not to exceed the maximum daily dose of 1gram ( 5 pea sized amounts applied to the whole face ). you should wash your hands immediately after applying this medicine. if your symptoms worsen during treatment with mirvaso ( increased redness, or burning ), stop treatment and make an appointment to see your doctor see also section 2 under <unk> warnings and precautions '. you must avoid the eyes, eyelids, lips, mouth, and the inside of the nose. should any gel get onto these areas, wash them immediately with plenty of water. if you experience worsening of redness or burning you should stop using mirvaso and contact your doctor if needed. do not apply any other skin medicines or cosmetics immediately before the daily application of mirvaso. you should use these products only after the applied mirvaso has dried. pay attention when opening the tube / pump for the first time, not to spill a larger quantity of gel than what is needed. if this occurs, you should discard the excess gel so as not to apply more than the recommended dose. see paragraph " how to use mirvaso " above. [ eu / 1 / 13 / 904 / 004 - 006 ] how to open the tube with a child - resistant cap to
like all medicines , this medicine can cause side effects , although not everybody gets them . if you develop uncommon side effects of severe skin irritation or inflammation , skin rash , skin pain or discomfort , dry skin , warm skin sensation , tingling or sensation of pins and needles or swelling of the face or common side effects like worsening of rosacea , discontinue the treatment and talk to your doctor since this medicine may not be suitable for you . in some cases , symptoms may extend beyond the treatment area . see also section 2 under ' warnings and precautions '. if you develop contact allergy ( e . g . allergic reaction , rash ) or rare angioedema ( a serious allergic reaction see rarely usually with swelling of the face , mouth or tongue ), stop using mirvaso and seek prompt medical advice . mirvaso may also cause the following other side effects : common side effects ( may affect up to 1 in 10 people ): - flushing - excessive whitening ( pallor ) where the gel is applied - skin redness , burning feeling of the skin or itching uncommon side effects ( may affect up to 1 in 100 people ): - acne - dry mouth - feeling cold in hands and feet - feeling hot - headache - nasal congestion - swelling of the eyelid - urticaria - dizziness 27 rare side effects ( may affect up to 1 in 1000 people ): - hypotension ( blood pressure decreased ) - heart rate decrease ( slow heart rate , known as bradycardia ). reporting of side effects if you get any side effects , talk to your doctor . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects , you can help provide more information on the safety of this medicine .
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the carton , tube and pump after exp . the expiry date refers to the last day of that month . this medicine does not require any special storage condition . do not freeze . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what mirvaso contains - the active substance is brimonidine . one gram of gel contains 3 . 3 mg of brimonidine , equivalent to 5 mg of brimonidine tartrate . - the other ingredients are carbomer , methylparahydroxybenzoate ( e218 ), phenoxyethanol , glycerol , titanium dioxide , propylene glycol ( e1520 ), sodium hydroxide , purified water . see end of section 2 for information on methylparahydroxybenzoate and propylene glycol . what mirvaso looks like and contents of the pack mirvaso is a white to light yellow , opaque gel . it is supplied in tubes containing 2 , 10 or 30 grams of gel or in airless pump system containing 30 g of gel . pack size of 1 tube or 1 pump . not all pack sizes may be marketed .
mvasi contains the active substance bevacizumab, which is a humanised monoclonal antibody ( a type of protein that is normally made by the immune system to help defend the body from infection and cancer ). bevacizumab binds selectively to a protein called human vascular endothelial growth factor ( vegf ), which is found on the lining of blood and lymph vessels in the body. the vegf protein causes blood vessels to grow within tumours, these blood vessels provide the tumour with nutrients and oxygen. once bevacizumab is bound to vegf, tumour growth is prevented by blocking the growth of the blood vessels which provide the nutrients and oxygen to the tumour. mvasi is a medicine used for the treatment of adult patients with advanced cancer in the large bowel, i. e., in the colon or rectum. mvasi will be administered in combination with chemotherapy treatment containing a fluoropyrimidine medicine. mvasi is also used for the treatment of adult patients with metastatic breast cancer. when used for patients with breast cancer, it will be administered with a chemotherapy medicinal product called paclitaxel. mvasi is also used for the treatment of adult patients with advanced non - small cell lung cancer. mvasi will be administered together with a chemotherapy regimen containing platinum. mvasi is also used for treatment of adult patients with advanced kidney cancer. when used for patients with kidney cancer, it will be administered with another type of medicine called interferon. mvasi is also used for the treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. when used for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, it will be administered in combination with carboplatin and paclitaxel. when used for those adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer whose disease has come back at least 6 months after the last time they were treated 64 with a chemotherapy regimen containing a
in order to improve the traceability of this medicine, your doctor or pharmacist should record the tradename and the lot number of the product you have been given in your patient file. you may also wish to make a note of these details in case you are asked for this information in the future. do not use mvasi if : you are allergic ( hypersensitive ) to bevacizumab or to any of the other ingredients of this medicine ( listed in section 6 ). you are allergic ( hypersensitive ) to chinese hamster ovary ( cho ) cell products or to other recombinant human or humanised antibodies. you are pregnant. warnings and precautions talk to your doctor, pharmacist or nurse before using mvasi it is possible that mvasi may increase the risk of developing holes in the gut wall. if you have conditions causing inflammation inside the abdomen ( e. g. diverticulitis, stomach ulcers, colitis associated with chemotherapy ), please discuss this with your doctor. mvasi may increase the risk of developing an abnormal connection or passageway between two organs or vessels. the risk of developing connections between the vagina and any parts of the gut can increase if you have persistent, recurrent or metastatic cervical cancer. mvasi can increase the risk of bleeding or increase the risk of problems with wound healing after surgery. if you are going to have an operation, if you have had major surgery within the last 28 days or if you still have an unhealed wound following surgery, you should not receive this medicine. mvasi may increase the risk of developing serious infections of the skin or deeper layers under the skin, especially if you had holes in the gut wall or problems with wound healing. mvasi can increase the incidence of high blood pressure. if you have high blood pressure which is not well controlled with blood pressure medicines, please consult your doctor as it is important to make sure that your blood pressure is under control before starting mvasi treatment. mvasi increases the risk of having protein in your urine especially if you already have high blood pressure. the risk of developing blood clots in your arteries ( a type of blood vessel )
dosage and frequency of administration the dose of mvasi needed depends on your body weight and the kind of cancer to be treated. the recommended dose is 5 mg, 7. 5 mg, 10 mg or 15 mg per kilogram of your body weight. your doctor will prescribe a dose of mvasi that is right for you. you will be treated with mvasi once every 2 or 3 weeks. the number of infusions that you receive will depend on how you are responding to treatment ; you should continue to receive this medicine until mvasi fails to stop your tumour growing. your doctor will discuss this with you. method and route of administration mvasi is a concentrate for solution for infusion. depending on the dose prescribed for you, some or all of the contents of the mvasi vial will be diluted with sodium chloride solution before use. a doctor or nurse will give you this diluted mvasi solution by intravenous infusion ( a drip into your vein ). the first infusion will be given to you over 90 minutes. if this is well - tolerated the second infusion may be given over 60 minutes. later infusions may be given to you over 30 minutes. the administration of mvasi should be temporarily discontinued if you develop severe high blood pressure requiring treatment with blood pressure medicines, if you have problems with wound healing following surgery, if you undergo surgery. the administration of mvasi should be permanently discontinued if you develop severe high blood pressure which cannot be controlled by blood pressure medicines ; or a sudden severe rise in blood pressure, presence of protein in your urine accompanied by swelling of your body, a hole in your gut wall, an abnormal tube - like connection or passage between the windpipe and the gullet, between internal organs and skin, between the vagina and any parts of the gut or between other tissues that are not normally connected ( fistula ), and are judged by your doctor to be severe, serious infections of the skin or deeper layers under the skin, a blood clot in your arteries, a blood clot in the blood vessels of your lungs, any severe bleeding. if too much mvasi is given you may
like all medicines, this medicine can cause side effects, although not everybody gets them. if you get any side effects talk to your doctor, pharmacist or nurse. this includes any possible side effects not listed in this leaflet. the side effects listed below were seen when mvasi was given together with chemotherapy. this does not necessarily mean that these side effects were strictly caused by mvasi. allergic reactions if you have an allergic reaction, tell your doctor or a member of the medical staff straight away. the signs may include : difficulty in breathing or chest pain. you could also experience redness or flushing of the skin or a rash, chills and shivering, feeling sick ( nausea ) or being sick ( vomiting ). you should seek help immediately if you suffer from any of the below mentioned side effects. severe side effects, which may be very common ( may affect more than 1 in 10 people ), include : high blood pressure, feeling of numbness or tingling in hands or feet, decreased number of cells in the blood, including white cells that help to fight against infections ( this may be accompanied by fever ), and cells that help the blood to clot, feeling weak and having no energy, tiredness, diarrhoea, nausea, vomiting and abdominal pain. severe side effects, which may be common ( may affect up to 1 in 10 people ), include : perforation of the gut, bleeding, including bleeding in the lungs in patients with non - small cell lung cancer, blocking of the arteries by a blood clot, blocking of the veins by a blood clot, blocking of the blood vessels of the lungs by a blood clot, blocking of the veins of the legs by a blood clot, heart failure, problems with wound healing after surgery, redness, peeling, tenderness, pain, or blistering on the fingers or feet, decreased number of red cells in the blood, lack of energy, stomach and intestinal disorder, muscle and joint pain, muscular weakness, dry mouth in combination with thirst and / or reduced or darkened urine, inflammation of the moist lining
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the outer carton and on the vial label after the abbreviation exp . the expiry date refers to the last day of that month . store in a refrigerator ( 2 - 8 ). do not freeze . keep the vial in the outer carton in order to protect from light . infusion solutions should be used immediately after dilution . if not used immediately , in - use storage times and conditions are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 , unless the infusion solutions have been prepared in a sterile environment . when dilution has taken place in a sterile environment , mvasi is stable for 35 days at 2 to 8 plus an additional 48 hours at temperatures not exceeding 30 . do not use mvasi if you notice any particulate matter or discolouration prior to administration . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help to protect the environment .
what mvasi contains the active substance is bevacizumab . each ml of concentrate contains 25 mg of bevacizumab , corresponding to 1 . 4 to 16 . 5 mg / ml when diluted as recommended . each 4 ml vial contains 100 mg of bevacizumab , corresponding to 1 . 4 mg / ml when diluted as recommended . each 16 ml vial contains 400 mg of bevacizumab , corresponding to 16 . 5 mg / ml when diluted as recommended . the other ingredients are trehalose dihydrate , sodium phosphate , polysorbate 20 and water for injections . what mvasi looks like and contents of the pack mvasi is a concentrate for solution for infusion . the concentrate is a clear to slightly opalescent , colourless to slightly yellow liquid in a glass vial with a rubber stopper . each vial contains 100 mg bevacizumab in 4 ml of solution or 400 mg bevacizumab in 16 ml of solution . each pack of mvasi contains one vial .
tecartus is a gene therapy medicine used for treating mantle cell lymphoma in adults . it is used when other medicines have stopped working for you ( relapsed or refractory mantle cell lymphoma ). the medicine is made specially for you from your own white blood cells that have been modified and are known as autologous anti - cd19 - transduced cd3 + cells . mantle cell lymphoma is a cancer of a part of the immune system ( the body ' s defences ). it affects a type of white blood cell called b - lymphocytes . in mantle cell lymphoma , b - lymphocytes grow in an uncontrolled way and build up in the lymph tissue , bone marrow or blood . how tecartus works the white blood cells are taken from your blood and are genetically modified so that they can target the cancer cells in your body . when tecartus is infused into your blood , the modified white blood cells will kill the cancer cells .
you are not to be given tecartus if you are allergic to any of the ingredients of this medicine ( listed in section 6 ). if you think you may be allergic, ask your doctor for advice. if you can't receive the medicine to reduce the number of white blood cells in your blood ( lymphodepleting chemotherapy ) ( see also section 3, how tecartus is given ). warnings and precautions tecartus is made from your own white blood cells and should only be given to you ( autologous use ). tests and checks before you are given tecartus your doctor will : check your lungs, heart, kidney and blood pressure. look for signs of infection or inflammation ; and decide whether you need to be treated before you are given tecartus. check if your cancer is getting worse. look for signs of graft - versus - host disease that can happen after a transplant. this happens when transplanted cells attack your body, causing symptoms such as rash, nausea, vomiting, diarrhoea and bloody stools. check your blood for uric acid and for how many cancer cells there are in your blood. this will show if you are likely to develop a condition called tumour lysis syndrome. you may be given medicines to help prevent the condition. check for hepatitis b, hepatitis c or hiv infection. check if you had a vaccination in the previous 6 weeks or are planning to have one in the next few months. check if you have previously received a treatment that attaches to the protein called cd19. in some cases, it might not be possible to go ahead with the planned treatment with tecartus. if tecartus infusion is delayed for more than 2 weeks after you have received lymphodepleting chemotherapy you may have to receive more chemotherapy ( see also section 3, how tecartus is given ). after you have been given tecartus tell your doctor or nurse immediately or get emergency help right away if you have any of the following : chills, extreme tiredness, weakness, dizziness, headache, cough, short
tecartus will always be given to you by a healthcare professional. since tecartus is made from your own white blood cells, your cells will be collected from you to prepare your medicine. your doctor will take some of your blood using a catheter placed in your vein ( a procedure call leukapheresis ). some of your white blood cells are separated from your blood and the rest of your blood is returned to your vein. this can take 3 to 6 hours and may need to be repeated. your white blood cells are sent away to a manufacturing center to make your tecartus. it usually takes about 2 to 3 weeks to make tecartus but the time may vary. medicines given before tecartus treatment a few days before you receive tecartus, you will be given lymphodepleting chemotherapy, which will allow the modified white blood cells in tecartus to multiply in your body when the medicine is given to you. during the 30 to 60 minutes before you are given tecartus you may be given other medicines. this is to help prevent infusion reactions and fever. these other medicines may include : paracetamol. an antihistamine such as diphenhydramine. how you are given tecartus tecartus will always be given to you by a doctor in a qualified treatment centre. tecartus is given in a single dose. your doctor or nurse will give you a single infusion of tecartus through a catheter placed into your vein ( intravenous infusion ) over about 30 minutes. tecartus is the genetically modified version of your white blood cells. your healthcare professional handling the treatment will therefore take appropriate precautions ( wearing gloves and glasses ) to avoid potential transmission of infectious diseases and will follow local guidelines on handling of waste of human - derived material to clean up or dispose of any material that has been in contact with it. after you are given tecartus you should stay close to the hospital where you were treated for at least 4 weeks after tecartus treatment. your doctor will recommend that you return to the hospital daily for at least 10 days or that you stay at the hospital as an in - patient for the first 10 days after tecartus treatment. this is so your
like all medicines, this medicine can cause side effects, although not everybody gets them. do not try to treat your side effects on your own. tecartus can cause side effects that may be serious or life - threatening. get urgent medical attention if you get any of the following side effects after the tecartus infusion. very common : may affect more than 1 in 10 people fever, chills, reduced blood pressure which may cause symptoms such as dizziness, lightheadedness, fluid in the lungs, which may be severe and can be fatal ( all symptoms of a condition called cytokine release syndrome ). loss of consciousness or decreased level of consciousness, confusion or memory loss due to disturbances of brain function, difficulty speaking or slurred speech, involuntary shaking ( tremor ), fits ( seizures ), sudden confusion with agitation, disorientation, hallucination or irritability ( delirium ). fever, chills, which may be signs of an infection. other possible side effects other side effects are listed below. if these side effects become severe or serious, tell your doctor immediately. very common : may affect more than 1 in 10 people abnormally low number of white blood cells, which may increase your risk of infection. low number of cells that help clot the blood ( thrombocytopenia ), alteration of the blood's ability to form clots : symptoms can include excessive or prolonged bleeding or bruising. high blood pressure. decrease in the number of red blood cells ( cells that carry oxygen ): symptoms can include extreme tiredness with a loss of energy. extreme tiredness. fast or slow heartbeat. decrease of oxygen reaching body tissues : symptoms can include changes to the colour of your skin, confusion, rapid breathing. shortness of breath, cough. nausea, constipation, diarrhoea, abdominal pain, vomiting, difficulty swallowing. muscle pain, joint pain, bone pain, pain in the extremities of the body. lack of energy or strength, muscular weakness, difficulty moving, muscle spasm. headache. kidney problems
the following information is intended for doctors only . keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the container label and infusion bag after exp . store frozen in vapour phase of liquid nitrogen â¤ â 150 until thawed for use . do not refreeze . this medicine contains genetically modified human blood cells . local guidelines on handling of waste of human - derived material should be followed for unused medicinal product or waste material . as this 36 medicine will be given by qualified healthcare professionals , they are responsible for the correct disposal of the product . these measures will help protect the environment .
what tecartus contains the active substance is autologous anti - cd19 - transduced cd3 + cells . each patient - specific single infusion bag contains a dispersion of anti - cd19 car t cells in approximately 68 ml for a target dose of 2 Ã 106 anti - cd19 car - positive viable t cells / kg . the other ingredients ( excipients ) are : cryostor cs10 , sodium chloride , human albumin . see section 2 " tecartus contains sodium ". what tecartus looks like and contents of the pack tecartus is a clear to opaque , white to red dispersion for infusion , supplied in an infusion bag individually packed in a metal cassette . a single infusion bag contains approximately 68 ml of cell dispersion .
januvia contains the active substance sitagliptin which is a member of a class of medicines called dpp - 4 inhibitors ( dipeptidyl peptidase - 4 inhibitors ) that lowers blood sugar levels in adult patients with type 2 diabetes mellitus . this medicine helps to increase the levels of insulin produced after a meal and decreases the amount of sugar made by the body . your doctor has prescribed this medicine to help lower your blood sugar , which is too high because of your type 2 diabetes . this medicine can be used alone or in combination with certain other medicines ( insulin , metformin , sulphonylureas , or glitazones ) that lower blood sugar , which you may already be taking for your diabetes together with a food and exercise plan . what is type 2 diabetes ? type 2 diabetes is a condition in which your body does not make enough insulin , and the insulin that your body produces does not work as well as it should . your body can also make too much sugar . when this happens , sugar ( glucose ) builds up in the blood . this can lead to serious medical problems like heart disease , kidney disease , blindness , and amputation .
do not take januvia - if you are allergic to sitagliptin or any of the other ingredients of this medicine ( listed in section 6 ). warnings and precautions cases of inflammation of the pancreas ( pancreatitis ) have been reported in patients receiving januvia ( see section 4 ). if you encounter blistering of the skin it may be a sign for a condition called bullous pemphigoid. your doctor may ask you to stop januvia. tell your doctor if you have or have had : - a disease of the pancreas ( such as pancreatitis ) - gallstones, alcohol dependence or very high levels of triglycerides ( a form of fat ) in your blood. these medical conditions can increase your chance of getting pancreatitis ( see section 4 ). - type 1 diabetes - diabetic ketoacidosis ( a complication of diabetes with high blood sugar, rapid weight loss, nausea or vomiting ) - any past or present kidney problems - an allergic reaction to januvia ( see section 4 ) this medicine is unlikely to cause low blood sugar because it does not work when your blood sugar is low. however, when this medicine is used in combination with a sulphonylurea medicine or with insulin, low blood sugar ( hypoglycaemia ) can occur. your doctor may reduce the dose of your sulphonylurea or insulin medicine. children and adolescents children and adolescents below 18 years should not use this medicine. it is not effective in children and adolescents between the ages of 10 and 17 years. it is not known if this medicine is safe and effective when used in children younger than 10 years. other medicines and januvia tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. in particular, tell your doctor if you are taking digoxin ( a medicine used to treat irregular heart beat and other heart problems ). the level of digoxin in your blood may need to be checked if taking with januvia. pregnancy and breast - feeding if you are pregnant or breast - feeding, think you
always take this medicine exactly as your doctor has told you . check with your doctor or pharmacist if you are not sure . the usual recommended dose is : one 100 mg film - coated tablet 63 once a day by mouth if you have kidney problems , your doctor may prescribe lower doses ( such as 25 mg or 50 mg ). you can take this medicine with or without food and drink . your doctor may prescribe this medicine alone or with certain other medicines that lower blood sugar . diet and exercise can help your body use its blood sugar better . it is important to stay on the diet and exercise recommended by your doctor while taking januvia . if you take more januvia than you should if you take more than the prescribed dosage of this medicine , contact your doctor immediately . if you forget to take januvia if you miss a dose , take it as soon as you remember . if you do not remember until it is time for your next dose , skip the missed dose and go back to your regular schedule . do not take a double dose of this medicine . if you stop taking januvia continue to take this medicine as long as your doctor prescribes it so you can continue to help control your blood sugar . you should not stop taking this medicine without talking to your doctor first . if you have any further questions on the use of this medicine , ask your doctor or pharmacist .
like all medicines, this medicine can cause side effects, although not everybody gets them. stop taking januvia and contact a doctor immediately if you notice any of the following serious side effects : severe and persistent pain in the abdomen ( stomach area ) which might reach through to your back with or without nausea and vomiting, as these could be signs of an inflamed pancreas ( pancreatitis ). if you have a serious allergic reaction ( frequency not known ), including rash, hives, blisters on the skin / peeling skin and swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing, stop taking this medicine and call your doctor right away. your doctor may prescribe a medicine to treat your allergic reaction and a different medicine for your diabetes. some patients have experienced the following side effects after adding sitagliptin to metformin : common ( may affect up to 1 in 10 people ): low blood sugar, nausea, flatulence, vomiting uncommon ( may affect up to 1 in 100 people ): stomach ache, diarrhoea, constipation, drowsiness some patients have experienced different types of stomach discomfort when starting the combination of sitagliptin and metformin together ( frequency is common ). some patients have experienced the following side effects while taking sitagliptin in combination with a sulphonylurea and metformin : very common ( may affect more than 1 in 10 people ): low blood sugar common : constipation some patients have experienced the following side effects while taking sitagliptin and pioglitazone : common : flatulence, swelling of the hands or legs 64 some patients have experienced the following side effects while taking sitagliptin in combination with pioglitazone and metformin : common : swelling of the hands or legs some patients have experienced the following side effects while taking sitagliptin in combination with insulin ( with or without metformin ): common : flu uncommon : dry mouth some patients have experienced the following side effects while taking sitagliptin alone in clinical studies, or during post - approval use alone and / or with
what januvia contains - the active substance is sitagliptin . each film - coated tablet ( tablet ) contains sitagliptin phosphate monohydrate , equivalent to 25 mg sitagliptin . - the other ingredients are : in the tablet core : microcrystalline cellulose ( e460 ), calcium hydrogen phosphate , anhydrous ( e341 ), croscarmellose sodium ( e468 ), magnesium stearate ( e470b ), and sodium stearyl fumarate . the tablet film coating contains : poly ( vinyl alcohol ), macrogol 3350 , talc ( e553b ), titanium dioxide ( e171 ), red iron oxide ( e172 ), and yellow iron oxide ( e172 ). what januvia looks like and contents of the pack round , pink film - coated tablet with " 221 " on one side . opaque blisters ( pvc / pe / pvdc and aluminium ). packs of 14 , 28 , 30 , 56 , 84 , 90 or 98 film - coated tablets and 50 x 1 film - coated tablets in perforated unit dose blisters . not all pack sizes may be marketed .
what xultophy is used for xultophy is used to improve blood glucose ( sugar ) levels in adult patients with type 2 diabetes mellitus . you have diabetes because your body : does not make enough insulin to control the level of sugar in your blood or is not able to use the insulin properly . how xultophy works xultophy contains two active substances that help your body control your blood sugar : insulin degludec a long - acting basal insulin which lowers your blood sugar levels . liraglutide a ' glp - 1 analogue ' that helps your body make more insulin during meals and lowers the amount of sugar made by your body . xultophy and oral medicines for diabetes xultophy is used with oral medicines for diabetes ( such as metformin , pioglitazone and sulfonylurea medicines ). it is prescribed when these medicines ( used alone or with glp - 1 treatment or with basal insulin ) are not enough to control your blood sugar levels . if you use glp - 1 treatment you should stop your glp - 1 treatment prior to starting on xultophy . if you use insulin you should stop your insulin treatment prior to starting on xultophy .
do not use xultophy if you are allergic to insulin degludec or liraglutide or any of the other ingredients of this medicine ( listed in section 6 ). warnings and precautions 39 talk to your doctor, pharmacist or nurse before using xultophy. if you are also taking a sulfonylurea ( such as glimepiride or glibenclamide ), your doctor may tell you to lower your sulfonylurea dose depending on your blood sugar levels. do not use xultophy if you have type 1 diabetes mellitus or if you have'ketoacidosis'( a condition with a build - up of acid in the blood ). the use of xultophy is not recommended in patients with inflammatory bowel disease or delayed gastric emptying ( diabetic gastroparesis ). be especially aware of the following when using xultophy : low blood sugar ( hypoglycaemia ) if your blood sugar is low, follow the advice in section 4'low blood sugar ( hypoglycaemia )'. high blood sugar ( hyperglycaemia ) if your blood sugar is high, follow the advice in section 4'high blood sugar ( hyperglycaemia )'. ensuring you use the right medicine always check the pen label before each injection to avoid accidentally confusing xultophy with other products. important things to know before you use this medicine : tell your doctor if you : have eye problems. fast improvements in blood sugar control may make diabetic eye problems get worse for a short time. the long - term improvements in blood sugar control may ease the eye problems. have or have had a thyroid disease. important things to know while you are using this medicine : if you have a severe stomach ache which does not go away, tell your doctor this could be a sign of inflamed pancreas ( acute pancreatitis ). dehydration ( loss of fluids from the body ) can happen if you are feeling or being sick ( nausea or vomiting ) or have diarrhoea it is important to drink plenty of fluid
always use this medicine exactly as your doctor has told you. check with your doctor, pharmacist or nurse if you are not sure. if you are blind or have poor eyesight and cannot read the dose counter on the pen, do not use this pen without help. get help from a person with good eyesight who is trained to use the xultophy pre - filled pen. your doctor will tell you : how much xultophy you will need each day when to check your blood sugar level how to adjust the dose. your dose of xultophy is administered as'dose steps '. the dose counter on the pen shows the number 41 of dose steps. dosing time use xultophy once each day, preferably at the same time every day. choose a time of the day that works best for you. if it is not possible to use xultophy at the same time every day, it can be used at a different time of the day. make sure to have a minimum of 8 hours between the doses. you do not have to use xultophy with a meal. always follow your doctor's advice for dose and dose adjustment. if you want to change your usual diet, check with your doctor, pharmacist or nurse first as a change in diet may alter your need for xultophy. how to handle xultophy xultophy is a pre - filled dial - a - dose pen. xultophy is administered as'dose steps '. the dose counter on the pen shows the number of dose steps. one dose step contains 1 unit of insulin degludec and 0. 036 mg of liraglutide. the maximum daily dose of xultophy is 50 dose steps ( 50 units of insulin degludec and 1. 8 mg of liraglutide ). carefully read the'instructions on how to use'on the other side of this leaflet and use the pen as described. always check the pen label before you inject your medicine to ensure that you use the correct pen. how to inject before you use xultophy for the first time, your doctor or nurse
like all medicines, this medicine can cause side effects, although not everybody gets them. the following serious side effects may happen with this medicine : low blood sugar ( very common : may affect more than 1 in 10 people ). if your blood sugar level gets low you may pass out ( become unconscious ). serious hypoglycaemia may cause brain damage and may be life - threatening. if you have signs of low blood sugar, take actions to increase your blood sugar level straight away. see advice in'low blood sugar ( hypoglycaemia )' further down in this section. serious allergic reaction ( anaphylactic reaction ) ( not known : frequency cannot be estimated from the available data ). if you have a serious allergic reaction to any of the ingredients in xultophy, stop using xultophy and see a doctor straight away. the signs of a serious allergic reaction are : local reactions spread to other parts of your body you suddenly feel unwell with sweating you have difficulty breathing you get a fast heartbeat or feel dizzy. other side effects include : common ( may affect up to 1 in 10 people ) lower appetite, feeling or being sick ( nausea or vomiting ), diarrhoea, constipation, indigestion ( dyspepsia ), inflamed lining of the stomach ( gastritis ), stomach ache, heartburn or bloating these usually go away after a few days or weeks. injection site reactions. the signs may include bruising, bleeding, pain, redness, hives, swelling or itching these usually go away after a few days. see your doctor if they do not disappear after a few weeks. stop using xultophy and see a doctor straight away if they become serious. increase of pancreatic enzymes, such as lipase and amylase. uncommon ( may affect up to 1 in 100 people ) hives ( red bumps on your skin that are sometimes itchy ). allergic reactions ( hypersensitivity ) such as rash, itching and swelling of the face. dehydration ( loss of fluid from the body ) it is important to drink plenty
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the pen label and carton after ' exp '. the expiry date refers to the last day of that month . before opening store in a refrigerator ( 2 to 8 ). keep away from the freezing element . do not freeze . during use do not freeze . you can carry xultophy with you and keep it at room temperature ( no more than 30 ) or in a refrigerator ( 2 to 8 ) for up to 21 days . the product should be thrown away 21 days after first opening . always keep the cap on the pre - filled pen when you are not using it in order to protect it from light . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what xultophy contains the active substances are insulin degludec and liraglutide . each ml of solution contains 100 units of insulin degludec and 3 . 6 mg liraglutide . each unused pre - filled pen ( 3 ml ) contains 300 units of insulin degludec and 10 . 8 mg liraglutide . the other ingredients are glycerol , phenol , zinc acetate , hydrochloric acid and sodium hydroxide ( for ph adjustment ), and water for injections . see also section 2 ' important information about some of the ingredients of xultophy ' for information on sodium . what xultophy looks like and contents of the pack xultophy is a clear and colourless solution . pack sizes of 1 , 3 , 5 and a multipack containing 10 ( 2 packs of 5 ) pens of 3 ml . not all pack sizes may be marketed .
giotrif is a medicine which contains the active substance afatinib . it works by blocking the activity of a group of proteins called the erbb family ( including egfr [ epidermal growth factor receptor or erbb1 ], her2 [ erbb2 ], erbb3 and erbb4 ). these proteins are involved in the growth and spread of cancer cells , and can be affected by changes ( mutations ) in the genes that produce them . by blocking the activity of these proteins this medicine can inhibit growth and spread of cancer cells . this medicine is used on its own to treat adult patients with a specific type of cancer of the lung ( non - small cell lung cancer ): that is identified by a change ( mutation ) in the gene for egfr . giotrif can be prescribed to you as your first treatment or if prior chemotherapy treatment has been insufficient . of squamous type if prior chemotherapy treatment has been insufficient .
do not take giotrif - if you are allergic to afatinib or any of the other ingredients of this medicine ( listed in section 6 ). warnings and precautions talk to your doctor or pharmacist before taking this medicine : if you are female, have a low body weight of less than 50 kg or have kidney problems. if any of these apply to you, your doctor may monitor you more closely as the side effects may be more pronounced. if you have a history of lung inflammation ( interstitial lung disease ). if you have liver problems. your doctor may do some liver tests. treatment with this medicine is not recommended if you have a severe liver disease. if you have a history of eye problems such as severe dry eyes, inflammation of the transparent layer at the front of the eye ( cornea ) or ulcers involving the outer part of the eye, or if you use contact lenses. if you have a history of heart problems. your doctor may want to monitor you more closely. inform your doctor immediately while taking this medicine : if you develop diarrhoea. treatment at the first signs of diarrhoea is important. if you develop skin rash. early treatment of skin rash is important. if you develop new or sudden worsening of shortness of breath, possibly with a cough or fever. these could be symptoms of an inflammation of the lungs ( interstitial lung disease ) and can be life - threatening. if you have severe pain in your stomach or intestines, fever, chills, sickness, vomiting, or abdominal rigidity or bloating, as these could be symptoms of a tear in the wall of your stomach or intestines (' gastrointestinal perforation '). also, tell your doctor if you had gastrointestinal ulcers or diverticular disease in the past, or are concomitantly treated with anti - inflammatory drugs ( nsaids ) ( used to treat pain relief and swelling ) or steroids ( used for inflammation and allergies ), as this may increase this risk. if you develop acute or worsening redness and pain in the eye,
always take this medicine exactly as your doctor has told you. check with your doctor or pharmacist if you are not sure. dosage the recommended dose is 40 mg each day. your doctor may adjust ( increase or decrease ) your dose depending on how well you tolerate this medicine. when to take giotrif it is important to take this medicine without food take this medicine at least 1 hour before eating, or if you have already eaten, wait at least 3 hours before taking this medicine. take this medicine once daily about the same time each day. this makes it easier to remember to take this medicine. do not break, chew or crush the tablet. swallow the tablet whole with a glass of still water. giotrif is to be taken by mouth. if you have difficulties swallowing the tablet, dissolve it in a glass of still water. no other liquids should be used. drop the tablet into the water without crushing it, and occasionally stir for up to 15 min until the tablet is broken up into very small particles. drink the liquid straight away. then fill the glass again with water and drink it to make sure all medicine is taken. if you are not able to swallow and have a gastric tube your doctor might suggest that the medicine is given to you via the tube. if you take more giotrif than you should contact your doctor or pharmacist immediately. you may experience increased side effects and your doctor may interrupt your treatment and provide supportive care. if you forget to take giotrif if your next scheduled dose is more than 8 hours away, take the missed dose as soon as you remember. if your next scheduled dose is due within 8 hours, skip the missed dose and take your next dose at the usual time. then carry on taking your tablets at regular times as usual. do not take a double dose ( two tablets instead of one at the same time ) to make up for a missed dose. if you stop taking giotrif do not stop taking this medicine without first consulting your doctor. it is important to take this medicine every day, as long as your doctor prescribes it for you. if you do not take this medicine as prescribed by your doctor your cancer may grow again. if you have any further questions on the use of this medicine
like all medicines, giotrif can cause side effects, although not everybody gets them. contact your doctor as soon as possible if you suffer from any of the serious side effects listed below. in some cases your doctor may need to interrupt treatment and reduce your dose or stop treatment : diarrhoea ( very common, may affect more than 1 in 10 people ). diarrhoea lasting more than 2 days or more severe diarrhoea may lead to fluid loss ( common, may affect up to 1 in 10 people ), low blood potassium ( common ) and worsening kidney function ( common ). diarrhoea can be treated. at the first signs of diarrhoea drink plenty of fluids. contact your doctor immediately and start appropriate antidiarrhoeal treatment as soon as possible. you should have antidiarrhoeal medicine available prior to taking giotrif. skin rash ( very common ). it is important to treat the rash early. tell your doctor if a rash starts. if treatment for rash is not working and the rash is getting more severe ( for example, you have peeling or blistering of the skin ) you should notify your doctor immediately, since your doctor may decide to stop your treatment with giotrif. rash may occur or worsen in areas exposed to sun. sun protection with protective clothing and sunscreen is recommended. inflammation of the lungs ( uncommon, may affect up to 1 in 100 people ) called " interstitial lung disease ". tell your doctor immediately if you develop new or sudden worsening of shortness of breath, possibly with a cough or fever. eye irritation or inflammation eye irritation or inflammation may occur ( conjunctivitis / keratoconjunctivitis occurs commonly and keratitis uncommonly ). tell your doctor if you have sudden or worsening of eye symptoms such as pain or redness or dry eye. if you experience any of the symptoms above, contact your doctor as soon as possible. the following other side effects have also been reported : very common side effects ( may affect more than 1 in 10 people ): mouth sores and inflammation
what giotrif contains - the active substance is afatinib . each film - coated tablet contains 20 mg of afatinib ( as dimaleate ). - the other ingredients are lactose monohydrate , microcrystalline cellulose ( e460 ), colloidal anhydrous silica ( e551 ), crospovidone type a , magnesium stearate ( e470b ), hypromellose ( e464 ), macrogol 400 , titanium dioxide ( e171 ), talc ( e553b ), polysorbate 80 ( e433 ). what giotrif looks like and contents of the pack giotrif 20 mg film - coated tablets are white to yellowish and round shaped . they are debossed with the code " t20 " on one side and the boehringer ingelheim company logo on the other . giotrif film - coated tablets are available in packs containing 1 , 2 or 4 perforated unit dose blisters . each blister contains 7 x 1 film - coated tablets and is packed in an aluminium pouch together with a desiccant sachet that should not be swallowed . not all pack sizes may be marketed .
orkambi contains two active substances , lumacaftor and ivacaftor . it is a medicine used for long - term treatment of cystic fibrosis ( cf ) in patients aged 6 years and older who have a specific change ( called f508del mutation ) affecting the gene for a protein called cystic fibrosis transmembrane conductance regulator ( cftr ), which plays an important role in regulating the flow of mucus in the lungs . people with the mutation will produce an abnormal cftr protein . cells contain two copies of the cftr gene ; orkambi is used in patients in whom both copies are affected by the f508del mutation ( homozygotes ). lumacaftor and ivacaftor work together to improve the function of the abnormal cftr protein . lumacaftor increases the amount of cftr available and ivacaftor helps the abnormal protein to work more normally . orkambi may help your breathing by improving your lung function . you may also notice that it is easier to gain weight . .
do not take orkambi if you are allergic to lumacaftor, ivacaftor, or any of the other ingredients of this medicine ( listed in section 6 ). warnings and precautions talk to your doctor or pharmacist before taking orkambi. orkambi should not be used in patients other than those who have two copies of the f508del mutation in their cftr gene. talk to your doctor before taking orkambi if you have been told you have liver or kidney disease as your doctor may need to adjust the dose of orkambi. abnormal blood tests of the liver have been commonly seen in some people receiving orkambi. tell your doctor straight away if you have any of these symptoms, which may be a sign of liver problems : pain or discomfort in the upper right stomach ( abdominal ) area yellowing of your skin or the white part of your eyes loss of appetite nausea or vomiting dark urine confusion your doctor should do some blood tests to check your liver before and while you are taking orkambi, particularly during the first year. respiratory events such as shortness of breath or chest tightness or narrowing of the airways were seen in patients when starting orkambi, especially in patients who have poor lung function. if you have poor lung function your doctor may monitor you more closely when you start orkambi. an increase in blood pressure has been seen in some patients treated with orkambi. your doctor may monitor your blood pressure during treatment with orkambi. abnormality of the lens of the eye ( cataract ) without any effect on vision has been noted in some children and adolescents treated with orkambi and ivacaftor alone ( one of the components of orkambi ). your doctor may perform some eye examinations prior to and during treatment with orkambi. orkambi is not recommended in patients who have undergone an organ transplant. children under 6 years old orkambi tablets should not be used in children under the age of 6 years. other forms of this medicine ( granules in a sachet ) are more suitable for children under 6 years of age, ask your doctor or pharmacist. other medicines and orkambi tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines
always take this medicine exactly as your doctor has told you. check with your doctor if you are not sure. recommended dose the recommended dose for patients aged 6 years and over is two tablets in the morning, and two tablets in the evening ( 12 hours apart ). that is a total of four tablets per day, to be taken with food containing fat. there are different strengths of orkambi tablet for different age groups. check you have been given the right tablet ( below ). age tablets dose 6 to 11 years orkambi 100 mg / 125 mg 2 tablets in the morning 2 tablets in the evening 12 years and older orkambi 200 mg / 125 mg 2 tablets in the morning 2 tablets in the evening you may start taking orkambi on any day of the week. if you have moderate or severe problems with liver function, your doctor may need to reduce the dose of orkambi as your liver will not clear orkambi as fast as in people who have normal liver function. moderate liver problems : the dose may be reduced to two tablets in the morning and one tablet in the evening. severe liver problems : the dose may be reduced to one tablet in the morning and one tablet in the evening. method of administration orkambi is for oral use. swallow the tablets whole. do not chew, break, or dissolve the tablets. taking orkambi with fat - containing food is important to get the right levels of medicine in your body. a fat - containing meal or snack should be consumed just before or just after taking orkambi. meals and snacks recommended in cf guidelines or meals recommended in standard nutritional guidelines contain adequate amounts of fat. examples of meals or snacks that contain fat are those prepared with butter or oils or those containing eggs. examples of other fat - containing foods are : cheese, whole milk, whole - milk dairy products meats, oily fish avocados, hummus, soy - based products ( tofu ) nutritional bars or drinks 91 if you take more orkambi than you should contact your doctor or pharmacist for advice. if possible, have your medicine and this leaflet with you. you may experience side effects, including those mentioned in section 4 below. if you forget to take ork
like all medicines, this medicine can cause side effects although not everybody gets them. the side effects reported with orkambi and ivacaftor alone ( one of the active substances of orkambi ) are listed below and may occur with the use of orkambi. serious side effects for orkambi include raised levels of liver enzymes in the blood, liver injury, and worsening of pre - existing severe liver disease. the worsening of liver function can be fatal. these serious side effects are uncommon ( may affect up to 1 in 100 people ). tell your doctor straight away if you have any of the following symptoms : pain or discomfort in the upper right stomach ( abdominal ) area yellowing of your skin or the white part of your eyes loss of appetite nausea or vomiting confusion dark urine other side effects very common ( may affect more than 1 in 10 people ) cough with sputum nasal congestion shortness of breath headache abdominal pain ( stomach ache ) diarrhoea increase in sputum nausea common cold * dizziness * changes in the type of bacteria in mucus * common ( may affect up to 1 in 10 people ) chest tightness narrowing of the airways sinus congestion * stuffy or runny nose upper respiratory tract infection sore throat redness in the throat * rash 92 passing gas vomiting increase of an enzyme in your blood ( blood creatine phosphokinase ) high levels of liver enzymes, shown by blood test irregular periods ( menses ) or pain with menses ear pain, ear discomfort * ringing in the ears * redness inside the ear * inner ear disorder ( feeling dizzy or spinning )* breast mass * uncommon ( may affect up to 1 in 100 people ) abnormal periods, including the absence or infrequent menses, or more frequent or heavier menstrual bleeding increase in blood pressure ear congestion * breast inflammation * enlargement of the breast in males * nipple changes or pain * * side effects seen for ivacaftor alone. side effects in children side effects seen in children are similar to those seen in adults and adolescents. however, increased liver enzymes in the blood have been seen more frequently in younger children than in adults. reporting of side effects if you get any side effects
what orkambi contains the active substances are lumacaftor and ivacaftor. orkambi 100 mg / 125 mg film - coated tablets : each film - coated tablet contains 100 mg of lumacaftor and 125 mg of ivacaftor. orkambi 200 mg / 125 mg film - coated tablets : each film - coated tablet contains 200 mg of lumacaftor and 125 mg of ivacaftor. orkambi 100 mg / 125 mg film - coated tablets and orkambi 200 mg / 125 mg film - coated tablets : the other ingredients are : tablet core : cellulose, microcrystalline ; croscarmellose sodium ; hypromellose acetate succinate ; povidone ( k30 ); sodium laurilsulfate ; and magnesium stearate ( see section 2 " orkambi contains sodium "). tablet coating : polyvinyl alcohol ; titanium dioxide ( e171 ); macrogol 3350 ; talc ; carmine ( e120 ); brilliant blue fcf aluminium lake ( e133 ); and indigo carmine aluminium lake ( e132 ). printing ink : shellac ; iron oxide black ( e172 ); propylene glycol ; and ammonium hydroxide. what orkambi looks like and contents of the pack orkambi 100 mg / 125 mg film - coated tablets orkambi 100 mg / 125 mg film - coated tablets ( tablets ) are pink, oval - shaped tablets ( dimensions 14 <unk> 7. 6 <unk> 4. 9 mm ) printed with " 1v125 " in black ink on one side. orkambi 100 mg / 125 mg is available in packs containing 112 film - coated tablets ( 4 packs of 28 film - coated tablets ). orkambi 200 mg / 125 mg film - coated tablets orkambi 200 mg / 125 mg film - coated tablets ( tablets ) are pink, oval - shaped tablets ( dimensions 14 <unk> 8. 4 <unk> 6
what lynparza is and how it works lynparza contains the active substance olaparib . olaparib is a type of cancer medicine called a parp inhibitor ( poly [ adenosine diphosphate - ribose ] polymerase inhibitor ). in patients with mutations ( changes ) in certain genes called brca ( breast cancer gene ), who are at risk of developing some forms of cancer , parp inhibitors are able to trigger the death of cancer cells by blocking an enzyme that helps repair dna . what lynparza is used for lynparza is used for the treatment of a type of ovarian cancer called " brca - mutated ovarian cancer ". it is used after the cancer has responded to previous treatment with standard platinum - based chemotherapy . a test is used to determine whether you have brca - mutated cancer .
do not take lynparza if you are allergic to olaparib or any of the other ingredients of this medicine ( listed in section 6 ) if you are breast - feeding ( see section 2 below for more information ). do not take lynparza if any of the above apply to you. if you are not sure, talk to your doctor, pharmacist or nurse before taking lynparza. warnings and precautions talk to your doctor, pharmacist or nurse before or during treatment with lynparza if you have low blood cell counts on testing. these may be low counts for red or white blood cells or low platelet counts. see section 4 for more information about these side effects, 75 including the signs and symptoms you need to look out for ( for example, fever or infection, bruising or bleeding ). rarely, these may be a sign of more serious problems with the bone marrow such as'myelodysplastic syndrome'( mds ) or'acute myeloid leukaemia'( aml ). if you experience any new or worsening symptoms of shortness of breath, coughing, or wheezing. a small number of patients treated with lynparza reported inflammation of the lungs ( pneumonitis ). pneumonitis is a serious condition that can often require hospital treatment. if you think any of these may apply to you, talk to your doctor, pharmacist or nurse before or during treatment with lynparza. tests and checks your doctor will check your blood before and during treatment with lynparza. you will have a blood test before treatment every month for the first year of treatment at regular intervals decided by your doctor after the first year of treatment. if your blood count falls to a low level, you may need to have a blood transfusion ( where you are given new blood or blood - based products from a donor ). other medicines and lynparza tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. this includes medicines obtained without a prescription and herbal medicines. this is because lynparza can affect the way
your doctor has prescribed lynparza capsules for you. please note lynparza is also available as a 100 mg and 150 mg tablet. the doses of lynparza capsules and tablets are not the same. taking the wrong dose or a tablet instead of a capsule could lead to lynparza not working properly or to more side effects. always take this medicine exactly as your doctor, pharmacist or nurse has told you. check with your doctor, pharmacist or nurse if you are not sure. how to take take one dose ( 8 capsules ) of lynparza by mouth with water, once in the morning and once in the evening. take lynparza at least one hour after eating food. do not eat preferably for up to 2 hours after taking lynparza. how much to take your doctor will tell you how many capsules of lynparza to take. it is important that you take the total recommended dose each day. keep doing so for as long as your doctor, pharmacist or nurse tells you to. the usual recommended dose is 8 capsules ( 400 mg ) taken by mouth twice a day ( a total of 16 capsules each day ). your doctor may prescribe a different dose if you have problems with your kidneys. you will be asked to take 6 capsules ( 300 mg ) twice a day - a total of 12 capsules each day. you are taking certain medicines that may affect lynparza ( see section 2 ). you have certain side effects while you are taking lynparza ( see section 4 ). your doctor may lower your dose or stop treatment, either for a short time or permanently. if you take more lynparza than you should if you take more lynparza than your normal dose, contact your doctor or nearest hospital straight away. if you forget to take lynparza if you forget to take lynparza, take your next normal dose at its scheduled time. do not take a double dose ( two doses at the same time ) to make up for a forgotten dose. if you have any further questions on the use of this medicine, ask your doctor, pharmacist
like all medicines, this medicine can cause side effects, although not everybody gets them. tell your doctor straight away if you notice any of the following very common ( may affect more than 1 in 10 people ) feeling short of breath, feeling very tired, pale skin or fast heart beat - these may be symptoms of a decrease in the number of red blood cells ( anaemia ). uncommon ( may affect up to 1 in 100 people ) allergic reactions ( e. g. hives, difficulty breathing or swallowing, dizziness which are signs and symptoms of hypersensitivity reactions ). other side effects include very common ( may affect more than 1 in 10 people ) feeling sick ( nausea ) being sick ( vomiting ) feeling tired or weak indigestion or heartburn ( dyspepsia ) pain in the stomach area under the ribs ( upper abdominal pain ) loss of appetite headache changes in taste of foods ( dysgeusia ) feeling dizzy cough shortness of breath diarrhoea if it gets severe, tell your doctor straight away. very common side effects that may show up in blood tests decrease in the number of platelets in blood ( thrombocytopenia ) - you may notice the following symptoms : o bruising or bleeding for longer than usual if you hurt yourself low white blood cell count ( leukopenia or neutropenia ) which may decrease your ability to fight infection and may be associated with fever. common ( may affect up to 1 in 10 people ) rash or itchy rash on swollen, reddened skin ( dermatitis ) sore mouth ( stomatitis ). common side effects that may show up in blood tests 78 low white blood cell count ( lymphopenia ) which may decrease your ability to fight infection and may be associated with fever increase in blood creatinine - this test is used to check how your kidneys are working. uncommon side effects that may show up in blood tests increase in the size of red blood cells ( not associated with any symptoms ). your doctor will test your blood every month for the first year of treatment and at regular intervals after that. your doctor will tell you if there are any changes in your blood test that might need treatment
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the carton and the bottle after exp . the expiry date refers to the last day of that month . store in a refrigerator ( 2 8 ). do not freeze . throw away any lynparza capsules that have been frozen . if preferred , you can keep lynparza capsules out of the refrigerator ( below 30 ) for up to 3 months . after this period , throw away any capsules that have not been used . it is recommended that you record the date when the capsules are removed from refrigerator and the date after which they should be discarded . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what lynparza contains the active substance is olaparib . each hard capsule contains 50 mg of olaparib . the other ingredients ( excipients ) are capsule content : lauroyl macrogol - 32 glycerides . capsule shell : hypromellose , titanium dioxide ( e171 ), gellan gum ( e418 ), potassium acetate . printing ink : shellac , iron oxide black ( e172 ). what lynparza looks like and contents of the pack lynparza is a white , opaque , hard capsule , marked with " olaparib 50 mg " and the astrazeneca logo in black ink . lynparza is provided in hdpe plastic bottles containing 112 hard capsules . one pack contains 448 capsules ( 4 bottles of 112 capsules ).
this medicine contains the active substance naloxone . naloxone temporarily reverses the effects of opioids such as heroin , methadone , fentanyl , oxycodone , buprenorphine and morphine . nyxoid is a nasal spray used for the emergency treatment of opioid overdose or possible opioid overdose in adults and adolescents over 14 years . signs of overdose include : breathing problems severe sleepiness not responding to a loud noise or touch . if you are at risk of an opioid overdose you should always carry your nyxoid with you . nyxoid works for a short time only to reverse the effects of opioids while you wait for emergency medical attention . it is not a substitute for emergency medical care . nyxoid is intended for use by appropriately trained individuals . always tell your friends and family that you carry nyxoid with you .
do not use nyxoid if you are allergic to naloxone or any of the other ingredients of this medicine ( listed in section 6 ). warnings and precautions nyxoid will be supplied to you only after you or your carer have been taught how to use it. it is to be given right away and does not take the place of emergency medical care. emergency services should be called if an opioid overdose is suspected. the signs and symptoms of an opioid overdose can return after this nasal spray is given. if this happens, further doses may be given after 2 to 3 minutes using a new nasal spray. the patient should be monitored closely until emergency help has arrived after being given this medicine. conditions to look out for if you are physically dependent on opioids or if you have received high doses of opioids ( for example heroin, methadone, fentanyl, oxycodone, buprenorphine or morphine ). you may get strong withdrawal symptoms with this medicine ( see later in section 4 of this leaflet under'conditions to look out for ') if you take opioids to control pain. the pain may increase when you receive nyxoid. if you use buprenorphine. nyxoid may not fully reverse breathing problems. tell your doctor if you have damage to the inside of your nose as this could affect how nyxoid works. children and adolescents nyxoid is not for use in children or adolescents under 14 years. receiving nyxoid close to giving birth tell your midwife or doctor if you have received nyxoid close to or during labour. your baby could suffer from sudden opioid withdrawal syndrome, which could be life - threatening if not treated. watch out for the following symptoms in your baby during the first 24 hours after the baby is born : seizures ( fits ) crying more than usual increased reflexes. other medicines and nyxoid tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. pregnancy, breastfeeding and fertility if you are pregnant or breastfeeding, think
always use this medicine exactly as your doctor, pharmacist or nurse has told you. check with your doctor, pharmacist or nurse if you are not sure. training will be provided on how to use nyxoid before it is supplied to you. below is a step by step guide. instructions for giving nyxoid nasal spray : 1. check for symptoms and response. - check for a response, to see if the person is conscious. you can shout their name, gently shake their shoulders, talk loudly into their ears, rub their breastbone ( sternum ), pinch their ear or the bed of their fingernail. - check airways and breathing. clear the mouth and nose of any blockages. for 10 seconds check for breathing is the chest moving? can you hear breathing sounds? can you feel breath on the cheek? - check for signs of overdose, such as : no response to touch or sounds, slow uneven breathing or no breathing, snoring, gasping or gulping, blue or purple fingernails or lips. - if an overdose is suspected nyxoid should be given. 2. call for an ambulance. nyxoid is not a substitute for emergency medical care. 3. peel off the back of the blister from the corner to remove the nasal spray from the container. place the nasal spray within easy reach. 4. lay the patient on their back. support the back of the neck and allow the head to tilt back. clear away anything blocking their nose. 5. hold the nasal spray with your thumb on the bottom of the plunger and your first and middle fingers on either side of the nozzle. do not prime or test the nyxoid nasal spray before use as it contains only one dose of naloxone and cannot be reused. 6. gently insert the device nozzle in one nostril. press firmly on the plunger until it clicks to give the dose. remove the nasal spray nozzle from the nostril after giving the dose. 7. place the patient into the recovery position on their side with mouth open pointing towards the ground
like all medicines , this medicine can cause side effects although not everyone gets them . the side effects below may happen with this medicine . conditions to look out for nyxoid can cause acute withdrawal symptoms if the patient is dependent on opioid drugs . symptoms can include : fast heart rate , high blood pressure body aches and stomach cramps feeling sick , vomiting , diarrhoea sweating , fever , goose bumps , shivering or trembling changes in behaviour including violent behaviour , nervousness , anxiety , excitement , restlessness or irritability unpleasant or uncomfortable mood increased skin sensitivity difficulty in sleeping . acute withdrawal symptoms occur uncommonly ( may affect up to 1 in 100 people ). tell your doctor if you experience any of these symptoms . very common : may affect more than 1 in 10 people feeling sick common : may affect up to 1 in 10 people dizziness , headache fast heart rate high blood pressure , low blood pressure being sick ( vomiting ) uncommon : may affect up to 1 in 100 people tremor slow heart rate sweating irregular heart beat diarrhoea dry mouth rapid breathing very rare : may affect up to 1 in 10 , 000 people allergic reactions such as swelling of the face , mouth , lips or throat , allergic shock life - threatening irregular heartbeat , heart attack build - up of fluid in the lungs skin problems such as itching , rash , redness , swelling , severe flaking or peeling of the skin . reporting of side effects if you get any side effects , talk to your doctor , pharmacist or nurse . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the carton , blister pack and the label after exp . the expiry date refers to the last day of that month . do not freeze . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to dispose of medicines no longer required . these measures will help to protect the environment .
what nyxoid contains - the active substance is naloxone . each nasal spray contains 1 . 8 mg of naloxone ( as hydrochloride dihydrate ). - the other ingredients are trisodium citrate dihydrate , sodium chloride , hydrochloric acid , sodium hydroxide and purified water . what nyxoid looks like and contents of the pack this medicine contains naloxone in 0 . 1 ml of a clear , colourless to pale yellow solution in a pre - filled nasal spray , solution in a single dose container . nyxoid is packed in a carton containing 2 nasal sprays individually sealed in blisters . each nasal spray contains one single dose of naloxone .
what ovaleap is this medicine contains the active substance follitropin alfa , which is almost identical to a natural hormone produced by your body called " follicle - stimulating hormone " ( fsh ). fsh is a gonadotropin , a type of hormone that plays an important role in human fertility and reproduction . in women , fsh is needed for the growth and development of the sacs ( follicles ) in the ovaries that contain the egg cells . in men , fsh is needed for the production of sperm . what ovaleap is used for in adult women , ovaleap is used : to help ovulation ( release of a mature egg cell from the follicle ) in women that cannot ovulate and that have not responded to treatment with a medicine called " clomifene citrate ". to help follicles develop in women undergoing assisted reproductive technology procedures ( procedures that may help you to become pregnant ) such as " in vitro fertilisation ", " gamete intra - fallopian transfer " or " zygote intra - fallopian transfer ". in combination with a medicine called " lutropin alfa " ( a version of another gonadotropin , " luteinising hormone " or lh ) to help ovulation in women that are not ovulating because their body is producing too little fsh and lh . in adult men , ovaleap is used : in combination with a medicine called " human chorionic gonadotropin " ( hcg ) to help produce sperm in men that are infertile due to low levels of certain hormones .
do not use ovaleap : if you are allergic to follitropin alfa, follicle stimulating hormone ( fsh ) or any of the other ingredients of this medicine ( listed in section 6 ). if you have a tumour in your hypothalamus or pituitary gland ( parts of the brain ). if you are a woman with : - large ovaries or sacs of fluids within the ovaries ( ovarian cysts ) of unknown origin. - unexplained vaginal bleeding. - cancer in your ovaries, womb or breasts. - any condition that usually makes normal pregnancy impossible, such as ovarian failure ( early menopause ), fibroid tumours of the womb or malformed reproductive organs. if you are a man with : - testicular failure that is not treatable. do not use this medicine if any of the above applies to you. if you are not sure, talk to your doctor or pharmacist before using this medicine. warnings and precautions before the treatment is started you and your partner's fertility should be evaluated by a doctor experienced in treating fertility disorders. porphyria tell your doctor before you start treatment, if you or any member of your family have porphyria. this is a condition that may be passed on from parents to children which means that you have an inability to break down porphyrins ( organic compounds ). tell your doctor straight away if : your skin becomes fragile and easily blistered, especially skin that has been frequently in the sun, and / or you have stomach, arm or leg pain. if you experience the above symptoms your doctor may recommend that you stop treatment. ovarian hyper - stimulation syndrome ( ohss ) if you are a woman, this medicine increases your risk of developing ohss. this is when your follicles develop too much and become large cysts. talk to your doctor straight away if : you get pain in the lower part of the abdomen ( belly ), you gain any weight rapidly, you feel sick or are vomiting
always use this medicine exactly as your doctor or pharmacist has told you. check with your doctor or pharmacist if you are not sure. this medicine is given as an injection into the tissue just under the skin ( subcutaneous injection ). your doctor or nurse will show you how to inject the medicine. if you administer this medicine to yourself, please carefully read and follow the " instructions for use " of the pen. what the recommended dose is your doctor will decide how much medicine you will take and how often. the doses described below are stated in international units ( iu ). women if you are not ovulating and have irregular or no periods this medicine is usually given every day. if you have irregular periods, start using this medicine within the first 7 days of your menstrual cycle. if you do not have periods, you can start using the medicine on any convenient day. the usual starting dose of this medicine is 75 to 150 iu each day. your dose of this medicine may be increased every 7 or every 14 days by 37. 5 to 75 iu, until you get the desired response. the maximum daily dose of this medicine is usually not higher than 225 iu. when you get the desired response, you will be given hcg or " recombinant hcg " ( r - hcg, an hcg made in a laboratory by a special dna technique ). the single injection will be 250 micrograms of r - hcg or 5, 000 to 10, 000 iu of hcg, 24 to 48 hours after your last ovaleap injection. the best time to have sex is on the day of the hcg injection and the day after. alternatively, intrauterine insemination may be performed by placing the sperm into the womb cavity. if your doctor cannot see a desired response after 4 weeks, that treatment cycle with ovaleap should be stopped. for the following treatment cycle, your doctor will give you a higher starting dose of this medicine than before. if your body responds too strongly, your treatment will be stopped and you will not be given any hcg [ see
like all medicines, this medicine can cause side effects, although not everybody gets them. important side effects serious side effects in men and women allergic reactions such as skin rash, raised itchy areas of skin and severe allergic reactions with weakness, drop in blood pressure, difficulty breathing and swelling of the face have been 37 reported very rarely ( may affect up to 1 in 10, 000 people ). if you think you are having this type of reaction, you must stop your ovaleap injection and get medical help immediately. serious side effects in women lower stomach ache together with nausea or vomiting may be the symptoms of ovarian hyper - stimulation syndrome ( ohss ). this may indicate that the ovaries over - reacted to the treatment and that large ovarian cysts developed [ see also section 2 under " ovarian hyper - stimulation syndrome ( ohss )"]. this side effect is common ( may affect up to 1 in 10 people ). ohss may become severe with clearly enlarged ovaries, decreased urine production, weight gain, difficulty in breathing and / or possible fluid accumulation in your stomach or chest. this side effect is uncommon ( may affect up to 1 in 100 people ). complications of ohss such as twisting of ovaries or blood clotting may occur rarely ( may affect up to 1 in 1, 000 people ). serious blood clotting complications ( thromboembolic events ), sometimes independent of ohss, may be found very rarely ( may affect up to 1 in 10, 000 people ). this could cause chest pain, breathlessness, stroke or heart attack [ see also section 2 under " blood clotting problems ( thromboembolic events )"]. if you notice any of the above - listed side effects you should immediately contact your doctor who may ask you to stop using ovaleap. other side effects in women very common ( may affect more than 1 in 10 people ) local reactions at the injection site, such as pain, redness, bruising, swelling and / or irritation headache sacs of fluid within the ovaries ( ovarian cysts ) common ( may affect up to 1 in 10 people ) stomach ache abdominal bloating
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the label and outer carton after exp . the expiry date refers to the last day of that month . store in a refrigerator ( 2 - 8 ). do not freeze . keep the cartridge in the outer carton in order to protect from light . before opening and within its shelf life , you may remove this medicine from the refrigerator , without being refrigerated again , for up to 3 months . do not store above 25 . you must discard this medicine if it has not been used after 3 months . once opened , the cartridge in - use in the pen may be stored for a maximum of 28 days . do not store above 25 . write down the date of first use in the patient diary , which will be provided with the ovaleap pen . put the pen cap back on the ovaleap pen after each injection in order to protect the cartridge from light . do not use this medicine if you notice it is cloudy or there are particles in it . do not throw away any medicines via wastewater . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what ovaleap contains - the active substance is follitropin alfa . ovaleap 300 iu / 0 . 5 ml : each cartridge contains 300 iu ( equivalent to 22 micrograms ) follitropin alfa in 0 . 5 ml solution . ovaleap 450 iu / 0 . 75 ml : each cartridge contains 450 iu ( equivalent to 33 micrograms ) follitropin alfa in 0 . 75 ml solution . ovaleap 900 iu / 1 . 5 ml : each cartridge contains 900 iu ( equivalent to 66 micrograms ) follitropin alfa in 1 . 5 ml solution . each ml of the solution contains 600 iu ( equivalent to 44 micrograms ) follitropin alfa . - the other ingredients are sodium dihydrogen phosphate dihydrate , sodium hydroxide ( 2 m ) ( for ph adjustment ), mannitol , methionine , polysorbate 20 , benzyl alcohol , benzalkonium chloride and water for injections . all strengths listed above contain the other ingredients . what ovaleap looks like and contents of the pack ovaleap is a solution for injection ( injection ). ovaleap is a clear and colourless solution . ovaleap 300 iu / 0 . 5 ml is available in packs containing 1 cartridge and 10 injection needles . ovaleap 450 iu / 0 . 75 ml is available in packs containing 1 cartridge and 10 injection needles . ovaleap 900 iu / 1 . 5 ml is available in packs containing 1 cartridge and 20 injection needles . not all pack sizes may be marketed .
voriconazole accord contains the active substance voriconazole . voriconazole accord is an antifungal medicine . it works by killing or stopping the growth of the fungi that cause infections . it is used for the treatment of patients ( adults and children over the age of 2 ) with : invasive aspergillosis ( a type of fungal infection due to aspergillus sp ), candidaemia ( another type of fungal infection due to candida sp ) in non - neutropenic patients ( patients without abnormally low white blood cells count ), serious invasive candida sp . infections when the fungus is resistant to fluconazole ( another antifungal medicine ), serious fungal infections caused by scedosporium sp . or fusarium sp . ( two different species of fungi ). voriconazole accord is intended for patients with worsening , possibly life - threatening , fungal infections . prevention of fungal infections in high risk bone marrow transplant recipients . this product should only be taken under the supervision of a doctor .
do not take voriconazole accord if you are allergic to voriconazole or any of the other ingredients of this medicine ( listed in section 6 ). it is very important that you inform your doctor or pharmacist if you are taking or have taken any other medicines, even those that are obtained without a prescription, or herbal medicines. the medicines in the following list must not be taken during your course of voriconazole accord treatment : 46 terfenadine ( used for allergy ) astemizole ( used for allergy ) cisapride ( used for stomach problems ) pimozide ( used for treating mental illness ) quinidine ( used for irregular heart beat ) rifampicin ( used for treating tuberculosis ) efavirenz ( used for treating hiv ) in doses of 400 mg and above once daily carbamazepine ( used to treat seizures ) phenobarbital ( used for severe insomnia and seizures ) ergot alkaloids ( e. g., ergotamine, dihydroergotamine ; used for migraine ) sirolimus ( used in transplant patients ) ritonavir ( used for treating hiv ) in doses of 400 mg and more twice daily st john's wort ( herbal supplement ) warnings and precautions talk to your doctor, pharmacist or nurse before taking voriconazole accord if : you have had an allergic reaction to other azoles. you are suffering from, or have ever suffered from liver disease. if you have liver disease, your doctor may prescribe a lower dose of voriconazole accord. your doctor should also monitor your liver function while you are being treated with voriconazole accord by doing blood tests. you are known to have cardiomyopathy, irregular heart beat, slow heart rate or an abnormality of electrocardiogram ( ecg ) called'long qtc syndrome '. you should avoid any sunlight and sun exposure while being treated. it is important to cover sun exposed areas of skin and use sunscreen with high sun protection factor ( spf ),, as an increased sensitivity of skin to
always take this medicine exactly as your doctor has told you. check with your doctor or pharmacist if you are not sure. your doctor will determine your dose depending on your weight and the type of infection you have. the recommended dose for adults ( including elderly patients ) is as follows : tablets patients 40 kg and above patients less than 40 kg dose for the first 24 hours ( loading dose ) 400 mg every 12 hours for the first 24 hours 200 mg every 12 hours for the first 24 hours dose after the first 24 hours ( maintenance dose ) 200 mg twice a day 100 mg twice a day depending on your response to treatment, your doctor may increase the daily dose to 300 mg twice a day. the doctor may decide to decrease the dose if you have mild to moderate cirrhosis. use in children and adolescents the recommended dose for children and teenagers is as follows : tablets children aged 2 to less than 12 years and teenagers aged 12 to 14 years weighing less than 50 kg teenagers aged 12 to 14 years weighing 50 kg or more ; and all teenagers older than 14 dose for the first 24 hours ( loading dose ) your treatment will be started as an infusion 400 mg every 12 hours for the first 24 hours dose after the first 24 hours ( maintenance dose ) 9 mg / kg twice a day ( a maximum dose of 350 mg twice daily ) 200 mg twice a day depending on your response to treatment, your doctor may increase or decrease the daily dose. tablets must only be given if the child is able to swallow tablets. take your tablet at least one hour before, or one hour after a meal. swallow the tablet whole with some water. if you or your child are taking voriconazole accord for prevention of fungal infections, your doctor may stop giving voriconazole accord if you or your child develop treatment related side effects. if you take more voriconazole accord than you should if you take more tablets than prescribed ( or if someone else takes your tablets ) you must seek medical advice or go to the nearest hospital casualty department immediately. take your box of voriconazole accord tablets with you. you may experience abnormal intolerance to light as a result of taking more voriconazole accord than you should. if you forget to
like all medicines, this medicine can cause side effects, although not everybody gets them. if any side effects occur, most are likely to be minor and temporary. however, some may be serious and need medical attention. serious side effects stop taking voriconazole accord and see a doctor immediately - rash - jaundice ; changes in blood tests of liver function - pancreatitis other side effects very common : may affect more than 1 in 10 people - visual impairment ( change in vision including blurred vision, visual color alterations, abnormal intolerance to visual perception of light, colour blindness, eye disorder, halo vision, night blindness, swinging vision, seeing sparks, visual aura, visual acuity reduced, visual brightness, loss of part of the usual field of vision, spots before the eyes ) - fever - rash - nausea, vomiting, diarrhoea - headache - swelling of the extremities - stomach pains - breathing difficulties - elevated liver enzymes common : may affect up to 1 in 10 people - inflammation of the sinuses, inflammation of the gums, chills, weakness - low numbers of some types, including severe, of red ( sometimes immune - related ) and / or white blood cells ( sometimes with fever ), low numbers of cells called platelets that help the blood to clot - low blood sugar, low blood potassium, low sodium in the blood - anxiety, depression, confusion, agitation, inability to sleep, hallucinations - seizures, tremors or uncontrolled muscle movements, tingling or abnormal skin sensations, increase in muscle tone, sleepiness, dizziness - bleeding in the eye - heart rhythm problems including very fast heartbeat, very slow heartbeat, fainting, low blood pressure, inflammation of a vein ( which may be associated with the formation of a blood clot ) 50 - acute breathing difficulty, chest pain, swelling of the face ( mouth, lips and around eyes ), fluid accumulation in the lungs - constipation, indigestion
what voriconazole accord contains the active substance is voriconazole . each tablet contains either 50 mg voriconazole ( for voriconazole accord 50 mg film - coated tablets ) or 200 mg voriconazole ( for voriconazoleaccord 200 mg film - coated tablets ). the other ingredients are lactose monohydrate , pregelatinised starch , croscarmellose sodium , povidone and magnesium stearate which make up the tablet core and hypromellose , titanium dioxide ( e171 ), lactose monohydrate and triacetin which make up the film - coat . what voriconazole accord looks like and contents of the pack voriconazole accord 50 mg film - coated tablets are supplied as white to off white , round , approximate 7 . 0mm in diameter , film - coated tablets , debossed with ' v50 ' on one side and plain on the other side . voriconazole accord 200 mg film - coated tablets are supplied as white to off white , oval , approximately 15 . 6 mm in length and 7 . 8 mm in width , film - coated tablets , debossed with ' v200 ' on one side and plain on the other side . voriconazole accord 50 mg film - coated tablets and 200mg film - coated tablets are available as packs of 2 , 10 , 14 , 20 , 28 , 30 , 50 , 56 and 100 or unit dose blister packs ( pvc / aluminium ) containing 10x1 , 14x1 , 28x1 , 30x1 , 56x1 or 100x1 film - coated tablets . not all pack sizes may be marketed .
what is mvabea mvabea is a vaccine used to protect against ebola virus disease in the future. it is given to people aged 1 year and older who may possibly come into contact with ebola virus. mvabea is given as the second dose of a 2 - dose course of vaccinations to protect you from getting ebola virus disease caused by the zaire ebolavirus, which is a type of filovirus. this vaccine will not protect you against the other types of filovirus. because mvabea does not contain the whole ebola virus, it cannot give you ebola virus disease. the 2 - dose course of vaccinations consists of : a first dose of zabdeno vaccine, followed around 8 weeks later by a dose with mvabea vaccine. even after you have had the course of zabdeno and mvabea vaccination you should be very careful not to come into contact with ebola virus. as with all vaccinations, the vaccination course may not fully protect everyone from ebola virus disease. the zabdeno and mvabea 2 - dose course of vaccinations should be used according to official recommendations. what is ebola ebola is a serious disease caused by a virus. people catch ebola from people or animals who are infected with ebola virus or who died from ebola. you can catch ebola from blood and body fluids like urine, stools, saliva, vomit, sweat, breast milk, semen and vaginal fluids of people who are infected with ebola virus. you can also catch ebola from things that have touched the blood or body fluids of a person or animal with ebola ( like clothes or objects in direct contact ). ebola is not spread through the air, water or food. ebola virus disease usually causes a high fever and it can stop the blood from clotting, causing severe bleeding (' severe haemorrhagic fever '). this can lead to serious illness,
to make sure that the vaccination course is suitable for you or your child, it is important to tell your doctor, pharmacist or nurse if any of the points below apply to you or your child. if there is anything you do not understand, ask your doctor, pharmacist or nurse to explain. do not have the vaccine if you or your child have ever had a severe allergic reaction to any of the active substances or any of the other ingredients listed in section 6. you or your child have ever had a severe allergic reaction to chicken or eggs or an antibiotic known as'gentamicin '. if you are not sure, talk to your doctor, pharmacist or nurse before you are given the vaccine. warnings and precautions talk to your doctor, pharmacist or nurse before you are given mvabea if you or your child : have ever had a severe allergic reaction after any other vaccine injection, have ever fainted, after having an injection, have a problem with bleeding or you bruise easily, currently have a fever or an infection, are taking medicines that weaken the immune system, such as high - dose corticosteroids ( such as prednisone ) or chemotherapy ( cancer medicines ), have a weak immune system for example, due to hiv infection or an illness that runs in the family (' genetic disorder '). if any of the above apply to you or your child ( or you are not sure ), talk to your doctor, pharmacist or nurse before you are given mvabea. if you are at high risk of being in contact with the ebola virus, a booster vaccination with zabdeno may be recommended for you or your child. talk to your doctor, pharmacist or nurse if this applies to you or your child. if you or your child only have one of the vaccines, zabdeno or mvabea, it may give less protection from ebola virus disease than having a course of both vaccines. as with all vaccines, the zabdeno and mvabea 2 - dose course of vaccination may not fully protect everyone from ebola virus disease and it is not known how long you will be protected. people
your doctor or nurse will inject the vaccine into a muscle ( intramuscular injection ) in the upper arm or thigh. mvabea must not be injected into a blood vessel. the 2 - dose course of vaccination consists of : a dose of zabdeno vaccine, followed around 8 weeks later by a dose of mvabea vaccine. your doctor will tell you the date for the second vaccine. how much vaccine will you or your child get primary vaccination first vaccination with zabdeno red cap vial ( 0. 5 ml ). second vaccination with mvabea yellow cap vial ( 0. 5 ml ), given around 8 weeks after the first vaccination with zabdeno. booster vaccination with zabdeno ( an extra dose of zabdeno to increase or renew the effect of an earlier zabdeno and mvabea 2 - dose course of vaccination ) the booster vaccination is recommended for you or your child if you are at high risk of being in contact with the ebola virus and you completed the 2 - dose course of vaccination more than 4 months ago. ask your doctor if you or your child should consider getting the booster vaccination. during and after the injection of the vaccine, the doctor will watch over you or your child for around 15 minutes or longer as necessary in case of a severe allergic reaction. instructions for preparing the vaccine for medical and healthcare professionals are included at the end of the leaflet. if you have an unintended or accidental injection of zabdeno or mvabea if you or your child are accidently given mvabea as the first vaccination you will get zabdeno as the second vaccination around 8 weeks later. if you or your child are accidently given zabdeno as the first and the second vaccination you will get mvabea around 8 weeks after the second vaccination with zabdeno. if you or your child are accidently given mvabea as the first and the second vaccination you will get zabdeno around 8 weeks after the second vaccination with mvabea. if you or your child have not been given mvabea around 8 weeks
like all medicines , this vaccine can cause side effects , although not everybody gets them . most of the side effects happen within 7 days of getting the injection . the following side effects can happen in adults . very common ( may affect more than 1 in 10 people ) pain , warmth , or swelling where the injection is given feeling very tired muscle ache joint pain common ( may affect up to 1 in 10 people ) being sick ( vomiting ) itching where the injection is given uncommon ( may affect up to 1 in 100 people ) redness and skin hardness where the injection is given generalised itching the following side effects can happen in children and young people 1 to 17 years of age . very common ( may affect more than 1 in 10 people ) pain where the injection is given feeling very tired common ( may affect up to 1 in 10 people ) swelling , itching or redness where the injection is given fever chills muscle ache joint pain most of these side effects are mild to moderate in intensity and are not long - lasting . reporting of side effects if you get any side effects , talk to your doctor , pharmacist or nurse . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
what mvabea contains one dose ( 0 . 5 ml ) contains : the active substance is modified vaccinia ankara bavarian nordic virus * encoding the : zaire ebolavirus mayinga variant glycoprotein ( gp ) sudan ebolavirus gulu variant gp 29 tai forest ebolavirus nucleoprotein marburg marburgvirus musoke variant gp not less than 0 . 7 x 108 infectious units * produced in chicken embryo fibroblast cells and by recombinant dna technology . this product contains genetically modified organisms ( gmos ). this vaccine contains trace residues of gentamicin ( see section 2 ). the other ingredients ( excipients ) are sodium chloride , trometamol , water for injections and hydrochloric acid ( for ph adjustment ). what mvabea looks like and contents of the pack mvabea is a suspension in a single - dose glass vial ( 0 . 5 ml ) with a rubber stopper and yellow cap . light yellow , clear to milky suspension . mvabea is available in a pack containing 20 single - dose vials .
bondronat contains the active substance ibandronic acid . this belongs to a group of medicines called bisphosphonates . bondronat is used in adults and prescribed to you if you have breast cancer that has spread to your bones ( called ' bone ' metastases '). it helps to prevent your bones from breaking ( fractures ) it helps to prevent other bone problems that may need surgery or radiotherapy bondronat can also be prescribed if you have a raised calcium level in your blood due to a tumour . bondronat works by reducing the amount of calcium that is lost from your bones . this helps to stop your bones from getting weaker .
do not receive bondronat : if you are allergic to ibandronic acid or any of the other ingredients of this medicine that are listed in section 6 if you have, or have ever had low levels of calcium in your blood do not receive this medicine if any of the above apply to you. if you are not sure, talk to your doctor or pharmacist before having bondronat. warnings and precautions a side effect called osteonecrosis of the jaw ( onj ) ( bone damage in the jaw ) has been reported very rarely in the post marketing setting in patients receiving bondronat for cancer - related conditions. onj can also occur after stopping treatment. it is important to try and prevent onj developing as it is a painful condition that can be difficult to treat. in order to reduce the risk of developing osteonecrosis of the jaw, there are some precautions you should take. before receiving treatment, tell your doctor / nurse ( health care professional ) if : you have any problems with your mouth or teeth such as poor dental health, gum disease, or a planned tooth extraction you don't receive routine dental care or have not had a dental check up for a long time you are a smoker ( as this may increase the risk of dental problems ) you have previously been treated with a bisphosphonate ( used to treat or prevent bone disorders ) you are taking medicines called corticosteroids ( such as prednisolone or dexamethasone ) you have cancer. your doctor may ask you to undergo a dental examination before starting treatment with bondronat. while being treated, you should maintain good oral hygiene ( including regular teeth brushing ) and receive routine dental check - ups. if you wear dentures you should make sure these fit properly. if you are under dental treatment or will undergo dental surgery ( e. g. tooth extractions ), inform your doctor about your dental treatment and tell your dentist that you are being treated with bondronat. contact your doctor and dentist immediately if you experience any problems with your mouth or teeth such as loose teeth, pain or swelling, non - healing of sores or discharge, as these could be signs of osteo
receiving this medicine bondronat is normally given by a doctor or other medical staff who have experience with the treatment of cancer it is given as an infusion into your vein your doctor may do regular blood tests while you are receiving bondronat . this is to check that you are being given the right amount of this medicine . how much to receive your doctor will work out how much bondronat you will be given depending on your illness . if you have breast cancer that has spread to your bones , then the recommended dose is 3 vials ( 6 mg ) every 3 - 4 weeks , as an infusion in your vein over at least 15 minutes . if you have a raised calcium level in your blood due to a tumour then the recommended dose is a single administration of 1 vial ( 2 mg ) or 2 vials ( 4 mg ), depending on the severity of your illness . the medicine should be administered as an infusion in your vein over two hours . a repeated dose may be considered in case of insufficient response or if your illness reappears . your doctor may adjust your dose and duration of intravenous infusion if you have kidney problems . if you have any further questions on the use of this medicine , ask your doctor or pharmacist .
like all medicines, this medicine can cause side effects although not everybody gets them. talk to a nurse or a doctor straight away if you notice any of the following serious side effects you may need urgent medical treatment : rare ( may affect up to 1 in 1, 000 people ) persistent eye pain and inflammation new pain, weakness or discomfort in your thigh, hip or groin. you may have early signs of a possible unusual fracture of the thigh bone very rare ( may affect up to 1 in 10, 000 people ) pain or sore in your mouth or jaw. you may have early signs of severe jaw problems ( necrosis ( dead bone tissue ) in the jaw bone ) talk to your doctor if you have ear pain, discharge from the ear, and / or an ear infection. these could be signs of bone damage in the ear. itching, swelling of your face, lips, tongue and throat, with difficulty breathing. you may be having a serious, potentially life threatening allergic reaction ( see section 2 ) severe adverse skin reactions not known ( frequency cannot be estimated from the available data ) asthma attack 58 other possible side effects common ( may affect up to 1 in 10 people ) flu - like symptoms, including fever, shaking and shivering, feeling of discomfort, fatigue, bone pain and aching muscles and joints. these symptoms usually disappear within a couple of hours or days. talk to a nurse or doctor if any effects become troublesome or last more than a couple of days rise in body temperature stomach and tummy pain, indigestion, being sick, vomiting or having diarrhoea ( loose bowels ) low calcium or phosphate levels in your blood changes in blood test results such as gamma gt or creatinine a heart rhythm problem called'bundle branch block'pain in your bone or muscles headache, feeling dizzy or feeling weak feeling thirsty, sore throat, changes in taste swollen legs or feet aching joints, arthritis, or other joint problems problems with your parathyroid gland bruising infections a problem with your eyes called'cataracts'skin problems tooth problems uncommon (
keep this medicine out of the sight and reach of children do not use this medicine after the expiry date which is stated on the folding box and on the label after exp . the expiry date refers to the last day of that month after dilution the infusion solution is stable for 24 hours at 2 - 8 ( in a refrigerator ) do not use this medicine if you notice that the solution is not clear or contains particles
what bondronat contains the active substance is ibandronic acid . one vial with 2 ml of a concentrate for solution for infusion contains 2 mg ibandronic acid ( as sodium monohydrate ) the other ingredients are sodium chloride , acetic acid , sodium acetate and water for injections what bondronat looks like and contents of the pack bondronat is a colourless , clear solution . bondronat is supplied as packs containing 1 vial ( 2 ml type i glass vial with a bromobutyl rubber stopper ).
what zeposia is zeposia contains the active substance ozanimod that belongs to a group of medicines which can reduce the number of white blood cells ( lymphocytes ) circulating freely round the body . what zeposia is used for zeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis ( rrms ) with active disease . what multiple sclerosis is multiple sclerosis ( ms ) is a disease in which the immune system ( the body ' s defenses , including white blood cells ) wrongly attack the protective coat around the nerves in the brain and spinal cord . this stops the nerves from working properly and may result in symptoms such as : numbness , difficulty in walking , and problems with vision and balance . in relapsing remitting multiple sclerosis , attacks on the nerve cells are followed by periods of recovery . the symptoms may disappear during the recovery periods , but some problems may remain . how zeposia works zeposia helps to protect against attacks on the nerves by stopping lymphocytes reaching the brain and spine where they could cause inflammation and damage the nerves protective coating .
do not take zeposia : if you are allergic to ozanimod or any of the other ingredients of this medicine ( listed in section 6 ) if your healthcare professional has told you that you have a severely weakened immune system if you have had a heart attack, angina, stroke or mini - stroke ( transient ischemic attack - tia ), or certain types of severe heart failure in the last 6 months if you have certain types of irregular or abnormal heartbeats ( arrhythmia ) your doctor will check your heart before starting treatment if you have severe infection such as hepatitis or tuberculosis if you have cancer if you have severe liver problems if you are pregnant or a women of childbearing potential not using effective contraception. warnings and precautions talk to your doctor or pharmacist before taking zeposia if : you have a slow heart rate or you are taking or have recently taken medicines that slow your heart rate ( such as beta blockers or calcium channel blockers ); you have untreated severe breathing problems when you sleep ( severe sleep apnoea ); you have problems with your liver ; you have an infection ; you have low levels of a type of white blood cell - called lymphocytes ; you have never had, or are not sure if you have had chickenpox ; you have recently had or are planning to have a vaccination ; you or others notice worsening of your ms symptoms as well as any new or unfamiliar symptoms. these may be due to a rare infection of the brain called progressive multifocal leukoencephalopathy ( pml ); you have ever had problems with your vision or other symptoms of build - up of fluid in the central area of the retina called the macula ( a condition called macular oedema ); you have inflammation of the eye ( uveitis ); you have diabetes ( which can cause problems with your eyes ); you have severe lung disease ( pulmonary fibrosis or chronic obstructive pulmonary disease ); before you start taking zeposia, your doctor will check your heart using an electrocardiogram ( ecg ). if you have certain heart
always take this medicine exactly as your doctor has told you. check with your doctor or pharmacist if you are not sure. how much to take when you first start taking zeposia, you need to take at a low dose and gradually build up, to reduce any effect in slowing your heart rate. you will be given a'treatment initiation pack'to help you start treatment in this way. it contains : o 4 light - grey capsules, containing 0. 23 mg ozanimod. you take one of these on days 1 to 4 of treatment. o 3 light - grey and orange capsules, containing 0. 46 mg ozanimod. you take one of these on days 5, 6 and 7. on day 8 and thereafter, once you have completed the'initiation pack ', you will move on to a'maintenance pack'with orange capsules each containing the recommended dose of 0. 92 mg ozanimod. you will continue regular treatment with one 0. 92 mg capsule daily. how to take zeposia zeposia is for oral use. swallow the capsule whole. you can take the capsule either with or without food. if you take more zeposia than you should if you take more zeposia than you should, talk to a doctor or go to a hospital straight away. take the medicine pack and this leaflet with you. if you forget to take zeposia if you forget a dose of zeposia, take it as soon as you remember. however, if you forget the dose for the whole day skip the missed dose and take the next dose at your usual time. do not take a double dose to make up for a forgotten dose. if you miss one or more doses during the first 14 days of starting zeposia, talk to your doctor about how to re - start your treatment. if you stop taking zeposia do not stop taking zeposia without talking to your doctor first. talk to your doctor about how to re - start your treatment if you have stopped taking zeposia :
like all medicines , this medicine can cause side effects , although not everybody gets them . serious side effects tell your doctor or pharmacist immediately if you notice any of the serious side effects listed below : common : may affect up to 1 in 10 people - slow heart rate - urinary tract infection - increase in blood pressure uncommon : may affect up to 1 in 100 people - allergic reaction the signs may include a rash . other side effects tell your doctor or pharmacist if you notice any of the following side effects : very common : may affect more than 1 in 10 people - infections of the nose or nostrils , nasal cavity , mouth , throat ( pharynx ), or voice box ( larynx ) caused by viruses - low level of a type of white blood cell called lymphocytes common : may affect up to 1 in 10 people - inflammation of the throat ( pharyngitis ) - respiratory infection ( sign of lungs infection ) - drop in blood pressure - increased liver enzyme levels in blood tests ( a sign of liver problems ) or yellow pigmentation of the skin , mucus membrane or eyes ( jaundice ) - lung abnormalities which can cause breathlessness uncommon : may affect up to 1 in 100 people - herpes zoster ( shingles ) - blurred vision ( macular oedema ) reporting of side effects if you get any side effects , talk to your doctor or pharmacist . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the blister and carton after exp . the expiry date refers to the last day of that month . do not store above 25 . do not use this medicine if you notice any damage or signs of tampering with the pack . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what zeposia contains the active substance is ozanimod. - zeposia 0. 23 mg hard capsules each hard capsule contains 0. 23 mg of ozanimod ( as hydrochloride ). - zeposia 0. 46 mg hard capsules each hard capsule contains 0. 46 mg of ozanimod ( as hydrochloride ). - zeposia 0. 92 mg hard capsules each hard capsule contains 0. 92 mg of ozanimod ( as hydrochloride ). the other ingredients are - capsule content : microcrystalline cellulose, silica, colloidal anhydrous, croscarmellose sodium, magnesium stearate. - capsule shell : each 0. 23 mg capsule contains gelatin, titanium dioxide ( e171 ), yellow iron oxide ( e172 ), black iron oxide ( e172 ) and red iron oxide ( e172 ). each 0. 46 mg capsule contains gelatin, titanium dioxide ( e171 ), yellow iron oxide ( e172 ), black iron oxide ( e172 ) and red iron oxide ( e172 ). each 0. 92 mg capsule contains gelatin, titanium dioxide ( e171 ), yellow iron oxide ( e172 ) and red iron oxide ( e172 ). - printing ink : iron oxide black ( e172 ), shellac ( e904 ), propylene glycol ( e1520 ), ammonia solution, concentrated ( e527 ), potassium hydroxide ( e525 ) what zeposia looks like and contents of the pack the zeposia 0. 23 mg, 14. 3 mm hard capsule has light grey opaque cap and body imprinted in black ink with " oza " on the cap and " 0. 23 mg " on the body. the zeposia 0. 46 mg, 14. 3 mm hard capsule has orange opaque cap and light grey opaque body imprinted in black ink with " oza " on the cap and " 0. 46 mg "
what temybric ellipta is temybric ellipta contains three active substances called fluticasone furoate , umeclidinium bromide and vilanterol . fluticasone furoate belongs to a group of medicines called corticosteroids , often simply called steroids . umeclidinium bromide and vilanterol belong to a group of medicines called bronchodilators . what temybric ellipta is used for temybric ellipta is used to treat chronic obstructive pulmonary disease ( copd ) in adults . copd is a long - term condition characterised by breathing difficulties that slowly get worse . in copd the muscles around the airways tighten , making breathing difficult . this medicine widens these muscles in the lungs , reducing the swelling and irritation in the small air passages and making it easier for air to get in and out of the lungs . when used regularly , it can help to control your breathing difficulties and reduce the effects of copd on your everyday life . temybric ellipta should be used every day and not only when you have breathing problems or other symptoms of copd . it should not be used to relieve a sudden attack of breathlessness or wheezing . if you get this sort of attack you must use a quick - acting inhaler ( such as salbutamol ).
don't use temybric ellipta : - if you are allergic to fluticasone furoate, umeclidinium, vilanterol or any of the other ingredients of this medicine ( listed in section 6 ). warnings and precautions talk to your doctor before using temybric ellipta - if you have asthma ( don't use temybric ellipta to treat asthma ) - if you have heart problems or high blood pressure - if you have liver problems - if you have tuberculosis ( tb ) of the lung, or any long standing or untreated infections - if you have an eye problem called narrow - angle glaucoma - if you have an enlarged prostate, difficulty passing urine or a blocking in your bladder - if you suffer from epilepsy - if you have thyroid gland problems - if you have low potassium in your blood - if you have a history of diabetes - if you experience blurred vision or other visual disturbances check with your doctor if you think any of these may apply to you. immediate breathing difficulties if you get tightness of the chest, coughing, wheezing or breathlessness immediately after using your temybric ellipta inhaler : stop using this medicine and seek medical help immediately, as you may have a serious condition called paradoxical bronchospasm. eye problems during treatment with temybric ellipta if you get eye pain or discomfort, temporary blurring of vision, visual halos or coloured images as well as red eyes during treatment with temybric ellipta : stop using this medicine and seek medical help immediately, these may be signs of an acute attack of narrow - angle glaucoma. infection of the lung because you are using this medicine for copd, you may be at an increased risk of developing an infection of the lungs known as pneumonia. see section 4'possible side effects'for information on symptoms to look out for while you are using this medicine. tell your doctor as soon as possible if you develop
always use this medicine exactly as your doctor has told you. check with your doctor or pharmacist if you are not sure. the recommended dose is one inhalation every day at the same time of day. you only need to inhale once a day because the effect of this medicine lasts for 24 hours. don't use more than your doctor tells you to use. use temybric ellipta regularly it is very important that you use temybric ellipta every day, as instructed by your doctor. this will help to keep you free of symptoms throughout the day and night. temybric ellipta should not be used to relieve a sudden attack of breathlessness or wheezing. if you get this sort of attack you must use a quick - acting reliever inhaler ( such as salbutamol ). how to use the inhaler see'step - by - step instructions'in this leaflet for full information. once the tray is opened temybric ellipta is ready to use. if your symptoms do not improve if your copd symptoms ( breathlessness, wheezing, cough ) do not improve or get worse, or if you are using your quick - acting inhaler more often : contact your doctor as soon as possible. if you use more temybric ellipta than you should if you use too much of this medicine, contact your doctor or pharmacist for advice immediately as you may need medical attention. if possible, show them the inhaler, the package or this leaflet. you may notice that your heart is beating faster than usual, you feel shaky, you have visual disturbances, have a dry mouth, or have a headache. if you forget to use temybric ellipta 36 don't inhale a double dose to make up for a forgotten dose. just inhale your next dose at the usual time. if you become wheezy or breathless, use your quick - acting inhaler ( such as salbutamol ), then seek medical advice. if
like all medicines , this medicine can cause side effects , although not everybody gets them . immediate breathing difficulties if your breathing or wheezing gets worse straight after using this medicine , stop using it and get medical help immediately . pneumonia ( infection of the lung ) in copd patients ( common side effect ) tell your doctor if you have any of the following while using temybric ellipta these could be symptoms of a lung infection : fever or chills increased mucus production , change in mucus colour increased cough or increased breathing difficulties common side effects these may affect up to 1 in 10 people : sore , raised patches in the mouth or throat caused by a fungal infection ( candidiasis ). rinsing your mouth out with water immediately after using temybric ellipta may help prevent this side effect . infection of the nose , sinuses or throat infection of the upper airways itchy , runny or blocked nose pain in the back of the mouth and throat inflammation of the sinuses inflammation of the lungs ( bronchitis ) flu ( influenza ) common cold headache cough painful and frequent urination ( may be signs of a urinary tract infection ) joint pain back pain constipation . uncommon side effects these may affect up to 1 in 100 people : irregular heart beat faster heart beat hoarseness weakening of the bones , leading to fractures . other side effects other side effects have occurred but their exact frequency is not known ( frequency cannot be estimated from the available data ): blurred vision 37 reporting of side effects if you get any side effects , talk to your doctor , pharmacist or nurse . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
what temybric ellipta contains the active substances are fluticasone furoate , umeclidinium bromide and vilanterol . each single inhalation provides a delivered dose ( the dose leaving the mouthpiece ) of 92 micrograms of fluticasone furoate , 65 micrograms umeclidinium bromide equivalent to 55 micrograms umeclidinium and 22 micrograms of vilanterol ( as trifenatate ). the other ingredients are lactose monohydrate ( see section 2 under ' temybric ellipta contains lactose ') and magnesium stearate . what temybric ellipta looks like and contents of the pack the ellipta inhaler consists of a light grey plastic body , a beige coloured mouthpiece cover and a dose counter . it is packaged in a foil laminate tray with a peelable foil lid . the tray contains a desiccant sachet , to reduce moisture in the packaging . the active substances are present as a white powder in separate blister strips inside the inhaler . each inhaler contains either 14 or 30 doses ( 14 or 30 day supply ). multipacks containing 90 ( 3 inhalers of 30 ) doses ( 90 day supply ) are also available . not all pack sizes may be marketed in your country .
what zinforo is zinforo is an antibiotic medicine that contains the active substance ceftaroline fosamil . it belongs to a group of medicines called ' cephalosporin antibiotics .' what zinforo is used for zinforo is used to treat children ( from birth ) and adults with : infections of the skin and the tissues below the skin an infection of the lungs called ' pneumonia ' how zinforo works zinforo works by killing certain bacteria , which can cause serious infections .
do not use zinforo : if you are allergic to ceftaroline fosamil or any of the other ingredients of this medicine ( listed in section 6 ). if you are allergic to other cephalosporin antibiotics if you have had previous severe allergic reactions to other antibiotics like penicillin or carbapenem. do not use zinforo if any of the above applies to you. if you are not sure, talk to your doctor or nurse before using zinforo. warnings and precautions talk to your doctor or nurse before using zinforo : if you have kidney problems ( your doctor may have to prescribe a lower dose ) if you have ever had fits ( seizures or convulsions ) if you have ever had any non - severe allergic reactions to other antibiotics like penicillin or carbapenem 26 if you have had severe diarrhoea whilst taking antibiotics in the past you may get another infection caused by another bacteria during or following treatment with zinforo. you may develop signs and symptoms of severe skin reactions such as fever, joint pain, skin rash, red scaly rash, skin bumps that contain pus, blisters or peeling of skin, red circular patches often with central blisters on the trunk, ulcers of mouth, throat, nose, genitals and eyes. if this happens talk to your doctor or nurse immediately. lab test you may develop an abnormal lab test ( called coombs test ) that looks for certain antibodies which may act against your red blood cells. if the level of your red blood cells fall your doctor may check to see if these antibodies have caused this. if any of the above apply to you ( or you are not sure ), talk to your doctor or nurse before using zinforo. other medicines and zinforo tell your doctor or nurse if you are using, have recently used or might use any other medicines. pregnancy and breast - feeding tell your doctor before using zinforo if you are pregnant. do not use this medicine during pregnancy unless your doctor has told you to. if you are pregnant or breast - feeding, think you may be pregnant or are planning
zinforo will be given to you by a doctor or nurse . how much to use the usual recommended dose for adults is 600 mg every 12 hours . your doctor may increase your dose to 600 mg every 8 hours for some infections . the usual recommended dose for children depends on the age and weight of the child and is given every 8 or 12 hours . it is given as a drip into a vein lasting 5 to 60 minutes if you receive the usual dose or 120 minutes if you receive an increased dose . a course of treatment usually lasts for 5 to 14 days for skin infections and 5 to 7 days for pneumonia . patients with kidney problems if you have kidney problems your doctor may lower your dose because zinforo is removed from your body by the kidneys . if you use more zinforo than you should if you think you have been given too much zinforo , tell your doctor or nurse straight away . if you miss a dose of zinforo if you think you have missed a dose , tell your doctor or nurse straight away . if you have any further questions on the use of this medicine , ask your doctor or nurse .
like all medicines, this medicine can cause side effects, although not everybody gets them. the following side effects may happen with this medicine : tell your doctor straight away if you get these symptoms as you may need urgent medical treatment : sudden swelling of your lips, face, throat or tongue ; a severe rash ; and, swallowing or breathing problems. these may be signs of a severe allergic reaction ( anaphylaxis ) and may be life - threatening ; diarrhoea that becomes severe or does not go away or stool that contains blood or mucus during or after treatment with zinforo. in this situation, you should not take medicines that stop or slow bowel movement. very common ( may affect more than 1 in 10 people ) changes in a blood test called a'coombs test'commonly seen in patients receiving this type of antibiotic. this test looks for certain antibodies which may act against your red blood cells. common ( may affect up to 1 in 10 people ) fever headache feeling dizzy itching, skin rash diarrhoea, stomach pain feeling sick ( nausea ) or being sick ( vomiting ) more enzymes produced by your liver ( as shown in blood tests ) pain and irritation of the veins redness, pain or swelling where the injection was given. uncommon ( may affect up to 1 in 100 people ) anaemia raised itchy rash ( hives ) an increase in the level of creatinine in your blood. creatinine shows how well your kidneys are working. bleeding or bruising more than usual. this may be because the level of platelets in your blood has dropped. changes in tests which measure how well your blood clots. a decrease in the total number of white blood cells, ora certain type of white blood cells in your blood ( leucopenia and neutropenia ). rare ( may affect up to 1 in 1, 000 people ) a significant decrease in the number of certain white blood cells in your blood ( agranulocytosis ). you may experience fever, flu - like symptoms, sore throat, or any other infection which may be serious. an increase in the number of
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the container . the expiry date refers to the last day of that month . store below 30 . store in the original package in order to protect from light . medicines should not be disposed of via wastewater or household waste . the hospital will dispose of any waste materials safely . these measures will help to protect the environment .
what zinforo contains each vial contains 600 mg of ceftaroline fosamil . the other ingredient is arginine . what zinforo looks like and contents of the pack zinforo is a pale yellowish - white to light yellow powder for concentrate for solution for infusion in a vial . it is available in packs containing 10 vials .
pregabalin pfizer belongs to a group of medicines used to treat epilepsy , neuropathic pain and generalised anxiety disorder ( gad ) in adults . peripheral and central neuropathic pain : pregabalin pfizer is used to treat long lasting pain caused by damage to the nerves . a variety of diseases can cause peripheral neuropathic pain , such as diabetes or shingles . pain sensations may be described as hot , burning , throbbing , shooting , stabbing , sharp , cramping , aching , tingling , numbness , pins and needles . peripheral and central neuropathic pain may also be associated with mood changes , sleep disturbance , fatigue ( tiredness ), and can have an impact on physical and social functioning and overall quality of life . epilepsy : pregabalin pfizer is used to treat a certain form of epilepsy ( partial seizures with or without secondary generalisation ) in adults . your doctor will prescribe pregabalin pfizer for you to help treat your epilepsy when your current treatment is not controlling your condition . you should take pregabalin pfizer in addition to your current treatment . pregabalin pfizer is not intended to be used alone , but should always be used in combination with other anti - epileptic treatment . generalised anxiety disorder : pregabalin pfizer is used to treat generalised anxiety disorder ( gad ). the symptoms of gad are prolonged excessive anxiety and worry that are difficult to control . gad can also cause restlessness or feeling keyed up or on edge , being easily fatigued ( tired ), having difficulty concentrating or mind going blank , feeling irritable , having muscle tension or sleep disturbance . this is different to the stresses and strains of everyday life .
do not take pregabalin pfizer : if you are allergic to pregabalin or any of the other ingredients of this medicine ( listed in section 6 ). warnings and precautions talk to your doctor or pharmacist before taking pregabalin pfizer. some patients taking pregabalin pfizer have reported symptoms suggesting an allergic reaction. these symptoms include swelling of the face, lips, tongue, and throat, as well as diffuse skin rash. should you experience any of these reactions, you should contact your physician immediately. pregabalin pfizer has been associated with dizziness and somnolence, which could increase the occurrence of accidental injury ( fall ) in elderly patients. therefore, you should be careful until you are used to any effect the medicine might have. pregabalin pfizer may cause blurring or loss of vision, or other changes in eyesight, many of which are temporary. you should immediately tell your doctor if you experience any changes in your vision. some patients with diabetes who gain weight while taking pregabalin may need an alteration in their diabetic medicines. certain side effects may be more common, such as sleepiness, because patients with spinal cord injury may be taking other medicines to treat, for example, pain or spasticity, that have similar side effects to pregabalin and the severity of these effects may be increased when taken together. there have been reports of heart failure in some patients when taking pregabalin pfizer ; these patients were mostly elderly with cardiovascular conditions. before taking this medicine you should tell your doctor if you have a history of heart disease. there have been reports of kidney failure in some patients when taking pregabalin pfizer. if while taking pregabalin pfizer you notice decreased urination, you should tell your doctor as stopping the medicine may improve this. a small number of people being treated with anti - epileptics such as pregabalin pfizer have had thoughts of harming or killing themselves. if at any time you have these thoughts, immediately contact your doctor. when pregabalin pfizer is taken with other medicines that may cause constipation (
always take this medicine exactly as your doctor has told you. check with your doctor or pharmacist if you are not sure. your doctor will determine what dose is appropriate for you. pregabalin pfizer is for oral use only. peripheral and central neuropathic pain, epilepsy or generalised anxiety disorder : take the number of capsules as instructed by your doctor. the dose, which has been adjusted for you and your condition, will generally be between 150 mg and 600 mg each day. your doctor will tell you to take pregabalin pfizer either twice or three times a day. for twice a day take pregabalin pfizer once in the morning and once in the evening, at about the same time 59 each day. for three times a day take pregabalin pfizer once in the morning, once in the afternoon and once in the evening, at about the same time each day. if you have the impression that the effect of pregabalin pfizer is too strong or too weak, talk to your doctor or pharmacist. if you are an elderly patient ( over 65 years of age ), you should take pregabalin pfizer normally except if you have problems with your kidneys. your doctor may prescribe a different dosing schedule and / or dose if you have problems with your kidneys. swallow the capsule whole with water. continue taking pregabalin pfizer until your doctor tells you to stop. if you take more pregabalin pfizer than you should call your doctor or go to the nearest hospital emergency unit immediately. take your box or bottle of pregabalin pfizer capsules with you. you may feel sleepy, confused, agitated, or restless as a result of taking more pregabalin pfizer than you should. fits have also been reported. if you forget to take pregabalin pfizer it is important to take your pregabalin pfizer capsules regularly at the same time each day. if you forget to take a dose, take it as soon as you remember unless it is time for your next dose. in that case
like all medicines, this medicine can cause side effects, although not everybody gets them. very common : may affect more than 1 in 10 people dizziness, drowsiness, headache. common : may affect up to 1 in 10 people increased appetite. feeling of elation, confusion, disorientation, decrease in sexual interest, irritability. disturbance in attention, clumsiness, memory impairment, loss of memory, tremor, difficulty with speaking, tingling feeling, numbness, sedation, lethargy, insomnia, fatigue, feeling abnormal. blurred vision, double vision. vertigo, problems with balance, fall. dry mouth, constipation, vomiting, flatulence, diarrhoea, nausea, swollen abdomen. difficulties with erection. swelling of the body including extremities. feeling drunk, abnormal style of walking. weight gain. muscle cramp, joint pain, back pain, pain in limb. sore throat. uncommon : may affect up to 1 in 100 people loss of appetite, weight loss, low blood sugar, high blood sugar. change in perception of self, restlessness, depression, agitation, mood swings, difficulty finding words, hallucinations, abnormal dreams, panic attack, apathy, aggression, elevated mood, mental impairment, difficulty with thinking, increase in sexual interest, problems with sexual functioning including inability to achieve a sexual climax, delayed ejaculation. changes in eyesight, unusual eye movement, changes in vision including tunnel vision, flashes of light, jerky movements, reduced reflexes, increased activity, dizziness on standing, sensitive skin, loss of taste, burning sensation, tremor on movement, decreased consciousness, loss of consciousness, fainting, increased sensitivity to noise, feeling unwell. dry eyes, eye swelling, eye pain, weak eyes, watery eyes, eye irritation. heart rhythm disturbance
what pregabalin pfizer contains the active substance is pregabalin. each hard capsule contains either 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg or 300 mg pregabalin. the other ingredients are : lactose monohydrate, maize starch, talc, gelatine, titanium dioxide ( e171 ), sodium laurilsulphate, anhydrous colloidal silica, black ink, ( which contains shellac, black iron oxide ( e172 ), propylene glycol, potassium hydroxide ) and water. the 75 mg, 100 mg, 200 mg, 225 mg and 300 mg capsules also contain red iron oxide ( e172 ). what pregabalin pfizer looks like and contents of the pack 25 mg capsules white hard capsules, with " pfizer " marked on the cap and " pgn 25 " on the body. 50 mg capsules white hard capsules, with " pfizer " marked on the cap and " pgn 50 " on the body. the capsule body is marked with a black band. 75 mg capsules white and orange hard capsules with " pfizer " marked on the cap and " pgn 75 " on the body. 100 mg capsules orange hard capsules, with " pfizer " marked on the cap and " pgn 100 " on the body. 150 mg capsules white hard capsules, with " pfizer " marked on the cap and " pgn 150 " on the body. 200 mg capsules light orange hard capsules, with " pfizer " marked on the cap and " pgn 200 " on the body. 225 mg capsules white and light orange hard capsules, with " pfizer " marked on the cap and " pgn 225 " on the body. 300 mg capsules white and orange hard capsules, with " pfizer " marked on the cap and " pgn 300 " on the body. pregabalin pfizer is available in seven pack sizes made
xadago is a medicine that contains the active substance safinamide . it acts to increase the level of a substance called dopamine in the brain , which is involved in the control of movement and is present in reduced amounts in the brain of patients with parkinson ' s disease . xadago is used for the treatment of parkinson ' s disease in adults . in mid - to late - stage patients experiencing sudden switches between being " on " and able to move and being " off " and having difficulties moving about , xadago is added to a stable dose of the medicine called levodopa alone or in combination with other medicines for parkinson ' s disease .
do not take xadago - if you are allergic to safinamide or any of the other ingredients of this medicine ( listed in section 6 ). - if you are taking any of the following medicines : - monoamine oxidase ( mao ) inhibitors such as selegiline, rasagiline, moclobemide, phenelzine, isocarboxazid, tranylcypromine ( e. g. for treatment of parkinson's disease or depression, or used for any other condition ). - pethidine ( a strong pain killer ). you must wait at least 7 days after stopping xadago treatment before starting treatment with mao inhibitors or pethidine. - if you have been told that you have severe liver problems - if you have an eye condition which might put you at risk of potential damage to your retina ( the light sensitive layers at the back of your eyes ), e. g. albinism ( lack of pigment in your skin and eyes ), retinal degeneration ( loss of cells from light sensitive layer at the back of the eye ), or uveitis ( inflammation inside of the eye ), inherited retinopathy ( inherited disorders of the vision ), or severe progressive diabetic retinopathy ( a progressive decrease of the vision due to diabetes ). warnings and precautions talk to your doctor before taking xadago - if you have liver problems - patients and carers should be made aware that certain compulsive behaviours such as compulsions, obsessive thoughts, pathological gambling, increased libido, hypersexuality, impulsive behaviour and compulsive spending or buying have been reported with other medicines for parkinson's disease. - uncontrollable jerky movements may occur or worsen when xadago is used together with levodopa. children and adolescents xadago is not recommended for use in children and adolescents, below 18 years old due to the lack of data on safety and efficacy in this population. other
always take this medicine exactly as your doctor has told you . check with your doctor if you are not sure . the recommended starting dose of xadago is one 50 mg tablet that may be increased to one 100 mg tablet , taken once daily preferably in the morning by mouth with water . xadago may be taken with or without food . if you suffer from moderately reduced liver function , you should not take more than 50 mg a day ; your doctor will advise if this applies to you . if you take more xadago than you should if you have taken too many xadago tablets , you may develop raised blood pressure , anxiety , confusion , forgetfulness , sleepiness , lightheadedness ; feel sick or be sick ; dilated pupils or develop involuntary jerky movements . contact your doctor immediately and take the xadago pack with you . if you forget to take xadago do not take a double dose to make up for a forgotten dose . skip the missed dose and take the next dose at the time you normally take it . if you stop taking xadago do not stop taking xadago without first talking to your doctor . if you have any further questions on the use of this medicine , ask your doctor or pharmacist .
like all medicines, this medicine can cause side effects, although not everybody gets them. seek medical advice in case of hypertensive crisis ( very high blood pressure, collapse ), neuroleptic malignant syndrome ( confusion, sweating, muscle rigidity, hyperthermia, increase level of enzyme creatine kinase in your blood ), serotonin syndrome ( confusion, hypertension, muscle stiffness, hallucinations ), and hypotension. the following side effects have been reported in patients at a mid - to late - stage of parkinson's disease ( patients taking safinamide as add - on to levodopa alone or in combination with other medicines for parkinson's disease ): common ( may affect up to 1 in 10 people ): insomnia, difficulty in performing voluntary movements, feeling sleepy, dizziness, headache, worsening of parkinson's disease, clouding of the lens of the eye, fall in blood pressure when rising to a standing position, nausea, falling. uncommon ( may affect up to 1 in 100 people ): urine infection, skin cancer, low iron in your blood, low white cell count, red blood cell abnormality, decreased appetite, high fat in blood, increased appetite, high blood sugar, seeing things that are not there, feeling sad, abnormal dreams, fear and worry, confusional state, mood swings, increased interest in sex, abnormal thinking and perception, restlessness, sleep disorder, numbness, unsteadiness, loss of sensation, sustained abnormal muscle contraction, head discomfort, difficulty in speaking, fainting, memory impairment, blurring of vision, blind spot, double vision, aversion to light, disorders of the light sensitive layer at the back of your eye, redness of the eyes, increased pressure in the eye, sensation of room spinning, feeling of heart beating, fast heartbeat, irregular heartbeat, slowed heartbeat, high blood pressure, low blood pressure, veins that have become large and twisted, cough
what xadago contains - the active substance is safinamide . each tablet contains 50 mg or 100 mg of safinamide ( as methansulfonate ). - the other ingredients are : - tablet core : microcrystalline cellulose , crospovidone type a , magnesium stearate , silica colloidal anhydrous - tablet coating : hypromellose , macrogol ( 6000 ), titanium dioxide ( e171 ), iron oxide red ( e172 ), mica ( e555 ). what xadago looks like and contents of the pack xadago 50 mg are orange to copper , round , biconcave film - coated tablets of 7 mm diameter with metallic gloss , embossed with " 50 " on one side of the tablet . xadago 100 mg are orange to copper , round , biconcave film - coated tablets 9 mm diameter with metallic gloss , embossed with " 100 " on one side of the tablet . xadago is supplied in packs containing 14 , 28 , 30 , 90 or 100 film coated tablets . not all pack sizes may be marketed .
zytiga contains a medicine called abiraterone acetate . it is used to treat prostate cancer in adult men that has spread to other parts of the body . zytiga stops your body from making testosterone ; this can slow the growth of prostate cancer . when zytiga is prescribed for the early stage of disease where it is still responding to hormone therapy , it is used with a treatment that lowers testosterone ( androgen deprivation therapy ). when you take this medicine your doctor will also prescribe another medicine called prednisone or prednisolone . this is to lower your chances of getting high blood pressure , having too much water in your body ( fluid retention ), or having reduced levels of a chemical known as potassium in your blood .
do not take zytiga - if you are allergic to abiraterone acetate or any of the other ingredients of this medicine ( listed in section 6 ). - if you are a woman, especially if pregnant. zytiga is for use in male patients only. - if you have severe liver damage. - in combination with ra - 223 ( which is used to treat prostate cancer ). do not take this medicine if any of the above apply to you. if you are not sure, talk to your doctor or pharmacist before taking this medicine. warnings and precautions talk to your doctor or pharmacist before taking this medicine : - if you have liver problems - if you have been told you have high blood pressure or heart failure or low blood potassium ( low blood potassium may increase the risk of heart rhythm problems ) - if you have had other heart or blood vessel problems - if you have an irregular or rapid heart rate - if you have shortness of breath 65 - if you have gained weight rapidly - if you have swelling in the feet, ankles, or legs - if you have taken a medicine known as ketoconazole in the past for prostate cancer - about the need to take this medicine with prednisone or prednisolone - about possible effects on your bones - if you have high blood sugar. tell your doctor if you have been told you have any heart or blood vessel conditions, including heart rhythm problems ( arrhythmia ), or are being treated with medicines for these conditions. tell your doctor if you have yellowing of the skin or eyes, darkening of the urine, or severe nausea or vomiting, as these could be signs or symptoms of liver problems. rarely, failure of the liver to function ( called acute liver failure ) may occur, which can lead to death. decrease in red blood cells, reduced sex drive ( libido ), muscle weakness and / or muscle pain may occur. zytiga must not be given in combination with ra - 223 due to a possible increase in the risk of bone fracture or death. if you plan to take ra -
always take this medicine exactly as your doctor has told you . check with your doctor or pharmacist if you are not sure . how much to take the recommended dose is 1 , 000 mg ( four tablets ) once a day . taking this medicine - take this medicine by mouth . - do not take zytiga with food . - take zytiga at least one hour before or at least two hours after eating ( see section 2 , " zytiga with food "). - swallow the tablets whole with water . - do not break the tablets . - zytiga is taken with a medicine called prednisone or prednisolone . take the prednisone or prednisolone exactly as your doctor has told you . - you need to take prednisone or prednisolone every day while you are taking zytiga . - the amount of prednisone or prednisolone you take may need to change if you have a medical emergency . your doctor will tell you if you need to change the amount of prednisone or prednisolone you take . do not stop taking prednisone or prednisolone unless your doctor tells you to . your doctor may also prescribe other medicines while you are taking zytiga and prednisone or prednisolone . if you take more zytiga than you should if you take more than you should , talk to your doctor or go to a hospital immediately . if you forget to take zytiga - if you forget to take zytiga or prednisone or prednisolone , take your usual dose the following day . - if you forget to take zytiga or prednisone or prednisolone for more than one day , talk to your doctor without delay . if you stop taking zytiga do not stop taking zytiga or prednisone or prednisolone unless your doctor tells you to . if you have any further questions on the use of this medicine , ask your doctor or pharmacist .
like all medicines , this medicine can cause side effects , although not everybody gets them . stop taking zytiga and see a doctor immediately if you notice any of the following : - muscle weakness , muscle twitches or a pounding heart beat ( palpitations ). these may be signs that the level of potassium in your blood is low . other side effects include : very common ( may affect more than 1 in 10 people ): fluid in your legs or feet , low blood potassium , liver function test increases , high blood pressure , urinary tract infection , diarrhoea . common ( may affect up to 1 in 10 people ): high fat levels in your blood , chest pain , irregular heart beat ( atrial fibrillation ), heart failure , rapid heart rate , severe infections called sepsis , bone fractures , indigestion , blood in urine , rash . uncommon ( may affect up to 1 in 100 people ): adrenal gland problems ( related to salt and water problems ), abnormal heart rhythm ( arrhythmia ), muscle weakness and / or muscle pain rare ( may affect up to 1 in 1 , 000 people ): lung irritation ( also called allergic alveolitis ). failure of the liver to function ( also called acute liver failure ). not known ( frequency cannot be estimated from the available data ): heart attack , changes in ecg - electrocardiogram ( qt prolongation ), and serious allergic reactions with difficulty swallowing or breathing , swollen face , lips , tongue or throat , or an itchy rash . bone loss may occur in men treated for prostate cancer . zytiga in combination with prednisone or prednisolone may increase bone loss . reporting of side effects if you get any side effects , talk to your doctor or pharmacist . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
what zytiga contains - the active substance is abiraterone acetate . each tablet contains 250 mg abiraterone acetate . - the other ingredients are microcrystalline cellulose , croscarmellose sodium , lactose monohydrate , magnesium stearate , povidone ( k29 / k32 ), colloidal anhydrous silica , and sodium laurilsulfate ( see section 2 , " zytiga contains lactose and sodium "). what zytiga looks like and contents of the pack - zytiga tablets are white to off - white , oval shaped ( 15 . 9 mm long x 9 . 5 mm wide ), with " aa250 " written on one side . - the tablets are provided in a plastic bottle with a child - resistant closure . each bottle contains 120 tablets . each carton contains one bottle .
hefiya contains the active substance adalimumab, a medicine that acts on your body's immune ( defence ) system. hefiya is intended for the treatment of the following inflammatory diseases : polyarticular juvenile idiopathic arthritis, enthesitis - related arthritis paediatric plaque psoriasis, paediatric crohn's disease, paediatric non - infectious uveitis. the active ingredient in hefiya, adalimumab, is a monoclonal antibody. monoclonal antibodies are proteins that attach to a specific target in the body. the target of adalimumab is another protein called tumour necrosis factor ( tnf<unk> ), which is present at increased levels in the inflammatory diseases listed above. by attaching to tnf<unk>, hefiya blocks its action and reduces the inflammation in these diseases. polyarticular juvenile idiopathic arthritis and enthesitis - related arthritis polyarticular juvenile idiopathic arthritis and enthesitis - related arthritis are inflammatory diseases of the joints that usually first appear in childhood. hefiya is used to treat polyarticular juvenile idiopathic arthritis in children and adolescents aged 2 to 82 17 years and enthesitis - related arthritis in children and adolescents aged 6 to 17 years. patients may first be given other disease - modifying medicines, such as methotrexate. if these medicines do not work well enough, patients will be given hefiya to treat their polyarticular juvenile idiopathic arthritis or enthesitis - related arthritis. paediatric plaque psoriasis plaque psoriasis is an inflammatory skin condition that causes red, flaky, crusty patches of skin covered with silvery scales. plaque psoriasis can also affect the nails, causing them to crumble, become thickened and lift away from the nail bed which can be painful. p
do not use hefiya if your child is allergic to adalimumab or any of the other ingredients of this medicine ( listed in section 6 ). if your child has a severe infection, including tuberculosis, sepsis ( blood poisoning ) or other opportunistic infections ( unusual infections associated with a weakened immune system ). it is important that you tell your doctor if your child shows symptoms of infections, e. g. fever, wounds, feeling tired, dental problems ( see " warnings and precautions "). if your child has moderate or severe heart failure. it is important to tell your doctor if your child has had or has a serious heart condition ( see " warnings and precautions "). warnings and precautions talk to your doctor or pharmacist before using hefiya. allergic reaction if your child has allergic reactions with symptoms such as chest tightness, wheezing, dizziness, swelling or rash, do not inject more hefiya and contact your doctor immediately, since in rare cases, these reactions can be life - threatening. infection if your child has an infection, including long - term or localised infection ( for example leg ulcer ), consult your doctor before starting hefiya. if you are unsure, contact your doctor. your child might get infections more easily while he / she is receiving hefiya treatment. this risk may increase if your child's lung function is reduced. these infections may be more serious and include tuberculosis, infections caused by viruses, fungi, parasites or bacteria, or other unusual infectious organisms and sepsis ( blood poisoning ). in rare cases, these infections may be life - threatening. it is important to tell your doctor if your child shows symptoms such as fever, wounds, feeling tired or dental problems. your doctor may recommend temporarily stopping hefiya. tuberculosis ( tb ) as cases of tuberculosis have been reported in patients treated with adalimuma
always use this medicine exactly as your doctor or pharmacist has told you. check with your doctor or pharmacist if you are not sure. hefiya is available as a 40 mg pen as well as 20 mg and 40 mg pre - filled syringes for patients to administer a full 20 mg or 40 mg dose. polyarticular juvenile idiopathic arthritis age and body weight how much and how often to take? notes children, adolescents and adults from 2 years of age weighing 30 kg or more 40 mg every other week not applicable children, adolescents and adults from 2 years of age weighing 10 kg to less than 30 kg 20 mg every other week not applicable enthesitis - related arthritis age and body weight how much and how often to take? notes children, adolescents and adults from 6 years of age weighing 30 kg or more 40 mg every other week not applicable children, adolescents and adults from 6 years of age weighing 15 kg to less than 30 kg 20 mg every other week not applicable paediatric plaque psoriasis age and body weight how much and how often to take? notes children and adolescents from 4 to 17 years of age weighing 30 kg or more first dose of 40 mg, followed by 40 mg one week later. thereafter, the usual dose is 40 mg every other week. not applicable children and adolescents from 4 to 17 years of age weighing 15 kg to less than 30 kg first dose of 20 mg, followed by 20 mg one week later. thereafter, the usual dose is 20 mg every other week. not applicable paediatric crohn's disease age and body weight how much and how often to take? notes children and adolescent from 6 to 17 years of age first dose of 80 mg ( as two 40 mg injections in one day ), followed by 40 mg every other week starting two weeks later. if this dose does not work well enough, your child's doctor may increase the dosage to 40 mg every week or 80 mg 87 weighing 40 kg or more if a faster response is required your doctor may prescribe a first dose of 160 mg ( as four 40 mg injections in one day or two 40 mg injections per day for two consecutive days ), followed by 80 mg ( as two 40 mg injections in
like all medicines, this medicine can cause side effects, although not everybody gets them. most side effects are mild to moderate. however, some may be serious and require treatment. side effects may occur up to 4 months or more after the last hefiya injection. seek medical attention urgently, if you notice any of the following signs of allergic reaction or heart failure : severe rash, hives ; swollen face, hands, feet ; trouble breathing, swallowing ; shortness of breath with exertion or upon lying down or swelling of the feet. tell your doctor as soon as possible, if you notice any of the following : signs and symptoms of infection such as fever, feeling sick, wounds, dental problems, burning on urination, feeling weak or tired or coughing ; symptoms of nerve problems such as tingling, numbness, double vision or arm or leg weakness ; signs of skin cancer such as a bump or open sore that doesn't heal ; signs and symptoms suggestive of blood disorders such as persistent fever, bruising, bleeding, paleness. the following side effects have been observed with adalimumab : very common ( may affect more than 1 in 10 people ) injection site reactions ( including pain, swelling, redness or itching ); respiratory tract infections ( including cold, runny nose, sinus infection, pneumonia ); headache ; abdominal ( belly ) pain ; nausea and vomiting ; rash ; pain in the muscles. common ( may affect up to 1 in 10 people ) serious infections ( including blood poisoning and influenza ); intestinal infections ( including gastroenteritis ); skin infections ( including cellulitis and shingles ); ear infections ; mouth infections ( including tooth infections and cold sores ); reproductive tract infections ; 89 urinary tract infection ; fungal infections ; joint infections ; benign tumours ; skin cancer ; allergic reactions ( including seasonal allergy ); dehydration ; mood swings ( including depression ); anxiety ; difficulty sleeping ; sensation disorders such as tingling, prickling or numbness ; migraine ; symptoms of
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the label / blister / carton after exp . the expiry date refers to the last day of that month . store in a refrigerator ( 28 ). do not freeze . do not shake . keep the pre - filled syringe in the outer carton in order to protect from light . alternative storage : when needed ( for example when you are travelling ), hefiya may be stored at room temperature ( up to 25 ) for a maximum period of 14 days be sure to protect it from light . once removed from the refrigerator for room temperature storage , your pre - filled syringe must be used within 14 days or discarded , even if it is later returned to the refrigerator . you should record the date when your pre - filled syringe is first removed from the refrigerator , and the date after which it should be discarded . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what hefiya contains the active substance is adalimumab . each pre - filled syringe contains 20 mg of adalimumab in 0 . 4 ml of solution . the other ingredients are adipic acid , citric acid monohydrate , sodium chloride , mannitol , polysorbate 80 , hydrochloric acid , sodium hydroxide and water for injections . what hefiya looks like and contents of the pack hefiya 20 mg solution for injection ( injection ) in pre - filled syringe for paediatric use is supplied as a 0 . 4 ml clear to slightly opalescent , colourless to slightly yellowish solution . hefiya is supplied in a single - use clear type i glass syringe with a stainless steel needle with a needle guard with finger flange , rubber needle cap and plastic plunger rod , containing 0 . 4 ml of solution . carton contains 2 pre - filled syringes of hefiya . not all pack sizes may be marketed . hefiya is available as a pre - filled syringe and a pre - filled pen ( sensoready ).
what ritemvia is ritemvia contains the active substance " rituximab ". this is a type of protein called a " monoclonal antibody ". it sticks to the surface of a type of white blood cell called " b - lymphocyte ". when rituximab sticks to the surface of this cell , the cell dies . what ritemvia is used for ritemvia may be used for the treatment of several different conditions in adults . your doctor may prescribe ritemvia for the treatment of : a ) non - hodgkin ' s lymphoma this is a disease of the lymph tissue ( part of the immune system ) that affects a type of white blood cell called b - lymphocytes . ritemvia can be given alone or with other medicines called " chemotherapy ". in patients where the treatment is working , ritemvia may be continued for 2 years after completing the initial treatment . b ) granulomatosis with polyangiitis or microscopic polyangiitis ritemvia is used for the treatment of granulomatosis with polyangiitis ( formerly called wegener ' s granulomatosis ) or microscopic polyangiitis , taken in combination with corticosteroids . granulomatosis with polyangiitis and microscopic polyangiitis are two forms of inflammation of the blood vessels which mainly affects the lungs and kidneys , but may affect other organs as well . b - lymphocytes are involved in the cause of these conditions . c ) pemphigus vulgaris ritemvia is used for the treatment of patients with moderate to severe pemphigus vulgaris . pemphigus vulgaris is an autoimmune condition that causes painful blisters on the skin and lining of the mouth , nose , throat and genitals .
do not take ritemvia if : you are allergic to rituximab, other proteins which are like rituximab, or any of the other ingredients of this medicine ( listed in section 6 ) you have a severe active infection at the moment you have a weak immune system you have severe heart failure or severe uncontrolled heart disease and have granulomatosis with polyangiitis, microscopic polyangiitis or pemphigus vulgaris. do not have ritemvia if any of the above apply to you. if you are not sure, talk to your doctor, pharmacist or nurse before you are given ritemvia. warnings and precautions talk to your doctor, pharmacist or nurse before you are given ritemvia if : you have ever had or might now have a hepatitis infection. this is because in a few cases, ritemvia could cause hepatitis b to become active again, which can be fatal in very rare cases. patients who have ever had hepatitis b infection will be carefully checked by their doctor for signs of this infection. you have ever had heart problems ( such as angina, palpitations or heart failure ) or breathing problems. if any of the above apply to you ( or you are not sure ), talk to your doctor, pharmacist or nurse before you are given ritemvia. your doctor may need to take special care of you during your treatment with ritemvia. if you have granulomatosis with polyangiitis, microscopic polyangiitis or pemphigus vulgaris also tell your doctor if you think you may have an infection, even a mild one like a cold. the cells that are affected by ritemvia help to fight infection and you should wait until the infection has passed before you are given ritemvia. also please tell your doctor if you had a lot of infections in the past or suffer from severe infections. if you think you may need any vaccinations in the near future, including vaccinations needed to travel to other countries. some vaccines should not be given at the same time as ritem
how it is given ritemvia will be given to you by a doctor or nurse who is experienced in the use of this treatment. they will watch you closely while you are being given this medicine. this is in case you get any side effects. you will always be given ritemvia as a drip ( intravenous infusion ). medicines given before each ritemvia administration before you are given ritemvia, you will be given other medicines ( pre - medication ) to prevent or reduce possible side effects. how much and how often you will receive your treatment a ) if you are being treated for non - hodgkin's lymphoma if you are having ritemvia alone ritemvia will be given to you once a week for 4 weeks. repeated treatment courses with ritemvia are possible. if you are having ritemvia with chemotherapy ritemvia will be given to you on the same day as your chemotherapy. this is usually given every 3 weeks up to 8 times. if you respond well to treatment, you may be given ritemvia every 2 or 3 months for two years. your doctor may change this, depending on how you respond to the medicine. b ) if you are being treated for granulomatosis with polyangiitis or microscopic polyangiitis treatment with ritemvia uses four separate infusions given at weekly intervals. corticosteroids will usually be given by injection before the start of ritemvia treatment. corticosteroids given by mouth may be started at any time by your doctor to treat your condition. if you respond well to treatment, you may be given ritemvia as a maintenance treatment. this will be administered as 2 separate infusions which are given 2 weeks apart, followed by 1 infusion every 6 months for at least 2 years. your doctor may decide to treat you longer with ritemvia ( up to 5 years ), depending on how you respond to the medicine. c ) if you are being treated for pemphigus vulgaris each course of treatment is made up of two separate infusions which are given 2 weeks apart. if you respond well to treatment, you may
like all medicines, this medicine can cause side effects, although not everybody gets them. most side effects are mild to moderate but some may be serious and require treatment. rarely, some of these reactions have been fatal. infusion reactions during or within the first 24 hours of the infusion you may develop fever, chills and shivering. less frequently, some patients may experience pain at the infusion site, blisters, itching, sickness ( nausea ), tiredness, headache, breathing difficulties, blood pressure raised, wheezing, throat discomfort, tongue or throat swelling, itchy or runny nose, vomiting, flushing or palpitations, heart attack or low number of platelets. if you have heart disease or angina, these reactions might get worse. tell the person giving you the infusion immediately if you develop any of these symptoms, as the infusion may need to be slowed down or stopped. you may require additional treatment such as an antihistamine or paracetamol. when these symptoms go away, or improve, the infusion can be continued. these reactions are less likely to happen after the second infusion. your doctor may decide to stop your ritemvia treatment if these reactions are serious. infections tell your doctor immediately if you get signs of an infection including : fever, cough, sore throat, burning pain when passing urine or feeling weak or generally unwell memory loss, trouble thinking, difficulty walking or sight loss these may be due to a very rare, serious brain infection, which has been fatal ( progressive multifocal leukoencephalopathy or pml ). you might get infections more easily during your treatment with ritemvia. these are often colds, but there have been cases of pneumonia or urinary infections. these are listed below under " other side effects ". if you are being treated for granulomatosis with polyangiitis, microscopic polyangiitis or pemphigus vulgaris, you will also find this information in the patient alert card you have been given by your doctor. it is important that you keep this alert card and show it to your partner or caregiver. skin reactions very rarely
what ritemvia contains the active ingredient in ritemvia is called rituximab . the vial contains 100 mg of rituximab . each ml of concentrate contains 10 mg of rituximab . the other ingredients are sodium chloride , tri - sodium citrate dihydrate , polysorbate 80 and water for injections . what ritemvia looks like and contents of the pack ritemvia is a clear , colourless solution , supplied as a concentrate for solution for infusion in a glass vial . pack of 2 vials .
capecitabine teva belongs to the group of medicines called " cytostatic medicines ", which stop the growth of cancer cells . capecitabine teva contains capecitabine , which itself is not a cytostatic medicine . only after being absorbed by the body is it changed into an active anti - cancer medicine ( more in tumour tissue than in normal tissue ). capecitabine teva is used in the treatment of colon , rectal , gastric , or breast cancers . furthermore , capecitabine teva is used to prevent new occurrence of colon cancer after complete removal of the tumour by surgery . capecitabine teva may be used either alone or in combination with other medicines .
do not take capecitabine teva - if you are allergic to capecitabine or any of the other ingredients of this medicine ( listed in section 6 ). you must inform your doctor if you know that you have an allergy or over - reaction to this medicine, - if you previously have had severe reactions to fluoropyrimidine therapy ( a group of anticancer medicines such as fluorouracil ), - if you are pregnant or breast - feeding, - if you have severely low levels of white cells or platelets in the blood ( leucopenia, neutropenia or thrombocytopenia ), - if you have severe liver or kidney problems, - if you know that you do not have any activity of the enzyme dihydropyrimidine dehydrogenase ( dpd ) ( complete dpd deficiency ), - if you are being treated now or have been treated in the last 4 weeks with brivudine as part of herpes zoster ( chickenpox or shingles ) therapy. warnings and precautions talk to your doctor or pharmacist before taking capecitabine teva - if you know that you have a partial deficiency in the activity of the enzyme dihydropyrimidine dehydrogenase ( dpd ) - if you have a family member who has partial or complete deficiency of the enzyme dihydropyrimidine dehydrogenase ( dpd ) - if you have liver or kidney diseases - if you have or had heart problems ( for example an irregular heartbeat or pains to the chest, jaw and back brought on by physical effort and due to problems with the blood flow to the heart ) - if you have brain diseases ( for example, cancer that has spread to the brain, or nerve damage ( neuropathy ) - if you have calcium imbalances ( seen in blood tests ) - if you have diabetes - if you cannot keep food or water in your body because of severe nausea and vomiting - if you have diarrhoea - if you are, or become de
always take this medicine exactly as your doctor or pharmacist has told you. check with your doctor or pharmacist if you are not sure. capecitabine should only be prescribed by a doctor experienced in the use of anticancer medicines. your doctor will prescribe a dose and treatment regimen that is right for you. the dose of capecitabine teva is based on your body surface area. this is calculated from your height and weight. the usual dose for adults is 1250 mg / m2 of body surface area taken two times daily ( morning and evening ). two examples are provided here : a person whose body weight is 64 kg and height is 1. 64 m has a body surface area of 1. 7 m2 and should take 4 tablets of 500 mg and 1 tablet of 150 mg two times daily. a person whose body weight is 80 kg and height is 1. 80 m has a body surface area of 2. 00 m2 and should take 5 tablets of 500 mg two times daily. your doctor will tell you what dose you need to take, when to take it and for how long you need to take it. your doctor may want you to take a combination of 150 mg and 500 mg tablets for each dose. - take the tablets morning and evening as prescribed by your doctor. - take the tablets within 30 minutes after the end of a meal ( breakfast and dinner ) and swallow whole with water. do not crush or cut tablets. if you cannot swallow capecitabine teva tablets whole, tell your healthcare provider. - it is important that you take all your medicine as prescribed by your doctor. capecitabine teva tablets are usually taken for 14 days followed by a 7 day rest period ( when no tablets are taken ). this 21 day period is one treatment cycle. in combination with other medicines the usual dose for adults may be less than 1250 mg / m2 of body surface area, and you may need to take the tablets over a different time period ( e. g. every day, with no rest period ). if you take more capecitabine teva than you should if you take more capecitabine teva than you should, contact your doctor as soon
like all medicines, this medicine can cause side effects, although not everybody gets them. stop taking capecitabine teva immediately and contact your doctor if any of these symptoms occur : diarrhoea : if you have an increase of 4 or more bowel movements compared to your normal bowel movements each day or any diarrhoea at night. vomiting : if you vomit more than once in a 24 - hour time period. nausea : if you lose your appetite, and the amount of food you eat each day is much less than usual. stomatitis : if you have pain, redness, swelling or sores in your mouth and / or throat. hand - and - foot skin - reaction : if you have pain, swelling, redness or tingling of hands and / or feet fever : if you have a temperature of 38 or greater. infection : if you experience signs of infection caused by bacteria or virus, or other organisms. chest pain : if you experience pain localised to the centre of the chest, especially if it occurs during exercise. stevens - johnson syndrome : if you experience painful red or purplish rash that spreads and blisters and / or other lesions begin to appear in the mucous membrane ( e. g. mouth and lips ), in particular if you had before light sensitivity, infections of the respiratory system ( e. g. bronchitis ) and / or fever. dpd deficiency : if you have a known dpd deficiency, you are at an increased risk of acute early - onset of toxicity and severe, life - threatening, or fatal adverse reactions caused by capecitabine teva ( e. g. stomatitis, mucosal inflammation, diarrhoea, neutropenia, and neurotoxicity ). if caught early, these side effects usually improve within 2 to 3 days after treatment discontinuation. if these
what capecitabine teva contains - the active substance is capecitabine . capecitabine teva 150 mg film - coated tablets each film - coated tablet contains 150 mg capecitabine . capecitabine teva 500 mg film - coated tablets each film - coated tablet contains 500 mg capecitabine . - the other ingredients are : tablet core : lactose , microcrystalline cellulose , hypromellose , croscarmellose sodium , magnesium stearate . tablet coating : macrogol 400 , hypromellose , titanium dioxide ( e171 ), yellow iron oxide ( e172 ), red iron oxide ( e172 ). what capecitabine teva looks like and contents of the pack capecitabine teva 150 mg film - coated tablets oval biconvex light peach film - coated tablets with inscription " c " on one side and " 150 " on the other side . the tablets are available in blisters containing 10 film - coated tablets . each pack contains 60 tablets . capecitabine teva 500 mg film - coated tablets oval biconvex light peach film - coated tablets with inscription " c " on one side and " 500 " on the other side . the tablets are available in blisters containing 10 film - coated tablets . each pack contains 120 tablets .
what silodosin recordati is silodosin recordati belongs to a group of medicines called alpha1a - adrenoreceptor blockers . silodosin recordati is selective for the receptors located in the prostate , bladder and urethra . by blocking these receptors , it causes smooth muscle in these tissues to relax . this makes it easier for you to pass water and relieves your symptoms . what silodosin recordati is used for silodosin recordati is used in adult men to treat the urinary symptoms associated with benign enlargement of the prostate ( prostatic hyperplasia ), such as : difficulty in starting to pass water , a feeling of not completely emptying the bladder , a more frequent need to pass water , even at night .
do not take silodosin recordati if you are allergic to silodosin or any of the other ingredients of this medicine ( listed in section 6 ). warnings and precautions talk to your doctor or pharmacist before taking silodosin recordati if you are undergoing eye surgery because of cloudiness of the lens ( cataract surgery ), it is important that you immediately inform your eye specialist that you are using or have previously 26 used silodosin recordati. this is because some patients treated with this kind of medicine experienced a loss of muscle tone in the iris ( the coloured circular part of the eye ) during such a surgery. the specialist can take appropriate precautions with respect to medicine and surgical techniques to be used. ask your doctor whether or not you should postpone or temporarily stop taking silodosin recordati when undergoing cataract surgery. if you have ever fainted or felt dizzy when suddenly standing up, please inform your doctor before taking silodosin recordati. dizziness when standing up and occasionally fainting may occur when taking silodosin recordati, particularly when starting treatment or if you are taking other medicines that lower blood pressure. if this occurs, make sure you sit or lie down straight away until the symptoms have disappeared and inform your doctor as soon as possible ( see also section " driving and using machines "). if you have severe liver problems, you should not take silodosin recordati, as it was not tested in this condition. if you have problems with your kidneys, please ask your doctor for advice. if you have moderate kidney problems, your doctor will start silodosin recordati with caution and possibly with a lower dose ( see section 3 " dose "). if you have severe kidney problems, you should not take silodosin recordati. since a benign enlargement of the prostate and prostate cancer may present the same symptoms, your doctor will check you for prostate cancer before starting treatment with silodosin recordati. silodosin recordati does not treat prostate cancer. the treatment with silo
always use this medicine exactly as your doctor or pharmacist has told you . check with your doctor or pharmacist if you are not sure . the recommended dose is one capsule of silodosin recordati 8 mg per day by oral administration . take the capsule always with food , preferably at the same time every day . do not break or chew the capsule , but swallow it whole , preferably with a glass of water . patients with kidney problems if you have moderate kidney problems , your doctor may prescribe a different dose . for this purpose silodosin recordati 4 mg hard capsules are available . if you take more silodosin recordati than you should if you have taken more than one capsule , inform your doctor as soon as possible . if you become dizzy or feel weak , tell your doctor straight away . if you forget to take silodosin recordati you may take your capsule later the same day if you have forgotten to take it earlier . if it is almost time for the next dose , skip the dose you missed . do not take a double dose to make up for a forgotten capsule . if you stop taking silodosin recordati if you stop treatment , your symptoms may re - appear . if you have any further questions on the use of this medicine , ask your doctor or pharmacist .
like all medicines, this medicine can cause side effects, although not everybody gets them. contact your doctor immediately if you notice any of the following allergic reactions : swelling of the face or throat, difficulty in breathing, feeling faint, itchy skin or hives since the consequences could become serious. the most common side effect is a decrease in the amount of semen released during sex. this effect disappears after discontinuation of silodosin recordati. please inform your doctor if you are planning to have children. dizziness, including dizziness when standing up, and occasionally fainting, may occur. if you do feel weak or dizzy, make sure you sit or lie down straight away until the symptoms have disappeared. if dizziness when standing up or fainting occurs, please inform your doctor as soon as possible. silodosin recordati may cause complications during a cataract surgery ( eye surgery because of cloudiness of the lens, see section " warnings and precautions "). it is important that you immediately inform your eye specialist if you are using or have previously used silodosin recordati. the possible side effects are listed below : very common side effects ( may affect more than 1 in 10 people ) abnormal ejaculation ( less or no noticeable semen is released during sex, see section " warnings and precautions ") common side effects ( may affect up to 1 in 10 people ) dizziness, including dizziness when standing up ( see also above, in this section ) runny or blocked nose diarrhoea uncommon side effects ( may affect up to 1 in 100 people ) decreased sexual drive nausea dry mouth difficulties in getting or keeping an erection faster heart rate symptoms of allergic reaction affecting the skin like rash, itching, hives and rash caused by a medicine abnormal results of liver function tests low blood pressure rare side effects ( may affect up to 1 in 1, 000 people ) fast or irregular heart beats ( called palpitations ) fainting / loss of consciousness very rare side effects ( may affect up to 1 in 10, 000 people ) other allergic reactions with swelling of the face or throat not known
what silodosin recordati contains silodosin recordati 8 mg the active substance is silodosin . each capsule contains 8 mg of silodosin . the other ingredients are pregelatinised maize starch , mannitol ( e421 ), magnesium stearate , sodium laurilsulfate , gelatin , titanium dioxide ( e171 ). silodosin recordati 4 mg the active substance is silodosin . each capsule contains 4 mg of silodosin . the other ingredients are pregelatinised maize starch , mannitol ( e421 ), magnesium stearate , sodium laurilsulfate , gelatin , titanium dioxide ( e171 ), yellow iron oxide ( e172 ). what silodosin recordati looks like and contents of the pack silodosin recordati 8 mg are white , opaque , hard gelatin capsules , size 0 ( approximately 21 . 7 x 7 . 6 mm ). silodosin recordati 4 mg are yellow , opaque , hard gelatin capsules , size 3 ( approximately 15 . 9 x 5 . 8 mm ). silodosin recordati is available in packs containing 10 , 20 , 30 , 50 , 90 , 100 capsules . not all pack sizes may be marketed .
kinzalmono belongs to a class of medicines known as angiotensin ii receptor antagonists . angiotensin ii is a substance produced in your body which causes your blood vessels to narrow , thus increasing your blood pressure . kinzalmono blocks the effect of angiotensin ii so that the blood vessels relax , and your blood pressure is lowered . kinzalmono is used to treat essential hypertension ( high blood pressure ) in adults . ' essential ' means that the high blood pressure is not caused by any other condition . high blood pressure , if not treated , can damage blood vessels in several organs , which could lead sometimes to heart attack , heart or kidney failure , stroke , or blindness . there are usually no symptoms of high blood pressure before damage occurs . thus it is important to regularly measure blood pressure to verify if it is within the normal range . kinzalmono is also used to reduce cardiovascular events ( i . e . heart attack or stroke ) in adults who are at risk because they have a reduced or blocked blood supply to the heart or legs , or have had a stroke or have high risk diabetes . your doctor can tell you if you are at high risk for such events .
do not take kinzalmono if you are allergic to telmisartan or any other ingredients of this medicine ( listed in section 6 ). if you are more than 3 months pregnant. ( it is also better to avoid kinzalmono in early pregnancy see pregnancy section.) if you have severe liver problems such as cholestasis or biliary obstruction ( problems with drainage of the bile from the liver and gall bladder ) or any other severe liver disease. if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren. if any of the above applies to you, tell your doctor or pharmacist before taking kinzalmono. warnings and precautions talk to your doctor before taking kinzalmono if you are suffering or have ever suffered from any of the following conditions or illnesses : kidney disease or kidney transplant. renal artery stenosis ( narrowing of the blood vessels to one or both kidneys ). liver disease. heart trouble. raised aldosterone levels ( water and salt retention in the body along with imbalance of various blood minerals ). low blood pressure ( hypotension ), likely to occur if you are dehydrated ( excessive loss of body water ) or have salt deficiency due to diuretic therapy (' water tablets '), low - salt diet, diarrhoea, or vomiting. elevated potassium levels in your blood. diabetes. talk to your doctor before taking kinzalmono : if you are taking any of the following medicines used to treat high blood pressure : - an ace - inhibitor ( for example enalapril, lisinopril, ramipril ), in particular if you have diabetes - related kidney problems. - aliskiren. your doctor may check your kidney function, blood pressure, and the amount of electrolytes ( e. g. potassium ) in your blood at regular intervals. see also information under the heading " do not take kinzalmono ". if you are taking digoxin. you must tell your doctor if you think you are
always take this medicine exactly as your doctor has told you . check with your doctor or pharmacist if you are not sure . the recommended dose is one tablet a day . try to take the tablet at the same time each day . you can take kinzalmono with or without food . the tablets should be swallowed with some water or other non - alcoholic drink . it is important that you take kinzalmono every day until your doctor tells you otherwise . if you have the impression that the effect of kinzalmono is too strong or too weak , talk to your doctor or pharmacist . for treatment of high blood pressure , the usual dose of kinzalmono for most patients is one 40 mg tablet once a day to control blood pressure over the 24 - hour period . your doctor has recommended a lower dose of one 20 mg tablet daily . kinzalmono may also be used in combination with diuretics (' water tablets ') such as hydrochlorothiazide which has been shown to have an additive blood pressure lowering effect with kinzalmono . for reduction of cardiovascular events , the usual dose of kinzalmono is one 80 mg tablet once a day . at the beginning of the preventive therapy with kinzalmono 80 mg , blood pressure should be frequently monitored . if your liver is not working properly , the usual dose should not exceed 40 mg once daily . if you take more kinzalmono than you should if you accidentally take too many tablets , contact your doctor , pharmacist , or your nearest hospital emergency department immediately . if you forget to take kinzalmono if you forget to take a dose , do not worry . take it as soon as you remember then carry on as before . if you do not take your tablet on one day , take your normal dose on the next day . do not take a double dose to make up for forgotten individual doses . if you have any further questions on the use of this medicine , ask your doctor or pharmacist .
like all medicines, this medicine can cause side effects, although not everybody gets them. some side effects can be serious and need immediate medical attention you should see your doctor immediately if you experience any of the following symptoms : sepsis * ( often called " blood poisoning ", is a severe infection with whole - body inflammatory response ), rapid swelling of the skin and mucosa ( angioedema ); these side effects are rare ( may affect up to 1 in 1, 000 people ) but are extremely serious and patients should stop taking the medicine and see their doctor immediately. if these effects are not treated they could be fatal. possible side effects of kinzalmono common side effects ( may affect up to 1 in 10 people ): low blood pressure ( hypotension ) in users treated for reduction of cardiovascular events. uncommon side effects ( may affect up to 1 in 100 people ): urinary tract infections, upper respiratory tract infections ( e. g. sore throat, inflamed sinuses, common cold ), deficiency in red blood cells ( anaemia ), high potassium levels, difficulty falling asleep, feeling sad ( depression ), fainting ( syncope ), feeling of spinning ( vertigo ), slow heart rate ( bradycardia ), low blood pressure ( hypotension ) in users treated for high blood pressure, dizziness on standing up ( orthostatic hypotension ), shortness of breath, cough, abdominal pain, diarrhoea, discomfort in the abdomen, bloating, vomiting, itching, increased sweating, drug rash, back pain, muscle cramps, muscle pain ( myalgia ), kidney impairment including acute kidney failure, pain in the chest, feeling of weakness, and increased level of creatinine in the blood. rare side effects ( may affect up to 1 in 1, 000 people ): sepsis * ( often called " blood poisoning ", is a severe infection with whole - body inflammatory response which can lead to death ), increase in certain white blood cells ( eosinophilia ), low platelet count ( thrombocytopenia ), severe allergic
keep out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the carton after " exp ". the expiry date refers to the last day of that month . this medicine does not require any special temperature storage conditions . you should store your medicine in the original package in order to protect the tablets from moisture . remove your kinzalmono tablet from the blister only directly prior to intake . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what kinzalmono contains the active substance is telmisartan . each tablet contains 20 mg telmisartan . the other ingredients are povidone , meglumine , sodium hydroxide , sorbitol ( e420 ) and magnesium stearate . what kinzalmono looks like and contents of the pack kinzalmono 20 mg tablets are white , round and engraved with the code number ' 50h ' on one side and the company logo on the other side . kinzalmono is available in blister packs containing 14 , 28 , 56 or 98 tablets . not all pack sizes may be marketed in your country .
afstyla is a human clotting ( coagulation ) factor viii product that is produced by recombinant dna technology . the active substance in afstyla is lonoctocog alfa . afstyla is used to treat and prevent bleeding episodes in patients with haemophilia a ( inborn factor viii deficiency ). factor viii is involved in blood clotting . lack of this factor means that blood does not clot as quickly as it should so there is an increased tendency to bleed . afstyla works by replacing the missing factor viii in haemophilia a patients to enable their blood to clot normally . afstyla can be used for all age groups .
do not use afstyla if you have had an allergic reaction to afstyla, or any of its ingredients ( listed in section 6 ). if you are allergic to hamster proteins. warnings and precautions traceability 46 it is strongly recommended that every time afstyla is given, you record the date of administration, the batch number and the injected volume in your treatment diary. talk to your doctor, pharmacist or nurse before using afstyla. allergic ( hypersensitivity ) reactions are possible. the product contain traces of hamster proteins ( see also " do not use afstyla "). if symptoms of allergic reactions occur, stop using the medicine immediately and contact your doctor. your doctor should inform you of the early signs of allergic reactions. these include hives, generalised skin rash, tightness of the chest, wheezing, fall in blood pressure and anaphylaxis ( a serious allergic reaction that causes severe difficulty in breathing, and dizziness ). the formation of inhibitors ( antibodies ) is a known complication that can occur during treatment with all factor viii medicines. these inhibitors, especially at high levels, stop the treatment working properly and you or your child will be monitored carefully for the development of these inhibitors. if you or your child <unk> s bleeding is not being controlled with afstyla, tell your doctor immediately. if you have been told you have heart disease or are at risk for heart disease, tell your doctor or pharmacist. if you need a central venous access device ( cvad for injection of afstyla ), the risk of complications including local infections, bacteria in the blood ( bacteremia ) and the formation of a blood clot in the blood vessel ( thrombosis ) where the catheter is inserted should be considered by your doctor. other medicines and afstyla tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. pregnancy and breast - feeding if you are pregnant or breast - feeding, think you may be pregnant or are
your treatment should be monitored by a doctor who is experienced in the treatment of blood clotting disorders. always take this medicine exactly as your doctor has told you. check with your doctor if you are not sure. dose the amount of afstyla you need to take and the duration of treatment depend on : the severity of your disease the site and intensity of the bleeding your clinical condition and response your body weight follow the directions given to you by your doctor. reconstitution and administration general instructions the powder must be mixed with the solvent ( liquid ) and withdrawn from the vial under aseptic conditions. afstyla must not be mixed with other medicines or solvents except those mentioned in section 6. the solution should be clear or slightly opalescent, yellow to colourless, i. e., it might be sparkling when held up to the light but must not contain any obvious particles. after filtering or withdrawal ( see below ) the solution should be checked by eye, before it is used. do not use the solution if it is visibly cloudy or if it contains flakes or particles. any unused product or waste material should be disposed of in accordance with local requirements and as instructed by your doctor. reconstitution and administration without opening the vials, warm the afstyla powder and the liquid to room or body temperature. this can be done either by leaving the vials at room temperature for about an hour, or by holding them in your hands for a few minutes. do not expose the vials to direct heat. the vials must not be heated above body temperature ( 37 ). carefully remove the protective caps from the vials, and clean the exposed rubber stoppers with an alcohol swab. allow the vials to dry before opening the mix2vial package ( which contains the filter transfer device ), then follow the instructions given below. 1 1. open the mix2vial by peeling off the lid. do not remove the mix2vial from the blister package! 2 2. place the solvent vial on an even, clean surface and hold the vial tight. take the mix2vial together with the blister package and push the spike of the blue adapter end
like all medicines , afstyla can cause side effects , although not everybody gets them . please stop using the medicine immediately and contact your doctor if : you notice symptoms of allergic reactions allergic reactions may include the following symptoms : hives , generalised urticaria ( itchy rash ), tightness of the chest , difficulty in breathing , wheezing , low blood pressure , dizziness , and anaphylaxis . if this happens , you should stop using the medicine immediately and contact your doctor . you notice that the medicine stops working properly ( bleeding is not stopped ) for children not previously treated with factor viii medicines , inhibitor antibodies ( see section 2 ) may form very commonly ( more than 1 in 10 patients ); however patients who have received previous treatment with factor viii ( more than 150 days of treatment ) the risk is uncommon ( less than 1 in 100 patients ). if this happens you or your child Â´ s medicines may stop working properly and you or your child may experience persistent bleeding . if this happens , you should contact your doctor immediately . common side effects ( may affect up to 1 in 10 users ) allergic reaction dizziness tingling or numbness ( paraesthesia ) rash fever uncommon side effects ( may affect up to 1 in 100 users ) itching redness of the skin pain at the injection site chills feeling hot side effects in children and adolescents no age - specific differences in adverse reactions were observed between children , adolescents and adult subjects . reporting of side effects if you get any side effects , talk to your doctor , pharmacist or nurse . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date , which is stated on the label and carton . store in a refrigerator ( 2 to 8 ). before the afstyla powder is reconstituted it may be kept at room temperature ( below 25 ) for a single period not exceeding 3 months , within the expiration date printed on the cartons and the vials . please record the date from when you start to store afstyla at room temperature on the product carton . once the product has been taken out of the refrigerator , the product must not be returned to the refrigerator . do not freeze . keep the vial in the outer carton in order to protect from light . the reconstituted product should preferably be used immediately . if the reconstituted product is not administered immediately , storage times and conditions prior to use are in the responsibility of the user .
what afstyla contains the active substance is : 250 iu per vial ; after reconstitution with 2. 5 ml of water for injections the solution contains 100 iu / ml of lonoctocog alfa. iu per vial ; after reconstitution with 2. 5 ml of water for injections the solution contains 200 iu / ml of lonoctocog alfa. 1000 iu per vial ; after reconstitution with 2. 5 ml of water for injections the solution contains 400 iu / ml of lonoctocog alfa. 1500 iu per vial ; after reconstitution with 5 ml of water for injections the solution contains 300 iu / ml of lonoctocog alfa. 2000 iu per vial ; after reconstitution with 5 ml of water for injections the solution contains 400 iu / ml of lonoctocog alfa. 2500 iu per vial ; after reconstitution with 5 ml of water for injections the solution contains 500 iu / ml of lonoctocog alfa. 3000 iu per vial ; after reconstitution with 5 ml of water for injections the solution contains 600 iu / ml of lonoctocog alfa. the other ingredients are : l - histidine, polysorbate 80, calcium chloride dihydrate, sodium chloride ( see last paragraph of section 2 ), sucrose. solvent : water for injections. what afstyla looks like and contents of the pack afstyla is presented as white or slightly yellow powder or friable mass and clear, colourless solvent for solution for injection. the reconstituted solution should be clear to slightly opalescent, yellow to colourless i. e., it might sparkle when held up to the light but must not contain any obvious particles. presentations one pack with 250, 500 or 1000 iu containing : 1 vial with powder 1 vial
what praxbind is praxbind contains the active substance idarucizumab . idarucizumab is a reversal agent specific for dabigatran ( pradaxa ), a blood thinner medicine that blocks a substance in the body , which is involved in blood clot formation . praxbind is used to rapidly trap dabigatran in order to inactivate its effect . what praxbind is used for praxbind is used in adults in emergency situations where your doctor decides that rapid inactivation of the effect of pradaxa is required : - for emergency surgery / urgent procedures ; - in life - threatening or uncontrolled bleeding .
warnings and precautions talk to your doctor or nurse before receiving praxbind : - if you are allergic to idarucizumab or to any other of the substances listed in section 6 . - if you have a genetic disease called hereditary fructose intolerance . in this case , the substance sorbitol contained in this medicine may cause serious adverse reactions . they will take this into account before treating you with praxbind . this medicine will only remove dabigatran from your body . it will not remove other medicines used to prevent the formation of blood clots . after dabigatran has been removed from your body , you are not protected from the formation of blood clots . your doctor will continue treating you with medicines used to prevent the formation of blood clots as soon as your medical condition allows . children and adolescents there is no information on the use of praxbind in children . other medicines and praxbind tell your doctor if you are taking , have recently taken or might take any other medicines . this medicine has been designed to only bind to dabigatran . it is unlikely that praxbind will influence the effect of other medicines or that other medicines will influence praxbind . pregnancy and breast - feeding if you are pregnant or breast - feeding , think you may be pregnant or are planning to have a baby , ask your doctor for advice before receiving this medicine . there is no information on the effects of this medicine in pregnant or breast - feeding women . praxbind does not affect any functions in the body as such , so your doctor may decide to give you this medicine , if the expected benefits outweigh any potential risks . praxbind contains sodium this medicine contains 50 mg sodium ( main component of cooking / table salt ) in each dose . this is equivalent to 2 . 5 % of the recommended maximum daily dietary intake of sodium for an adult .
this medicine is for hospital use only . the recommended dose is 5 g ( 2 vials of 2 . 5 g / 50 ml ). in rare cases you may still have too much dabigatran in your blood after a first dose of this medicine and your doctor may decide to give you a second 5 g dose in specific situations . your doctor or nurse will give you this medicine by injection or infusion into a vein . after you have received this medicine , your doctor will decide on the continuation of your treatment to prevent blood clot formation . dabigatran can be given again 24 hours after administration of this medicine . detailed instructions for your doctor or nurse on how to administer this medicine can be found at the end of this package leaflet ( see ' handling instructions '). if you have any further questions on the use of this medicine , ask your doctor .
like all medicines , this medicine may cause side effects , although not everybody gets them . until now , no side effects have been identified . reporting of side effects if you get any side effects , talk to your doctor or nurse . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
what praxbind contains - the active substance is idarucizumab . - the other ingredients are : sodium acetate trihydrate ( e262 ), acetic acid ( e260 , for ph adjustment ), sorbitol ( e420 ), polysorbate 20 ( e432 ) and water for injections . what praxbind looks like and contents of the pack praxbind is a clear to slightly opalescent , colourless to slightly yellow solution supplied in a glass vial closed with a butyl rubber stopper and an aluminium cap . each pack contains two vials .
temomedac contains a medicine called temozolomide . this medicine is an antitumour agent . temomedac is used for the treatment of specific forms of brain tumours : - in adults with newly - diagnosed glioblastoma multiforme . temomedac is first used together with radiotherapy ( concomitant phase of treatment ) and after that alone ( monotherapy phase of treatment ). - in children 3 years and older and adult patients with malignant glioma , such as glioblastoma multiforme or anaplastic astrocytoma . temomedac is used in these tumours if they return or get worse after standard treatment .
do not take temomedac - if you are allergic to temozolomide or any of the other ingredients of this medicine ( listed in section 6 ). - if you have had an allergic reaction to dacarbazine ( an anticancer medicine sometimes called dtic ). signs of allergic reaction include feeling itchy, breathlessness or wheezing, swelling of the face, lips, tongue or throat. - if certain kinds of blood cells are severely reduced ( myelosuppression ), such as your white blood cell count and platelet count. these blood cells are important for fighting infection and for proper blood clotting. your doctor will check your blood to make sure you have enough of these cells before you begin treatment. warnings and precautions talk to your doctor, pharmacist or nurse before taking temomedac, 44 - as you should be observed closely for the development of a serious form of chest infection called pneumocystis jirovecii pneumonia ( pcp ). if you are a newly - diagnosed patient ( glioblastoma multiforme ) you may be receiving temomedac for 42 days in combination with radiotherapy. in this case, your doctor will also prescribe medicine to help you prevent this type of pneumonia ( pcp ). - if you have ever had or might now have a hepatitis b infection. this is because temomedac could cause hepatitis b to become active again, which can be fatal in some cases. patients will be carefully checked by their doctor for signs of this infection before treatment is started. - if you have low counts of red blood cells ( anaemia ), white blood cells and platelets, or blood clotting problems before starting the treatment, or if you develop them during treatment. your doctor may decide to reduce the dose, interrupt, stop or change your treatment. you may also need other treatments. in some cases, it may be necessary to stop treatment with temomedac. your blood will be tested frequently during treatment to monitor the side effects of temomedac on your blood cells. - as
always take this medicine exactly as your doctor or pharmacist has told you. check with your doctor or pharmacist if you are not sure. dosage and duration of treatment your doctor will work out your dose of temomedac. this is based on your size ( height and weight ) and if you have a recurrent tumour and have had chemotherapy treatment in the past. you may be given other medicines ( anti - emetics ) to take before and / or after taking temomedac to prevent or control nausea and vomiting. patients with newly - diagnosed glioblastoma multiforme if you are a newly - diagnosed patient, treatment will occur in two phases : - treatment together with radiotherapy ( concomitant phase ) first - followed by treatment with only temomedac ( monotherapy phase ). during the concomitant phase, your doctor will start temomedac at a dose of 75 mg / m2 ( usual dose ). you will take this dose every day for 42 days ( up to 49 days ) in combination with radiotherapy. the temomedac dose may be delayed or stopped, depending on your blood counts and how you tolerate your medicine during the concomitant phase. once the radiotherapy is completed, you will interrupt treatment for 4 weeks. this will give your body a chance to recover. then, you will start the monotherapy phase. during the monotherapy phase, the dose and way you take temomedac will be different. your doctor will work out your exact dose. there may be up to 6 treatment periods ( cycles ). each one lasts 28 days. you will take your new dose of temomedac alone once daily for the first 5 days (" dosing days ") of each cycle. the first dose will be 150 mg / m2. then you will have 23 days without temomedac. this adds up to a 28 day treatment cycle. after day 28, the next cycle will begin. you will again take temomedac once daily for 5 days followed by 23 days without temomedac. the temomedac dose may be adjusted
like all medicines, this medicine can cause side effects, although not everybody gets them. contact your doctor immediately if you have any of the following : - a severe allergic ( hypersensitive ) reaction ( hives, wheezing or other breathing difficulty ), - uncontrolled bleeding, - seizures ( convulsions ), - fever, - chills, - severe headache that does not go away. temomedac treatment can cause a reduction in certain kinds of blood cells. this may cause you to have increased bruising or bleeding, anaemia ( a shortage of red blood cells ), fever, and reduced resistance to infections. the reduction in blood cell counts is usually short - lived. in some cases, it may be prolonged and may lead to a very severe form of anaemia ( aplastic anaemia ). your doctor will monitor your blood regularly for any changes, and will decide if any specific treatment is needed. in some cases, your temomedac dose will be reduced or treatment stopped. side effects from clinical studies : temomedac in combination treatment with radiotherapy in newly - diagnosed glioblastoma patients receiving temomedac in combination with radiotherapy may experience different side effects than patients taking temomedac alone. the following side effects may occur, and may require medical attention. very common ( may affect more than 1 in 10 people ): loss of appetite, headache, constipation ( difficulty passing stools ), nausea ( feeling sick in your stomach ), vomiting, rash, hair loss, tiredness. common ( may affect up to 1 in 10 people ): oral infections, wound infection, reduced number of blood cells ( neutropenia, thrombocytopenia, lymphopenia, leukopenia ), increased sugar in the blood, loss of weight, change in mental status or alertness, anxiety / depression, sleepiness, difficulty speaking, impaired balance, dizziness, confusion, forgetfulness, difficulty concentrating, inability to fall asleep or stay asleep, tingling sensation, bruising, shaking
keep this medicine out of the sight and reach of children , preferably in a locked cupboard . accidental ingestion can be lethal for children . do not use this medicine after the expiry date which is stated on the label and carton . the expiry date refers to the last day of that month . do not store above 30 . store in the original package in order to protect from moisture . keep the bottle tightly closed . tell your pharmacist if you notice any change in the appearance of the capsules . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what temomedac contains - the active substance is temozolomide. temomedac 5 mg hard capsules : each capsule contains 5 mg temozolomide. temomedac 20 mg hard capsules : each capsule contains 20 mg temozolomide. temomedac 100 mg hard capsules : each capsule contains 100 mg temozolomide. temomedac 140 mg hard capsules : each capsule contains 140 mg temozolomide. temomedac 180 mg hard capsules : each capsule contains 180 mg temozolomide. temomedac 250 mg hard capsules : each capsule contains 250 mg temozolomide. - the other ingredients are : capsule content : anhydrous lactose, colloidal anhydrous silica, sodium starch glycolate type a, tartaric acid, stearic acid ( see section 2 " temomedac contains lactose "). capsule shell ( including printing ink ): temomedac 5 mg hard capsules : gelatin, titanium dioxide ( e 171 ), shellac, propylene glycol, indigo carmine ( e 132 ) aluminium lake, yellow iron oxide ( e 172 ) temomedac 20 mg hard capsules : gelatine, titanium dioxide ( e 171 ), shellac, propylene glycol, sunset yellow fcf aluminium lake ( e 110 ). temomedac 100 mg hard capsules : gelatin, titanium dioxide ( e 171 ), red iron oxide ( e 172 ), shellac, propylene glycol and yellow iron oxide ( e 172 ). temomedac 140 mg hard capsules : gelatin, titanium dioxide ( e 171 ), shellac, propylene glycol, indigo carmine ( e 132 ) aluminium lake. temomedac 180 mg hard capsules : gelatin, titanium dioxide ( e 171 ), shellac
cialis is a treatment for adult men with erectile dysfunction . this is when a man cannot get , or keep a hard , erect penis suitable for sexual activity . cialis has been shown to significantly improve the ability of obtaining a hard erect penis suitable for sexual activity . cialis contains the active substance tadalafil which belongs to a group of medicines called phosphodiesterase type 5 inhibitors . following sexual stimulation cialis works by helping the blood vessels in your penis to relax , allowing the flow of blood into your penis . the result of this is improved erectile function . cialis will not help you if you do not have erectile dysfunction . it is important to note that cialis does not work if there is no sexual stimulation . you and your partner will need to engage in foreplay , just as you would if you were not taking a medicine for erectile dysfunction .
do not take cialis if you : - are allergic to tadalafil or any of the other ingredients of this medicine ( listed in section 6 ). - are taking any form of organic nitrate or nitric oxide donors such as amyl nitrite. this is a group of medicines (" nitrates ") used in the treatment of angina pectoris (" chest pain "). cialis has been shown to increase the effects of these medicines. if you are taking any form of nitrate or are unsure tell your doctor. - have serious heart disease or recently had a heart attack within the last 90 days. - recently had a stroke within the last 6 months. - have low blood pressure or uncontrolled high blood pressure. - ever had loss of vision because of non - arteritic anterior ischemic optic neuropathy ( naion ), a condition described as " stroke of the eye ". - are taking riociguat. this drug is used to treat pulmonary arterial hypertension ( i. e., high blood pressure in the lungs ) and chronic thromboembolic pulmonary hypertension ( i. e., high blood pressure in the lungs secondary to blood clots ). pde5 inhibitors, such as cialis, have been shown to increase the hypotensive effects of this medicine. if you are taking riociguat or are unsure tell your doctor. warnings and precautions talk to your doctor before taking cialis. be aware that sexual activity carries a possible risk to patients with heart disease because it puts an extra strain on your heart. if you have a heart problem you should tell your doctor. before taking the tablets, tell your doctor if you have : - sickle cell anaemia ( an abnormality of red blood cells ). - multiple myeloma ( cancer of the bone marrow ). - leukaemia ( cancer of the blood cells ). - any deformation of your penis. - a serious liver problem. - a severe kidney problem
always take this medicine exactly as your doctor has told you . check with your doctor or pharmacist if you are not sure . cialis tablets are for oral use in men only . swallow the tablet whole with some water . the tablets can be taken with or without food . the recommended dose is one 5 mg tablet taken once a day at approximately the same time of the day . your doctor may adjust the dose to 2 . 5 mg based on your response to cialis . this will be given as a 2 . 5mg tablet . do not take cialis more than once a day . once a day dosing of cialis may be useful to men who anticipate having sexual activity two or more times per week . when taken once a day cialis allows you to obtain an erection , when sexually stimulated , at any time point during the 24 hours of the day . it is important to note that cialis does not work if there is no sexual stimulation . you and your partner will need to engage in foreplay , just as you would if you were not taking a medicine for erectile dysfunction . drinking alcohol may affect your ability to get an erection and may temporarily lower your blood pressure . if you have taken or are planning to take cialis , avoid excessive drinking ( blood alcohol level of 0 . 08 % or greater ), since this may increase the risk of dizziness when standing up . if you take more cialis than you should contact your doctor . you may experience side effects described in section 4 . if you forget to take cialis take your dose as soon as you remember but do not take a double dose to make up for a forgotten tablet . you should not take cialis more than once a day . if you have any further questions on the use of this medicine , ask your doctor or pharmacist .
like all medicines, this medicine can cause side effects, although not everybody gets them. these effects are normally mild to moderate in nature. if you experience any of the following side effects stop using the medicine and seek medical help immediately : - allergic reactions including rashes ( frequency uncommon ). - chest pain - do not use nitrates but seek immediate medical assistance ( frequency uncommon ). - priapsim, a prolonged and possibly painful erection after taking cialis ( frequency rare ). if you have such an erection, which lasts continuously for more than 4 hours you should contact a doctor immediately. - sudden loss of vision ( frequency rare ). other side effects have been reported : common ( seen in 1 to 10 in every 100 patients ) - headache, back pain, muscle aches, pain in arms and legs, facial flushing, nasal congestion and indigestion. uncommon ( seen in 1 to 10 in every 1, 000 patients ) - dizziness, stomach ache, feeling sick, being sick ( vomiting ), reflux, blurred vision, eye pain, difficulty in breathing, presence of blood in urine, prolonged erection, pounding heartbeat sensation, a fast heart rate, high blood pressure, low blood pressure, nose bleeds, ringing in the ears, swelling of the hands, feet or ankles and feeling tired. rare ( seen in 1 to 10 in every 10, 000 patients ) - fainting, seizures and passing memory loss, swelling of the eyelids, red eyes, sudden decrease or loss of hearing, hives ( itchy red welts on the surface of the skin ), penile bleeding, presence of blood in semen and increased sweating. heart attack and stroke have also been reported rarely in men taking cialis. most of these men had known heart problems before taking this medicine. partial, temporary, or permanent decrease or loss of vision in one or both eyes has been rarely reported. some additional rare side effects have been reported in men taking cialis that were not seen in clinical trials. these include : - migraine, swelling of the
what cialis contains - the active substance is tadalafil . each tablet contains 2 . 5 mg of tadalafil . - the other ingredients are : tablet core : lactose monohydrate ( see end of section 2 ), croscarmellose sodium , hydroxypropylcellulose , microcrystalline cellulose , sodium laurilsulfate , magnesium stearate . film - coat : lactose monohydrate , hypromellose , triacetin , titanium dioxide ( e171 ), iron oxide yellow ( e172 ), iron oxide red ( e172 ), talc . what cialis looks like and contents of the pack cialis 2 . 5 mg is a light orange - yellow film - coated tablet in the shape of an almond and has " c 2 Â½ " marked on one side . cialis 2 . 5 mg is available in blister packs containing 28 tablets .
enyglid is an oral antidiabetic medicine containing repaglinide which helps your pancreas produce more insulin and thereby lower your blood sugar ( glucose ). type 2 diabetes is a disease in which your pancreas does not make enough insulin to control the sugar in your blood or where your body does not respond normally to the insulin it produces . enyglid is used to control type 2 diabetes in adults as an add - on to diet and exercise : treatment is usually started if diet , exercise and weight reduction alone have not been able to control ( or lower ) your blood sugar . enyglid can also be given with metformin , another medicine for diabetes . enyglid has been shown to lower the blood sugar , which helps to prevent complications from your diabetes .
do not take enyglid if you are allergic to repaglinide or any of the other ingredients of this medicine ( listed in section 6 ). if you have type 1 diabetes. if the acid level in your blood is raised ( diabetic ketoacidosis ). if you have a severe liver disease. if you take gemfibrozil ( a medicine used to lower increased fat levels in the blood ). warning and precautions talk to your doctor before taking enyglid : if you have liver problems. enyglid is not recommended in patients with moderate liver 28 disease. enyglid should not be taken if you have a severe liver disease ( see do not take enyglid ). if you have kidney problems. enyglid should be taken with caution. if you are about to have major surgery or you have recently suffered a severe illness or infection. at such times diabetic control may be lost. if you are under 18 or over 75 years of age. enyglid is not recommended. it has not been studied in these age groups. talk to your doctor if any of the above applies to you. enyglid may not be suitable for you. your doctor will advise you. children and adolescents do not take this medicine if you are under 18 years of age. if you get a hypo ( low blood sugar ) you may get a hypo ( short for hypoglycaemia ) if your blood sugar gets too low. this may happen : if you take too much enyglid if you exercise more than usual if you take other medicines or suffer from liver or kidney problems ( see other sections of 2. what you need to know before you take enyglid ). the warning signs of a hypo may come on suddenly and can include : cold sweat, cool pale skin, headache, rapid heart beat, feeling sick, feeling very hungry, temporary changes in vision, drowsiness, unusual tiredness and weakness, nervousness or tremor, feeling anxious, feeling confused, difficulty in concentrating. if your blood sugar is low or you feel a hypo coming on eat glucose
always take this medicine exactly as your doctor has told you . check with your doctor if you are not sure . your doctor will work out your dose . the normal starting dose is 0 . 5 mg before each main meal . swallow the tablets with a glass of water immediately before or up to 30 minutes before each main meal . the dose may be adjusted by your doctor by up to 4 mg to be taken immediately before or up to 30 minutes before each main meal . the maximum recommended daily dose is 16 mg . do not take more enyglid than your doctor has recommended . if you take more enyglid than you should if you take too many tablets , your blood sugar may become too low , leading to a hypo . please see if you get a hypo on what a hypo is and how to treat it . if you forget to take enyglid if you miss a dose , take the next dose as usual . do not take a double dose to make up for a forgotten tablet . if you stop taking enyglid be aware that the desired effect is not achieved if you stop taking enyglid . your diabetes may get worse . if any change of your treatment is necessary contact your doctor first . if you have any further questions on the use of this medicine , ask your doctor or pharmacist .
like all medicines , this medicine can cause side effects , although not everybody gets them . hypoglycaemia the most frequent side effect is hypoglycaemia which may affect up to 1 in 10 people ( see if you get a hypo in section 2 ). hypoglycaemic reactions are generally mild / moderate but may occasionally develop into hypoglycaemic unconsciousness or coma . if this happens , medical assistance is needed immediately . allergy allergy is very rare ( may affect up to 1 in 10 , 000 people ). symptoms such as swelling , difficulty in breathing , rapid heartbeat , feeling dizzy and sweating could be signs of anaphylactic reaction . contact a doctor immediately . other side effects common ( may affect up to 1 in 10 people ): stomach pain diarrhoea rare ( may affect up to 1 in 1 , 000 people ): acute coronary syndrome ( but it may not be due to the medicine ). very rare ( may affect up to 1 in 10 , 000 people ): vomiting constipation visual disturbances severe liver problems , abnormal liver function such as , increased liver enzymes in your blood . not known ( frequency cannot be estimated from the available data ): hypersensitivity ( such as rash , itchy skin , redening of the skin , swelling of the skin ) feeling sick ( nausea ) reporting of side effects if you get any side effects , talk to your doctor or pharmacist . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system 31 listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
what enyglid contains the active substance is repaglinide . each tablet contains 0 . 5 mg , 1 mg , 2 mg repaglinide . the other ingredients are : microcrystalline cellulose ( e460 ); calcium hydrogen phosphate , anhydrous ; croscarmellose sodium ; povidone k25 ; glycerol ; magnesium stearate ; meglumine ; poloxamer ; yellow iron oxide ( e172 ) only in the 1 mg tablets and red iron oxide ( e172 ) only in the 2 mg tablets what enyglid looks like and contents of the pack the 0 . 5 mg tablets are white , round and biconvex with bevelled edges . the 1 mg tablets are pale brown - yellow , round , biconvex with bevelled edges and possible darker spots . the 2 mg tablets are pink , marbled , round , biconvex with bevelled edges and possible darker spots . boxes of 30 , 60 , 90 , 120 , 180 , 270 or 360 tablets in blisters are available . not all pack sizes may be marketed .
what azacitidine mylan is azacitidine mylan is an anti - cancer agent which belongs to a group of medicines called ' anti - metabolites '. azacitidine mylan contains the active substance ' azacitidine '. what azacitidine mylan is used for azacitidine mylan is used in adults who are not able to have a stem cell transplantation to treat : higher - risk myelodysplastic syndromes ( mds ). chronic myelomonocytic leukaemia ( cmml ). acute myeloid leukaemia ( aml ). these are diseases which affect the bone marrow and can cause problems with normal blood cell production . how azacitidine mylan works azacitidine mylan works by preventing cancer cells from growing . azacitidine becomes incorporated into the genetic material of cells ( ribonucleic acid ( rna ) and deoxyribonucleic acid ( dna )). it is thought to work by altering the way the cell turns genes on and off and also by interfering with the production of new rna and dna . these actions are thought to correct problems with the maturation and growth of young blood cells in the bone marrow that cause myelodysplastic disorders , and to kill cancerous cells in leukaemia . talk to your doctor or nurse if you have any questions about how azacitidine mylan works or why this medicine has been prescribed for you .
do not use azacitidine mylan if you are allergic to azacitidine or any of the other ingredients of this medicine ( listed in section 6 ). if you have advanced liver cancer. if you are breast - feeding. warnings and precautions talk to your doctor, pharmacist or nurse before using azacitidine mylan : if you have decreased counts of platelets, red or white blood cells. if you have kidney disease. if you have liver disease. if you have ever had a heart condition or heart attack or any history of lung disease. blood test you will have blood tests before you begin treatment with azacitidine mylan and at the start of each period of treatment ( called a'cycle '). this is to check that you have enough blood cells and that your liver and kidneys are working properly. children and adolescents azacitidine mylan is not recommended for use in children and adolescents below the age of 18. other medicines and azacitidine mylan tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. this is because azacitidine mylan may affect the way some other medicines work. also, some other medicines may affect the way azacitidine mylan works. pregnancy, breast - feeding and fertility if you are pregnant or breast - feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. pregnancy you should not use azacitidine mylan during pregnancy as it may be harmful to the baby. use an effective method of contraception during and up to 3 months after treatment. tell your doctor straight away if you become pregnant during treatment. breast - feeding you must not breast - feed when using azacitidine mylan. it is not known if this medicine passes into human milk. fertility men should not father a child while receiving treatment with azacitidine mylan. use an effective method of contraception during and up to 3 months after treatment with this medicine. talk to your doctor if you wish to conserve your sperm before starting this treatment. driving and using machines do not drive or use any tools or machines if you
before giving you azacitidine mylan , your doctor will give you another medicine to prevent nausea and vomiting at the start of each treatment cycle . the recommended dose is 75 mg per m2 body surface area . your doctor will decide your dose of this medicine , depending on your general condition , height and weight . your doctor will check your progress and may change your dose if necessary . azacitidine mylan is given every day for one week , followed by a rest period of 3 weeks . this " treatment cycle " will be repeated every 4 weeks . you will usually receive at least 6 treatment cycles . this medicine will be given to you as an injection under the skin ( subcutaneously ) by a doctor or nurse . it may be given under the skin on your thigh , tummy or upper arm . if you have any further questions on the use of this medicine , ask your doctor , pharmacist or nurse .
like all medicines, this medicine can cause side effects, although not everybody gets them. tell your doctor straight away if you notice any of the following side effects : drowsiness, shaking, jaundice, abdominal bloating and easy bruising. these may be symptoms of liver failure and can be life - threatening. swelling of the legs and feet, back pain, reduced passing of water, increased thirst, rapid pulse, dizziness and nausea, vomiting or reduced appetite and feelings of confusion, restlessness or fatigue. these may be symptoms of kidney failure and can be life - threatening. a fever. this could be due to an infection as a result of having low levels of white blood cells, which can be life - threatening. chest pain or shortness of breath which may be accompanied with a fever. this may be due to an infection of the lung called " pneumonia " and can be life - threatening. bleeding. such as blood in the stools due to bleeding in the stomach or gut, or such as bleeding inside your head. these may be symptoms of having low levels of platelets in your blood. difficulty breathing, swelling of the lips, itching or rash. this may be due to an allergic ( hypersensitivity ) reaction. other side effects include : very common side effects ( may affect more than 1 in 10 people ) reduced red blood count ( anaemia ). you may feel tired and pale. reduced white blood cell count. this may be accompanied by a fever. you are also more likely to get infections. a low blood platelet count ( thrombocytopenia ). you are more prone to bleeding and bruising. constipation, diarrhoea, nausea, vomiting. pneumonia. chest pain, being short of breath. tiredness ( fatigue ). injection site reaction including redness, pain or a skin reaction. loss of appetite. joint aches. bruising. rash. red or purple spots under your skin. pain in your belly ( abdominal pain ). itching. fever. sore nose and throat. dizziness. headache. having
your doctor , pharmacist or nurse are responsible for storing azacitidine mylan . they are also responsible for preparing and disposing of any unused azacitidine mylan correctly . keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the vial label and the carton . the expiry date refers to the last day of that month . for unopened vials of this medicine there are no special storage conditions . when using immediately once the suspension has been prepared it should be administered within 1 hour . when using later on if the azacitidine mylan suspension is prepared using water for injections that has not been refrigerated , the suspension must be placed in the refrigerator ( 2 8 ) immediately after it is prepared and kept refrigerated for up to a maximum of 8 hours . if the azacitidine mylan suspension is prepared using water for injections that has been stored in the refrigerator ( 2 8 ), the suspension must be placed in the refrigerator ( 2 8 ) immediately after it is prepared and kept refrigerated for up to a maximum of 22 hours . the suspension should be allowed to reach room temperature ( 20 25 ) up to 30 minutes prior to administration . if large particles are present in the suspension it should be discarded . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what azacitidine mylan contains - the active substance is azacitidine . one vial of powder contains 100 mg azacitidine . after reconstitution with 4 ml of water for injections , the reconstituted suspension contains 25 mg / ml azacitidine . - the other ingredient is mannitol ( e421 ). what azacitidine mylan looks like and contents of the pack azacitidine mylan is a white powder for suspension for injection and is supplied in a glass vial containing 100 mg of azacitidine . each pack contains 1 or 7 vials .
duotrav eye drop solution is a combination of two active substances ( travoprost and timolol ). travoprost is a prostaglandin analogue which works by increasing the outflow of aqueous fluid from the eye , which lowers its pressure . timolol is a beta blocker which works by reducing the production of fluid within the eye . the two substances work together to reduce pressure within the eye . duotrav eye drops are used to treat high pressure in the eye in adults , including the elderly . this pressure can lead to an illness called glaucoma .
do not use duotrav if you are allergic to travoprost, prostaglandins, timolol, beta blockers or any of the other ingredients of this medicine ( listed in section 6 ). if you have now or have had in the past respiratory problems such as asthma, severe chronic obstructive bronchitis ( severe lung disease which may cause wheeziness, difficulty in breathing and / or long - standing cough ), or other types of breathing problems. if you have severe hay fever. if you have a slow heartbeat, heart failure or a disorder of heart rhythm ( irregular heartbeat ). if the surface of your eye is cloudy. ask your doctor for advice if any of these applies to you. warning and precautions talk to your doctor before using duotrav if you have now or have had in the past coronary heart disease ( symptoms can include chest pain or tightness, breathlessness or choking ), heart failure, low blood pressure. disturbances of heart rate such as slow heartbeat. breathing problems, asthma or chronic obstructive pulmonary disease. poor blood circulation disease ( such as raynaud's disease or raynaud's syndrome ). diabetes ( as timolol may mask signs and symptoms of low blood sugar ). overactivity of the thyroid gland ( as timolol may mask signs and symptoms of thyroid disease ). myasthenia gravis ( chronic neuromuscular weakness ). cataract surgery. eye inflammation. if you need to have any type of surgery, tell your doctor that you are using duotrav as timolol may change the effects of some medicines used during anaesthesia. if you get any severe allergic reaction ( skin rash, redness and itching of the eye ) while using duotrav, whatever the cause, adrenaline treatment may not be as effective. it is therefore important to tell the doctor that you are using duotrav when you are to receive any other treatment. duotrav may change the colour of your iris ( the coloured part of your eye ). this change may be permanent.
always use this medicine exactly as your doctor has told you. check with your doctor or pharmacist if you are not sure. the recommended dose is one drop in the affected eye or eyes once a day in the morning or in the evening. use at the same time each day. only use duotrav in both eyes if your doctor told you to do so. only use duotrav as eye drops. 1 2 3 4 immediately before using a bottle for the first time, tear open the overwrap ( picture 1 ), remove the bottle and write the date of opening on the label in the space provided. make sure you have a mirror available. wash your hands. twist off the bottle cap. hold the bottle, pointing down, between your thumb and fingers. tilt your head back. pull your lower eyelid down with a clean finger until there is a " pocket " between the eyelid and your eye. the drop will go in here ( picture 2 ). bring the bottle dropper close to the eye. use the mirror if it helps. do not touch your eye or eyelid, the surrounding areas or other surfaces with the dropper. it could infect the drops. gently squeeze the bottle to release one drop of duotrav at a time ( picture 3 ). if a drop misses your eye, try again. after using duotrav, press your finger into the corner of your eye by your nose for 2 minutes ( picture 4 ). this helps to stop duotrav getting into the rest of the body. if you have to use duotrav in both eyes, repeat the above steps for your other eye. close the bottle cap firmly immediately after use. only use one bottle at a time. do not open the overwrap until you need to use the bottle. use duotrav for as long as your doctor has told you to. if you use more duotrav than you should if you use more duotrav than you should, rinse it all out with warm water. do not put in any more drops until it is time for your next regular dose. if you forget to use duotrav if you forget to use duotrav, continue with the next
like all medicines, this medicine can cause side effects although not everybody gets them. you can usually carry on using the drops, unless the effects are serious. if you are worried, talk to a doctor or pharmacist. do not stop using duotrav without speaking to your doctor. very common side effects ( may affect more than 1 in 10 people ) effects in the eye eye redness. common side effects ( may affect up to 1 in 10 people ) effects in the eye eye surface inflammation with surface damage, eye pain, blurred vision, abnormal vision, dry eye, itchy eye, eye discomfort, signs and symptoms of eye irritation ( e. g. burning, stinging ). uncommon side effects ( may affect up to 1 in 100 people ) effects in the eye inflammation of the eye surface, inflammation of the eyelid, swollen conjunctiva, increased growth of eyelashes, iris inflammation, eye inflammation, sensitivity to light, reduced vision, tired eyes, eye allergy, eye swelling, increased tear production, eyelid redness, eyelid colour change, skin darkening ( around the eye ). general side effects allergic reaction to active substance, dizziness, headache, increased or decreased blood pressure, shortness of breath, excessive hair growth, drip at back of throat, skin inflammation and itching, decreased heart rate. rare side effects ( may affect up to 1 in 1, 000 people ) effects in the eye thinning of the eye surface, inflammation of the eyelid glands, broken blood vessel in the eye, eyelid crusting, abnormally positioned eyelashes, abnormal growth of lashes. general side effects nervousness, irregular heart rate, loss of hair, voice disorders, difficulty breathing, cough, throat irritation, hives, abnormal liver blood tests, skin discolouration, thirst, tiredness, discomfort inside of nose, coloured urine, pain in hands and feet. not known ( frequency cannot be estimated from the available data ) effects in the eye droopy eyelid ( making the eye stay half closed ), sunken eyes ( eyes appear more in
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the bottle label and carton after exp . the expiry date refers to the last day of that month . do not store above 30 . you must throw away the bottle 4 weeks after you first opened it to prevent the risk of infections . each time you start a new bottle write down the date you open it in the spaces on the bottle label and carton . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you longer use . these measures will help protect the environment .
what duotrav contains - the active substances are travoprost and timolol . each ml of solution contains 40 micrograms of travoprost and 5 mg of timolol ( as timolol maleate ). - the other ingredients are polyquaternium - 1 , mannitol ( e421 ), propylene glycol ( e1520 ), polyoxyethylene hydrogenated castor oil 40 , boric acid , sodium chloride , sodium hydroxide or hydrochloric acid ( to adjust ph ), purified water . tiny amounts of sodium hydroxide or hydrochloric acid are added to keep acidity levels ( ph levels ) normal . what duotrav looks like and contents of the pack duotrav is a liquid ( a clear , colourless solution ) supplied in a 2 . 5 ml plastic bottle with a screw cap . each bottle is packed in an overwrap . packs of 1 , 3 or 6 bottles . not all pack sizes may be marketed .
nplate ' s active ingredient is romiplostim , which is a protein used to treat low platelet counts in patients with immune ( idiopathic ) thrombocytopenic purpura ( called itp ). itp is a disease in which your body ' s immune system destroys its own platelets . platelets are the cells in your blood that help seal cuts and form blood clots . very low platelet counts can cause bruising and serious bleeding . nplate is used to treat patients aged 1 year and over who may or may not have had their spleen removed for chronic itp and who have been previously treated with corticosteroids or immunoglobulins , where these treatments don ' t work . nplate works by stimulating the bone marrow ( part of the bone which makes blood cells ) to produce more platelets . this should help to prevent bruising and bleeding associated with itp .
do not use nplate : if you are allergic to romiplostim or any of the other ingredients of this medicine ( listed in section 6 ). if you are allergic to other medicines that are produced by dna technology using the micro - organism escherichia coli ( e. coli ). warnings and precautions if you stop taking nplate a low blood platelet count ( thrombocytopenia ) is likely to reoccur. if you stop taking nplate your platelet count will have to be monitored, and your doctor will discuss appropriate precautions with you. if you are at risk of blood clots or if blood clots are common in your family. the risk of blood clotting may also be increased if you : - have liver problems ; - are elderly (<unk> 65 years ); - are bedridden ; - have cancer ; - are taking the contraceptive pill or hormone replacement therapy ; - have recently had surgery or suffered an injury ; - are obese ( overweight ); - are a smoker. talk to your doctor, pharmacist or nurse before using nplate. if you have very high blood platelet counts this may increase the risk of blood clotting. your doctor will adjust your dose of nplate to ensure that your platelet count does not become too high. bone marrow changes ( increased reticulin and possible bone marrow fibrosis ) long - term use of nplate may cause changes in your bone marrow. these changes may lead to abnormal blood cells or your body making less blood cells. the mild form of these bone marrow changes is called " increased reticulin " and has been observed in nplate clinical trials. it is not known if this may progress to a more severe form called " fibrosis." signs of bone marrow changes may show up as abnormalities in your blood tests. your doctor will decide if abnormal blood tests mean that you should have bone marrow tests or if you should stop taking nplate. worsening of blood cancers your doctor may decide to take a bone marrow biopsy if they decide it
adult and children ( 1 to 17 years ): nplate will be given under the direct supervision of your doctor, who will closely control the amount of nplate given to you. nplate is administered once a week as an injection under the skin ( subcutaneous ). your initial dose is 1 microgram of nplate per kilogram of your body weight once a week. your doctor will tell you how much you must take. nplate should be injected once per week in order to keep your platelet counts up. your doctor will take regular blood samples to measure how your platelets are responding and may adjust your dose as necessary. once your platelet count is under control, your doctor will continue to regularly check your blood. your dose may be adjusted further in order to maintain long - term control of your platelet count. children ( 1 to 17 years old ): in addition to adjusting your dose based on platelet counts, your doctor will also regularly reassess your body weight in order to adjust your dose. if you use more nplate than you should your doctor will ensure that you receive the right amount of nplate. if you have been given more nplate than you should, you may not experience any physical symptoms but your blood platelet counts may rise to very high levels and this may increase the risk of blood clotting. therefore if your doctor suspects that you have been given more nplate than you should, it is recommended that you are monitored for any signs or symptoms of side effects and that you are given appropriate treatment immediately. if you use less nplate than you should your doctor will ensure that you receive the right amount of nplate. if you have been given less nplate than you should, you may not experience any physical symptoms but your blood platelet counts may become low and this may increase the risk of bleeding. therefore if your doctor suspects that you have been given less nplate than you should, it is recommended that you are monitored for any signs or symptoms of side effects and that you are given appropriate treatment immediately. if you forget to use nplate if you have missed a dose of nplate, your doctor will discuss with you when you should have your next dose. if you stop using nplate if
like all medicines, this medicine can cause side effects, although not everybody gets them. possible side effects in adults with itp very common : may affect more than 1 in 10 people headache ; allergic reaction ; upper respiratory tract infection. common : may affect up to 1 in 10 people bone marrow disorder, including increased bone marrow fibres ( reticulin ); trouble sleeping ( insomnia ); dizziness ; tingling or numbness of the hands or feet ( paraesthesia ); migraine ; redness of the skin ( flushing ); blood clot in a lung artery ( pulmonary embolism ); nausea ; diarrhoea ; abdominal pain ; indigestion ( dyspepsia ); constipation ; itching of the skin ( pruritis ); bleeding under the skin ( ecchymosis ); bruising ( contusion ); rash ; joint pain ( arthralgia ); muscles pain or weakness ( myalgia ); pain in your hands and feet ; muscle spasm ; back pain ; bone pain ; tiredness ( fatigue ); injection site reactions ; swelling in the hands and feet ( oedema peripheral ); flu like symptoms ( influenza like illness ); pain ; weakness ( asthenia ); fever ( pyrexia ); chills ; contusion ; 76 swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing ( angioedema ); gastroenteritis ; palpitations. common : may affect up to 1 in 10 people ( may show up in blood or urine tests ) low blood platelet count ( thrombocytopenia ) and low blood platelet count ( thrombocytopenia ) after stopping nplate ; higher than normal platelet counts ( thrombocytosis ); anaemia. uncommon : may affect up to 1 in 100 people bone marrow failure ; disorder of the bone marrow that causes scarring ( myelofibrosis ); enlarged spleen ( splenomegaly ); bleeding of the vagina ( vaginal haemorr
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the carton and vial label after exp . the expiry date refers to the last day of that month . store in a refrigerator ( 2Âºc 8Âºc ). do not freeze . store in the original carton in order to protect from light . this medicine may be removed from the refrigerator for a period of 30 days at room temperature ( up to 25Âºc ) when stored in the original carton . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what nplate contains - the active substance is romiplostim . each vial of nplate 125 micrograms powder for solution for injection contains a total of 230 micrograms of romiplostim . an additional overfill is included in each vial to ensure that 125 micrograms of romiplostim can be delivered . after dissolving , a deliverable amount of 0 . 25 ml solution contains 125 micrograms of romiplostim ( 500 micrograms / ml ). each vial of nplate 250 micrograms powder for solution for injection contains a total of 375 micrograms of romiplostim . an additional overfill is included in each vial to ensure that 250 micrograms of romiplostim can be delivered . after dissolving , a deliverable amount of 0 . 5 ml solution contains 250 micrograms of romiplostim ( 500 micrograms / ml ). each vial of nplate 500 micrograms powder for solution for injection contains a total of 625 micrograms of romiplostim . an additional overfill is included in each vial to ensure that 500 micrograms of romiplostim can be delivered . after dissolving , a deliverable amount of 1 ml solution contains 500 micrograms of romiplostim ( 500 micrograms / ml ). - the other ingredients are mannitol ( e421 ), sucrose , l - histidine , hydrochloric acid ( for ph adjustment ) and polysorbate 20 . what nplate looks like and contents of the pack nplate is a white powder for solution for injection supplied in a single - dose glass vial . carton containing 1 or 4 vials of either 125 micrograms ( beige cap ), 250 micrograms ( red cap ) or 500 micrograms of romiplostim ( blue cap ). not all pack sizes may be marketed .
what tovanor breezhaler is this medicine contains an active substance called glycopyrronium bromide . this belongs to a group of medicines called bronchodilators . what tovanor breezhaler is used for this medicine is used to make breathing easier for adult patients who have breathing difficulties due to a lung disease called chronic obstructive pulmonary disease ( copd ). in copd the muscles around the airways tighten . this makes breathing difficult . this medicine blocks the tightening of these muscles in the lungs , making it easier for air to get in and out of the lungs . if you use this medicine once a day , it will help to reduce the effects of copd on your everyday life .
do not use tovanor breezhaler - if you are allergic to glycopyrronium bromide or any of the other ingredients of this medicine ( listed in section 6 ). warnings and precautions talk to your doctor before using tovanor breezhaler, if any of the following applies to you : - you have kidney problems. - you have an eye problem called narrow - angle glaucoma. - you have difficulty passing urine. during treatment with tovanor breezhaler, stop taking this medicine and tell your doctor immediately : - if you experience tightness of the chest, coughing, wheezing or breathlessness immediately after using tovanor breezhaler ( signs of bronchospasm ). - if you experience difficulties in breathing or swallowing, swelling of the tongue, lips or face, skin rash, itching and hives ( signs of allergic reaction ). - if you experience eye pain or discomfort, temporary blurring of vision, visual halos or coloured images in association with red eyes. these may be signs of an acute attack of narrow - angle glaucoma. tovanor breezhaler is used as a maintenance treatment for your copd. do not use this medicine to treat a sudden attack of breathlessness or wheezing. children and adolescents do not give this medicine to children or adolescents below the age of 18 years. other medicines and tovanor breezhaler tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. this includes medicines similar to tovanor breezhaler used for your lung disease, such as ipratropium, oxitropium or tiotropium ( so called anticholinergics ). no specific side effects have been reported when tovanor breezhaler has been used together with other medicines used to treat copd such as reliever inhalers ( e. g. salbutamol ), methylxanthines ( e. g. theophylline ) and / or oral and inhaled steroids ( e. g
always use this medicine exactly as your doctor or pharmacist has told you. check with your doctor or pharmacist if you are not sure. how much tovanor breezhaler to use the usual dose is to inhale the content of one capsule each day. you only need to inhale once a day because the effect of this medicine lasts for 24 hours. do not use more than your doctor tells you to use. elderly people you can use this medicine if you are aged 75 years and over at the same dose as for other adults. when to inhale tovanor breezhaler use this medicine at the same time each day. this will also help you to remember to use it. you can inhale this medicine anytime before or after food or drink. how to inhale tovanor breezhaler - in this pack, you will find an inhaler and capsules ( in blisters ) that contain the medicine as inhalation powder. only use the capsules with the inhaler provided in this pack ( tovanor breezhaler inhaler ). the capsules should remain in the blister until you need to use them. - do not push the capsule through the foil. - when you start a new pack, use the new tovanor breezhaler inhaler that is supplied in the pack. - dispose of each inhaler after after all capsules in that pack have been used. - do not swallow the capsules. - please read the instructions at the end of this leaflet for more information on how to use the inhaler. if you use more tovanor breezhaler than you should if you have inhaled too much of this medicine or if someone else accidentally uses your capsules, you must immediately either tell your doctor or go to the nearest emergency unit. show the pack of tovanor breezhaler. medical attention may be needed. if you forget to use tovanor breezhaler if you forget to inhale a dose, take one as soon as possible. however, do not take two doses on the same day. then take the next dose as usual. how long to continue your treatment with tovan
what tovanor breezhaler contains - the active substance is glycopyrronium bromide . each capsule contains 63 micrograms of glycopyrronium bromide ( equivalent to 50 micrograms glycopyrronium ). the delivered dose ( the dose that leaves the mouthpiece of the inhaler ) is equivalent to 44 micrograms of glycopyrronium . - the other ingredients of the inhalation powder are lactose monohydrate and magnesium stearate . what tovanor breezhaler looks like and contents of the pack tovanor breezhaler 44 micrograms inhalation powder , hard capsules are transparent and orange and contain a white powder . they have the product code " gpl50 " printed in black above and a company logo ( ) printed in black below a black bar . each pack contains a device called an inhaler , together with capsules in blisters . each blister strip contains either 6 or 10 hard capsules . the following pack sizes are available : packs containing 6x1 , 10x1 , 12x1 or 30x1 hard capsules , together with one inhaler . multipacks containing 90 ( 3 packs of 30x1 ) hard capsules and 3 inhalers . multipacks containing 96 ( 4 packs of 24x1 ) hard capsules and 4 inhalers . multipacks containing 150 ( 15 packs of 10x1 ) hard capsules and 15 inhalers . multipacks containing 150 ( 25 packs of 6x1 ) hard capsules and 25 inhalers . not all pack sizes may be available in your country .
adasuve contains the active substance loxapine , which belongs to a group of medicines called antipsychotics . adasuve works by blocking certain chemicals in the brain ( neurotransmitters ) such as dopamine and serotonin thus causing calming effects and relieving aggressive behaviour . adasuve is used to treat acute symptoms of mild - to - moderate agitation that may occur in adult patients who have schizophrenia or bipolar disorder . these are diseases characterised by symptoms such as : ( schizophrenia ) hearing , seeing , or sensing things which are not there , suspiciousness , mistaken beliefs , incoherent speech and behaviour and emotional flatness . people with this condition may also feel depressed , guilty , anxious or tense . ( bipolar disorder ) feeling " high ", having excessive amounts of energy , needing much less sleep than usual , talking very quickly with racing ideas , and sometimes severe irritability .
do not use adasuve if you are allergic to loxapine or amoxapine ; if you have symptoms of wheezing or shortness of breath ; if you have lung problems like asthma or chronic obstructive pulmonary disease ( which your doctor may have called " copd "). warnings and precautions your doctor or nurse will talk to you before you use adasuve and determine whether it is appropriate for you. adasuve may cause narrowing of the airways ( bronchospasm ) and may cause you to wheeze, cough, feel chest tightness or have shortness of breath. typically, this will occur within 25 minutes of use. neuroleptic malignant syndrome ( nms ) is a set of symptoms that can occur if you are taking antipsychotic medicines, including adasuve. these symptoms can be high fever, rigid muscles, 47 irregular or fast heart rate or pulse. nms can cause death. do not use adasuve again if nms occurs. antipsychotic medicines like adasuve can cause movements that you may not be able to control including making faces, sticking out your tongue, smacking or puckering your lips, blinking rapidly, or moving your legs, arms or fingers rapidly. treatment with adasuve may have to be stopped if this occurs. adasuve should be used with caution in patients who are intoxicated or delirious. before treatment with adasuve, tell your doctor or nurse if you : have or had breathing problems like asthma or other chronic lung diseases such as bronchitis or emphysema have or had heart problems or stroke have or had low or high blood pressure have or had seizures ( convulsions ) have or had glaucoma ( increased pressure in the eye ) have or had urinary retention ( incomplete emptying of the bladder ) already used adasuve and you developed symptoms of wheezing or shortness of breath ever had muscle or eye movements you can't control, lack of coordination, sustained muscle contraction, or
always use this medicine exactly as your doctor or nurse has told you . check with your doctor or nurse if you are not sure . the recommended initial dose is 9 . 1 mg . after 2 hours , your doctor may prescribe a second dose after carefully considering your condition and your dose may be reduced to 4 . 5 mg if your doctor believes that this is a more appropriate dose to treat your condition . you will use adasuve under the supervision of a doctor or nurse . adasuve is for inhalation use . after the doctor or nurse has prepared adasuve for you to use , you will be asked to take the device in your hand , exhale and then put the mouthpiece in your mouth , inhale the medicine through the device and then hold your breath briefly . if you use more adasuve than you should if you are concerned that you are given more adasuve than you feel necessary , tell your doctor or nurse of your concern . patients who have been given more adasuve than they should may experience any of the following symptoms : extreme tiredness or sleepiness , trouble breathing , low blood pressure , throat irritation or a bad taste in the mouth , muscle or eye movements you can ' t control . if you have any further questions on the use of this medicine , ask your doctor or nurse .
like all medicines , this medicine can cause side effects , although not everybody gets them . if you get any of the following side effects , talk to your doctor immediately and stop taking the medicine : any breathing symptoms such as wheezing , cough , shortness of breath , or chest tightness , as these could mean that the medicine is irritating your airways ( uncommon occurrence unless you have asthma or copd ); light - headedness or fainting , as these could mean that the medicine is lowering your blood pressure ( uncommon occurrence ); worsening agitation or confusion , especially combined with fever or muscle stiffness ( rare occurrence ). these can be associated with a severe condition called neuroleptic malignant syndrome ( nms ) also talk to your doctor if you have any of the following side effects that could also happen with other forms of this medicine : very common ( may affect more than 1 in 10 people ): bad taste in the mouth or sleepiness . common ( may affect up to 1 in 10 people ): dizziness , throat irritation , dry mouth or tiredness . uncommon ( may affect up to 1 in 100 people ): muscle or eye movements you can ' t control , lack of coordination , sustained muscle contraction , or feeling restless or unable to sit still . additional side effects which have been related to long term use of loxapine by mouth and which may be relevant for adasuve include faintness upon standing , increased heart rate , increased blood pressure , blurred vision , dry eyes , and decreased urination . reporting of side effects if you get any side effects , talk to your doctor or nurse . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
keep this medicine out of the sight and reach of children . do not use adasuve after the expiry date which is stated on the product label . the expiry date refers to the last day of that month . store in the original pouch until ready for use in order to protect from light and moisture . do not use adasuve if you notice an open or torn pouch or any signs of physical damage to the medicine . do not throw away any medicines via household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what adasuve contains the active substance is loxapine . each single - dose inhaler contains 5 mg loxapine and delivers 4 . 5 mg of loxapine . what adasuve looks like and contents of the pack adasuve 4 . 5 mg inhalation powder , pre - dispensed consists of a single - dose , disposable white plastic inhaler that contains loxapine . each inhaler is packaged in a sealed foil pouch . adasuve 4 . 5 mg is supplied in a carton of 1 or 5 single dose inhalers .
what azacitidine betapharm is azacitidine betapharm is an anti - cancer agent which belongs to a group of medicines called ' anti - metabolites '. azacitidine betapharm contains the active substance ' azacitidine '. what azacitidine betapharm is used for azacitidine betapharm is used in adults who are not able to have a stem cell transplantation to treat : higher - risk myelodysplastic syndromes ( mds ). chronic myelomonocytic leukaemia ( cmml ). acute myeloid leukaemia ( aml ). these are diseases which affect the bone marrow and can cause problems with normal blood cell production . how azacitidine betapharm works azacitidine betapharm works by preventing cancer cells from growing . azacitidine becomes incorporated into the genetic material of cells ( ribonucleic acid ( rna ) and deoxyribonucleic acid ( dna )). it is thought to work by altering the way the cell turns genes on and off and also by interfering with the production of new rna and dna . these actions are thought to correct problems with the maturation and growth of young blood cells in the bone marrow that cause myelodysplastic disorders , and to kill cancerous cells in leukaemia . talk to your doctor or nurse if you have any questions about how azacitidine betapharm works or why this medicine has been prescribed for you .
do not use azacitidine betapharm if you are allergic to azacitidine or any of the other ingredients of this medicine ( listed in section 6 ). if you have advanced liver cancer. if you are breast - feeding. warnings and precautions talk to your doctor, pharmacist or nurse before using azacitidine betapharm : if you have decreased counts of platelets, red or white blood cells. if you have kidney disease. if you have liver disease. if you have ever had a heart condition or heart attack or any history of lung disease. blood test you will have blood tests before you begin treatment with azacitidine betapharm and at the start of each period of treatment ( called a'cycle '). this is to check that you have enough blood cells and that your liver and kidneys are working properly. children and adolescents azacitidine betapharm is not recommended for use in children and adolescents below the age of 18. other medicines and azacitidine betapharm tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. this is because azacitidine betapharm may affect the way some other medicines work. also, some other medicines may affect the way azacitidine betapharm works. pregnancy, breast - feeding and fertility if you are pregnant or breast - feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. pregnancy you should not use azacitidine betapharm during pregnancy as it may be harmful to the baby. use an effective method of contraception during and up to 3 months after treatment. tell your doctor straight away if you become pregnant during treatment. breast - feeding you must not breast - feed when using azacitidine betapharm. it is not known if this medicine passes into human milk. fertility men should not father a child while receiving treatment with azacitidine betapharm. use an effective method of contraception during and up to 3 months after treatment with this medicine. talk to your doctor if you wish to conserve your sperm before starting this treatment. driving and using machines do not
before giving you azacitidine betapharm , your doctor will give you another medicine to prevent nausea and vomiting at the start of each treatment cycle . the recommended dose is 75 mg per m2 body surface area . your doctor will decide your dose of this medicine , depending on your general condition , height and weight . your doctor will check your progress and may change your dose if necessary . azacitidine betapharm is given every day for one week , followed by a rest period of 3 weeks . this " treatment cycle " will be repeated every 4 weeks . you will usually receive at least 6 treatment cycles . this medicine will be given to you as an injection under the skin ( subcutaneously ) by a doctor or nurse . it may be given under the skin on your thigh , tummy or upper arm . if you have any further questions on the use of this medicine , ask your doctor , pharmacist or nurse .
like all medicines, this medicine can cause side effects, although not everybody gets them. tell your doctor straight away if you notice any of the following side effects : drowsiness, shaking, jaundice, abdominal bloating and easy bruising. these may be symptoms of liver failure and can be life - threatening. swelling of the legs and feet, back pain, reduced passing of water, increased thirst, rapid pulse, dizziness and nausea, vomiting or reduced appetite and feelings of confusion, restlessness or fatigue. these may be symptoms of kidney failure and can be life - threatening. a fever. this could be due to an infection as a result of having low levels of white blood cells, which can be life - threatening. chest pain or shortness of breath which may be accompanied with a fever. this may be due to an infection of the lung called " pneumonia ", and can be life - threatening. bleeding. such as blood in the stools due to bleeding in the stomach or gut, or such as bleeding inside your head. these may be symptoms of having low levels of platelets in your blood. difficulty breathing, swelling of the lips, itching or rash. this may be due to an allergic ( hypersensitivity ) reaction. other side effects include : very common side effects ( may affect more than 1 in 10 people ) reduced red blood count ( anaemia ). you may feel tired and pale. reduced white blood cell count. this may be accompanied by a fever. you are also more likely to get infections. a low blood platelet count ( thrombocytopenia ). you are more prone to bleeding and bruising. constipation, diarrhoea, nausea, vomiting. pneumonia. chest pain, being short of breath. tiredness ( fatigue ). injection site reaction including redness, pain or a skin reaction. loss of appetite. joint aches. bruising. rash. red or purple spots under your skin. pain in your belly ( abdominal pain ). itching. fever. sore nose and throat. dizziness. headache.
your doctor , pharmacist or nurse are responsible for storing azacitidine betapharm . they are also responsible for preparing and disposing of any unused azacitidine betapharm correctly . keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the vial label and the carton . the expiry date refers to the last day of that month . for unopened vials of this medicine there are no special storage conditions . when using immediately once the suspension has been prepared it should be administered within 45 minutes . when using later on if the azacitidine betapharm suspension is prepared using water for injections that has not been refrigerated , the suspension must be placed in the refrigerator ( 2 to 8 ) immediately after it is prepared and kept refrigerated for up to a maximum of 8 hours . if the azacitidine betapharm suspension is prepared using water for injections that has been stored in the refrigerator ( 2 to 8 ), the suspension must be placed in the refrigerator ( 2 to 8 ) immediately after it is prepared and kept refrigerated for up to a maximum of 22 hours . the suspension should be allowed to reach room temperature ( 20 to 25 ) up to 30 minutes prior to administration . if large particles are present in the suspension it should be discarded .
what azacitidine betapharm contains - the active substance is azacitidine . one vial contains 100 mg azacitidine . after reconstitution with 4 ml of water for injections , the reconstituted suspension contains 25 mg / ml azacitidine . - the other ingredient is mannitol ( e 421 ). what azacitidine betapharm looks like and contents of the pack azacitidine betapharm is a white to off - white powder for suspension for injection and is supplied in a glass vial containing 100 mg of azacitidine . each pack contains one vial .
cerdelga contains the active substance eliglustat and is used for the long term treatment of adult patients with gaucher disease type 1 . gaucher disease type 1 is a rare , inherited condition in which a substance called glucosylceramide is not effectively broken down by your body . as a result glucosylceramide builds up in your spleen , liver and bones . the build - up prevents these organs from working properly . cerdelga contains the active substance eliglustat which decreases the production of glucosylceramide , thereby preventing its build - up . in turn this helps your affected organs to work better . people differ in the speed that their body breaks down this medicine . as a result the amount of this medicine in the blood can differ between patients which could affect how a patient would respond . cerdelga is meant to be used in patients whose body breaks down this medicine at normal speed ( known as intermediate metabolisers and extensive metabolisers ) or slow speed ( known as poor metabolisers ). your doctor will determine if cerdelga is suitable for you before you start taking it , using a simple laboratory test . gaucher disease type 1 is a lifelong condition and you must continue to take this medicine as prescribed by your doctor to gain the maximum benefit from your medicine .
do not take cerdelga - if you are allergic to eliglustat or any of the other ingredients of this medicine ( listed in section 6 ). - if you are an intermediate or extensive metaboliser and use medicines known as strong or moderate cyp2d6 inhibitors ( examples are quinidine and terbinafine ) used in combination 31 with strong or moderate cyp3a inhibitors ( examples are erythromycin and itraconazole ). the combination of these medicines will interfere with your body's ability to break down cerdelga and this can result in higher levels of the active substance in your blood ( see the section'other medicines and cerdelga'for an expanded list of medicines ). - if you are a poor metaboliser and use medicines known as strong cyp3a inhibitors ( for example itraconazole ). medicines of this type will interfere with your body's abilty to break down cerdelga and this can result in higher levels of the active substance in your blood ( see the section'other medicines and cerdelga'for an expanded list of medicines ). - if you are an extensive metaboliser and you have severely reduced liver function. - if you are an extensive metaboliser and you have mildly or moderately reduced liver function while taking a strong or moderate cyp2d6 inhibitor. warnings and precautions talk to your doctor or pharmacist before taking cerdelga, if you : are currently treated, or about to start treatment with any of the medicines listed in section'other medicines and cerdelga.' have had a heart attack or heart failure. have a slow heart rate. have an irregular, or abnormal heart beat, inluding a heart condition called long qt syndrome. have any other heart problems. are taking an antiarrhythmic medicine ( used to treat irregular heart beat ) like quinidine, amiodarone or sotalol. are an extensive metaboliser and you have moderately reduced liver function. are an intermediate or poor metaboliser and you have any level
always take this medicine exactly as your doctor or pharmacist has told you . check with your doctor or pharmacist if you are not sure . if you are an intermediate metaboliser or extensive metaboliser : swallow one 84 mg capsule whole twice a day with water . it may be taken with or without food . take one capsule in the morning and one capsule at night . if you are a poor metaboliser : swallow one 84 mg capsule whole once a day with water . it may be taken with or without food . take one capsule at the same time every day . do not open , crush , dissolve , or chew the capsule before swallowing it . if you cannot swallow the capsule whole , tell your doctor . continue taking cerdelga every day for as long as your doctor tells you . how to pull the blister / wallet from the sleeve while pressing your thumb and finger together at one end of the sleeve ( 1 ) gently pull the blister / wallet out to open the sleeve ( 2 ). if you take more cerdelga than you should if you take more capsules than you were told to , consult your doctor immediately . you may experience dizziness marked by loss of balance , slow heart rate , nausea , vomiting and light - headedness . if you forget to take cerdelga take the next capsule at the usual time . do not take a double dose to make up for a forgotten dose . if you stop taking cerdelga do not stop taking cerdelga without talking to your doctor . if you have any further questions on the use of this medicine , ask your doctor or pharmacist .
like all medicines , this medicine can cause side effects , although not everybody gets them . common ( may affect up to 1 in 10 people ): headache dizziness change in taste ( dysgeusia ) palpitations throat irritation heartburn ( dyspepsia ) feeling sick ( nausea ) diarrhoea constipation abdominal pain stomach ache ( upper abdominal pain ) acid reflux disease ( gastrooesophageal reflux disease ) bloating ( abdominal distension ) inflammation of the stomach ( gastritis ) 34 difficulty swallowing ( dysphagia ) vomiting dry mouth gas ( flatulence ) dry skin hives ( urticaria ) joint pain ( arthalagia ) pain in arms , legs or back tiredness ( fatigue ) reporting of side effects if you get any side effects , talk to your doctor or pharmacist . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the carton , sleeve and blister after ' exp '. the expiry date refers to the last day of that month . this medicine does not require any special storage conditions . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what cerdelga contains the active substance is eliglustat ( as tartrate ). each capsule contains 84 mg eliglustat . the other ingredients are : o in the capsule : microcrystalline cellulose , lactose monohydrate ( see section 2 under ' cerdelga contains lactose '), hypromellose and glycerol dibehenate . o in the capsule shell : gelatin , potassium aluminium silicate ( e555 ), titanium dioxide ( e171 ), yellow iron oxide ( e172 ) and indigotine ( e132 ). o in the printing ink : shellac , black iron oxide ( e172 ), propylene glycol and ammonia solution , concentrated . what cerdelga looks like and contents of the pack cerdelga capsules have a pearl blue - green opaque cap and a pearl white opaque body with " gz02 " printed in black on the capsule . pack sizes of 14 hard capsules in 1 blister wallet , 56 hard capsules in 4 blister wallets of 14 capsules each or 196 hard capsules in 14 blister wallets of 14 capsules each not all packs may be marketed in your country .
the active substance in zoledronic acid hospira is zoledronic acid , which belongs to a group of substances called bisphosphonates . zoledronic acid works by attaching itself to the bone and slowing down the rate of bone change . it is used : to prevent bone complications , e . g . fractures , in adult patients with bone metastases ( spread of cancer from primary site to the bone ). to reduce the amount of calcium in the blood in adult patients where it is too high due to the presence of a tumour . tumours can accelerate normal bone change in such a way that the release of calcium from bone is increased . this condition is known as tumour - induced hypercalcaemia ( tih ).
follow carefully all instructions given to you by your doctor. your doctor will carry out blood tests before you start treatment with zoledronic acid hospira and will check your response to treatment at regular intervals. you should not be given zoledronic acid hospira : <unk> if you are breast - feeding. <unk> if you are allergic ( hypersensitive ) to zoledronic acid, another bisphosphonate ( the group of substances to which zoledronic acid belongs ), or any of the other ingredients of zoledronic acid hospira ( listed in section 6 ). warnings and precautions talk to your doctor before being given zoledronic acid hospira : <unk> if you have or have had a kidney problem. <unk> if you have or have had pain, swelling or numbness of the jaw, a feeling of heaviness in the jaw or loosening of a tooth. your doctor may recommend a dental examination before you start treatment with zoledronic acid hospira if you are having dental treatment or are due to undergo dental surgery, tell your dentist that you are being treated with zoledronic acid hospira and inform your doctor about your dental treatment. while being treated with zoledronic acid hospira, you should maintain good oral hygiene ( including regular teeth brushing ) and receive routine dental check - ups. contact your doctor and dentist immediately if you experience any problems with your mouth or teeth such as loose teeth, pain or swelling, or non - healing of sores or discharge, as these could be signs of a condition called osteonecrosis of the jaw. patients who are undergoing chemotherapy and / or radiotherapy, who are taking steroids, who are undergoing dental surgery, who do not receive routine dental care, who have gum disease, who are smokers, or who were previously treated with a bisphosphonate ( used to treat or prevent bone disorders ) may have a higher risk of developing osteonecrosis of the jaw. reduced levels of calcium in the blood ( hypocalcaemia ), sometimes leading to muscle cramps, dry skin,
â zoledronic acid hospira must only be given by healthcare professionals trained in administering bisphosphonates intravenously , i . e . through a vein ( also referred to as ' iv ' administration ). â your doctor will recommend that you drink enough water before each treatment to help prevent dehydration . carefully follow all the other instructions given to you by your doctor , nurse or pharmacist . how much zoledronic acid hospira is given the usual single dose given is 4 mg . if you have a kidney problem , your doctor will give you a lower dose depending on the severity of your kidney problem . how often zoledronic acid hospira is given if you are being treated for the prevention of bone complications due to bone metastases , you will be given one infusion of zoledronic acid hospira every three to four weeks . if you are being treated to reduce the amount of calcium in your blood , you will normally only be given one infusion of zoledronic acid hospira . how zoledronic acid hospira is given zoledronic acid hospira is given as a drip ( infusion ) into a vein which should take at least 15 minutes and should be administered as a single intravenous solution in a separate infusion line . patients whose blood calcium levels are not too high will also be prescribed calcium and vitamin d supplements to be taken each day . if you are given more zoledronic acid hospira than you should be if you have received doses higher than those recommended , you must be carefully monitored by your doctor . this is because you may develop serum electrolyte abnormalities ( e . g . abnormal levels of calcium , phosphorus and magnesium ) and / or changes in kidney function , including severe kidney impairment . if your level of calcium falls too low , you may have to be given supplemental calcium by infusion .
like all medicines, zoledronic acid hospira can cause side effects, although not everybody gets them. the most common ones are usually mild and will probably disappear after a short time. tell your doctor about any of the following serious side effects straight away : common ( may affect up to 1 in 10 people ): <unk> severe kidney impairment ( will normally be determined by your doctor with certain specific blood tests ). <unk> low level of calcium in the blood. uncommon ( may affect up to 1 in 100 people ): <unk> pain in the mouth, teeth and / or jaw, swelling or non - healing sores inside the mouth or jaw discharge, numbness or a feeling of heaviness in the jaw or loosening of a tooth. these could be signs of bone damage in the jaw ( osteonecrosis ). tell your doctor and dentist immediately if you experience such symptoms while being treated with zoledronic acid hospira or after stopping treatment. <unk> irregular heart rhythm ( atrial fibrillation ) has been seen in patients receiving zoledronic acid for postmenopausal osteoporosis. it is currently unclear whether zoledronic acid causes this irregular heart rhythm but you should report it to your doctor if you experience such symptoms after you have received zoledronic acid. <unk> severe allergic reaction : shortness of breath, swelling mainly of the face and throat. rare ( may affect up to 1 in 1, 000 people ): as a consequence of low calcium values : irregular heart beat ( cardiac arrhythmia ; secondary to hypocalcaemia ). a kidney function disorder called fanconi syndrome ( will normally be determined by your doctor with certain urine tests ). very rare ( may affect up to 1 in 10, 000 people ): <unk> as a consequence of low calcium values : seizures, numbness and tetany ( secondary to hypocalcaemia ). <unk> talk to your doctor if you have ear pain, discharge from the ear, and / or an ear infection. these could be signs of bone damage in the ear. <unk> osteonecrosis has also very rarely been seen occurring
your doctor , nurse or pharmacist knows how to store zoledronic acid hospira properly ( see section 6 ).
what zoledronic acid hospira contains â the active substance of zoledronic acid hospira is zoledronic acid . one vial contains 4 mg zoledronic acid ( as monohydrate ). â the other ingredients are : mannitol , sodium citrate , water for injections . what zoledronic acid hospira looks like and contents of the pack zoledronic acid hospira is supplied as a liquid concentrate ( referred to as a ' concentrate for solution for infusion ' or ' sterile concentrate ') in a vial . one vial contains 4 mg of zoledronic acid . each pack contains one vial with concentrate .
what varuby is varuby contains the active substance rolapitant . what varuby is used for varuby is used to help prevent adults with cancer feeling sick ( nauseous ) or being sick ( vomiting ) while having cancer treatment chemotherapy . how varuby works chemotherapy can cause the body to release " substance p ." substance p attaches to nerve cells in the brain ' s vomiting centre and makes you feel sick or be sick . rolapitant , the active substance in varuby , blocks substance p from attaching to these nerve cells and this helps prevent nausea and vomiting .
do not take varuby : - if you are allergic to rolapitant or any of the other ingredients of this medicine ( listed in section 6 ). - if you take an herbal medicine called st john's wort ( hypericum performatum ), used to treat depression and difficulty sleeping ( see section 2 under'other medicines and varuby '). if you are not sure, talk to your doctor, pharmacist or nurse before taking this medicine. warnings and precautions talk to your doctor, pharmacist or nurse before taking this medicine if : 27 - you have severe liver or kidney problems - you need to take certain medicines which may reduce the effectiveness of varuby, such as : - rifampicin, to treat tuberculosis and other infections - carbamazepine, to treat epilepsy and nerve pain - phenobarbital, to treat epilepsy - enzalutamide, to treat prostate cancer - phenytoin, to treat epilepsy - efavirenz, to treat human immunodeficiency virus ( hiv ) - rifabutin, to treat tuberculosis and other infections - other medicines that contain an nk1 antagonist, such as aprepitant and a combination of netupitant and palonosetron hydrochloride ( for the prevention of nausea and vomiting associated with cancer chemotherapy ) ( see section 2 under'other medicines and varuby ') children and adolescents varuby should not be taken by children and adolescents under 18 years because it has not been studied in this group. other medicines and varuby tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. varuby may affect how some other medicines work. these include : - propafenone ( used to treat irregular or abnormal heart beat ) - tamoxifen ( used to treat breast cancer ) - metoprolol ( used to treat high blood pressure and heart conditions ) - thioridazine ( used to treat psychiatric conditions like schizophrenia
always take this medicine exactly as your doctor has told you . check with your doctor , pharmacist or nurse if you are not sure . how much to take - the recommended dose is 180 mg ( two 90 mg tablets ). swallow the tablets whole , with some water . - take the tablets within 2 hours before you start your chemotherapy cycle . - you can take varuby with or without food . taking varuby before chemotherapy prevents sickness and feelings of sickness . do not take this medicine in the days after you have chemotherapy - unless you are about to have another chemotherapy cycle . do not take varuby more than once every two weeks . if you take more varuby than you should the usual dose is two tablets . if you think you may have taken more than you should , tell your doctor straight away . if you forget to take varuby if you have forgotten to take your dose , tell your doctor straight away . if you stop taking varuby varuby helps prevent feeling sick and being sick when you have chemotherapy . if you do not want to take this medicine , discuss this with your doctor . if you have any further questions on the use of this medicine , ask your doctor , pharmacist or nurse .
like all medicines, this medicine can cause side effects, although not everybody gets them. tell your doctor, pharmacist or nurse if you notice any of the following side effects : serious side effects : rare : may affect up to 1 in 1, 000 people if you have symptoms of an allergic reaction, such as sudden shortness of breath, swelling of the lips or tongue or change in taste, swelling of skin or tissue or sudden rash or fever, or faster heartbeats, tell your doctor or nurse immediately. they will provide appropriate treatment. other side effects : common : may affect up to 1 in 10 people - headache - constipation - feeling tired uncommon : may affect up to 1 in 100 people - sore or painful muscles 29 - feeling dizzy, difficulty concentrating, lack of energy, feeling sleepy ( somnolence ) or trouble sleeping ( insomnia ) - stomach problems including stomach discomfort, bloating, nausea, pain, indigestion, and diarrhoea - low levels of white blood cells which fight infections ( shown in blood tests ) - infection in the mouth - mouth sores - decreased appetite - hiccups - weakness rare : may affect up to 1 in 1, 000 people - thrush in the mouth or skin - a reduction in number of platelets ( shown in blood tests ) - increased risk of bleeding - decrease in white blood cells that fight infections ( shown in blood tests ) - dehydration - low levels of magnesium in the blood ( shown in blood tests ) - feelings of worry or fear, restlessness - teeth grinding - losing your balance - difficulty in moving - passing out or the feeling of nearly passing out - partial loss of hearing - ringing in the ears - blurry vision - heart rate increased - stomach discomfort - change in bowel habit - dry mouth - acid reflux or heartburn - gagging or sensation of throwing up - high blood pressure - hair loss - skin rash, similar to acne - dry skin - pain in joint - back pain - muscle weakness - muscle weakness, tenderness or pain and particularly,
what varuby contains the active substance is rolapitant . each tablet contains 90 mg of rolapitant . the other ingredients are : - tablet core : lactose monohydrate ( see section 2 under ' varuby contains lactose '), pregelatinised starch , microcrystalline cellulose ( e460 ), povidone ( k - 30 ), croscarmellose sodium , colloidal silicon dioxide and magnesium stearate . - film - coat : polyvinyl alcohol , titanium dioxide ( e171 ), macrogol , talc , indigo carmine ( e132 ), and polysorbate 80 . what varuby looks like and contents of the pack the tablets are blue , debossed with t0101 on one side and 100 on the other side . pack size of two tablets in a polyvinyl chloride / polychlorotrifluoroethylene / aluminium foil twinned blister .
what enerzair breezhaler is and how it works enerzair breezhaler contains three active substances : - indacaterol - glycopyrronium - mometasone furoate indacaterol and glycopyrronium belong to a group of medicines called bronchodilators . they work in different ways to relax the muscles of the small airways in the lungs . this helps to open the airways and makes it easier for air to get in and out of the lungs . when they are taken regularly , they help the small airways to remain open . mometasone furoate belongs to a group of medicines called corticosteroids ( or steroids ). corticosteroids reduce the swelling and irritation ( inflammation ) in the small airways in the lungs and so gradually ease breathing problems . corticosteroids also help to prevent attacks of asthma . what enerzair breezhaler is used for enerzair breezhaler is used regularly as treatment for asthma in adults . asthma is a serious , long - term lung disease where the muscles around the smaller airways become tight ( bronchoconstriction ) and inflamed . symptoms come and go and include shortness of breath , wheezing , chest tightness and cough . you should use enerzair breezhaler every day and not only when you have breathing problems or other symptoms of asthma . this will ensure that it controls your asthma properly . do not use this medicine to relieve a sudden attack of breathlessness or wheezing . if you have any questions about how enerzair breezhaler works or why this medicine has been prescribed for you , ask your doctor .
follow all the doctor's instructions carefully. do not use enerzair breezhaler - if you are allergic to indacaterol, glycopyrronium, mometasone furoate, or any of the other ingredients of this medicine ( listed in section 6 ). if you think you may be allergic, ask your doctor for advice. warnings and precautions talk to your doctor, pharmacist or nurse before using enerzair breezhaler if any of the following applies to you : - if you have heart problems, including an irregular or fast heartbeat. - if you have thyroid gland problems. - if you have ever been told you have diabetes or high blood sugar. - if you suffer from seizures or fits. - if you have severe kidney problems. - if you have severe liver problems. - if you have a low level of potassium in your blood. - if you have an eye problem called angle - closure glaucoma. - if you have difficulty passing urine. - if you have tuberculosis ( tb ) of the lung, or any long standing or untreated infections. during treatment with enerzair breezhaler stop using this medicine and get medical help immediately if you have any of the following : - tightness of the chest, coughing, wheezing or breathlessness immediately after using enerzair breezhaler ( signs the medicine is unexpectedly tightening the airways, known as paradoxical bronchospasm ). - difficulty breathing or swallowing, swelling of the tongue, lips or face, skin rash, itching and hives ( signs of allergic reaction ). - eye pain or discomfort, temporary blurring of vision, visual haloes ( seeing bright circles around lights ) or coloured images in association with red eyes ( signs of an attack of angle - closure glaucoma ). children and adolescents do not give this medicine to children or adolescents ( below the age of 18 years ) because it has not been studied in this age group. other medicines and
always use this medicine exactly as your doctor or pharmacist has told you. check with your doctor or pharmacist if you are not sure. how much enerzair breezhaler to inhale the usual dose is to inhale the content of one capsule each day. you only need to use the medicine once a day. do not use more than your doctor tells you to use. you should use enerzair breezhaler every day, even when your asthma is not troubling you. when to inhale enerzair breezhaler inhale enerzair breezhaler at the same time each day. this will help control your symptoms throughout the day and night. it will also help you to remember to use it. how to inhale enerzair breezhaler - enerzair breezhaler is for inhalation use. - in this pack, you will find an inhaler and capsules that contain the medicine. the inhaler enables you to inhale the medicine in the capsule. only use the capsules with the inhaler provided in this pack. the capsules should remain in the blister until you need to use them. - peel the backing away from the blister to open it, do not push the capsule through the foil. - when you start a new pack, use the new inhaler supplied in this new pack. - dispose of the inhaler in each pack after all capsules in that pack have been used. - do not swallow the capsules. - please read the instructions for use on the other side of this leaflet for more information on how to use the inhaler. if your pack contains a sensor for enerzair breezhaler - the sensor and app are not required in order for you to take your medicine. the sensor does not need to be connected to the app when taking your medicine. - your doctor will decide whether use of the sensor and app is appropriate for you. - the electronic sensor for enerzair breezhaler is to be attached to the base of the enerzair breezhaler inhaler. -
like all medicines , this medicine can cause side effects , although not everybody gets them . some side effects could be serious stop using enerzair breezhaler and get medical help immediately if you have any of the following : common : may affect up to 1 in every 10 people - difficulty breathing or swallowing , swelling of the tongue , lips or face , skin rash , itching and hives ( signs of allergic reaction ). other side effects other side effects include the following listed below . if these side effects become severe , please tell your doctor , pharmacist or nurse . very common : may affect more than 1 in 10 people - sore throat - runny nose - sudden difficulty breathing and feeling of tightness in chest with wheezing or coughing common : may affect up to 1 in every 10 people - oral thrush ( sign of candidiasis ). after you have finished taking your dose , rinse your mouth with water or a mouthwash solution and then spit this out . this will help to prevent thrush . - a frequent urge to urinate and pain or burning when urinating ( signs of urinary tract infection ) - headache - fast heart beat - cough - voice alteration ( hoarseness ) - diarrhoea , abdominal cramps , nausea , and vomiting ( gastroenteritis ) - pain in muscles , bones or joints ( signs of musculoskeletal pain ) - muscle spasm - fever 48 uncommon : may affect up to 1 in every 100 people - dry mouth - rash - high level of sugar in the blood - skin itching - difficulty and pain when passing urine ( signs of dysuria ) - clouding of the lens of your eyes ( signs of cataract ) reporting of side effects if you get any side effects , talk to your doctor , pharmacist or nurse . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
- keep this medicine out of the sight and reach of children . - do not use this medicine after the expiry date which is stated on the carton and blister after " exp ". the expiry date refers to the last day of that month . - this medicinal product does not require any special temperature storage conditions . - store the capsules in the original blister , in order to protect from light and moisture , and do not remove until immediately before use . - do not throw away any medicines via wastewater . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment . - if your pack contains an electronic sensor for enerzair breezhaler , see the instructions for use provided in the sensor pack for detailed instructions on how to store and when to discard it .
what enerzair breezhaler contains - the active substances are indacaterol ( as acetate ), glycopyrronium ( as bromide ) and mometasone furoate . each capsule contains 150 micrograms of indacaterol ( as acetate ), 63 micrograms of glycopyrronium bromide ( equivalent to 50 micrograms of glycopyrronium ) and 160 micrograms of mometasone furoate . each delivered dose ( the dose that leaves the mouthpiece of the inhaler ) contains 114 micrograms of indacaterol ( as acetate ), 58 micrograms of glycopyrronium bromide ( equivalent to 46 micrograms of glycopyrronium ) and 136 micrograms of mometasone furoate . - the other ingredients are lactose monohydrate and magnesium stearate ( see " enerzair breezhaler contains lactose " in section 2 ). what enerzair breezhaler looks like and contents of the pack in this pack , you will find an inhaler together with capsules in blisters . some packs also contain a sensor device . the capsules are transparent and contain a white powder . they have a black product code " igm150 - 50 - 160 " printed above two black bars on the body with a logo printed in black and surrounded by a black bar on the cap . the following pack sizes are available : single pack containing 10 x 1 , 30 x 1 or 90 x 1 hard capsules , together with 1 inhaler . pack containing 30 x 1 hard capsules , together with 1 inhaler and 1 sensor . multipacks comprising 15 cartons , each containing 10 x 1 hard capsules together with 1 inhaler . not all pack sizes may be available in your country .
clopidogrel acino pharma gmbh contains the active ingredient clopidogrel which belongs to a group of medicines called antiplatelet medicinal products . platelets ( so - called thrombocytes ) are very small structures , which clump together during blood clotting . by preventing this clumping , antiplatelet medicinal products reduce the chances of blood clots forming ( a process called thrombosis ). clopidogrel acino pharma gmbh is taken to prevent blood clots ( thrombi ) forming in hardened blood vessels ( arteries ), a process known as atherothrombosis , which can lead to atherothrombotic events ( such as stroke , heart attack , or death ). you have been prescribed clopidogrel acino pharma gmbh to help prevent blood clots and reduce the risk of these severe events because : - you have a condition of hardening of arteries ( also known as atherosclerosis ), and - you have previously experienced a heart attack , stroke or have a condition known as peripheral arterial disease ( disturbed blood flow in arms or legs caused by vascular occlusions )
do not take clopidogrel acino pharma gmbh : if you are allergic ( hypersensitive ) to clopidogrel or any of the other ingredients of clopidogrel acino pharma gmbh ; if you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain ; if you suffer from severe liver disease ; if you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking clopidogrel acino pharma gmbh. take special care with clopidogrel acino pharma gmbh : if any of the situations mentioned below apply to you, you should tell your doctor before taking clopidogrel acino pharma gmbh : if you have a risk of bleeding such as - a medical condition that puts you at risk of internal bleeding ( such as a stomach ulcer ) - a blood disorder that makes you prone to internal bleeding ( bleeding inside any tissues, organs or joints of your body ) - a recent serious injury - a recent surgery ( including dental ) - a planned surgery ( including dental ) in the next seven days if you have had a clot in an artery of your brain ( ischaemic stroke ) which occurred within the last seven days if you have kidney or liver disease while you are taking clopidogrel acino pharma gmbh : you should tell your doctor if a surgery ( including dental ) is planned. you should also tell your doctor immediately if you develop a medical condition ( also known as thrombotic thrombocytopenic purpura or ttp ) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes ( jaundice ) ( see section 4'possible side effects '). if you cut or injure yourself, it may take longer than usual for bleeding to stop. this is linked to
always take clopidogrel acino pharma gmbh exactly as your doctor has told you . you should check with your doctor or pharmacist if you are not sure . the usual dose is one 75 mg tablet of clopidogrel acino pharma gmbh per day to be taken orally with or without food , and at the same time each day . you should take clopidogrel acino pharma gmbh for as long as your doctor continues to prescribe it . if you take more clopidogrel acino pharma gmbh than you should contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding . if you forget to take clopidogrel acino pharma gmbh if you forget to take a dose of clopidogrel acino pharma gmbh , but remember within 12 hours of your usual time , take your tablet straight away and then take your next tablet at the usual time . if you forget for more than 12 hours , simply take the next single dose at the usual time . do not take a double dose to make up for the forgotten individual doses . if you stop taking clopidogrel acino pharma gmbh do not stop the treatment unless your doctor tells you so . contact your doctor or pharmacist before stopping . if you have any further questions on the use of this product , ask your doctor or pharmacist .
like all medicines, clopidogrel acino pharma gmbh can cause side effects, although not everybody gets them. the frequency of possible side effects listed below is defined using the following convention : very common ( affects more than 1 user in 10 ) common ( affects 1 to 10 users in 100 ) uncommon ( affects 1 to 10 users in 1, 000 ) rare ( affects 1 to 10 users in 10, 000 ) very rare ( affects less than 1 user in 10, 000 ) not known ( frequency cannot be estimated from the available data ) contact your doctor immediately if you experience : - fever, signs of infection or extreme tiredness. these may be due to rare decrease of some blood cells. - signs of liver problems such as yellowing of the skin and / or the eyes ( jaundice ), whether or not associated with bleeding which appears under the skin as red pinpoint dots and / or confusion ( see section 2'take special care with clopidogrel acino pharma gmbh '). - swelling in the mouth or skin disorders such as rashes and itching, blisters of the skin. these may be the signs of an allergic reaction. the most common side effect reported with clopidogrel is bleeding. bleeding may occur as bleeding in the stomach or bowels, bruising, haematoma ( unusual bleeding or bruising under the skin ), nose bleed, blood in the urine. in a small number of cases, bleeding in the eye, inside the head, the lung or the joints has also been reported. if you experience prolonged bleeding when taking clopidogrel acino pharma gmbh. if you cut or injure yourself, it may take longer than usual for bleeding to stop. this is linked to the way your medicine works as it prevents the ability of blood clots to form. for minor cuts and injuries e. g., cutting yourself, shaving, this is usually of no concern. however, if you are concerned by your bleeding, you should contact your doctor straightaway ( see section 2'take special care with clo
store in the original blister in order to protect from moisture . keep out of the reach and sight of children . do not use clopidogrel acino pharma gmbh after the expiry date which is stated on the carton and on the blister after exp . the expiry date refers to the last day of that month . do not use clopidogrel acino pharma gmbh if you notice any visible sign of damage of blister or film - coated tablets . medicines should not be disposed of via wastewater or household waste . ask your pharmacist how to dispose of medicines no longer required . these measures will help to protect the environment .
what clopidogrel acino pharma gmbh contains the active substance is clopidogrel . each tablet contains 75 mg of clopidogrel ( as besilate ). the other ingredients are : tablet core : macrogol 6000 cellulose , microcrystalline ( e460 ) crospovidone type a castor oil , hydrogenated film - coating : macrogol 6000 ethylcellulose ( e462 ) titanium dioxide ( e 171 ) what clopidogrel acino pharma gmbh looks like and contents of the pack clopidogrel acino pharma gmbh 75 mg film - coated tablets are white to off - white , marbled , round and biconvex . they are supplied in cardboard cartons containing 14 , 28 , 30 , 50 , 84 , 90 and 100 tablets in aluminium blisters . not all pack sizes may be marketed .
what delstrigo is delstrigo is used to treat hiv (' human immunodeficiency virus ') infection . it belongs to a group of medicines called ' antiretroviral medicines '. delstrigo contains the active substances : doravirine - a non - nucleoside reverse transcriptase inhibitor ( nnrti ) lamivudine - a nucleoside analogue reverse transcriptase inhibitor ( nrti ) tenofovir disoproxil - a nucleoside analogue reverse transcriptase inhibitor ( nrti ) what delstrigo is used for delstrigo is used to treat hiv infection in people 18 years of age and older . hiv is the virus that causes aids (' acquired immune deficiency syndrome '). you should not take delstrigo if your doctor has told you that the virus causing your infection is resistant to any of the medicines in delstrigo . how delstrigo works delstrigo works by preventing hiv from making more viruses in your body . this will help by : reducing the amount of hiv in your blood ( this is called your ' viral load ') increasing the number of white blood cells called ' cd4 + t '. this can make your immune system stronger . this may reduce your risk of early death or catching infections because your immune system is weak .
do not take delstrigo : if you are allergic to doravirine, lamivudine or tenofovir disoproxil or any of the other ingredients of this medicine listed in section 6. if you are taking any of the following medicines : - carbamazepine, oxcarbazepine, phenobarbital, phenytoin ( medicines for seizure ) - rifampicin, rifapentine ( medicines for tuberculosis ) - st. john's wort ( hypericum perforatum, a herbal remedy used for depression and anxiety ) or products that contain it - mitotane ( a medicine to treat cancer ) - enzalutamide ( a medicine to treat prostate cancer ) - lumacaftor ( a medicine to treat cystic fibrosis ) do not take delstrigo if the above applies to you. if you are not sure, talk to your doctor, pharmacist, or nurse before taking delstrigo. see also the list in section " other medicines and delstrigo ". warnings and precautions talk to your doctor, pharmacist, or nurse before taking delstrigo. passing hiv to others hiv is spread by contact with blood or through sexual contact with a person with hiv. you can still pass on hiv when taking delstrigo, although effective therapy lowers the risk. talk to your doctor about what you can do to avoid infecting other people. worsening of hepatitis b infection if you have both hiv and hepatitis b virus infections, your hepatitis b may get worse if you stop taking delstrigo. you may require blood tests for several months after stopping treatment. discuss your hepatitis b therapy with your doctor. new or worsening kidney problems, including kidney failure this can happen in some people who take delstrigo. your doctor will do blood tests to check your kidney function before and during treatment
always take this medicine exactly as your doctor, pharmacist, or nurse has told you. check with your doctor, pharmacist, or nurse if you are not sure. delstrigo is a complete regimen taken as a single tablet for the treatment of hiv infection. how much to take the recommended dose is 1 tablet once a day. if you take certain medicines your doctor may need to change the amount of doravirine you take. see " other medicines and delstrigo " section for a list of medicines. taking this medicine swallow the tablet whole ( do not crush or chew ). this medicine can be taken with food or between meals. if you take more delstrigo than you should do not take more than the recommended dose. if you accidentally take more, contact your doctor. if you forget to take delstrigo it is important that you do not miss or skip doses of delstrigo. if you forget a dose, take it as soon as you remember. but if your next dose is due within 12 hours, skip the dose you missed and take the next one at the usual time. then continue your treatment as before. do not take two doses of delstrigo at the same time to make up for a missed dose. if you are not sure what to do, call your doctor or pharmacist. if you stop taking delstrigo do not run out of delstrigo. refill your prescription or talk to your doctor before your delstrigo is all gone. if you stop taking delstrigo, your doctor will need to check your health often and do blood tests regularly for several months to check your hiv infection. if you have hiv infection and hepatitis b infection, it is especially important not to stop your delstrigo treatment without talking to your doctor first. some patients have had blood tests or symptoms indicating that their hepatitis has worsened after stopping lamivudine or tenofovir disoproxil ( two of the three active substances of delstrigo ). if delstrigo is stopped your doctor may recommend that you resume hepatitis
like all medicines, this medicine can cause side effects, although not everybody gets them. do not stop taking this medicine without first talking to your doctor. common : may affect up to 1 in 10 people : abnormal dreams, difficulty in sleeping ( insomnia ) headache, dizziness, sleepiness cough, nasal symptoms feeling sick ( nausea ), diarrhoea, stomach pain, vomiting, wind ( flatulence ) hair loss, rash muscle symptoms ( pain, stiffness ) feeling tired, fever blood tests may also show : increased levels in liver enzymes ( alt ) uncommon : may affect up to 1 in 100 people : nightmares, depression, anxiety, irritability, confusion, suicidal thoughts 45 trouble concentrating, memory problems, tingling of hands and feet, stiff muscles, poor quality of sleep high blood pressure constipation, stomach discomfort, swollen or bloated stomach ( abdominal distention ), indigestion, soft stools, stomach spasms, frequent bowel movements, inflammation of the pancreas ( pancreatitis ) ( causing stomach pain, vomiting ) itchiness joint pain, breakdown of muscle tissue, muscular weakness feeling weak, general feeling of being unwell blood tests may also show : decreased number of white blood cells in your blood ( neutropenia ) decreased number of red blood cells in your blood ( anaemia ) decreased levels of platelets in your blood ( you may bleed more easily ) decreased levels phosphate decreased levels of potassium in your blood increased levels of creatinine in your blood increased levels in liver enzymes ( ast ) increased levels of lipase increased levels of amylase decreased levels of haemoglobin the muscle pain, muscle weakness and decreases in potassium or phosphate in the blood may occur due to damage to kidney tubule cells. rare : may affect up to 1 in 1, 000 people aggression, hallucinations, difficulty adjusting to changes, mood changes, sleep walking difficulty breathing, enlarged tonsils feeling of incomplete defecation enlarged liver or fatty liver, yellow skin or eyes,
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the bottle after exp . the bottle contains desiccant protecting the tablets from moisture . there may be more than one in the bottle . keep desiccant inside the bottle and do not throw away until you have finished taking all of the medicine . keep the bottle tightly closed in order to protect from moisture . this medicinal product does not require any special temperature storage conditions . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what delstrigo contains the active substances are 100 mg of doravirine , 300 mg of lamivudine and 245 mg of tenofovir disoproxil ( as fumarate ) the other ingredients are croscarmellose sodium e468 ; hypromellose acetate succinate ; magnesium stearate e470b ; microcrystalline cellulose e460 ; silica , colloidal anhydrous e551 ; sodium stearyl fumarate . the tablets are film - coated with a coating material containing the following ingredients : carnauba wax e903 , hypromellose e464 ; iron oxide yellow e172 ; lactose monohydrate ; titanium dioxide e171 ; and triacetin e1518 . what delstrigo looks like and contents of the pack delstrigo is available as a yellow , oval - shaped , film - coated tablet , and is debossed with the corporate logo and 776 on one side and plain on the other side . the following pack sizes are available : 1 bottle with 30 film - coated tablets 90 film - coated tablets ( 3 bottles of 30 film - coated tablets ) not all pack sizes may be available in your country .
what spravato is spravato contains the active substance esketamine . this belongs to a group of medicines called anti - depressants and you have been given this medicine to treat your depression . what spravato is used for spravato is used in adults to reduce the symptoms of depression , such as , feeling sad , anxious , or worthless , sleeping difficulties , change in appetite , loss of interest in favourite activities , feeling of being slowed down . it is given , together with another antidepressant , if you have tried at least 2 other antidepressant medicines but they have not helped .
do not use spravato if you are allergic to esketamine, a similar medicine called ketamine used for anaesthesia, or any of the other ingredients of this medicine ( listed in section 6 ). if you have ever had certain conditions such as : - an aneurysm ( a weak spot in a blood vessel wall where it widens or bulges out ) - bleeding in the brain if you recently had a heart attack ( within 6 weeks ) this is because spravato can cause a temporary increase in blood pressure that may lead to serious complications in these conditions. do not use spravato if any of the above apply to you. if you are not sure, talk to your doctor before using spravato - your doctor will decide whether or not you can use this medicine. warnings and precautions talk to your doctor before using spravato if you have : a heart problem which is not well controlled such as : poor blood flow in the blood vessels of the heart frequently with chest pain ( such as angina ), high blood pressure, heart valve disease or heart failure 34 ever had problems with the blood supply to your brain ( such as a stroke ) ever had problems with drug abuse prescribed medicines or illegal drugs - or a problem with alcohol ever had a condition called psychosis - where you believe in things that are not true ( delusions ) or see, feel, or hear things that are not there ( hallucinations ) ever had a condition called bipolar disorder, or symptoms of mania ( where you become very over - active or over excited ) ever had an overactive thyroid that is not properly treated ( hyperthyroidism ) ever had lung problems causing breathing difficulty ( pulmonary insufficiency ), including chronic obstructive pulmonary disease ( copd ) sleep apnoea and are extremely overweight ever had slow or fast heartbeats causing shortness of breath, palpitations or chest discomfort, feeling light - headed or fainting had a serious head injury or serious problems affecting the brain, particularly where there is increased pressure in the brain severe liver problems. if any of the above apply
always use this medicine exactly as your doctor has told you . check with your doctor if you are not sure . you will use the spravato nasal spray yourself - under the supervision of your doctor or other healthcare professional in a healthcare setting , such as , the doctor ' s office or clinic . your doctor or other healthcare professional will show you how to use the nasal spray device ( see also instructions for use ). how much to use your doctor will decide if you need 1 , 2 or 3 nasal spray devices and how often you should go to the doctor ' s office or clinic for the medicine . one nasal spray device delivers two sprays ( one spray per nostril ) spravato is usually used twice a week for the first 4 weeks after the first 4 weeks , spravato is usually used once a week after this , spravato is usually used either once a week or once every 2 weeks . during and after each use of this medicine , your doctor will check you and decide how long to monitor you . food and drink some patients using spravato may experience nausea or vomiting . you should avoid eating for 2 hours before treatment and not drinking liquids for 30 minutes before using this medicine . nasal sprays if you need steroid or decongestant medicines as a nasal spray , avoid using them during the hour before your spravato treatment . if you use more spravato than you should you will use this medicine under the supervision of your doctor in the doctor ' s office or clinic . therefore , it is unlikely that you will use too much . if you use too much spravato , you are more likely to get side effects ( see " possible side effects "). if you stop using spravato it is important to make sure you come in for your scheduled appointments , so that this medicine is effective for you . if you have any further questions on the use of this medicine , ask your doctor .
like all medicines , this medicine can cause side effects , although not everybody gets them . tell your doctor if you notice any of the following side effects . very common ( may affect more than 1 in 10 people ) feeling disconnected from yourself , your thoughts , feelings and things around you feeling dizzy headache change in sense of taste feeling sleepy decreased feeling or sensitivity , including around the mouth area spinning sensation (" vertigo ") vomiting nausea common ( may affect up to 1 in 10 people ) feeling extremely happy (" euphoria ") feeling agitated feeling anxious eyes , ears , or sense of touch are deceived or tricked in some way ( something is not what it seems to be ) feeling irritable panic attacks change in perception of time 37 seeing , feeling , hearing or smelling things that are not there ( hallucinations ) feeling detached from reality problems with thinking muscle tremors feeling very sleepy with low energy difficulty speaking unusual feeling in the mouth ( such as tingling or a crawling feeling ) increased sensitivity to noise or sounds persistent ringing in the ears ( tinnitus ) blurred vision fast heartbeat nasal discomfort nasal dryness including dry crusts in the nose itchy nose dry mouth decreased feeling or sensitivity in the mouth excessive sweating frequent need to pass urine pain when passing urine urgent need to pass urine feeling abnormal feeling drunk feeling of body temperature change high blood pressure increased blood pressure uncommon ( may affect up to 1 in 100 people ) increased saliva reporting of side effects if you get any side effects , talk to your doctor or pharmacist . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
what spravato contains the active substance is esketamine . each nasal spray device contains esketamine hydrochloride corresponding to 28 mg esketamine . the other ingredients are : citric acid monohydrate disodium edetate sodium hydroxide ( for ph adjustment ) water for injections what spravato looks like and contents of the pack spravato is a nasal spray solution . this medicine is a clear , colourless solution , provided in a single - use nasal spray device . spravato is available in pack sizes containing 1 , 2 , 3 , or 6 nasal spray devices . each nasal spray device is individually packaged in a sealed blister . not all pack sizes may be marketed .
zelboraf is an anticancer medicine that contains the active substance vemurafenib . it is used to treat adult patients with melanoma that has spread to other parts of the body or cannot be removed by surgery . it can only be used in patients whose cancer has a change ( mutation ) in the " braf " gene . this change may have led to the development of melanoma . zelboraf targets proteins made from this modified gene and slows down or stops the development of your cancer .
do not take zelboraf : if you are allergic to vemurafenib or any of the other ingredients of this medicine ( listed in section 6 of this leaflet ). symptoms of allergic reactions may include swelling of the face, lips or tongue, difficulty breathing, rash, or fainting sensation. warnings and precautions talk to your doctor before taking zelboraf. allergic reactions allergic reactions can happen while taking zelboraf and may be severe. stop taking zelboraf and get medical help immediately if you have any symptoms of an allergic reaction such as swelling of the face, lips or tongue, difficulty breathing, rash, or fainting sensation. severe skin reactions severe skin reactions can happen while taking zelboraf. stop taking zelboraf and talk to your doctor immediately if you get a skin rash with any of the following symptoms : blisters on your skin, blisters or sores in your mouth, peeling of your skin, fever, redness or swelling of your face, hands, or soles of your feet. previous history of cancer tell your doctor if you have had a different type of cancer than melanoma, as zelboraf may cause progression of certain types of cancers. radiation therapy reactions tell your doctor if you have had, or are going to have radiotherapy, as zelboraf may worsen radiation treatment side effects. heart disorder tell your doctor if you have a heart disorder, such as an alteration of the electrical activity of your heart called " qt prolongation ". your doctor will run tests to check that your heart is working properly before and during your treatment with zelboraf. if necessary, your doctor may decide to interrupt your treatment temporarily or stop it altogether. eye problems you should have your eyes examined by your doctor while you are taking zelboraf. tell your doctor immediately if you get eye pain, swelling, redness, blurred vision or other vision changes during your treatment. musculoskeletal / connective tissue disorder tell your doctor if you observe any unusual thickening of the palms of your hands accompanied by tightening of the fingers inward
always take this medicine exactly as your doctor has told you . check with your doctor if you are not sure . how many tablets should you take the recommended dose is 4 tablets twice a day ( a total of 8 tablets ). take 4 tablets in the morning . then take 4 tablets in the evening . if you experience side effects , your doctor may decide to carry on your treatment but lower your dose . always take zelboraf exactly as your doctor has told you . in case of vomiting , continue to take zelboraf as usual and do not take an additional dose . taking your tablets do not take zelboraf regularly on an empty stomach . swallow the tablets whole with a glass of water . do not chew or crush the tablets . if you take more zelboraf than you should if you take more zelboraf than you should , talk to your doctor immediately . taking too much zelboraf may increase the likelihood and severity of side effects . no cases of overdose have been observed with zelboraf . if you forget to take zelboraf if you forget a dose and it is more than 4 hours before your next dose , just take your dose as soon as you remember it . take the next dose at the usual time . if it is less than 4 hours before your next dose , skip the missed dose . then take the next dose at the usual time . do not take a double dose to make up for a forgotten dose . if you stop taking zelboraf it is important to keep taking zelboraf for as long as your doctor prescribes it for you . if you have any further questions on the use of this medicine , ask your doctor .
like all medicines, zelboraf can cause side effects, although not everybody gets them. serious allergic reactions if you get any of these : swelling of the face, lips or tongue difficulty breathing rash fainting sensation. call a doctor immediately. do not use any more zelboraf until you have spoken to a doctor. worsening of radiation treatment side effects can occur in patients who are treated with radiation before, during, or after zelboraf treatment. this can occur on the area that was treated with radiation, such as the skin, esophagus, bladder, liver, rectum, and lungs. tell your doctor immediately if you experience any of the following symptoms : skin rash, blistering, peeling or discoloration of the skin shortness of breath, which may be accompanied by a cough, fever or chills ( pneumonitis ) difficulty or pain when swallowing, chest pain, heartburn or acid reflux ( esophagitis ). please talk to your doctor as soon as possible if you notice any changes in your skin. side effects are listed below by frequency : very common ( may affect more than 1 in 10 people ): rash, itching, dry or scaly skin skin problems including warts a type of skin cancer ( cutaneous squamous cell carcinoma ) palmar plantar syndrome ( i. e. redness, skin peeling or blisters on hands and feet ) sunburn, being more sensitive to sunlight loss of appetite headache changes in the way things taste diarrhoea constipation feeling sick ( nausea ), vomiting hair loss joint or muscle pain, musculoskeletal pain pain in the extremities back pain feeling tired ( fatigue ) dizziness fever swelling usually in the legs ( peripheral oedema ) cough. common ( may affect up to 1 in 10 people ): types of skin cancers ( basal cell carcinoma, new primary melanoma ) thickening of tissues underneath the palm of the hand which may cause tightening of the fingers inward ; it can be disabling if severe inflammation of the eye (
keep this medicine out of the sight and reach of children . do not use zelboraf after the expiry date which is stated on the carton and the blister after exp . the expiry date refers to the last day of that month . store in the original package in order to protect from moisture . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help to protect the environment .
what zelboraf contains the active substance is vemurafenib . each film - coated tablet contains 240 milligrams ( mg ) of vemurafenib ( as a co - precipitate of vemurafenib and hypromellose acetate succinate ). the other ingredients are : tablet core : colloidal anhydrous silica , croscarmellose sodium , hydroxypropyl cellulose and magnesium stearate film - coating : iron oxide red , macrogol 3350 , polyvinyl alcohol , talc and titanium dioxide . what zelboraf looks like and contents of the pack zelboraf 240 mg film - coated tablets are pinkish white to orange white . they are oval with " vem " engraved on one side . they are available in aluminium perforated unit dose blisters in packs of 56 x 1 tablets .
duoplavin contains clopidogrel and acetylsalicylic acid ( asa ) and belongs to a group of medicines called antiplatelet medicinal products . platelets are very small structures in the blood which clump together during blood clotting . by preventing this clumping in some types of blood vessels ( called arteries ), antiplatelet medicinal products reduce the chances of blood clots forming ( a process called atherothrombosis ). duoplavin is taken by adults to prevent blood clots forming in hardened arteries which can lead to atherothrombotic events ( such as stroke , heart attack , or death ). you have been prescribed duoplavin in place of the two separate medicines , clopidogrel and asa , to help prevent blood clots because you have experienced a severe type of chest pain known as ' unstable angina ' or heart attack ( myocardial infarction ). for the treatment of this condition your doctor may have placed a stent in the blocked or narrowed artery to restore effective blood flow .
do not take duoplavin if you are allergic to clopidogrel, acetylsalicylic acid ( asa ) or any of the other ingredients of this medicine ( listed in section 6 ). if you are allergic to other products called non - steroidal anti - inflammatory products usually used to treat painful and / or inflammatory conditions of muscles or joints. if you have a medical condition that includes the combination of asthma, nasal discharge ( runny nose ) and polyps ( a type of growth in the nose ). if you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain. if you suffer from severe liver disease. if you suffer from severe kidney disease. if you are in your last trimester of pregnancy. warnings and precautions if any of the situations mentioned below apply to you, you should tell your doctor before taking duoplavin : if you have a risk of bleeding such as : - a medical condition that puts you at risk of internal bleeding ( such as a stomach ulcer ). - a blood disorder that makes you prone to internal bleeding ( bleeding inside any tissues, organs or joints of your body ). - a recent serious injury. - a recent surgery ( including dental ). - a planned surgery ( including dental ) in the next seven days. if you have had a clot in an artery of your brain ( ischaemic stroke ) which occurred in the last seven days. if you have kidney or liver disease. if you have a history of asthma or allergic reactions including allergy to any medicine used to treat your disease. if you have gout. if you drink alcohol, because of the increased risk of bleeding or gastrointestinal injury. if you have a condition known as glucose - 6 - phosphate dehydrogenase ( g6pd ) deficiency because of the risk of a particular form of anaemia ( low number of red blood cells ). while you are taking duoplavin : you should tell your doctor - if a surgery ( including dental ) is planned
always take this medicine exactly as your doctor or pharmacist has told you . check with your doctor or pharmacist if you are not sure . the recommended dose is one tablet of duoplavin per day to be taken orally with a glass of water , with or without food . you should take your medicine at the same time each day . depending on your condition , your doctor will determine the length of time for which you need to take duoplavin . if you have had a heart attack , it should be prescribed for at least four weeks . in any case , you should take it for as long as your doctor continues to prescribe it . if you take more duoplavin than you should contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding . if you forget to take duoplavin if you forget to take a dose of duoplavin , but remember within 12 hours of your usual time , take your tablet straightaway and then take your next tablet at the usual time . if you forget for more than 12 hours , simply take the next single dose at the usual time . do not take a double dose to make up for a forgotten tablet . for the 14 , 28 and 84 tablets pack sizes you can check the day on which you last took a tablet of duoplavin by referring to the calendar printed on the blister . if you stop taking duoplavin do not stop the treatment unless your doctor tells you so . contact your doctor before stopping or restarting your treatment . if you have any further questions on the use of this medicine , ask your doctor or pharmacist .
like all medicines, this medicine can cause side effects, although not everybody gets them. contact your doctor immediately if you experience : fever, signs of infection or extreme tiredness. these may be due to rare decrease of some blood cells. signs of liver problems such as yellowing of the skin and / or the eyes ( jaundice ), whether or not associated with bleeding which appears under the skin as red pinpoint dots, and / or confusion ( see section 2'warnings and precautions '). swelling in the mouth or skin disorders such as rashes and itching, blisters of the skin. these may be the signs of an allergic reaction. the most common side effect which has been seen with duoplavin is bleeding. bleeding may occur as bleeding in the stomach or bowels, bruising, haematoma ( unusual bleeding or bruising under the skin ), nose bleed, blood in the urine. in a small number of cases, bleeding in the eye, inside the head ( especially in elderly ), the lung or the joints has also been reported. if you experience prolonged bleeding when taking duoplavin if you cut or injure yourself, it may take longer than usual for bleeding to stop. this is linked to the way your medicine works as it prevents the ability of blood clots to form. for minor cuts and injuries 45 e. g., cutting yourself, shaving, this is usually of no concern. however, if you are concerned by your bleeding, you should contact your doctor straightaway ( see section 2'warnings and precautions '). other side effects include : common side effects ( may affect up to 1 in 10 people ): diarrhoea, abdominal pain, indigestion or heartburn. uncommon side effects ( may affect up to 1 in 100 people ): headache, stomach ulcer, vomiting, nausea, constipation, excessive gas in stomach or intestines, rashes, itching, dizziness, sensation of tingling and numbness. rare side effect ( may affect up to 1 in 1000 people ): vertigo, enlarged breasts in males
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the carton and on the blister , after exp . the expiry date refers to the last day of that month . store below 25 . do not use this medicine if you notice any visible sign of deterioration . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help to protect the environment .
what duoplavin contains duoplavin 75 mg / 75 mg film - coated tablets 46 the active substances are clopidogrel and acetylsalicylic acid ( asa ). each tablet contains 75 mg of clopidogrel ( as hydrogen sulphate ) and 75 mg of acetylsalicylic acid. the other ingredients are : - tablet core : mannitol ( e421 ), macrogol 6000, microcrystalline cellulose, low substituted hydroxypropylcellulose, maize starch, hydrogenated castor oil ( see section 2'duoplavin contains hydrogenated castor oil '), stearic acid and colloidal anhydrous silica - tablet coating : lactose monohydrate ( see section 2'duoplavin contains lactose '), hypromellose ( e464 ), titanium dioxide ( e171 ), triacetin ( e1518 ), yellow iron oxide ( e172 ) - polishing agent : carnauba wax duoplavin 75 mg / 100 mg film - coated tablets the active substances are clopidogrel and acetylsalicylic acid ( asa ). each tablet contains 75 mg of clopidogrel ( as hydrogen sulphate ) and 100 mg of acetylsalicylic acid. the other ingredients are : - tablet core : mannitol ( e421 ), macrogol 6000, microcrystalline cellulose, low substituted hydroxypropylcellulose, maize starch, hydrogenated castor oil ( see section 2'duoplavin contains hydrogenated castor oil '), stearic acid and colloidal anhydrous silica - tablet coating : lactose monohydrate ( see section 2'duoplavin contains lactose '), hypromellose ( e464 ), titanium dioxide ( e171 ), triacetin ( e1518 ), red iron oxide ( e172 ) - polishing agent : carnauba wax what
simbrinza contains two active substances , brinzolamide and brimonidine tartrate . brinzolamide belongs to a group of medicines called carbonic anhydrase inhibitors and brimonidine tartrate belongs to a group of medicines called alpha - 2 adrenergic receptor agonists . both substances work together to reduce pressure within the eye . simbrinza is used to lower pressure in the eyes in adult patients ( aged 18 years and over ) who have eye conditions known as glaucoma or ocular hypertension and whose high pressure in the eyes cannot be controlled effectively by one medicine alone .
do not use simbrinza - if you are allergic to brinzolamide or brimonidine tartrate or any of the other ingredients of this medicine ( listed in section 6 ) - if you are allergic to sulphonamides ( examples include medicines used to treat diabetes and infections and also diuretics ( water tablets )) - if you are taking a monoamine oxidase ( mao ) inhibitors ( examples include medicines to treat depression or parkinson's disease ) or certain antidepressants. you must inform your doctor if you are taking any antidepressant medicines - if you have severe kidney problems - if you have too much acidity in your blood ( a condition called hyperchloraemic acidosis ) - in babies and infants aged less than 2 years. warnings and precautions talk to your doctor, optometrist ( optician ) or pharmacist before using simbrinza if you have now or have had in the past : - liver problems - a type of high pressure in the eyes called narrow - angle glaucoma - dry eyes or cornea problems - coronary heart disease ( symptoms can include chest pain or tightness, breathlessness or choking ), heart failure, high or low blood pressure - depression - disturbed or poor blood circulation ( such as raynaud's disease, raynaud's syndrome or cerebral insufficiency ). if you wear soft contact lenses, do not use the drops with your lenses in. see section " wearing contact lenses - simbrinza contains benzalkonium chloride " below ). children and adolescents simbrinza is not intended for use by children and adolescents aged below 18 years because it has not been studied in this age group. it is particularly important that the medicine is not used in children under the age of 2 years ( see section'do not use simbrinza'above ) because it is unlikely to be safe. other medicines and simbrinza tell your doctor, optometrist ( optician ) or pharmacist if you are using, have recently used, or might use any other medicines.
always use this medicine exactly as your doctor, optometrist ( optician ) or pharmacist has told you. check with your doctor, optometrist ( optician ) or pharmacist if you are not sure. only use simbrinza for your eyes. do not swallow or inject. the recommended dose is one drop in the affected eye or eyes two times a day. use at the same time each day. how to use wash your hands before you start. 1 2 shake well before use. twist off the bottle cap. after the cap is removed, if the tamper evident snap collar is loose, remove it before using the medicine. do not touch the dropper with your fingers when opening or closing the bottle. it could infect the drops. hold the bottle, pointing down, between your thumb and fingers. tilt your head back. pull down your lower eyelid with a clean finger, until there is a'pocket'between the eyelid and your eye. the drop will go in here ( picture 1 ). bring the bottle tip close to the eye. do this in front of a mirror if it helps. do not touch your eye or eyelid, surrounding areas or other surfaces with the dropper. it could infect the drops. gently press on the base of the bottle to release one drop of simbrinza. do not squeeze the bottle : it is designed so that a gentle press on the bottom is all that it needs ( picture 2 ). to reduce the amount of medicine that could come into the rest of the body after application of the eye drop, close your eye and apply gentle pressure to the corner of the eye next to the nose with a finger for at least 2 minutes. if you use drops in both eyes, repeat the steps for your other eye. it is not necessary to close and shake the bottle before you apply the drop in your other eye. close the bottle cap firmly immediately after use. if you are using other eye drops as well as simbrinza, wait at least five minutes between using simbrinza and the other drops. if a drop misses your eye, try again. if you use more simbrinza than you should
like all medicines, this medicine can cause side effects, although not everybody gets them. if you experience any of the following side effects, please stop using this medicine and seek immediate medical attention as these could be signs of a reaction to the medicine. the frequency of an allergic reaction to the medicine is not known ( frequency cannot be estimated from the available data ). severe skin reactions, including rash or redness or itching on your body or eyes trouble breathing chest pain, irregular heart beat contact your doctor immediately if you develop extreme tiredness or dizziness. the following side effects have been observed with simbrinza and other medicines containing brinzolamide or brimonidine alone. common side effects ( may affect up to 1 in 10 people ) effects in the eye : allergic conjunctivitis ( eye allergy ), eye surface inflammation, eye pain, eye discomfort, blurred or abnormal vision, eye redness general side effects : drowsiness, dizziness, bad taste in mouth, dry mouth uncommon side effects ( may affect up to 1 in 100 people ) effects in the eye : eye surface damage with loss of cells, inflammation of the eyelid, deposits on the eye surface, sensitivity to light, swelling of the eye ( affecting the cornea or eyelid ), dry eye, eye discharge, watery eye, eyelid redness, abnormal or decreased sensation in eye, tired eye, reduced vision, double vision, product particles in eyes. general side effects : decreased blood pressure, chest pain, irregular heartbeat, slow or fast heart rate, palpitations, difficulty sleeping ( insomnia ), nightmares, depression, generalised weakness, headache, dizziness, nervousness, irritability, general feeling of being unwell, memory loss, shortness of breath, asthma, nose bleeds, cold symptoms, dry nose or throat, sore throat, throat irritation, cough, runny nose, stuffy nose, sneezing, sinus infection, chest congestion, ringing in ear, indigestion, intestinal gas or stomach ache, nausea, diarrho
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the bottle and the carton after " exp ". the expiry date refers to the last day of that month . this medicine does not require any special storage conditions . throw away the bottle 4 weeks after first opening to prevent infections and use a new bottle . write down the date of opening on the carton in the space provided . do not throw away any medicines via wastewater or household waste . ask your optometrist ( optician ) or pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what simbrinza contains - the active substances are brinzolamide and brimonidine tartrate . one ml of suspension contains 10 mg of brinzolamide and 2 mg of brimonidine tartrate equivalent to 1 . 3 mg brimonidine . - the other ingredients are benzalkonium chloride ( see section 2 " wearing contact lenses - simbrinza contains benzalkonium chloride "), propylene glycol , carbomer 974p , boric acid , mannitol , sodium chloride , tyloxapol , hydrochloric acid and / or sodium hydroxide and purified water . tiny amounts of hydrochloric acid and / or sodium hydroxide are added to keep acidity levels ( ph levels ) normal . what simbrinza looks like and contents of the pack simbrinza eye drops , suspension , is a liquid ( white - to - off - white suspension ) supplied in a pack containing one or three 5 ml plastic bottles with screw cap . not all pack sizes may be marketed .
what filgrastim ratiopharm is filgrastim ratiopharm contains the active substance filgrastim . filgrastim is a protein produced by biotechnology in bacteria called escherichia coli . it belongs to a group of proteins called cytokines and is very similar to a natural protein ( granulocyte - colony stimulating factor [ g - csf ]) produced by your own body . filgrastim stimulates the bone marrow ( the tissue where new blood cells are made ) to produce more blood cells , especially certain types of white cells . white cells are important as they help your body fight infection . what filgrastim ratiopharm is used for your doctor has prescribed filgrastim ratiopharm for you to help your body make more white blood cells . your doctor will tell you why you are being treated with filgrastim ratiopharm . filgrastim ratiopharm is useful in several different conditions which are : - chemotherapy , - bone marrow transplantation , - severe chronic neutropenia , - neutropenia in patients with hiv infection , - peripheral blood stem cell mobilisation .
do not use filgrastim ratiopharm - if you are allergic ( hypersensitive ) to filgrastim or to any of the other ingredients of filgrastim ratiopharm . take special care with filgrastim ratiopharm - if you experience a cough , fever and difficulty breathing . it could be a consequence of a pulmonary disorder ( see section " 4 . possible side effects "). - if you have sickle cell disease ; or 57 - if you get left upper abdominal pain or pain at the tip of your shoulder . it could be a consequence of a spleen disorder ( see section " 4 . possible side effects "). you will need to have regular blood tests whilst being treated with filgrastim ratiopharm to count the number of neutrophils and other white blood cells in your blood . this will tell your doctor how well the treatment is working and will also indicate if treatment needs to be continued . using other medicines please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription . pregnancy and breast - feeding ask your doctor or pharmacist for advice before taking any medicine . filgrastim ratiopharm has not been tested in pregnant women . it is important to tell your doctor if you are pregnant , think you may be pregnant or plan to get pregnant , as the doctor may decide that you should not use this medicine . it is unknown whether filgrastim passes over to the breast milk . therefore , your doctor may decide that you should not use this medicine if you are breast - feeding . driving and using machines if you experience fatigue , do not drive or use any tools or machines . important information about some of the ingredients of filgrastim ratiopharm this medicine contains sorbitol ( a type of sugar ). if you have been told by your doctor that you have an intolerance to some sugars , contact your doctor before taking this medicine .
always use filgrastim ratiopharm exactly as your doctor has told you. you should check with your doctor or pharmacist if you are not sure. the usual dose is... the amount of filgrastim ratiopharm you need will depend on the condition you are taking filgrastim ratiopharm for and on your bodyweight. your doctor will tell you when to stop using filgrastim ratiopharm. it is quite normal to have a number of courses of filgrastim ratiopharm treatment. filgrastim ratiopharm and chemotherapy the usual dose is 0. 5 million international units ( miu ) per kilogram of bodyweight each day. for example, if you weigh 60 kg your daily dose will be 30 million international units ( miu ). your treatment will usually last for about 14 days. in some disease types however, longer treatment lasting up to about one month may be required. filgrastim ratiopharm and bone marrow transplantation the usual starting dose is 1 million international units ( miu ) per kilogram of bodyweight each day. for example, if you weigh 60 kg your daily dose will be 60 million international units ( miu ). you will normally receive your first dose of filgrastim ratiopharm at least 24 hours after your chemotherapy but within 24 hours of receiving your bone marrow transfusion. your doctor will test your blood daily to see how well the treatment is working and to find the dose that is best for you. the treatment will be discontinued when white cells in your blood reach a certain number. filgrastim ratiopharm and severe chronic neutropenia the usual starting dose is between 0. 5 million and 1. 2 million international units ( miu ) per kilogram bodyweight each day in a single or divided dose. your doctor will then test your blood to see how well your treatment is working and to find the dose that is best for you. long - term treatment with filgrastim ratiopharm is required for neutropenia. filgrastim ratiopharm and neutropenia in patients with hiv infection the usual starting dose is between 0. 1 and 0. 4 million international units ( miu ) per kilogram bodyweight each day. your doctor will test your blood at regular intervals
"). - if you have sickle cell disease ; or 57 - if you get left upper abdominal pain or pain at the tip of your shoulder. it could be a consequence of a spleen disorder ( see section " 4. possible side effects "). you will need to have regular blood tests whilst being treated with filgrastim ratiopharm to count the number of neutrophils and other white blood cells in your blood. this will tell your doctor how well the treatment is working and will also indicate if treatment needs to be continued. using other medicines please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. pregnancy and breast - feeding ask your doctor or pharmacist for advice before taking any medicine. filgrastim ratiopharm has not been tested in pregnant women. it is important to tell your doctor if you are pregnant, think you may be pregnant or plan to get pregnant, as the doctor may decide that you should not use this medicine. it is unknown whether filgrastim passes over to the breast milk. therefore, your doctor may decide that you should not use this medicine if you are breast - feeding. driving and using machines if you experience fatigue, do not drive or use any tools or machines. important information about some of the ingredients of filgrastim ratiopharm this medicine contains sorbitol ( a type of sugar ). if you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. 3. how to use filgrastim ratiopharm always use filgrastim ratiopharm exactly as your doctor has told you. you should check with your doctor or pharmacist if you are not sure. the usual dose is... the amount of filgrastim ratiopharm you need will depend on the condition you are taking filgrastim ratiopharm for and on your bodyweight. your doctor will tell you when to stop using filgrastim ratiopharm. it is quite normal to have a number of courses of filgrastim ratiopharm treatment. filgrastim ratiopharm and chemotherapy the usual dose is 0. 5 million international units ( miu ) per
keep out of the reach and sight of children . do not use filgrastim ratiopharm after the expiry date which is stated on the outer carton and on the pre - filled syringe after exp . the expiry date refers to the last day of that month . store in a refrigerator ( 2 8 ). do not use filgrastim ratiopharm if you notice it is cloudy or there are particles in it . medicines should not be disposed of via wastewater or household waste . ask your pharmacist how to dispose of medicines no longer required . these measures will help to protect the environment .
what filgrastim ratiopharm contains - the active substance is filgrastim . each ml of solution for injection or infusion contains 60 million international units [ miu ] ( 600 Âµicrogram ) of filgrastim . filgrastim ratiopharm 30 miu / 0 . 5 ml : each pre - filled syringe contains 30 million international units [ miu ] ( 300 microgram ) of filgrastim in 0 . 5 ml solution . filgrastim ratiopharm 48 miu / 0 . 8 ml : each pre - filled syringe contains 48 million international units [ miu ] ( 480 microgram ) of filgrastim in 0 . 8 ml solution . - the other ingredients are : sodium hydroxide , glacial acetic acid , sorbitol , polysorbate 80 , water for injections . you will find detailed information about the ingredient sorbitol ( a sugar ) in section 2 . under the heading " important information about some of the ingredients of filgrastim ratiopharm ". what filgrastim ratiopharm looks like and contents of the pack filgrastim ratiopharm is a solution for injection or infusion in a pre - filled syringe . filgrastim ratiopharm is a clear and colourless solution . each pre - filled syringe contains 0 . 5 ml or 0 . 8 ml of solution . filgrastim ratiopharm are supplied in packs of 1 , 5 or 10 pre - filled syringes or multipacks of 10 ( 2 packs of 5 ) pre - filled syringes . not all pack sizes may be marketed .
what riluzole zentiva is the active substance in riluzole zentiva is riluzole which acts on the nervous system . what riluzole zentiva is used for riluzole zentiva is used in patients with amyotrophic lateral sclerosis ( als ). als is a form of motor neurone disease where attacks of the nerve cells responsible for sending instructions to the muscles lead to weakness , muscle waste and paralysis . the destruction of nerve cells in motor neurone disease may be caused by too much glutamate ( a chemical messenger ) in the brain and spinal cord . riluzole zentiva stops the release of glutamate and this may help in preventing the nerve cells being damaged . please consult your doctor for more information about als and the reason why this medicine has been prescribed for you .
do not take riluzole zentiva - if you are allergic to riluzole or any of the other ingredients of this medicine ( listed in section 6 ), - if you have any liver disease or increased blood levels of some enzymes of the liver ( transaminases ), - if you are pregnant or breast - feeding . warnings and precautions talk to your doctor before taking riluzole zentiva : - if you have any liver problems : yellowing of your skin or the white of your eyes ( jaundice ), itching all over , feeling sick , being sick - if your kidneys are not working very well - if you have any fever : it may be due to a low number of white blood cells which can cause an increased risk of infection if any of the above applies to you , or if you are not sure , tell your doctor who will decide what to do . children and adolescents if you are less than 18 years of age , the use of riluzole zentiva is not recommended because there is no information available in this population . other medicines and riluzole zentiva tell your doctor if you are taking , have recently taken or might take any other medicines . pregnancy , breast - feeding and fertility you must not take riluzole zentiva if you are or think you may be pregnant , or if you are breast - feeding . if you think you may be pregnant , or if you intend to breast - feed , ask your doctor for advice before taking riluzole zentiva . driving and using machines you can drive or use any tools or machines , unless you feel dizzy or light headed after taking this medicine .
always take this medicine exactly as your doctor has told you . check with your doctor or pharmacist if you are not sure . the recommended dose is one tablet , twice a day . the tablets should be taken by mouth , every 12 hours , at the same time of the day each day ( e . g . in the morning and evening ). if you take more riluzole zentiva than you should if you take too many tablets , contact your doctor or the nearest hospital emergency department immediately . if you forget to take riluzole zentiva if you forget to take your tablet , leave out that dose completely and take the next tablet at the usual time . do not take a double dose to make up for a forgotten tablet . if you have any further questions on the use of this medicine , ask your doctor or pharmacist .
like all medicines , this medicine can cause side effects , although not everybody gets them . important tell your doctor immediately - if you experience any fever ( increase in temperature ) because riluzole zentiva may cause a decrease in the number of white blood cells . your doctor may want to take a blood sample to check the number of white blood cells , which are important in fighting infections . - if you experience any of the following symptoms : yellowing of your skin or the white of your eyes ( jaundice ), itching all over , feeling sick , being sick , as this may be signs of liver disease ( hepatitis ). your doctor may do regular blood tests while you are taking riluzole zentiva to make sure that this does not occur . - if you experience cough or difficulties in breathing , as this may be a sign of lung disease ( called interstitial lung disease ). other side effects very common side effects ( may affect more than 1 in 10 people ) of riluzole zentiva are : - tiredness - feeling sick - increased blood levels of some enzymes of the liver ( transaminases ). common side effects ( may affect up to 1 in 10 people ) of riluzole zentiva are : - dizziness - numbness or tingling of the mouth - vomiting - sleepiness - increase in heart beat - diarrhoea - headache - abdominal pain - pain uncommon side effects ( may affect up to 1 in 100 people ) of riluzole zentiva are : - anaemia - allergic reactions - inflammation of the pancreas ( pancreatitis ). reporting of side effects if you get any side effects , talk to your doctor or pharmacist . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
what riluzole zentiva contains - the active substance is riluzole . - the other ingredients are : core : anhydrous dibasic calcium phosphate , micro crystalline cellulose , anhydrous colloidal silica , magnesium stearate , croscarmellose sodium ; coating : hypromellose , macrogol 6000 , titanium dioxide ( e171 ). what riluzole zentiva looks like and content of the pack the tablets are film - coated , capsule - shaped and white . each tablet contains 50 mg of riluzole and is engraved with " rpr 202 " on one side . riluzole zentiva is available in a pack of 28 , 56 , 98 , 112 or 168 tablets to be taken orally . not all pack sizes may be marketed .
emgality contains galcanezumab , a medicine that stops the activity of a naturally occurring substance in the body called calcitonin gene - related peptide ( cgrp ). people with migraine may have increased levels of cgrp . emgality is used to prevent migraine in adult patients who have at least 4 migraines days per month . emgality can reduce the frequency of migraine headache and improve your quality of life . it starts working in about a week .
do not use emgality : - if you are allergic to galcanezumab or any of the other ingredients of this medicine ( listed in section 6 ). warnings and precautions talk to your doctor , pharmacist or nurse before or during treatment with emgality if : - you have a serious cardiovascular disease . emgality has not been studied in patients with serious cardiovascular diseases . look out for allergic reactions emgality can potentially cause serious allergic reactions . you must look out for signs of these reactions while you are using emgality . stop using emgality and tell your doctor or seek medical help 40 immediately if you notice any signs of a serious allergic reaction . such signs are listed under " serious side effects " in section 4 . children and adolescents this medicine should not be given to children and adolescents under 18 years of age because it has not been studied in this age group . other medicines and emgality tell your doctor , pharmacist or nurse if you are using , have recently used or might use any other medicines . pregnancy and breast - feeding if you are a woman able to have children , you are advised to avoid becoming pregnant while using emgality . if you are pregnant , think you may be pregnant or are planning to have a baby , ask your doctor for advice before taking this medicine . it is preferable to avoid the use of emgality in pregnancy as the effects of this medicine in pregnant women are not known . if you are breast - feeding or are planning to breast - feed , talk to your doctor before using this medicine . you and your doctor should decide if you should breast feed and use emgality . driving and using machines galcanezumab could have a minor effect on your ability to drive and use machines . some patients have had vertigo whilst using emgality . emgality contains sodium this medicine contains less than 1 mmol sodium ( 23 mg ) per 120 mg dose , that is to say it is essentially " sodium - free ".
always use this medicine exactly as your doctor , pharmacist or nurse has told you . check with your doctor , pharmacist or nurse if you are not sure . emgality pre - filled pen is for single use only and contains one dose of emgality ( 120 mg ). - the first time you receive emgality your doctor or nurse will inject two pens ( total 240 mg ). - after the first dose , you will use one pen ( 120 mg ) every month . your doctor will decide for how long you should use emgality . emgality is given by injection under your skin ( subcutaneous injection ). you and your doctor or nurse should decide if you can inject emgality yourself . it is important not to try to inject yourself until you have been trained by your doctor or nurse . a caregiver may also give you your emgality injection after proper training . the pen must not be shaken . read the " instructions for use " for the pen carefully before using emgality . if you use more emgality than you should if you have injected more emgality than you should , e . g . if after the first dose of 240 mg , you have injected it twice in a single month , or if anyone else has accidentally used emgality , contact your doctor immediately . if you forget to use emgality do not take a double dose to make up for forgotten injection if you have forgotten to inject a dose of emgality , inject the missed dose as soon as possible and then inject the next dose after a month from that date . if you stop using emgality you should not stop using emgality without speaking to your doctor first . if you have any further questions on the use of this medicine , ask your doctor , pharmacist or nurse .
like all medicines , this medicine can cause side effects , although not everybody gets them . serious side effects allergic reactions with emgality are usually mild to moderate ( such as rash or itching ). serious allergic reactions may occur rarely ( may affect up to 1 in 1 , 000 people ) and the signs may include : - difficulty breathing or swallowing , - low blood pressure , which can cause dizziness or light - headedness , - swelling of the neck , face , mouth , lips , tongue or throat which may develop rapidly , - severe itching of the skin , with a red rash or raised bumps . tell your doctor or get emergency medical help straight away if you notice any of those signs . other side effects that have been reported . very common side effects ( may affect more than 1 in 10 people ): - injection site pain - injection site reactions ( e . g . red skin , itching , bruising , swelling ) common side effects ( may affect up to 1 in 10 people ): - vertigo ( a feeling of dizziness or " spinning ") - constipation - itching - rash uncommon side effects ( may affect up to 1 in 100 people ): - hives ( raised itchy areas of skin ) reporting of side effects if you get any side effects , talk to your doctor , pharmacist or nurse . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the label and on the carton after " exp ." the expiry date refers to the last day of that month . store in a refrigerator ( 2 to 8 ). do not freeze . store in the original package in order to protect from light . emgality may be stored unrefrigerated for single period up to 7 days when stored at temperatures up to 30 . if the pen is stored at a higher temperature or for a longer period it must be discarded . do not use this medicine if you notice that the pen is damaged , or the medicine is cloudy or has particles in it . do not throw away any medicines via wastewater or household waste . ask your doctor , nurse or pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what emgality contains the active substance is galcanezumab . each pre - filled pen contains 120 mg of galcanezumab in 1 ml solution . the other ingredients are : l - histidine , l - histidine hydrochloride monohydrate , polysorbate 80 , sodium chloride and water for injections . what emgality looks like and contents of the pack emgality is a solution for injection in a clear glass syringe . its colour may vary from colourless to slightly yellow . the syringe is encased in a disposable , single - dose pen . pack sizes of 1 , 2 or 3 pre - filled pens . not all pack sizes may be marketed .
defitelio is a medicine that contains the active substance defibrotide . it is used to treat a condition called hepatic veno - occlusive disease , in which the blood vessels in the liver become damaged and obstructed by blood clots . this can be caused by medicines that are given prior to a stem cell transplantation . defibrotide works by protecting the cells of the blood vessels and preventing or breaking down the blood clots . this medicine can be used in adults , and in adolescents , children and infants over one month of age .
do not use defitelio if you are allergic to defibrotide or any of the other ingredients of this medicine ( listed in section 6 ) if you are using other medicines to break down blood clots such as tissue plasminogen activator warnings and precautions talk to your doctor before using defitelio : if you are taking medicine that increases the risk of bleeding if you have heavy bleeding and need a blood transfusion if you are undergoing surgery if you have problems with blood circulation because your body cannot maintain a constant blood pressure . children and adolescents defitelio is not recommended in children less than 1 month of age . other medicines and defitelio tell your doctor if you are taking medicines to prevent blood clotting such as acetylsalicylic acid , heparins , warfarin , dabigatran , rivaroxaban or apixaban or if you are taking anti - inflammatory medicines ( e . g ., ibuprofen , naproxen , diclofenac and other non - steroidal anti - inflammatory medicines ). pregnancy and breast - feeding do not use defitelio if you are pregnant unless your disease requires treatment with defitelio . if you are sexually active and you or your partner could become pregnant , you both must use effective contraception during treatment with defitelio and for 1 week after stopping the treatment . driving and using machines it is not expected that defitelio will affect your ability to drive and operate machines . defitelio contains sodium this medicine contains less than 23 mg of sodium , which means it is essentially " sodium - free ".
the treatment with defitelio can be initiated and continuously supervised only by an experienced doctor in a hospital or in a specialised centre for stem cells transplantation . it will be slowly injected ( over a 2 - hour period ) into one of your veins . this is called an ' intravenous infusion ' or drip . you will receive this treatment four times a day for at least 21 days or until your symptoms resolve . the recommended dose in children from one month to 18 years of age is the same as in adults . if a dose of defitelio has been forgotten as you will be given this medicine by a doctor or a nurse it is unlikely that a dose will be missed . however , tell your doctor or healthcare professional if you think that a dose has been forgotten . you must not be given a double dose to make up for a missed dose . if you have any further questions on the use of this medicine , ask your doctor , nurse or pharmacist .
like all medicines , defitelio can cause side effects , although not everybody gets them . for patients treated with defitelio the following side effects were reported . if you experience any of these side effects , you should contact your doctor immediately . very common ( may affect more than 1 in 10 people ) low blood pressure common ( may affect up to 1 in 10 people ) bleeding in general bleeding from the nose bleeding in the brain bleeding in the gut vomiting blood bleeding in the lungs bleeding from the infusion line blood in the urine bleeding from the mouth bleeding into the skin coagulopathy ( disturbance of blood clotting ) nausea vomiting diarrhoea rash itching fever uncommon ( may affect up to 1 in 100 people ) bleeding from the eye blood in the stool bleeding at the site of injection localized blood collection out of the vessel ( hematoma ) in the brain haemothorax ( accumulation of blood in the area between the heart and the lung ) bruising severe allergic reaction ( you might experience swelling of the hands , face , lips , tongue or throat , difficulty in breathing ). children and adolescents side effects in children ( 1 month to 18 years old ) are expected to be similar in type , severity and frequency and no other special precautions are needed . reporting of side effects if you get any side effects , talk to your doctor . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v by reporting side effects you can help provide more information on the safety of this medicine .
keep this medicine out of the sight and reach of children . do not use defitelio after the expiry date which is stated on the carton and vial label after exp . the expiry date refers to the last day of that month . do not freeze . once diluted for use the infusion storage should not exceed 24 hours at 2 - 8 unless dilution has taken place in controlled and validated aseptic conditions . defitelio should not be used if the solution is cloudy or contains particles . do not throw away any medicines via wastewater . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what defitelio contains the active substance is defibrotide . each 2 . 5 ml vial contains 200 mg defibrotide and each ml solution contains 80 mg defibrotide . the other ingredients are sodium citrate dihydrate , hydrochloric acid and sodium hydroxide ( both for ph - adjustment ) and water for injections ( see section 2 ' defitelio contains sodium '). what defitelio looks like and contents of the pack defitelio is a clear light yellow to brown concentrate for solution for infusion , free from particulate matter or turbidity . one carton contains 10 glass vials with 2 . 5 ml of concentrate each .
daklinza contains the active ingredient daclatasvir . it is used to treat adults with hepatitis c , an infectious disease that affects the liver , caused by the hepatitis c virus . this medicine works by stopping the hepatitis c virus from multiplying and infecting new cells . this lowers the amount of hepatitis c virus in your body and removes the virus from your blood over a period of time . daklinza must always be used together with other medicines against hepatitis c infection and must never be used by itself . it is very important that you also read the package leaflets for the other medicines that you will be taking with daklinza . if you have any questions about your medicines , please ask your doctor or pharmacist .
do not take daklinza if you are allergic to daclatasvir or any of the other ingredients of this medicine ( listed in section 6 of this leaflet ) if you are taking ( by mouth or other ways that affect the whole body ) any of the following medicines - phenytoin, carbamazepine, oxcarbazepine or phenobarbital, used to treat epileptic seizures - rifampicin, rifabutin or rifapentine, antibiotics used to treat tuberculosis - dexamethasone, a steroid used to treat allergic and inflammatory diseases - medicines containing st. john's wort ( hypericum perforatum, a herbal preparation ). these medicines lower the effect of daklinza and may result in your treatment not working. if you take any of these medicines, tell your doctor immediately. since daklinza must always be used in combination with other medicines against hepatitis c infection, please make sure that you read the " do not take " section of the package leaflets for these medicines. if you are unsure of any information in the package leaflets, please contact your doctor or pharmacist. warnings and precautions talk to your doctor or pharmacist before taking daklinza. tell your doctor if any of the following applies : you currently take, or have taken in the last few months, the medicine amiodarone to treat irregular heartbeats ( your doctor may consider alternative treatments if you have taken this medicine ) you have a current or previous infection with the hepatitis b virus, since your doctor may want to monitor you more closely your liver is damaged and not functioning properly ( decompensated liver disease ) you have diabetes. you may need closer monitoring of your blood glucose levels and / or adjustment of your diabetes medication after starting daklinza. some diabetic patients have experienced low sugar levels in the blood ( hypoglycaemia ) after starting treatment with medicines like daklinza. tell your doctor immediately if you are taking any medicines for heart problems and during treatment you experience : short
always take this medicine exactly as your doctor has told you. check with your doctor or pharmacist if you are not sure. recommended dose the recommended dose of daklinza is 60 mg once a day. swallow the tablet whole. do not chew or crush the tablet as it has a very unpleasant taste. daklinza can be taken with or without a meal. some other medicines can interact with daklinza, affecting the levels of daklinza in your body. if you are taking any of these medicines, your doctor may decide to change your daily dose of daklinza to ensure that the treatment is safe and effective for you. since daklinza must always be used with other medicines against hepatitis c infection, please read the package leaflets for these medicines. if you have any questions, ask your doctor or pharmacist. how long to take daklinza make sure you take daklinza for as long as your doctor has told you to take it. the duration of your treatment with daklinza will be either 12 or 24 weeks. the duration of your treatment will depend on whether you have previously received treatment for your hepatitis c 49 infection, the condition of your liver, and what other medicines you will take with daklinza. you may have to take your other medicines for different lengths of time. if you take more daklinza than you should if you accidentally take more daklinza tablets than your doctor recommended, contact your doctor at once or contact the nearest hospital for advice. keep the tablet blister with you so that you can easily describe what you have taken. if you forget to take daklinza it is important not to miss a dose of this medicine. if you do miss a dose : and you notice within 20 hours of the time you usually take daklinza, you must take the tablet as soon as possible. then take the next dose at your usual time. and you notice 20 hours or more after the time you usually take daklinza, wait and take the next dose at your usual time. do not take a double dose ( two doses close together ). if you stop taking daklinza it is important that you continue to take daklinza
like all medicines, this medicine can cause side effects, although not everybody gets them. when daklinza is used together with sofosbuvir ( without ribavirin ), the following side effects have been reported. very common ( may affect more than 1 in 10 people ): headache, fatigue common ( may affect up to 1 in 10 people ): difficulty sleeping dizziness migraine nausea ( feeling sick ), diarrhoea, abdominal pain joint pain, aching or tender muscles, not caused by exercise when daklinza is used together with sofosbuvir and ribavirin, the following side effects have been reported. very common ( may affect more than 1 in 10 people ): headache, nausea ( feeling sick ), fatigue reduction in red blood cells ( anaemia ) common ( may affect up to 1 in 10 people ): decreased appetite difficulty sleeping, irritability dizziness migraine shortness of breath, cough, nasal congestion ( blocked nose ) hot flush dry skin, unusual hair loss or thinning, rash, itching 50 diarrhoea, vomiting, abdominal pain, constipation, heartburn, excessive gas in the stomach or bowel dry mouth joint pain, aching or tender muscles, not caused by exercise when daklinza is used together with peginterferon alfa and ribavirin the reported side effects are the same as those listed in the package leaflets for these medicines. the most common of these side effects are listed below. very common ( may affect more than 1 in 10 people ): decreased appetite difficulty sleeping headache shortness of breath nausea fatigue flu - like illness, fever itching, dry skin, unusual hair loss or thinning, rash diarrhoea cough joint pain, aching or tender muscles, not caused by exercise, unusual weakness irritability reduction in red blood cells ( anaemia ), reduction in white blood cells reporting of side effects if you get any side effects, talk to your doctor or pharmacist. this includes any possible side effects not listed in this leaflet. you can also report side effects directly via the national reporting system listed in appendix v
what daklinza contains the active substance is daclatasvir . each film - coated tablet contains 30 mg or 60 mg daclatasvir ( as dihydrochloride ) the other ingredients are - tablet core : anhydrous lactose ( see section 2 ), microcrystalline cellulose , croscarmellose sodium , silicon dioxide ( e551 ) and magnesium stearate - film - coating : hypromellose , titanium dioxide ( e171 ), macrogol 400 , indigo carmine aluminum lake ( e132 ), yellow iron oxide ( e172 ) what daklinza looks like and contents of the pack 51 daklinza 30 mg : the film - coated tablet is green , biconvex , pentagonal shape with " bms " debossed on one side and " 213 " on the other side . daklinza 60 mg : the film - coated tablet is light green , biconvex , pentagonal shape with " bms " debossed on one side and " 215 " on the other side . daklinza 30 mg and 60 mg film - coated tablets are available in packs of 28 tablets in non - perforated calendar blisters and perforated unit dose blisters . not all packages may be marketed in your country .
proquad is a vaccine containing measles , mumps , rubella , and chickenpox ( varicella ) viruses that have been weakened . when a person is given the vaccine , the immune system ( the body ' s natural defences ) will make antibodies against the measles , mumps , rubella , and varicella viruses . the antibodies help protect against diseases caused by these viruses . proquad is given to help protect your child against measles , mumps , rubella , and chickenpox ( varicella ). the vaccine may be administered to persons from 12 months of age . proquad may also be administered to infants from 9 months of age under special circumstances ( to conform with national vaccination schedules , outbreak situations , or travel to a region with high prevalence of measles ). although proquad contains live viruses , they are too weak to cause measles , mumps , rubella , or chickenpox ( varicella ) in healthy people .
do not use proquad if the person to be vaccinated is allergic to any varicella vaccine or measles, mumps, or rubella vaccine or to any of the ingredients of this vaccine ( listed in section 6 ) including neomycin. if the person to be vaccinated has a blood disorder or any type of cancer that affects the immune system. if the person to be vaccinated is receiving treatment or taking medications that may weaken the immune system ( except low - dose corticosteroid therapy for asthma or replacement therapy ). if the person to be vaccinated has a weakened immune system because of a disease ( including aids ). if the person to be vaccinated has a family history of congenital or hereditary immunodeficiency, unless the immune competence of this person is demonstrated. if the person to be vaccinated has active untreated tuberculosis. if the person to be vaccinated has any illness with fever higher than 38. 5 ; however, low - grade fever itself is not a reason to delay vaccination. if the person to be vaccinated is pregnant ( in addition, pregnancy should be avoided for 1 month after vaccination, see pregnancy and breast - feeding ). warnings and precautions if the person to be vaccinated has experienced any of the following, talk to the doctor or pharmacist before proquad is given : an allergic reaction to eggs or anything that contained egg. a history or family history of allergies or of convulsions ( fits ). a side effect after vaccination with measles, mumps, and / or rubella - containing vaccines that involved easy bruising or bleeding for longer than usual. an infection with human immunodeficiency virus ( hiv ) without showing symptoms of hiv disease. however, vaccination may be less effective than for uninfected persons ( see do not use proquad ). if you have a blood clotting disorder or low levels of platelets in your blood, the injection will be given under the skin. in rare circumstances, it is possible to catch chickenpox
proquad should be injected into the muscle or under the skin either in the area of the outer thigh or of the upper arm . usually for injections into the muscle the thigh area is preferred in young children , whereas for older individuals the upper arm area is the preferred injection site . if the person to be vaccinated has a blood clotting disorder or low levels of platelets , the vaccine should be given under the skin because bleeding may occur following administration into the muscle . proquad is not to be injected directly into any blood vessel . proquad is given by injection as follows : infants between 9 and 12 months of age : proquad may be administered from 9 months of age . to ensure optimal protection against chickenpox and measles , two doses of proquad should be given at least three months apart . individuals 12 months of age and older : to ensure optimal protection against chickenpox , two doses of proquad should be given at least one month apart . the appropriate time and number of injections will be determined by your doctor in accordance with official recommendations . reconstitution instructions intended for medical and healthcare professionals are included at the end of the leaflet 44 if you forget to take proquad your doctor will decide when to give the missed dose .
like all vaccines and medicines, this vaccine can cause side effects, although not everybody gets them. allergic reactions ( hives ) may occur. some of these reactions may be serious and may include difficulty in breathing or swallowing. if the vaccinated person has an allergic reaction, call your doctor right away. other side effects have been reported following administration of proquad and some of these were serious. these included : uncommon ( may affect up to 1 in 100 people ): seizures with a fever. rare ( may affect up to 1 in 1, 000 people ): bronchiolitis ( difficulty breathing with or without cough ); unsteadiness with walking. the following other side effects reported with the use of proquad were : very common ( may affect more than 1 in 10 people ): injection site complaints including pain / tenderness / soreness, redness, fever ( 38. 9 or higher ); common ( may affect up to 1 in 10 people ): injection site complaints including swelling or bruising ; irritability ; rash ( including measles - like rash, varicella - like rash, and injection - site rash ); upper respiratory infection ; vomiting and diarrhoea. other side effects have been reported with the use of at least one of the following : proquad, previous formulations of monovalent and of the combined measles, mumps, and rubella vaccines manufactured by merck & co., inc., or varicella vaccine live ( oka / merck ). these adverse events include : uncommon ( may affect up to 1 in 100 people ): cough. rare ( may affect up to 1 in 1, 000 people ): skin infection ; chickenpox ( varicella ). not known ( frequency cannot be estimated from the available data ): unusual bleeding or bruising under the skin, swelling of the testicles ; tingling of the skin, herpes zoster ( shingles ); inflammation of the brain ( encephalitis ); inflammation of the coverings of the brain and spinal cord not caused by bacterial infection ( as
what proquad contains after reconstitution , one dose ( 0 . 5 ml ) contains : the active substances are : measles virus1 enders ' edmonston strain ( live , attenuated )........ not less than 3 . 00 log10 tcid50 * mumps virus1 jeryl lynn â¢ ( level b ) strain ( live , attenuated )... not less than 4 . 30 log10 tcid50 * rubella virus2 wistar ra 27 / 3 strain ( live , attenuated )............... not less than 3 . 00 log10 tcid50 * varicella virus3 oka / merck strain ( live , attenuated ) ................... not less than 3 . 99 log10 pfu ** * 50 % tissue culture infectious dose ** plaque - forming units ( 1 ) produced in chick embryo cells . ( 2 ) produced in human diploid lung ( wi - 38 ) fibroblasts . ( 3 ) produced in human diploid cells ( mrc - 5 ). the other ingredients are : powder sucrose , hydrolysed gelatin , urea , sodium chloride , sorbitol ( e 420 ), monosodium glutamate , sodium phosphate , sodium bicarbonate , potassium phosphate , potassium chloride , medium 199 with hanks ' salts , mem , neomycin , phenol red , hydrochloric acid and sodium hydroxide . solvent water for injections . what proquad looks like and contents of the pack the vaccine is a powder for suspension for injection contained in a single - dose vial , which should be mixed with solvent provided with the vial of powder . the powder is a white to pale yellow compact crystalline cake and the solvent is a clear colourless liquid . proquad is available in pack of 1 and pack of 10 . not all pack sizes may be marketed .
jylamvo is a medicine that : - suppresses the growth of certain cells in the body that multiply rapidly ( an anticancer medicine ) - reduces unwanted reactions by the body ' s own defense mechanisms ( an immunosuppressive agent ) - has an anti - inflammatory effect jylamvo is used in patients with : - the following rheumatic and skin diseases : o active rheumatoid arthritis ( ra ) in adults o polyarthritic forms ( when five or more joints are affected ) of active , severe juvenile idiopathic arthritis ( jia ) in adolescents and children aged 3 years and over when the response to non - steroidal anti - inflammatory drugs ( nsaids ) has been inadequate o severe , treatment - resistant , disabling psoriasis that does not respond sufficiently to other forms of treatment such as phototherapy , psoralen and ultraviolet a radiation ( puva ) therapy and retinoids , as well as in severe psoriasis that also affects the joints ( psoriatic arthritis ) in adult patients - acute lymphoblastic leukaemia ( all ) in adults , adolescents and children aged 3 years and over you must talk to a doctor if you do not feel better or if you feel worse
do not take jylamvo - if you are allergic to methotrexate or any of the other ingredients of this medicine ( listed in section 6 ) - if you have a severe kidney impairment ( or your doctor classes the impairment as severe ) - if you have a liver impairment - if you have blood disorders such as bone marrow hypoplasia, leukopenia, thrombocytopenia or significant anaemia 34 - if you drink alcohol excessively - if you have a weakened immune system - if you are suffering from a serious infection such as tuberculosis or hiv - if you have ulcers in the stomach or in the intestines - if you have an inflammation of the mucous membrane of the mouth or mouth ulcers - if you are breast - feeding and additionally, for non - oncologic indications ( for non - cancer treatment ) if you are pregnant ( see section " pregnancy, breast - feeding and fertility ") - if you have had a live vaccine recently or are about to have one warnings and precautions important warning about the dose of jylamvo ( methotrexate ): this oral solution contains 2 mg methotrexate in 1 ml solution and the scaling of the dosing syringe is in ml and not mg. take jylamvo only once a week for the treatment of rheumatic or skin diseases ( ra, jia and psoriasis or psoriatic arthritis ). taking too much of jylamvo ( methotrexate ) may be fatal. please read section 3 of this leaflet very carefully. if you have any questions, please talk to your doctor or pharmacist before you take this medicine. talk to your doctor or pharmacist before taking jylamvo : - if you have diabetes mellitus treated with insulin - if you are suffering from inactive, chronic infections ( e. g. tuberculosis, hepatitis b or c, shingles [
jylamvo should be prescribed only by doctors who are familiar with the properties of the medicine and how it works. always take this medicine exactly as your doctor has told you. check with your doctor or pharmacist if you are not sure. taking jylamvo incorrectly can result in severe side effects and even death. the duration of the treatment is determined by the treating physician. treatment of rheumatoid arthritis, severe juvenile idiopathic arthritis, severe psoriasis and severe psoriatic arthritis with jylamvo is a long - term treatment. recommended dose your doctor will decide what dose of jylamvo you should take according to the condition you are being treated for, how severe it is and your general health. keep to the dose exactly and follow your doctor's instructions exactly on when to take the medicine. dose in rheumatic and skin diseases ( ra, jia and psoriasis or psoriatic arthritis ) take jylamvo only once a week. decide with your doctor the most suitable day of the week to take the medicine. dosage in adult rheumatoid arthritis : the usual initial dose is 7. 5 mg ( 3. 75 ml ), once a week. dosage for psoriasis and psoriatic arthritis : the usual initial dose is 7. 5 mg ( 3. 75 ml ), once a week. the doctor may increase the dose if the used dose is not effective but tolerated well. your doctor may adjust the dose to suit you according to your response to treatment and side effects. dose in acute lymphoblastic leukaemia ( all ) your doctor will tell you what dose you should take for your condition and when you should take the dose. keep to this dose exactly. use in children and adolescents the doctor will calculate the dose required from the child's body surface area ( m2 ), and the dose is expressed as mg / m2. elderly because of the reduced liver and kidney function and the lower folate reserves in elderly patients, a relatively low dosage should be chosen for
like all medicines, this medicine can cause side effects, although not everybody gets them. tell your doctor immediately if you suddenly get wheeziness, difficulty in breathing, swelling of the eyelids, face or lips, rash or itching ( especially affecting your whole body ). contact your doctor immediately if you develop any of the side effects listed below : breathing problems ( these include a general feeling of illness, dry, irritating cough, shortness of breath, difficulty in breathing, chest pain or fever ) spitting or coughing blood * serious peeling or blistering of the skin unusual bleeding ( including vomiting blood ), bruising or nose bleeds nausea, vomiting, abdominal discomfort or severe diarrhoea mouth ulcers black or tarry stools blood in the urine or stool small red spots on the skin fever, sore throat, flu - like symptoms yellow colouring of the skin ( jaundice ) or dark urine pain or difficulties in passing urine thirst and / or frequent urination seizures ( convulsions ) unconsciousness blurred or restricted vision severe fatigue. * has been reported for methotrexate used in patients with underlying rheumatologic disease. the following side effects have also been reported : very common ( may affect more than 1 in 10 people ): loss of appetite, feeling sick ( nausea ), vomiting, abdominal pain, indigestion, inflammation and ulcers of the mouth and throat blood test showing raised liver enzymes. common ( may affect up to 1 in 10 people ): infections reduced blood cell formation with a decrease in white and / or red blood cells and / or platelets ( leucocytopenia, anaemia, thrombocytopenia ) headache, tiredness, lightheadedness inflammation of the lungs ( pneumonia ) with dry cough, shortness of breath and fever diarrhoea 40 skin rash, skin redness and itching. uncommon ( may affect up to 1 in 100 people ): lymphoma ( lump in neck, groin or armpits with associated backache, weight loss or night sweats ) severe allergic reactions diabetes depression dizziness, confusion
keep this medicine out of the sight and reach of children , preferably in a locked cupboard . accidental ingestion can be lethal for children . do not use the medicine after the expiry date which is stated on the carton and label after ' exp '. the expiry date refers to the last day of that month . do not store above 25 . keep the bottle tightly closed to prevent spoilage of the medicine and reduce the risk of accidental spillage . after first opening , throw away any unused medicine after 3 months . any unused medicine or waste material should be disposed of in accordance with local requirements for cytotoxic products - check with your pharmacist .
what jylamvo contains the active substance is methotrexate . one ml of solution contains 2 mg of methotrexate . the other ingredients are : macrogol 400 , glycerol , orange flavour , sucralose , ethyl parahydroxybenzoate ( e214 ), sodium methyl parahydroxybenzoate ( e219 ), citric acid , tri - sodium citrate , purified water . see section 2 " jylamvo contains ethyl parahydroxybenzoate and sodium methyl parahydroxybenzoate ". what jylamvo looks like and contents of the pack jylamvo is a clear yellow solution . it is presented in a brown glass bottle containing 60 ml of solution and capped with a child - resistant closure . each pack contains one bottle , a bottle adaptor and a white dosing syringe .
what enurev breezhaler is this medicine contains an active substance called glycopyrronium bromide . this belongs to a group of medicines called bronchodilators . what enurev breezhaler is used for this medicine is used to make breathing easier for adult patients who have breathing difficulties due to a lung disease called chronic obstructive pulmonary disease ( copd ). in copd the muscles around the airways tighten . this makes breathing difficult . this medicine blocks the tightening of these muscles in the lungs , making it easier for air to get in and out of the lungs . if you use this medicine once a day , it will help to reduce the effects of copd on your everyday life .
do not use enurev breezhaler - if you are allergic to glycopyrronium bromide or any of the other ingredients of this medicine ( listed in section 6 ). warnings and precautions talk to your doctor before using enurev breezhaler, if any of the following applies to you : - you have kidney problems. - you have an eye problem called narrow - angle glaucoma. - you have difficulty passing urine. during treatment with enurev breezhaler, stop taking this medicine and tell your doctor immediately : - if you experience tightness of the chest, coughing, wheezing or breathlessness immediately after using enurev breezhaler ( signs of bronchospasm ). - if you experience difficulties in breathing or swallowing, swelling of the tongue, lips or face, skin rash, itching and hives ( signs of allergic reaction ). - if you experience eye pain or discomfort, temporary blurring of vision, visual halos or coloured images in association with red eyes. these may be signs of an acute attack of narrow - angle glaucoma. enurev breezhaler is used as a maintenance treatment for your copd. do not use this medicine to treat a sudden attack of breathlessness or wheezing. children and adolescents do not give this medicine to children or adolescents below the age of 18 years. other medicines and enurev breezhaler tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. this includes medicines similar to enurev breezhaler used for your lung disease, such as ipratropium, oxitropium or tiotropium ( so called anticholinergics ). no specific side effects have been reported when enurev breezhaler has been used together with other medicines used to treat copd such as reliever inhalers ( e. g. salbutamol ), methylxanthines ( e. g. theophylline ) and / or oral and inhaled steroids
always use this medicine exactly as your doctor or pharmacist has told you. check with your doctor or pharmacist if you are not sure. how much enurev breezhaler to use the usual dose is to inhale the content of one capsule each day. you only need to inhale once a day because the effect of this medicine lasts for 24 hours. do not use more than your doctor tells you to use. elderly people you can use this medicine if you are aged 75 years and over at the same dose as for other adults. when to inhale enurev breezhaler use this medicine at the same time each day. this will also help you to remember to use it. you can inhale this medicine anytime before or after food or drink. how to inhale enurev breezhaler - in this pack, you will find an inhaler and capsules ( in blisters ) that contain the medicine as inhalation powder. only use the capsules with the inhaler provided in this pack ( enurev breezhaler inhaler ). the capsules should remain in the blister until you need to use them. - do not push the capsule through the foil. - when you start a new pack, use the new enurev breezhaler inhaler that is supplied in the pack. - dispose of each inhaler after after all capsules in that pack have been used. - do not swallow the capsules. - please read the instructions at the end of this leaflet for more information on how to use the inhaler. if you use more enurev breezhaler than you should if you have inhaled too much of this medicine or if someone else accidentally uses your capsules, you must immediately either tell your doctor or go to the nearest emergency unit. show the pack of enurev breezhaler. medical attention may be needed. if you forget to use enurev breezhaler if you forget to inhale a dose, take one as soon as possible. however, do not take two doses on the same day. then take the next dose as usual. how
like all medicines , this medicine can cause side effects , although not everybody gets them . some side effects may be serious but are uncommon ( may affect up to 1 in 100 people ) irregular heart beat high level of blood sugar ( hyperglycaemia : typical symptoms include excessive thirst or hunger and frequent urination ) rash , itching , hives , difficulty breathing or swallowing , dizziness ( possible signs of allergic reaction ) swelling mainly of the tongue , lips , face or throat ( possible signs of angioedema ) if you get any of these side effects , tell your doctor immediately . some side effects may be serious , but the frequency of these side effects is not known ( frequency cannot be estimated from the available data ) difficulty breathing with wheezing or coughing ( signs of paradoxical bronchospasm ) some side effects are common ( may affect up to 1 in 10 people ) dry mouth difficulty sleeping runny or stuffy nose , sneezing , sore throat diarrhoea or stomach ache musculoskeletal pain 36 some side effects are uncommon ( may affect up to 1 in 100 people ) difficulty and pain when passing urine painful and frequent urination palpitations rash numbness cough with sputum dental caries feeling of pressure or pain in the cheeks and forehead nose bleeds pain in arms or legs pain in muscles , bones or joints of the chest stomach discomfort after meals throat irritation tiredness weakness itching voice alteration ( hoarseness ) nausea vomiting some elderly patients above 75 years of age experienced headache ( frequency common ) and urinary tract infection ( frequency common ). reporting of side effects if you get any side effects , talk to your doctor or pharmacist . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
what enurev breezhaler contains - the active substance is glycopyrronium bromide . each capsule contains 63 micrograms of glycopyrronium bromide ( equivalent to 50 micrograms glycopyrronium ). the delivered dose ( the dose that leaves the mouthpiece of the inhaler ) is equivalent to 44 micrograms of glycopyrronium . - the other ingredients of the inhalation powder are lactose monohydrate and magnesium stearate . what enurev breezhaler looks like and contents of the pack enurev breeyhaler 44 micrograms inhalation powder , hard capsules are transparent and orange and contain a white powder . they have the product code " gpl50 " printed in black above and a company logo ( ) printed in black below a black bar . each pack contains a device called an inhaler , together with capsules in blisters . each blister strip contains either 6 or 10 hard capsules . the following pack sizes are available : packs containing 6x1 , 10x1 , 12x1 or 30x1 hard capsules , together with one inhaler . multipacks containing 90 ( 3 packs of 30x1 ) hard capsules and 3 inhalers . multipacks containing 96 ( 4 packs of 24x1 ) hard capsules and 4 inhalers . multipacks containing 150 ( 15 packs of 10x1 ) hard capsules and 15 inhalers . multipacks containing 150 ( 25 packs of 6x1 ) hard capsules and 25 inhalers . not all pack sizes may be available in your country .
what riximyo is riximyo contains the active substance " rituximab ". this is a type of protein called a " monoclonal antibody ". it sticks to the surface of a type of white blood cell called " b - lymphocyte ". when rituximab sticks to the surface of this cell, the cell dies. what riximyo is used for riximyo may be used for the treatment of several different conditions in adults. your doctor may prescribe riximyo for the treatment of : a ) non - hodgkin's lymphoma this is a disease of the lymph tissue ( part of the immune system ) that affects a type of white blood cell called b - lymphocytes. riximyo can be given alone or with other medicines called " chemotherapy ". in patients where the treatment is working, riximyo may be used as a maintenance treatment for 2 years after completing the initial treatment. b ) chronic lymphocytic leukaemia chronic lymphocytic leukaemia ( cll ) is the most common form of adult leukaemia. cll affects a particular lymphocyte, the b cell, which originates from the bone marrow and develops in the lymph nodes. patients with cll have too many abnormal lymphocytes, which accumulate mainly in the bone marrow and blood. the proliferation of these abnormal b - lymphocytes is the cause of symptoms you may have. riximyo in combination with chemotherapy destroys these cells which are gradually removed from the body by biological processes. c ) granulomatosis with polyangiitis or microscopic polyangiitis riximyo is used for the treatment of granulomatosis with polyangiitis ( formerly called wegener's granulomatosis ) or microscopic polyangiitis, taken in combination with corticosteroids. granulomatosis with polyangiitis and microscopic polyangi
do not take riximyo if you are allergic to rituximab, other proteins which are like rituximab, or any of the other ingredients of this medicine ( listed in section 6 ). you have a severe active infection at the moment you have a weak immune system. you have severe heart failure or severe uncontrolled heart disease and have granulomatosis with polyangiitis, microscopic polyangiitis or pemphigus vulgaris. do not have riximyo if any of the above apply to you. if you are not sure, talk to your doctor, pharmacist or nurse before you are given riximyo. warnings and precautions talk to your doctor, pharmacist or nurse before you are given riximyo if : you have ever had or might now have a hepatitis infection. this is because in a few cases, riximyo could cause hepatitis b to become active again, which can be fatal in very rare cases. patients who have ever had hepatitis b infection will be carefully checked by their doctor for signs of this infection. you have ever had heart problems ( such as angina, palpitations or heart failure ) or breathing problems. if any of the above apply to you ( or you are not sure ), talk to your doctor, pharmacist or nurse before you are given riximyo. your doctor may need to take special care of you during your treatment with riximyo. if you have granulomatosis with polyangiitis, microscopic polyangiitis or pemphigus vulgaris also tell your doctor if you think you may have an infection, even a mild one like a cold. the cells that are affected by riximyo help to fight infection and you should wait until the infection has passed before you are given riximyo. also please tell your doctor if you had a lot of infections in the past or suffer from severe infections. if you think you may need any vaccinations in the near future, including vaccinations needed to travel to other
how it is given riximyo will be given to you by a doctor or nurse who is experienced in the use of this treatment. they will watch you closely while you are being given this medicine. this is in case you get any side effects. you will always be given riximyo as a drip ( intra - venous infusion ). medicines given before each riximyo administration before you are given riximyo you will be given other medicines ( premedication ) to prevent or reduce possible side effects. how much and how often you will receive your treatment a ) if you are being treated for non - hodgkin's lymphoma if you are having riximyo alone riximyo will be given to you once a week for 4 weeks. repeated treatment courses with riximyo are possible. if you are having riximyo with chemotherapy riximyo will be given to you on the same day as your chemotherapy. this is usually given every 3 week up to 8 times. if you respond well to treatment, you may be given riximyo as a maintenance treatment every 2 or 3 months for two years. your doctor may change this, depending on how you respond to the medicine. b ) if you are being treated for chronic lymphocytic leukaemia when you are treated with riximyo in combination with chemotherapy, you will receive riximyo infusions on day 0 cycle 1 then day 1 of each cycle for 6 cycles in total. each cycle has a duration of 28 days. the chemotherapy should be given after the riximyo infusion. your doctor will decide if you should receive concomitant supportive therapy. c ) if you are being treated for granulomatosis with polyangiitis or microscopic polyangiitis treatment with riximyo uses four separate infusions given at weekly intervals. corticosteroids will usually be given by injection before the start of riximyo treatment. corticosteroids given by mouth may be started at any time by your doctor
like all medicines, this medicine can cause side effects, although not everybody gets them. most side effects are mild to moderate but some may be serious and require treatment. rarely, some of these reactions have been fatal. infusion reactions during or within the first 24 hours of the infusion you may develop fever, chills and shivering. less frequently, some patients may experience pain at the infusion site, blisters, itching, sickness ( nausea ), tiredness, headache, breathing difficulties, blood pressure raised, wheezing, throat discomfort, tongue or throat swelling, itchy or runny nose, vomiting, flushing or palpitations, heart attack or low number of platelets. if you have heart disease or angina, these reactions might get worse. tell the person giving you the infusion immediately if you develop any of these symptoms, as the infusion may need to be slowed down or stopped. you may require additional treatment such as an antihistamine or paracetamol. when these symptoms go away, or improve, the infusion can be continued. these reactions are less likely to happen after the second infusion. your doctor may decide to stop your riximyo treatment if these reactions are serious. infections tell your doctor immediately if you get signs of an infection including : fever, cough, sore throat, burning pain when passing urine or feeling weak or generally unwell memory loss, trouble thinking, difficulty walking or sight loss these may be due to a very rare, serious brain infection, which has been fatal ( progressive multifocal leukoencephalopathy or pml ). you might get infections more easily during your treatment with riximyo. these are often colds, but there have been cases of pneumonia or urinary infections. these are listed below under " other side effects ". if you are being treated for granulomatosis with polyangiitis, microscopic polyangiitis or pemphigus vulgaris, you will also find this information in the patient alert card you have been given by your doctor. it is important that you keep this alert card and show it to your partner or caregiver.
what riximyo contains the active ingredient in riximyo is called rituximab . the 10 ml vial contains 100 mg of rituximab ( 10 mg / ml ). the 50 ml vial contains 500 mg of rituximab ( 10 mg / ml ). the other ingredients are sodium citrate , polysorbate 80 , sodium chloride , sodium hydroxide , hydrochloric acid and water for injections ( see section 2 ). what riximyo looks like and contents of the pack riximyo is a clear , colourless to slightly yellowish solution , supplied as a concentrate for solution for infusion . ml vial - pack of 2 or 3 vials . ml vial - pack of 1 or 2 vials .
topotecan actavis contains the active substance topotecan which helps to kill tumour cells . topotecan actavis is used to treat : - small cell lung cancer that has come back after chemotherapy , or - advanced cervical cancer if surgery or radiotherapy is not possible . in this case topotecan actavis treatment is combined with medicines containing cisplatin .
do not use topotecan actavis - if you are allergic to topotecan or any of the other ingredients of this medicine ( listed in section 6 ); - if you are breast - feeding. you should stop breast - feeding before starting treatment with topotecan actavis ; - if your blood cell counts are too low. tell you doctor if you think any of these could apply to you. warnings and precautions talk to your doctor before using topotecan actavis : - if you have any kidney problems. your dose of topotecan actavis may need to be adjusted. topotecan actavis is not recommended in case of severe kidney impairment ; - if you have liver problems. topotecan actavis is not recommended in case of severe liver impairment ; - if you suffer from lung inflammation with signs such as cough, fever and difficulties in breathing, see also section 4 " possible side effects ". topotecan actavis may cause a decrease in the number of blood clotting cells ( platelets ). this can lead to severe bleeding from relatively small injuries such as a small cut. rarely, it can lead to more severe bleeding ( haemorrhage ). talk to your doctor for advice on how to minimize the risk of bleeding. the incidence of side effects is more frequent in patients who are in poor general health. the doctor will evaluate your general health during the treatment and you should tell him / her in case you have fever, infection or are in some ways feeling unwell. use in children and adolescents the experience in children and adolescents is limited and treatment is therefore not recommended. other medicines and topotecan actavis tell your doctor if you are taking, have recently taken or might take any other medicines. pregnancy and breast - feeding topotecan actavis should not be used in pregnant women, unless clearly necessary. if you are or think you might be pregnant, tell your doctor immediately. effective contraception methods should be used to avoid becoming pregnant / fathering a child while on treatment. ask your doctor for advice. patients who are concerned about their fertility should ask their doctor for counselling on fertility and family planning options prior to starting treatment.
your dose of topotecan actavis will depend on : - the disease being treated , - your body surface area ( m2 ), - the results of blood tests carried out before and during treatment , - how well you tolerate treatment . adults small cell lung cancer the usual dose is 1 . 5 mg per m2 of body surface area once daily for 5 days . this treatment cycle will normally be repeated every three weeks . cervical cancer the usual dose is 0 . 75 mg per m2 of body surface area once daily for 3 days . this treatment cycle will normally be repeated every three weeks . for cervical cancer , it will be used together with another anticancer medicines containing cisplatin . for more information about cisplatin , please refer to the corresponding package leaflet . patients with impaired kidney function your doctor might need to reduce your dose based on your kidney function . how topotecan actavis is prepared topotecan is supplied as a powder for concentrate for solution for infusion . the powder must be dissolved , and the resulting concentrate further diluted before administration . how topotecan actavis is given a doctor or nurse will give you the reconstituted and diluted topotecan actavis solution as an infusion ( drip ), usually into your arm , over about 30 minutes . if you are given too much topotecan actavis as this medicine is being given by your doctor or nurse , it is unlikely that you will be given too much . in the unlikely event of an overdose , your doctor will monitor you for side effects . tell your doctor or nurse if you have any concerns about the amount of medicine that you receive .
like all medicines, this medicine can cause side effects, although not everybody gets them. serious side effects you must tell your doctor immediately if you experience any of the following serious side effects. they may require hospitalisation and could even be life - threatening. - infections ( very common ; may affect more than 1 in 10 people ), with signs such as : - fever - serious decline of your general condition - local symptoms, such as sore throat or burning sensation when urinating - severe stomach pain, fever and possibly diarrhoea ( rarely with blood ) can be signs of bowel inflammation ( neutropenic colitis ) topotecan actavis may reduce your ability to fight infections. - lung inflammation ( rare ; may affect up to 1 in 1, 000 people ), with signs such as : - difficulty in breathing - cough - fever the risk of developing this severe condition ( interstitial lung disease ) is higher if you currently have lung problems, or if you have received previous radiation treatment or medicines that affected your lungs, see also section 2 " warnings and precautions ". this condition can be fatal. - severe allergic ( anaphylactic ) reactions ( rare ; may affect up to 1 in 1, 000 people ), with signs such as : - swelling of the face, lips, tongue or throat, difficulty breathing, low blood pressure, dizziness and itchy rash. other side effects with topotecan actavis include : very common side effects ( may affect more than 1 in 10 people ) - feeling generally weak and tired, which can be symptoms of a decrease in the number of red blood cells ( anaemia ). in some cases you may need a blood transfusion. - decrese in number of circulating white blood cells ( leucotyes ) in the blood. abnormal low number of neutrophil granulocytes ( a type of white blood cell ) in the blood, with or without fever. - unusual bruising or bleeding, sometimes severe, caused by a decrease in the number of blood clotting cells ( platelets ). - weight loss and loss of appetite ( anore
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the vial and carton . keep the vial in the outer carton in order to protect from light . storage after reconstitution and dilution chemical and physical stability of the concentrate has been demonstrated for 24 hours at 25 Â± 2 , in normal light conditions and 24 hours at 2 to 8 , protected from light . the physico - chemical stability of the drug product solution obtained after dilution in solutions for infusion ( nacl 0 . 9 % and glucose 5 %) has been demonstrated for 4 hours at room temperature , in normal lighting conditions , on samples reconstituted and stored for 12 hours and respectively 24 hours at 25oc Â± 2oc and then diluted . from a microbiological point of view , the product should be used immediately . if not used immediately , in - use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 , unless reconstitution / dilution has taken place in controlled and validated aseptic conditions . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help to protect the environment .
what topotecan actavis contains - the active substance is topotecan . each vial contains 1 mg or 4 mg topotecan ( as hydrochloride ). after reconstitution 1 ml concentrate contains 1 mg topotecan . - the other ingredients are : mannitol ( e421 ), tartaric acid ( e334 ), hydrochloric acid ( e507 ) and sodium hydroxide . what topotecan actavis looks like and contents of the pack topotecan actavis is supplied in type i colourless glass vials with grey bromobutylic stopper and aluminium seals with plastic flip - off caps . each vial is sheathed in a protective sleeve . packs : 1 x 1 mg vial ; 5 x 1 mg vial 1 x 4 mg vial ; 5 x 4 mg vial
the active substance of rivastigmine hexal is rivastigmine . rivastigmine belongs to a class of substances called cholinesterase inhibitors . in patients with alzheimer ' s dementia or dementia due to parkinson ' s disease , certain nerve cells die in the brain , resulting in low levels of the neurotransmitter acetylcholine ( a substance that allows nerve cells to communicate with each other ). rivastigmine works by blocking the enzymes that break down acetylcholine : acetylcholinesterase and butyrylcholinesterase . by blocking these enzymes , rivastigmine allows levels of acetylcholine to be increased in the brain , helping to reduce the symptoms of alzheimer ' s disease and dementia associated with parkinson ' s disease . rivastigmine hexal is used for the treatment of adult patients with mild to moderately severe alzheimer ' s dementia , a progressive brain disorder that gradually affects memory , intellectual ability and behaviour . the capsules and oral solution can also be used for the treatment of dementia in adult patients with parkinson ' s disease .
do not take rivastigmine hexal - if you are allergic to rivastigmine ( the active substance in rivastigmine hexal ) or any of the other ingredients of this medicine ( listed in section 6 ). - if you have had a previous skin reaction suggestive of allergic contact dermatitis with rivastigmine. if this applies to you, tell your doctor and do not take rivastigmine hexal. warnings and precautions talk to your doctor before taking rivastigmine hexal - if you have, or have ever had, irregular or slow heartbeat. - if you have, or have ever had, an active stomach ulcer. - if you have, or have ever had, difficulties in passing urine. - if you have, or have ever had, seizures. - if you have, or have ever had, asthma or severe respiratory disease. - if you have, or have ever had impaired kidney function. - if you have, or have ever had, impaired liver function. - if you suffer from trembling. - if you have a low body weight. - if you have gastrointestinal reactions such as feeling sick ( nausea ), being sick ( vomiting ) and diarrhoea. you may become dehydrated ( losing too much fluid ) if vomiting or diarrhoea are prolonged. if any of these apply to you, your doctor may need to monitor you more closely while you are on this medicine. if you have not taken rivastigmine hexal for more than three days, do not take the next dose until you have talked to your doctor. children and adolescents there is no relevant use of rivastigmine hexal in the paediatric population in the treatment of alzheimer's disease. other medicines and rivastigmine hexal tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. rivastigmine hexal should not
always take this medicine exactly as your doctor has told you . check with your doctor or pharmacist if you are not sure . how to start treatment your doctor will tell you what dose of rivastigmine hexal to take . treatment usually starts with a low dose . your doctor will slowly increase your dose depending on how you respond to treatment . the highest dose that should be taken is 6 . 0 mg twice a day . your doctor will regularly check if the medicine is working for you . your doctor will also monitor your weight whilst you are taking this medicine . if you have not taken rivastigmine hexal for more than three days , do not take the next dose until you have talked to your doctor . taking this medicine tell your caregiver that you are taking rivastigmine hexal . to benefit from your medicine , take it every day . take rivastigmine hexal twice a day in the morning and evening with food . swallow the capsules whole with a drink . do not open or crush the capsules . if you take more rivastigmine hexal than you should if you accidentally take more rivastigmine hexal than you should , inform your doctor . you may require medical attention . some people who have accidentally taken too much rivastigmine hexal have experienced feeling sick ( nausea ), being sick ( vomiting ), diarrhoea , high blood pressure and hallucinations . slow heartbeat and fainting may also occur . if you forget to take rivastigmine hexal if you find you have forgotten to take your dose of rivastigmine hexal , wait and take the next dose at the usual time . do not take a double dose to make up for a forgotten dose . if you have any further questions on the use of this medicine , ask your doctor or pharmacist .
like all medicines, this medicine can cause side effects, although not everybody gets them. you may have side effects more often when you start your medicine or when your dose is increased. usually, the side effects will slowly go away as your body gets used to the medicine. very common ( may affect more than 1 in 10 people ) feeling dizzy loss of appetite stomach problems such as feeling sick ( nausea ) or being sick ( vomiting ), diarrhoea common ( may affect up to 1 in 10 people ) anxiety sweating headache heartburn weight loss stomach pain feeling agitated feeling tired or weak generally feeling unwell trembling or feeling confused decreased appetite nightmares uncommon ( may affect up to 1 in 100 people ) depression difficulty in sleeping fainting or accidentally falling changes in how well your liver is working rare ( may affect up to 1 in 1, 000 people ) chest pain rash, itching fits ( seizures ) ulcers in your stomach or intestine very rare ( may affect up to 1 in 10, 000 people ) high blood pressure urinary tract infection seeing things that are not there ( hallucinations ) problems with your heartbeat such as fast or slow heartbeat bleeding in the gut shows as blood in stools or when being sick inflammation of the pancreas the signs include serious upper stomach pain, often with feeling sick ( nausea ) or being sick ( vomiting ) the signs of parkinson's disease get worse or getting similar signs such as stiff muscles, difficulty in carrying out movements not known ( frequency cannot be estimated from the available data ) being violently sick ( vomiting ) that can cause tearing of the tube that connects your mouth with your stomach ( oesophagus ) dehydration ( losing too much fluid ) liver disorders ( yellow skin, yellowing of the whites of the eyes, abnormal darkening of the urine or unexplained nausea, vomiting, tiredness and loss of appetite ) aggression, feeling restless uneven heartbeat patients with dementia and parkinson's disease these patients have some side effects more often. they also have some additional side effects : very common ( may affect more than 1 in 10 people ) 63 trembling fainting accidentally falling common ( may affect up to 1 in 10 people )
keep this medicine out of the sight and reach of children . do not use rivastigmine hexal after the expiry date which is stated on the carton . the expiry date refers to the last day of that month . do not store above 30 . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what rivastigmine hexal contains 64 - the active substance is rivastigmine hydrogen tartrate. - the other ingredients are : hypromellose, magnesium stearate, microcrystalline cellulose, colloidal anhydrous silica, gelatin, yellow iron oxide red iron oxide, titanium dioxide, and shellac. each rivastigmine hexal 1. 5 mg capsule contains 1. 5 mg of rivastigmine. each rivastigmine hexal 3 mg capsule contains 3 mg of rivastigmine. each rivastigmine hexal 4. 5 mg capsule contains 4. 5 mg of rivastigmine. each rivastigmine hexal 6 mg capsule contains 6 mg of rivastigmine. what rivastigmine hexal looks like and contents of the pack - rivastigmine hexal 1. 5 mg hard capsules, which contain an off - white to slightly yellow powder, have a yellow cap and yellow body, with a red imprint " riv 1. 5 mg " on the body. - rivastigmine hexal 3 mg hard capsules, which contain an off - white to slightly yellow powder, have an orange cap and orange body, with a red imprint " riv 3 mg " on the body. - rivastigmine hexal 4. 5 mg hard capsules, which contain an off - white to slightly yellow powder, have a red cap and red body, with a white imprint " riv 4. 5 mg " on the body. - rivastigmine hexal 6 mg hard capsules, which contain an off - white to slightly yellow powder, have a red cap and orange body, with a red imprint " riv 6 mg " on the body. they are packed in blisters available in three different pack sizes ( 28, 56 or 112 capsules ) and plastic bottles of 250 capsules, but these may not all be available in
what cabometyx is cabometyx is a cancer medicine that contains the active substance cabozantinib . it is used to treat : - advanced stages of a type of kidney cancer called renal cell carcinoma - liver cancer in adults who have been previously treated with a specific anticancer medicine ( sorafenib ). how cabometyx works cabometyx blocks the action of proteins called receptor tyrosine kinases ( rtks ), which are involved in the growth of cells and the development of new blood vessels that supply them . these proteins can be present in high amounts in cancer cells , and by blocking their action cabometyx can slow down the rate at which the tumour grows and help to cut off the blood supply that the cancer needs .
do not take cabometyx 45 - - if you are allergic to cabozantinib or any of the other ingredients of this medicine ( listed in section 6 ). warnings and precautions talk to your doctor or pharmacist before taking cabometyx if you : - have high blood pressure - have or have had an aneurysm ( enlargement and weakening of a blood vessel wall ) or a tear in a blood vessel wall - have diarrhoea - have a recent history of significant bleeding - have had surgery within the last month ( or if surgical procedures are planned ), including dental surgery - have inflammatory bowel disease ( for example, crohn's disease or ulcerative colitis, diverticulitis, or appendicitis ) - have a recent history of blood clot in the leg, stroke, or heart attack - have liver or kidney disease. tell your doctor if any of these affect you. you may need treatment for them, or your doctor may decide to change your dose of cabometyx, or stop treatment altogether. see also section 4 " possible side effects ". children and adolescents cabometyx is not recommended for children or adolescents. the effects of cabometyx in people younger than 18 years old are not known. other medicines and cabometyx please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. this is because cabometyx can affect the way some other medicines work. also, some medicines can affect the way cabometyx works. this could mean that your doctor needs to change the dose ( s ) that you take. you should tell your doctor about every medicine, but in particular if taking : - medicines that treat fungal infections, such as itraconazole, ketoconazole, and posaconazole - medicines used to treat bacterial infections ( antibiotics ) such as erythromycin, clarithromycin, and rifampicin - allergy medicines such as fexofen
always take this medicine exactly as your doctor or pharmacist has told you . check with your doctor or pharmacist if you are not sure . you should continue to take this medicine until your doctor decides to stop your treatment . if you get serious side effects , your doctor may decide to change your dose or stop treatment earlier than originally planned . your doctor will tell you if you need your dose adjusted . cabometyx should be taken once a day . the usual dose is 60 mg , however your doctor will decide on the right dose for you . cabometyx should not be taken with food . you should not eat anything for at least 2 hours before taking cabometyx and for 1 hour after taking the medicine . swallow the tablet with a full glass of water . do not crush the tablets . if you take more cabometyx than you should if you have taken more cabometyx than you have been instructed to , talk to a doctor or go to the hospital with the tablets and this leaflet straight away . if you forget to take cabometyx - if there are still 12 hours or more before your next dose is due , then take the missed dose as soon as you remember . take the next dose at the normal time . - if your next dose is due in less than 12 hours , then do not take the dose that you have missed . take your next dose at the normal time .
like all medicines, this medicine can cause side effects, although not everybody gets them. if you get side effects, your doctor may tell you to take cabometyx at a lower dose. your doctor may also prescribe other medicines to help control your side effects. tell your doctor straight away if you notice any of the following side effects you may need urgent medical treatment : symptoms including pain in the abdomen, nausea ( feeling sick ), vomiting, constipation, or fever. these may be signs of a gastrointestinal perforation, a hole that develops in your stomach or intestine that could be life - threatening. severe or uncontrollable bleeding with symptoms such as : vomiting blood, black stolls, bloody urine, headache, coughing up blood. swelling, pain in your hands and feet, or shortness of breath. a wound that does not heal. fits, headaches, confusion, or finding it difficult to concentrate. these may be signs of a condition called reversible posterior leukoencephalopathy syndrome ( rpls ). rpls is rare ( it affects less than 1 in 1000 people ). feeling drowsy, confused or loss of consciousness. this may be due to liver problems. other side effects include : very common side effects ( may affect more than 1 in 10 people ) stomach upset, including diarrhoea, nausea, vomiting, constipation, indigestion, abdominal pain, blisters, pain of the hands or soles of the feet, rash or redness of the skin decreased appetite, weight loss, altered sense of taste fatigue, weakness, headache, dizziness hypertension ( increase in blood pressure ) anaemia ( low levels of red blood cells ) redness, swelling or pain in the mouth or throat, difficulty in speaking, hoarseness, cough changes in blood tests used to monitor general health and function of your organs ( including the liver, and kidney ), low levels of electrolytes ( like magnesium, or potassium ) shortness of breath reduced thyroid activity ; symptoms can include : tiredness
what cabometyx contains the active substance is cabozantinib ( s )- malate . cabometyx 20 mg film - coated tablets : each tablet contains cabozantinib ( s )- malate equivalent to 20 mg of cabozantinib . cabometyx 40 mg film - coated tablets : each tablet contains cabozantinib ( s )- malate equivalent to 40 mg of cabozantinib . cabometyx 60 mg film - coated tablets : each tablet contains cabozantinib ( s )- malate equivalent to 60 mg of cabozantinib . the other ingredients are : - tablet contents : microcrystalline cellulose , lactose anhydrous , hydroxypropyl cellulose , croscarmellose sodium , colloidal silicon dioxide anhydrous , magnesium stearate . ( see section 2 for lactose content ) - film coating : hypromellose , titanium dioxide ( e171 ), triacetin , iron oxide yellow ( e172 ) what cabometyx looks like and contents of the pack cabometyx 20 mg film - coated tablets are yellow , round with no score , and identified with " xl " on one side and " 20 " on the other side . cabometyx 40 mg film - coated tablets are yellow , triangle shaped with no score , and identified with " xl " on one side and " 40 " on the other side . cabometyx 60 mg film - coated tablets are yellow , oval shaped with no score , and identified with " xl " on one side and " 60 " on the other side . cabometyx tablets are available in packs containing one plastic bottle with 30 tablets .
pemetrexed hospira is a medicine used in the treatment of cancer . pemetrexed hospira is given in combination with cisplatin , another anti - cancer medicine , as treatment for malignant pleural mesothelioma , a form of cancer that affects the lining of the lung , to patients who have not received prior chemotherapy . pemetrexed hospira is also given in combination with cisplatin for the initial treatment of patients with advanced stage of lung cancer . pemetrexed hospira can be prescribed to you if you have lung cancer at an advanced stage if your disease has responded to treatment or it remains largely unchanged after initial chemotherapy . pemetrexed hospira is also a treatment for patients with advanced stage of lung cancer whose disease has progressed after other initial chemotherapy has been used .
do not use pemetrexed hospira - if you are allergic ( hypersensitive ) to pemetrexed or any of the other ingredients of this medicine ( listed in section 6 ). - if you are breast - feeding ; you must discontinue breast - feeding during treatment with pemetrexed hospira. - if you have recently received or are about to receive a vaccine against yellow fever. warnings and precautions talk to your doctor or hospital pharmacist before receiving pemetrexed hospira. if you currently have or have previously had problems with your kidneys, talk to your doctor or hospital pharmacist as you may not be able to receive pemetrexed hospira. before each infusion you will have samples of your blood taken to evaluate if you have sufficient kidney and liver function and to check that you have enough blood cells to receive pemetrexed hospira. your doctor may decide to change the dose or delay treating you depending on your general condition and if your blood cell counts are too low. if you are also receiving cisplatin, your doctor will make sure that you are properly hydrated and receive appropriate treatment before and after receiving cisplatin to prevent vomiting. if you have had or are going to have radiation therapy, please tell your doctor, as there may be an early or late radiation reaction with pemetrexed hospira. if you have been recently vaccinated, please tell your doctor, as this can possibly cause bad effects with pemetrexed hospira. if you have heart disease or a history of heart disease, please tell your doctor. if you have an accumulation of fluid around your lungs, your doctor may decide to remove the fluid before giving you pemetrexed hospira. children and adolescents this medicine should not be used in children or adolescents, since there is no experience with this medicine in children and adolescents under 18 years of age. other medicines and pemetrexed hospira please tell your doctor if you are taking any medicine for pain or inflammation ( swelling ), such as medicines called " nonsteroidal anti - inflammatory drugs " ( nsaids ), including medicines purchased
the dose of pemetrexed hospira is 500 milligrams for every square metre of your body's surface area. your height and weight are measured to work out the surface area of your body. your doctor will use this body surface area to work out the right dose for you. this dose may be adjusted, or treatment may be delayed depending on your blood cell counts and on your general condition. a hospital pharmacist, nurse or doctor will have mixed the pemetrexed hospira powder with 9 mg / ml ( 0. 9 %) sodium chloride solution for injection before it is given to you. you will always receive pemetrexed hospira by infusion into one of your veins. the infusion will last approximately 10 minutes. when using pemetrexed hospira in combination with cisplatin : the doctor or hospital pharmacist will work out the dose you need based on your height and weight. cisplatin is also given by infusion into one of your veins, and is given approximately 30 minutes after the infusion of pemetrexed hospira has finished. the infusion of cisplatin will last approximately 2 hours. you should usually receive your infusion once every 3 weeks. additional medicines : corticosteroids : your doctor will prescribe you steroid tablets ( equivalent to 4 milligram of dexamethasone twice a day ) that you will need to take on the day before, on the day of, and the day after pemetrexed hospira treatment. this medicine is given to you to reduce the frequency and severity of skin reactions that you may experience during your anticancer treatment. vitamin supplementation : your doctor will prescribe you oral folic acid ( vitamin ) or a multivitamin containing folic acid ( 350 to 1, 000 micrograms ) that you must take once a day while you are taking pemetrexed hospira. you must take at least 5 doses during the seven days before the first dose of pemetrexed hospira. you must continue taking the folic acid for 21 days after the last dose of pemetrexed
like all medicines, this medicine can cause side effects, although not everybody gets them. you must contact your doctor immediately if you notice any of the following : fever or infection ( common ): if you have a temperature of 38oc or greater, sweating or other signs of infection ( since you might have fewer white blood cells than normal which is very common ). infection ( sepsis ) may be severe and could lead to death. if you start feeling chest pain ( common ) or having a fast heart rate ( uncommon ). if you have pain, redness, swelling or sores in your mouth ( very common ). allergic reaction : if you develop skin rash ( very common ) / burning or prickling sensation ( common ), or fever ( common ). rarely, skin reactions may be severe and could lead to death. contact your doctor if you get a severe rash, or itching, or blistering ( stevens - johnson syndrome or toxic epidermal necrolysis ). if you experience tiredness, feeling faint, becoming easily breathless or if you look pale ( since you might have less haemoglobin than normal which is very common ). if you experience bleeding from the gums, nose or mouth or any bleeding that would not stop, reddish or pinkish urine, unexpected bruising ( since you might have fewer platelets than normal which is very common ). if you experience sudden breathlessness, intense chest pain or cough with bloody sputum ( uncommon ) ( may indicate a blood clot in the blood vessels of the lungs ). side effects with pemetrexed may include : very common ( may affect more than 1 in 10 people ) infection pharyngitis ( a sore throat ) low number of neutrophil granulocytes ( a type of white blood cell ) low white blood cells low haemoglobin level pain, redness, swelling or sores in your mouth loss of appetite vomiting diarrhoea nausea skin rash flaking skin abnormal blood tests showing reduced functionality of kidneys fatigue ( tiredness ) common ( may affect up to 1 in 10 people
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the carton and vial label after exp . the expiry date refers to the last day of that month . this medicine does not require any special storage conditions . reconstituted and infusion solution : the product should be used immediately . when prepared as directed , chemical and physical in - use stability of reconstituted and infusion solutions of pemetrexed were demonstrated for 24 hours at refrigerated temperature ( 2 to 8 ). the reconstituted solution is clear and ranges in colour from colourless to yellow or green - yellow without adversely affecting product quality . parenteral medicines must be inspected visually for particulate matter and discolouration prior to administration . if particulate matter is observed , do not administer . this medicine is for single use only ; any unused solution must be disposed of in accordance with local requirements .
what pemetrexed hospira contains the active substance is pemetrexed . pemetrexed hospira 100 mg powder for concentrate for solution for infusion : each vial contains 100 milligrams of pemetrexed ( as pemetrexed disodium hemipentahydrate ). pemetrexed hospira 500 mg powder for concentrate for solution for infusion : each vial contains 500 milligrams of pemetrexed ( as pemetrexed disodium hemipentahydrate ). pemetrexed hospira 1 , 000 mg powder for concentrate for solution for infusion : each vial contains 1 , 000 milligrams of pemetrexed ( as pemetrexed disodium hemipentahydrate ). after reconstitution as directed , the solution contains 25 mg / ml of pemetrexed . further dilution by a healthcare provider is required prior to administration . the other ingredients are mannitol ( e421 ), hydrochloric acid ( for ph adjustment ) and sodium hydroxide ( for ph adjustment ). refer to section 2 " pemetrexed hospira contains sodium ". what pemetrexed hospira looks like and contents of the pack pemetrexed hospira is a powder for concentrate for solution for infusion in a glass vial . it is a white to either light yellow or green - yellow lyophilised powder . each pack contains one vial of 100 mg , 500 mg or 1 , 000 mg pemetrexed as ( pemetrexed disodium hemipentahydrate ).
ganfort contains two different active substances ( bimatoprost and timolol ) that both reduce pressure in the eye . bimatoprost belongs to a group of medicines called prostamides , a prostaglandin analogue . timolol belongs to a group of medicines called beta - blockers . your eye contains a clear , watery liquid that feeds the inside of the eye . liquid is constantly being drained out of the eye and new liquid is made to replace this . if the liquid cannot drain out quickly enough , the pressure inside the eye builds up and could eventually damage your sight ( an illness called glaucoma ). ganfort works by reducing the production of liquid and also increasing the amount of liquid that is drained . this reduces the pressure inside the eye . ganfort eye drops are used to treat high pressure in the eye in adults , including the elderly . this high pressure can lead to glaucoma . your doctor will prescribe you ganfort when other eye drops containing beta - blockers or prostaglandin analogues have not worked sufficiently on their own .
do not use ganfort eye drops, solution - if you are allergic to bimatoprost, timolol, beta - blockers or any of the other ingredients of ganfort ( listed in section 6 ) - if you have now or have had in past respiratory problems such as asthma, severe chronic obstructive bronchitis ( severe lung disease which may cause wheeziness, difficulty in breathing and / or long - standing cough ) - if you have heart problems such as low heart rate, heart block, or heart failure warnings and precautions before you use this medicine, tell your doctor if you have now or have had in the past - coronary heart disease ( symptoms can include chest pain or tightness, breathlessness or choking ), heart failure, low blood pressure, 44 - disturbances of heart rate such as slow heart beat - breathing problems, asthma or chronic obstructive pulmonary disease - poor blood circulation disease ( such as raynaud's disease or raynaud's syndrome ) - overactivity of the thyroid gland as timolol may mask signs and symptoms of thyroid disease - diabetes as timolol may mask signs and symptoms of low blood sugar - severe allergic reactions - liver or kidney problems - eye surface problems - separation of one of the layers within the eyeball after surgery to reduce the pressure in the eye - known risk factors for macular oedema ( swelling of the retina within the eye leading to worsening vision ), for example, cataract surgery tell your doctor before surgical anaesthesia that you are using ganfort as timolol may change effects of some medicines used during anaesthesia. ganfort may cause your eyelashes to darken and grow, and cause the skin around the eyelid to darken too. the colour of your iris may also go darker over time. these changes may be permanent. the change may be more noticeable if you are only treating one eye. ganfort may cause hair growth when in contact with the skin surface. children and adolescents ganfort should not be used in children and teenagers under
always use ganfort exactly as your doctor or pharmacist has told you. check with your doctor or pharmacist if you are not sure. the usual dose is one drop once a day, either in the morning or in the evening in each eye that needs treatment. use at the same time each day. instructions for use you must not use the bottle if the tamper - proof seal on the bottle neck is broken before you first use it. 5. 1. wash your hands. tilt your head back and look at the ceiling. 2. gently pull down the lower eyelid until there is a small pocket. 3. turn the bottle upside down and squeeze it to release one drop into each eye that needs treatment. 4. let go of the lower lid, and close your eye. 5. whilst keeping the eye closed, press your finger against the corner of the closed eye ( the site where the eye meets the nose ) and hold for 2 minutes. this helps to stop ganfort getting into the rest of the body. if a drop misses your eye, try again. to avoid contamination, do not let the tip of the bottle touch your eye or anything else. put the cap back on and close the bottle straight after you have used it. if you use ganfort with another eye medicine, leave at least 5 minutes between putting in ganfort and the other medicine. use any eye ointment or eye gel last. if you use more ganfort than you should if you use more ganfort than you should, it is unlikely to cause you any serious harm. put your next dose in at the usual time. if you are worried, talk to your doctor or pharmacist. if you forget to use ganfort if you forget to use ganfort, use a single drop as soon as you remember, and then go back to your regular routine. do not use a double dose to make up for a forgotten dose. if you stop using ganfort ganfort should be used every day to work properly. if you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
like all medicines, ganfort can cause side effects, although not everybody gets them. you can usually carry on taking the drops, unless the effects are serious. if you're worried, talk to a doctor or pharmacist. do not stop using ganfort without speaking to your doctor. the following side effects may be seen with ganfort ( multi - dose and / or single - dose ): very common side effects these may affect more than 1 user in 10 affecting the eye redness. common side effects these may affect 1 to 9 users in 100 affecting the eye burning, itching, stinging, irritation of the conjunctiva ( see - through layer of the eye ), sensitivity to light, eye pain, sticky eyes, dry eyes, a feeling of something in the eye, small breaks in the surface of the eye with or without inflammation, difficulty in seeing clearly, redness and itching of the eyelids, hair growing around the eye, darkening of the eyelids, darker skin colour around the eyes, longer eyelashes, eye irritation, watery eyes, swollen eyelids, reduced vision. affecting other parts of the body runny nose, headache. uncommon side effects these may affect 1 to 9 users in 1, 000 affecting the eye abnormal sensation in the eye, iris inflammation, swollen conjunctiva ( see - through layer of the eye ), painful eyelids, tired eyes, in - growing eyelashes, darkening of iris colour, eyes appear sunken, eyelid has moved away from the surface of the eye, darkening of eyelashes. affecting other parts of the body shortness of breath. side effects where the frequency is not known affecting the eye cystoid macular oedema ( swelling of the retina within the eye leading to worsening vision ), eye swelling, blurred vision, ocular discomfort. affecting other parts of the body difficulty breathing / wheezing, symptoms of allergic reaction ( swelling, redness of the eye and rash of the skin ), changes in your taste
keep ganfort out of the sight and reach of children . do not use ganfort after the expiry date which is stated on the bottle label and the carton after exp . the expiry date refers to the last day of that month . this medicine does not require any special storage conditions . once opened , solutions may become contaminated , which can cause eye infections . therefore , you must throw away the bottle 4 weeks after you first opened it , even if some solution is left . to help you remember , write down the date that you opened it in the space on the carton . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help to protect the environment .
what ganfort contains the active substances are bimatoprost 0 . 3 mg / ml and timolol 5 mg / ml corresponding to timolol maleate 6 . 8 mg / ml . the other ingredients are benzalkonium chloride ( a preservative ), sodium chloride , sodium phosphate dibasic heptahydrate , citric acid monohydrate and purified water . small amounts of hydrochloric acid or sodium hydroxide may be added to bring the solution to the correct ph ( acidity ) level . what ganfort looks like and contents of the pack ganfort is a colourless to slightly yellow , clear eye drop solution in a plastic bottle . each pack contains either 1 or 3 plastic bottles each with a screw - cap . each bottle is about half full and contains 3 millilitres of solution . this is enough for 4 weeks ' usage . not all pack sizes may be marketed .
gefitinib mylan contains the active substance gefitinib which blocks a protein called ' epidermal growth factor receptor ' ( egfr ). this protein is involved in the growth and spread of cancer cells . gefitinib mylan is used to treat adults with non - small cell lung cancer . this cancer is a disease in which malignant ( cancer ) cells form in the tissues of the lung .
do not take gefitinib mylan : - if you are allergic to gefitinib or any of the other ingredients of this medicine ( listed in section 6 ). - if you are breast - feeding. warnings and precautions talk to your doctor or pharmacist before taking gefitinib mylan - if you have ever had any other lung problems. some lung problems may get worse during treatment with gefitinib mylan. - if you have ever had problems with your liver. children and adolescents gefitinib mylan is not indicated in children and adolescents under 18 years. other medicines and gefitinib mylan tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. in particular, tell your doctor or pharmacist if you are taking any of the following medicines : - phenytoin or carbamazepine ( for epilepsy ). - rifampicin ( for tuberculosis ). - itraconazole ( for fungal infections ). - barbiturates ( a type of medicine used for sleeping problems ). - herbal remedies containing st john's wort ( hypericum perforatum, used for depression and anxiety ). - proton - pump inhibitors, h2 - antagonists and antacids ( for ulcers, indigestion, heartburn and to reduce acids in the stomach ). these medicines may affect the way this medicine works. - warfarin ( a so - called oral anticoagulant, to prevent blood clots ). if you are taking a medicine containing this active substance, your doctor may need to do blood tests more often. if any of the above applies to you, or if you are not sure, check with your doctor or pharmacist before taking gefitinib mylan. pregnancy and breast - feeding if you are pregnant or breast - feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. it is recommended that you avoid becoming pregnant during treatment with this medicine because gefitini
always take this medicine exactly as your doctor or pharmacist has told you . check with your doctor or pharmacist if you are not sure . the recommended dose is one 250 mg tablet per day . take the tablet at about the same time each day . you can take the tablet with or without food . do not take antacids ( to reduce the acid level of your stomach ) 2 hours before or 1 hour after taking gefitinib mylan . if you have trouble swallowing the tablet , dissolve it in half a glass of still ( non - fizzy ) water . do not use any other liquids . do not crush the tablet . swirl the water until the tablet has dissolved . this may take up to 20 minutes . drink the liquid straight away . to make sure that you have drunk all of the medicine , rinse the glass very well with half a glass of water and drink it . if you take more gefitinib mylan than you should if you have taken more tablets than you should , talk to a doctor or pharmacist straight away . if you forget to take gefitinib mylan what to do if you forget to take a tablet depends on how long it is until your next dose . if it is 12 hours or more until your next dose : take the missed tablet as soon as you remember . then take the next dose as usual . if it is less than 12 hours until your next dose : skip the missed tablet . then take the next tablet at the usual time . do not take a double dose ( two tablets at the same time ) to make up for a forgotten dose . if you have any further questions on the use of this medicine , ask your doctor or pharmacist .
like all medicines, this medicine can cause side effects, although not everybody gets them. tell your doctor immediately if you notice any of the following side effects - you may need urgent medical treatment : allergic reaction ( common ), particularly if symptoms include swollen face, lips, tongue or throat, difficulty to swallow, hives, nettle rash and difficulty breathing. serious breathlessness, or sudden worsening breathlessness, possibly with a cough or fever. this may mean that you have an inflammation of the lungs called'interstitial lung disease '. this may affect about 1 in 100 patients taking gefitinib and can be life - threatening. severe skin reactions ( rare ) affecting large areas of your body. the signs may include redness, pain, ulcers, blisters, and shedding of the skin. the lips, nose, eyes and genitals may also be affected. dehydration ( common ) caused by long term or severe diarrhoea, vomiting ( being sick ), nausea ( feeling sick ) or loss of appetite. eye problems ( uncommon ), such as pain, redness, watery eyes, light sensitivity, changes in vision or ingrowing eyelashes. this may mean that you have an ulcer on the surface of the eye ( cornea ). tell your doctor as soon as possible if you notice any of the following side effects : very common ( may affect more than 1 in 10 people ): diarrhoea. vomiting. nausea. skin reactions such as an acne - like rash, which is sometimes itchy with dry and / or cracked skin. loss of appetite. weakness. red or sore mouth. increase of a liver enzyme known as alanine aminotransferase in a blood test ; if too high, your doctor may tell you to stop taking this medicine. common ( may affect up to 1 in 10 people ): dry mouth. dry, red or itchy eyes. red and sore eyelids. nail problems. hair loss. fever. bleeding ( such as nose bleed or blood in your urine ). protein in
what gefitinib mylan contains - the active substance is gefitinib . each film - coated tablet contains 250 mg of gefitinib . - the other ingredients are lactose monohydrate , microcrystalline cellulose ( 101 ), crospovidone ( type a ), povidone ( k30 ), sodium laurilsulfate , magnesium stearate in the tablet core . the tablet coating contains polyvinyl alcohol ( e1203 ), macrogol 4000 ( e1521 ), talc ( e553b ), titanium dioxide ( e171 ), red iron oxide ( e172 ), yellow iron oxide ( e172 ). what gefitinib mylan looks like and contents of the pack gefitinib mylan tablets are brown , round , biconvex film - coated tablets with approximately 11 . 1 mm x 5 . 6 mm of dimension and marked with " 250 " on one side and plain on the other . it comes in pvc / pvdc / aluminium blisters in packs of 30 film - coated tablets or in pvc / pvdc / aluminium perforated unit dose blisters in packs of 30x1 film - coated tablets . the blisters may be packed into aluminium pouches . not all pack sizes may be marketed .
reblozyl contains the active substance luspatercept . it is used for : myelodysplastic syndromes myelodysplastic syndromes ( mds ) are a collection of many different blood and bone marrow disorders . red blood cells become abnormal and do not develop properly . patients can get a number of signs and symptoms including a low red blood cell count ( anaemia ) and may need red blood cell transfusions . reblozyl is used in adults with anaemia caused by mds , who need red blood cell transfusions . it is used in adults who have already had or are not able to have erythropoietin therapies . beta - thalassaemia Î² - thalassaemia is a blood problem that is passed down through genes . it affects the production of haemoglobin . patients can get a number of signs and symptoms including a low red blood cell count ( anaemia ) and may need red blood cell transfusions . reblozyl is used in adults with Î² - thalassaemia who need red blood cell transfusions . how reblozyl works reblozyl improves your body ' s ability to make red blood cells . red blood cells contain haemoglobin , which is a protein that carries oxygen throughout your body . as your body makes more red blood cells , your haemoglobin level increases . having reblozyl reduces the need for red blood cell transfusions . regular blood transfusions can cause abnormally high levels of iron in the blood and in different organs of the body . this can be harmful over time .
do not use reblozyl if you are allergic to luspatercept or any of the other ingredients of this medicine ( listed in section 6 ) if you are pregnant ( see section on pregnancy ) warnings and precautions talk to your doctor before being given this medicine if : you are a <unk> - thalassaemia patient and you have had your spleen removed. you may have a higher risk of getting a blood clot. your doctor will talk to you about other possible risk factors that may increase your risk these include : o hormone replacement therapy or o a previous blood clot your doctor may use preventive measures or medicines to reduce the chances of you getting a blood clot. you have ever had high blood pressure this is because reblozyl may increase it. your blood pressure will be checked before you are given reblozyl and throughout treatment. routine tests you will have a blood test before each dose of this medicine. this is because your doctor needs to make sure your haemoglobin level is suitable for you to be given treatment. if you have kidney problems, your doctor may perform additional tests. children and adolescents this medicine is not recommended for use in children and adolescents under 18 years. other medicines and reblozyl tell your doctor if you are taking, have recently taken or might take any other medicines. pregnancy do not use this medicine during pregnancy and for at least 3 months before getting pregnant. reblozyl may cause harm to your unborn baby. your doctor will arrange a pregnancy test before starting treatment. if you think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. breast - feeding do not breast - feed when using this medicine and for 3 months after your last dose. it is not known if it passes into the mother's milk. contraception you should use an effective method of contraception during treatment with reblozyl and for at least 3 months after your last dose. talk to your doctor about contraceptive methods that may be right for you while you are using this medicine. fertility if you are a woman, this medicine may cause fertility problems. this could affect your ability to
before you are given this medicine , your doctor will have carried out blood tests and decided you need reblozyl . reblozyl will be given by an injection under your skin ( subcutaneously ). how much will you be given the dose is based on how much you weigh in kilograms . the injections will be given by a doctor , nurse or other healthcare professional . the recommended starting dose is 1 . 0 mg for each kilogram of body weight . this dose should be given once every three weeks . your doctor will check your progress and may change your dose if needed . your doctor will monitor your blood pressure while you are using reblozyl . myelodysplastic syndromes the maximum single dose is 1 . 75 mg for each kilogram of body weight . beta - thalassaemia the maximum single dose is 1 . 25 mg for each kilogram of body weight . if you miss a dose if you miss an injection of reblozyl , or an appointment is delayed , you will receive a reblozyl injection as soon as possible . then , your dose will continue as prescribed with at least 3 weeks between doses . if you have any further questions on the use of this medicine , ask your doctor or nurse .
like all medicines , this medicine may cause side effects , although not everybody gets them . serious side effects tell your doctor straight away if you notice the following : difficulty in walking or speaking , dizziness , loss of balance and coordination , numbness or paralysis in the face , leg or arm ( often on one side of your body ), blurred vision . they may all be symptoms of a stroke . blood clots swelling of the area around the eyes , the face , lips , mouth , tongue or throat allergic reactions rashes 36 other side effects include : very common side effects ( may affect more than 1 in 10 people ): chest infection difficulty in breathing or shortness of breath urinary tract infection dizziness , headache diarrhoea , feeling sick ( nausea ) back , joint or bone pain feeling tired or weak common side effects ( may affect up to 1 in 10 people ): flu symptoms fainting , spinning feeling high blood pressure associated with no symptoms or with headache redness , burning and pain at the site of injection ( injection site reactions ) high level of uric acid in the blood ( shown in tests ) reporting of side effects if you get any side effects , talk to your doctor or nurse . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the carton and the vial after exp . the expiry date refers to the last day of that month . unopened vials : store in a refrigerator ( 2 8 ). do not freeze . store in the original carton in order to protect from light . after first opening and reconstitution , reblozyl should be used immediately . if not used immediately , when held in the original carton the reconstituted medicinal product may be stored for up to 8 hours at room temperature (â¤ 25 ) or for up to 24 hours at 2 8 . do not freeze the reconstituted solution . any unused medicinal product or waste material should be disposed of in accordance with local requirements .
what reblozyl contains - the active substance is luspatercept . each vial contains 25 mg or 75 mg of luspatercept . after reconstitution , each ml of solution contains 50 mg luspatercept . - the other excipients are citric acid monohydrate ( e330 ), sodium citrate ( e331 ), polysorbate 80 , sucrose , hydrochloric acid ( for ph adjustment ) and sodium hydroxide ( for ph adjustment ). what reblozyl looks like and contents of the pack reblozyl is a white to off - white powder for solution for injection . reblozyl is supplied in glass vials containing 25 mg or 75 mg of luspatercept . each pack contains 1 vial .
the active substance in fotivda is tivozanib , which is a protein kinase inhibitor . tivozanib reduces the supply of blood to the cancer , which slows down the growth and spread of cancer cells . it works by blocking the action of a protein called vascular endothelial growth factor ( vegf ). blocking the action of vegf prevents the formation of new blood vessels . fotivda is used to treat adults with advanced kidney cancer . it is used where other treatments such as interferon - alpha or interleukin - 2 have either not yet been used or have not helped to stop your disease .
do not take fotivda : if you are allergic to tivozanib or any of the other ingredients of this medicine ( listed in section 6 ); if you are taking st. john's wort ( also known as hypericum perforatum, a herbal remedy used for treatment of depression and anxiety ). warnings and precautions talk to your doctor, pharmacist or nurse before taking fotivda : if you have high blood pressure. fotivda can increase your blood pressure. your doctor will monitor your blood pressure regularly and, if it is too high, may either give you a medicine to lower it, or reduce your dose of fotivda. however, if your blood pressure remains too high, your doctor may decide to interrupt or to stop treatment with fotivda. if you are already taking a medicine to treat high blood pressure, and your doctor reduces the dose of fotivda or interrupts or stops treatment, you will be regularly checked for low blood pressure. if you have or have had an aneurysm ( enlargement and weakening of a blood vessel wall ) or a tear in a blood vessel wall. if you have had problems with blood clots. treatment with fotivda may raise the risk of developing a blood clot ( thrombus ) in your blood vessels that could break loose and be carried by the blood stream to block another blood vessel. tell your doctor if you have ever had one of the following : o a blood clot in your lungs ( with cough, chest pain, sudden shortness of breath or coughing up blood ), o blood clot in your legs or arms, eye, or brain ( with pain or swelling in your hands or feet, reduced vision, or changes in your mental state ) o a stroke, or signs and symptoms of a'mini - stroke'( transient ischaemic attack ) o a heart attack o high blood pressure o diabetes o major surgery o multiple injuries such as broken bones and damage to internal organs o inability to move for a long period o heart
always take this medicine exactly as your doctor has told you. check with your doctor or pharmacist if you are not sure. recommended dose the recommended dose is one fotivda 1340 microgram capsule, taken once daily for 21 days ( 3 weeks ), followed by a 7 - day ( 1 - week ) period when no capsules are taken. this schedule is repeated in cycles of 4 weeks. your doctor will check you regularly, and you will normally continue to take fotivda as long as it is working, and you do not suffer unacceptable side effects. reduced dose in case you experience severe side effects, your doctor may decide to interrupt fotivda therapy and / or lower the dose to : one fotivda 890 microgram capsule, taken once daily for 21 days ( 3 weeks ), followed by a 7 - day ( 1 - week ) period when no capsules are taken. this schedule is repeated in cycles of 4 weeks. liver problems if you have liver problems, your doctor may reduce how often you take your dose to every other day ( i. e. one 1340 microgram capsule every other day ). taking with food and drink fotivda must be taken with a glass of water and can be taken either with or without food. swallow the capsule whole. do not chew, dissolve or open the capsule before swallowing. if you take more fotivda than you should tell your doctor straightaway if you have taken more than your prescribed dose of 1 capsule per day. days ( three weeks ) one fotivda capsule taken once daily 7 days ( 1 week ) no capsules are taken 36 taking too much fotivda makes side effects more likely or to become more severe, especially high blood pressure. get medical help straightaway if you experience confusion, changes in your mental state or headaches. these are all symptoms of high blood pressure. if you forget to take fotivda if you have missed taking a capsule do not take a replacement capsule. continue to take your next dose at the usual time. do not take a double dose to make up for a forgotten capsule. if you vomit after taking fotivda, do not take a replacement capsule. continue to
like all medicines, this medicine can cause side effects, although not everybody gets them. serious side effects high blood pressure is the most serious and a very common side effect ( see also in section 2 " warnings and precautions "). tell your doctor immediately if you think you have high blood pressure. symptoms include severe headaches, blurred vision, shortness of breath, changes in your mental state, such as feeling anxious, confused or disorientated your doctor will check your blood pressure regularly during treatment with fotivda. if you develop high blood pressure, your doctor may prescribe a medicine to treat your high blood pressure, lower your dose of fotivda, or stop your treatment with fotivda. other side effects very common ( may affect more than 1 in 10 people ) difficulty speaking diarrhoea loss of appetite ; weight loss. headache difficult breathing ; shortness of breath during exercise ; coughing. tiredness ; unusual weakness ; pain ( including in the mouth, bone, extremities, side of the body, groin, tumour ). inflammation of the mouth ; slight mouth pain or discomfort ; feeling sick ; pain, discomfort and tightness in the stomach. hand - foot - syndrome with skin reddening, swelling, numbness and skin peeling on palms and soles. back pain tiredness and lack of energy. common ( may affect up to 1 in 10 people ) underactive thyroid gland which may cause symptoms such as tiredness, lethargy, muscle weakness, slow heart rate, weight gain. unable to sleep. nerve damage including numbness, pins and needles, sensitive skin or numbness and weakness in the arms and legs. sight problems including blurred vision. rapid heart rate ; tightness of the chest ; heart attack / reduced blood flow to heart ; blood clot in an artery ( blood vessel ). blood clot in the lung. symptoms include cough, chest pain, sudden shortness of breath or coughing up blood. blood clot in a deep vein such as in the leg. very high blood pressure leading to a stroke ; flushed skin
what fotivda contains fotivda 890 microgram hard capsules the active substance is tivozanib. each capsule contains tivozanib hydrochloride monohydrate equivalent to 890 microgram of tivozanib. the other ingredients are : - capsule content : mannitol, magnesium stearate. - capsule shell : gelatin, titanium dioxide ( e171 ), indigo carmine ( e132 ), yellow iron oxide ( e172 ). - printing ink, yellow : shellac, propylene glycol, strong ammonia solution, titanium dioxide ( e171 ), tartrazine aluminium lake ( e102 ). - printing ink, blue : shellac, propylene glycol, strong ammonia solution, indigo carmine aluminium lake ( e132 ). fotivda 1340 microgram hard capsules the active substance is tivozanib. each capsule contains tivozanib hydrochloride monohydrate equivalent to 1340 microgram of tivozanib. the other ingredients are : - capsule content : mannitol, magnesium stearate. - capsule shell : gelatin, titanium dioxide ( e171 ), yellow iron oxide ( e172 ). - printing ink, blue : shellac, propylene glycol, strong ammonia solution, indigo carmine aluminium lake ( e132 ). what fotivda looks like and contents of the pack fotivda 890 microgram hard capsules have a dark blue opaque cap and bright yellow opaque body, printed with yellow ink " tivz " on the cap and with dark blue ink " ld " on the body. fotivda 1340 microgram hard capsules have a bright yellow opaque cap and bright yellow opaque body, printed with dark blue ink " tivz " on the cap and with dark blue ink " sd " on the body. fotivda 890 microgram and fotivda 1340 microgram are available as packs of 21 capsule
stribild contains four active substances : elvitegravir , an antiretroviral medicine known as an integrase inhibitor cobicistat , a booster ( pharmacokinetic enhancer ) of the effects of elvitegravir emtricitabine , an antiretroviral medicine known as a nucleoside reverse transcriptase inhibitor ( nrti ) tenofovir disoproxil , an antiretroviral medicine known as a nucleotide reverse transcriptase inhibitor ( ntrti ) stribild is a single tablet regimen for the treatment of human immunodeficiency virus ( hiv ) infection in adults . stribild is also used to treat hiv - 1 infected adolescents aged 12 to less than 18 years who weigh at least 35 kg , and who have already been treated with other hiv medicines that have caused side effects . stribild reduces the amount of hiv in your body . this will improve your immune system and reduce the risk of developing illnesses linked to hiv infection .
do not take stribild if you are allergic to elvitegravir, cobicistat, emtricitabine, tenofovir, tenofovir disoproxil, or any of the other ingredients of this medicine ( listed in section 6 of this leaflet ). if you stopped treatment with any medicine containing tenofovir disoproxil on the advice of your doctor following problems with your kidney function. if you are taking one of these medicines : - alfuzosin ( used to treat an enlarged prostate gland ) - amiodarone, quinidine ( used to correct irregular heartbeats ) 47 - dabigatran ( used to prevent and treat blood clots ) - carbamazepine, phenobarbital, phenytoin ( used to prevent seizures ) - rifampicin ( used to prevent and treat tuberculosis and other infections ) - dihydroergotamine, ergotamine, ergometrine ( used to treat migraine headache ) - cisapride ( used to relieve certain stomach problems ) - st. john's wort ( hypericum perforatum, a herbal remedy used for depression and anxiety ) or products that contain it - lovastatin, simvastatin ( used to lower blood cholesterol ) - pimozide, lurasidone ( used to treat abnormal thoughts or feelings ) - sildenafil ( used to treat pulmonary arterial hypertension a lung disease that makes breathing difficult ) - orally administered midazolam, triazolam ( used to help you sleep and / or relieve anxiety ) if any of these applies to you, you should not take stribild and you should tell your doctor immediately. warnings and precautions you must remain under the care of your doctor while taking stribild. you can still pass on hiv when taking this medicine, although the risk is lowered by effective antiretroviral therapy. discuss with your doctor the precautions needed to avoid
always take this medicine exactly as your doctor has told you. check with your doctor or pharmacist if you are not sure. recommended dose for adults and adolescents aged 12 to less than 18 years who weigh at least 35 kg : one tablet each day by mouth, with food. do not chew, crush or split the tablet. always take the dose recommended by your doctor. this is to make sure that your medicine is fully effective, and to reduce the risk of developing resistance to the treatment. do not change the dose unless your doctor tells you to. if you are taking medicines, oral supplements, antacids or laxatives containing minerals ( such as magnesium, aluminium, calcium, iron, zinc ), take them at least 4 hours before or at least 4 hours after stribild. if you take more stribild than you should if you accidentally take more than the recommended dose of stribild you may be at increased risk of experiencing possible side effects with this medicine ( see section 4, possible side effects ). contact your doctor or nearest emergency department immediately for advice. keep the tablet bottle with you so that you can easily describe what you have taken. if you forget to take stribild it is important not to miss a dose of stribild. if you do miss a dose : and you notice within 18 hours of the time you usually take stribild, you must take the tablet as soon as possible. always take the tablet with food. then take the next dose as usual. and you notice 18 hours or more after the time you usually take stribild, then do not take the missed dose. wait and take the next dose, with food, at your usual time. if you vomit less than 1 hour after taking stribild, take another tablet with food. do not stop taking stribild do not stop taking stribild without talking to your doctor. stopping stribild can seriously affect your response to future treatment. if stribild is stopped for any reason, speak to your doctor before you restart taking stribild tablets. when your supply of stribild starts to run low, get more from your doctor or pharmacist. this is very
during hiv therapy there may be an increase in weight and in levels of blood lipids and glucose. this is partly linked to restored health and life style, and in the case of blood lipids sometimes to the hiv medicines themselves. your doctor will test for these changes. like all medicines, this medicine can cause side effects, although not everybody gets them. when treating hiv infection, it is not always possible to tell whether some of the unwanted effects are caused by stribild or by other medicines that you are taking at the same time, or by the hiv disease itself. possible serious side effects : tell a doctor immediately lactic acidosis ( excess lactic acid in the blood ) is a rare but potentially life - threatening side effect of some hiv medicines. lactic acidosis occurs more often in women particularly if they are overweight and in people with liver disease. the following may be signs of lactic acidosis : - deep, rapid breathing - tiredness or drowsiness - feeling sick ( nausea ), being sick ( vomiting ) - stomach pain if you think you may have lactic acidosis, tell your doctor immediately. any signs of inflammation or infection. in some patients with advanced hiv infection ( aids ) and a history of opportunistic infections ( infections that occur in people with a weak immune system ), signs and symptoms of inflammation from previous infections may occur soon after anti - hiv treatment is started. it is thought that these symptoms are due to an improvement in the body's immune response, enabling the body to fight infections that may have been present with no obvious symptoms. in addition to the opportunistic infections, autoimmune disorders ( a condition that occurs when the immune system attacks healthy body tissue ) may also occur after you start taking medicines for the treatment of your hiv infection. autoimmune disorders may occur many months after the start of treatment. if you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment. if you notice any symptoms
what stribild contains the active substances are elvitegravir , cobicistat , emtricitabine and tenofovir disoproxil . each stribild film - coated tablet contains 150 mg of elvitegravir , 150 mg of cobicistat , 200 mg of emtricitabine and 245 mg of tenofovir disoproxil ( equivalent to 300 mg of tenofovir disoproxil fumarate or 136 mg of tenofovir ). the other ingredients are tablet core : croscarmellose sodium , hydroxypropyl cellulose , lactose monohydrate , magnesium stearate , microcrystalline cellulose , silicon dioxide , sodium lauryl sulfate . film - coating : indigo carmine aluminium lake ( e132 ), macrogol 3350 ( e1521 ), polyvinyl alcohol ( partially hydrolysed ) ( e1203 ), talc ( e553b ), titanium dioxide ( e171 ), yellow iron oxide ( e172 ). what stribild looks like and contents of the pack stribild film - coated tablets are green , capsule - shaped tablets , debossed on one side with " gsi " and the number " 1 " surrounded by a square box on the other side of the tablet . stribild comes in bottles of 30 tablets ( with a silica gel desiccant that must be kept in the bottle to help protect your tablets ). the silica gel desiccant is contained in a separate sachet or canister and should not be swallowed . the following pack sizes are available : outer cartons containing 1 bottle of 30 film - coated tablets and 90 ( 3 bottles of 30 ) film - coated tablets . not all pack sizes may be marketed .
zyprexa contains the active substance olanzapine . zyprexa belongs to a group of medicines called antipsychotics and is used to treat the following conditions : schizophrenia , a disease with symptoms such as hearing , seeing or sensing things which are not there , mistaken beliefs , unusual suspiciousness , and becoming withdrawn . people with this disease may also feel depressed , anxious or tense . moderate to severe manic episodes , a condition with symptoms of excitement or euphoria . zyprexa has been shown to prevent recurrence of these symptoms in patients with bipolar disorder whose manic episode has responded to olanzapine treatment .
do not take zyprexa if you are allergic ( hypersensitive ) to olanzapine or any of the other ingredients of this medicine ( listed in section 6 ). an allergic reaction may be recognised as a rash, itching, a swollen face, swollen lips or shortness of breath. if this has happened to you, tell your doctor. if you have been previously diagnosed with eye problems such as certain kinds of glaucoma ( increased pressure in the eye ). warnings and precautions talk to your doctor or pharmacist before you take zyprexa. the use of zyprexa in elderly patients with dementia is not recommended as it may have serious side effects. medicines of this type may cause unusual movements mainly of the face or tongue. if this happens after you have been given zyprexa tell your doctor. very rarely, medicines of this type cause a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness. if this happens, contact your doctor at once. weight gain has been seen in patients taking zyprexa. you and your doctor should check your weight regularly. consider referral to a dietician or help with a diet plan if necessary. high blood sugar and high levels of fat ( triglycerides and cholesterol ) have been seen in patients taking zyprexa. your doctor should do blood tests to check blood sugar and certain fat levels before you start taking zyprexa and regularly during treatment. tell the doctor if you or someone else in your family has a history of blood clots, as medicines like these have been associated with the formation of blood clots. if you suffer from any of the following illnesses tell your doctor as soon as possible : stroke or " mini " stroke ( temporary symptoms of stroke ) parkinson's disease prostate problems a blocked intestine ( paralytic ileus ) liver or kidney disease blood disorders heart disease diabetes seizures if you know that you may have salt depletion as a result of prolonged severe diarrhoea and vomiting ( being sick ) or usage of diuretics ( water tablets )
always take this medicine exactly as your doctor has told you. check with your doctor or pharmacist if you are not sure. your doctor will tell you how many zyprexa tablets to take and how long you should continue to take them. the daily dose of zyprexa is between 5 mg and 20 mg. consult your doctor if your symptoms return but do not stop taking zyprexa unless your doctor tells you to. you should take your zyprexa tablets once a day following the advice of your doctor. try to take your tablets at the same time each day. it does not matter whether you take them with or without food. zyprexa coated tablets are for oral use. you should swallow the zyprexa tablets whole with water. if you take more zyprexa than you should patients who have taken more zyprexa than they should have experienced the following symptoms : rapid beating of the heart, agitation / aggressiveness, problems with speech, unusual movements ( especially of the face or tongue ) and reduced level of consciousness. other symptoms may be : acute confusion, seizures ( epilepsy ), coma, a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness, slowing of the breathing rate, aspiration, high blood pressure or low blood pressure, abnormal rhythms of the heart. contact your doctor or hospital straight away if you experience any of the above symptoms. show the doctor your pack of tablets. if you forget to take zyprexa take your tablets as soon as you remember. do not take two doses in one day. if you stop taking zyprexa do not stop taking your tablets just because you feel better. it is important that you carry on taking zyprexa for as long as your doctor tells you. if you suddenly stop taking zyprexa, symptoms such as sweating, unable to sleep, tremor, anxiety or nausea and vomiting might occur. your doctor may suggest you to reduce the dose gradually before stopping treatment. if you have any further questions on the use of this medicine, ask your doctor or pharmacist.
like all medicines, this medicine can cause side effects, although not everybody gets them. tell your doctor immediately if you have : unusual movement ( a common side effect that may affect up to 1 in 10 people ) mainly of the face or tongue ; blood clots in the veins ( an uncommon side effect that may affect up to 1 in 100 people ) especially in the legs ( symptoms include swelling, pain, and redness in the leg ), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing. if you notice any of these symptoms seek medical advice immediately ; a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness ( the frequency of this side effect cannot be estimated from the available data ). very common side effects ( may affect more than 1 in 10 people ) include weight gain ; sleepiness ; and increases in levels of prolactin in the blood. in the early stages of treatment, some people may feel dizzy or faint ( with a slow heart rate ), especially when getting up from a lying or sitting position. this will usually pass on its own but if it does not, tell your doctor. common side effects ( may affect up to 1 in 10 people ) include changes in the levels of some blood cells, circulating fats and early in treatment, temporary increases in liver enzymes ; increases in the level of sugars in the blood and urine ; increases in levels of uric acid and creatine phosphokinase in the blood ; feeling more hungry ; dizziness ; restlessness ; tremor ; unusual movements ( dyskinesias ); constipation ; dry mouth ; rash ; loss of strength ; extreme tiredness ; water retention leading to swelling of the hands, ankles or feet ; fever ; joint pain ; and sexual dysfunctions such as decreased libido in males and females or erectile dysfunction in males. uncommon side effects ( may affect up to 1 in 100 people ) include hypersensitivity ( e. g. swelling in the mouth and throat, itching, rash ); diabetes or the worsening of diabetes
keep this medicine out of sight and reach of children . do not use this medicine after the expiry date , which is stated on the carton . zyprexa should be stored in its original pack in order to protect from light and moisture . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help to protect the environment .
what zyprexa contains the active substance is olanzapine. each zyprexa tablet contains either 2. 5 mg, 5 mg, 7. 5 mg, 10 mg, 15 mg or 20 mg of the active substance. the exact amount is shown on your zyprexa tablet pack. the other ingredients are - ( tablet core ) lactose monohydrate, hyprolose, crospovidone, microcrystalline cellulose, magnesium stearate and - ( tablet coating ) hypromellose, titanium dioxide ( e171 ), carnauba wax. in addition the different zyprexa tablet strengths also contain the following ingredients : tablet strength other ingredients zyprexa 2. 5 mg, 5 mg, 7. 5 mg and 10 mg tablets ( tablet coating ) shellac, macrogol, propylene glycol, polysorbate 80 and indigo carmine colour ( e132 ), ethanol anhydrous, isopropyl alcohol, butyl alcohol, ammonium hydroxide zyprexa 15 mg tablets ( tablet coating ) triacetin and indigo carmine colour ( e132 ) zyprexa 20 mg tablets ( tablet coating ) macrogol and synthetic red iron oxide ( e172 ) what zyprexa looks like and contents of the pack zyprexa 2. 5 mg coated tablets are white imprinted with " lilly " and a numeric identicode " 4112 ". zyprexa 5 mg coated tablets are white imprinted with " lilly " and a numeric identicode " 4115 ". zyprexa 7. 5 mg coated tablets are white imprinted with " lilly " and a numeric identicode " 4116 ". zyprexa 10 mg coated tablets are white imprinted with " lilly " and a numeric identicode " 4117 ". zyprexa 15 mg coated tablets are blue. zyprexa 20 mg coated tablets are pink. zyprexa is available in packs containing
what prolia is and how it works prolia contains denosumab , a protein ( monoclonal antibody ) that interferes with the action of another protein , in order to treat bone loss and osteoporosis . treatment with prolia makes bone stronger and less likely to break . bone is a living tissue and is renewed all the time . oestrogen helps keep bones healthy . after the menopause , oestrogen level drops which may cause bones to become thin and fragile . this can eventually lead to a condition called osteoporosis . osteoporosis can also occur in men due to a number of causes including ageing and / or a low level of the male hormone , testosterone . it can also occur in patients receiving glucocorticoids . many patients with osteoporosis have no symptoms , but they are still at risk of breaking bones , especially in the spine , hips and wrists . surgery or medicines that stop the production of oestrogen or testosterone used to treat patients with breast or prostate cancer can also lead to bone loss . the bones become weaker and break more easily . what prolia is used for prolia is used to treat : osteoporosis in women after the menopause ( postmenopausal ) and men who have an increased risk of fracture ( broken bones ), reducing the risk of spinal , non - spinal and hip fractures . bone loss that results from a reduction in hormone ( testosterone ) level caused by surgery or treatment with medicines in patients with prostate cancer . bone loss that results from long - term treatment with glucocorticoids in patients who have an increased risk of fracture .
do not use prolia if you have low calcium levels in the blood ( hypocalcaemia ). if you are allergic to denosumab or any of the other ingredients of this medicine ( listed in section 6 ). warnings and precautions talk to your doctor or pharmacist before using prolia whilst being treated with prolia you may develop a skin infection with symptoms such as a swollen, red area of skin, most commonly in the lower leg, that feels hot and tender ( cellulitis ), and possibly with symptoms of fever. please tell your doctor immediately if you develop any of these symptoms. please tell your doctor if you have an allergy to latex ( the needle cover on the pre - filled syringe contains a derivative of latex ). you should also take calcium and vitamin d supplements while being on treatment with prolia. your doctor will discuss this with you. you may have low levels of calcium in your blood while receiving prolia. please tell your doctor immediately if you notice any of the following symptoms : spasms, twitches, or cramps in your muscle, and / or numbness or tingling in your fingers, toes or around your mouth, and / or seizures, confusion, or loss of consciousness. tell your doctor if you have or have ever had severe kidney problems, kidney failure or have needed dialysis or are taking medicines called glucocorticoids ( such as prednisolone or dexamethasone ), which may increase your risk of getting low blood calcium if you do not take calcium supplements. problems with your mouth, teeth or jaw a side effect called osteonecrosis of the jaw ( onj ) ( bone damage in the jaw ) has been reported rarely ( may affect up to 1 in 1, 000 people ) in patients receiving prolia for osteoporosis. the risk of onj increases in patients treated for a long time ( may affect up to 1 in 200 people if treated for 10 years ). onj can also occur after stopping treatment. it is important to try to prevent onj developing as it may be a painful condition that can be
the recommended dose is one pre - filled syringe of 60 mg administered once every 6 months , as a single injection under the skin ( subcutaneous ). the best places to inject are the top of your thighs and the abdomen . your carer can also use the outer area of your upper arm . each pack of prolia contains a reminder card with stickers that can be removed from the carton . use the peel - off stickers to mark the next injection date on your personal calendar and / or the reminder card to keep a record of the next injection date . you should also take calcium and vitamin d supplements while being on treatment with prolia . your doctor will discuss this with you . your doctor may decide that it is best for you or a carer to inject prolia . your doctor or healthcare provider will show you or your carer how to use prolia . for instructions on how to inject prolia , please read the section at the end of this leaflet . do not shake . if you forget to use prolia if a dose of prolia is missed , the injection should be administered as soon as possible . thereafter , injections should be scheduled every 6 months from the date of the last injection . if you stop using prolia to get the most benefit from your treatment , it is important to use prolia for as long as your doctor prescribes it for you . please talk to your doctor before you consider stopping the treatment .
like all medicines, this medicine can cause side effects, although not everybody gets them. uncommonly, patients receiving prolia may develop skin infections ( predominantly cellulitis ). please tell your doctor immediately if you develop any of these symptoms while being on treatment with prolia : swollen, red area of skin, most commonly in the lower leg, that feels hot and tender, and possibly with symptoms of fever. rarely, patients receiving prolia may develop pain in the mouth and / or jaw, swelling or non - healing of sores in the mouth or jaw, discharge, numbness or a feeling of heaviness in the jaw, or loosening of a tooth. these could be signs of bone damage in the jaw ( osteonecrosis ). tell your doctor and dentist immediately if you experience such symptoms while being treated with prolia or after stopping treatment. rarely, patients receiving prolia may have low calcium levels in the blood ( hypocalcaemia ). symptoms include spasms, twitches, or cramps in your muscles, and / or numbness or tingling in your fingers, toes or around your mouth and / or seizures, confusion, or loss of consciousness. if any of these apply to you, tell your doctor immediately. low calcium in the blood may also lead to a change in heart rhythm called qt prolongation which is seen by electrocardiogram ( ecg ). rarely unusual fractures of the thigh bone may occur in patients receiving prolia. contact your doctor if you experience new or unusual pain in your hip, groin or thigh as this may be an early indication of a possible fracture of the thigh bone. rarely, allergic reactions may occur in patients receiving prolia. symptoms include swelling of the face, lips, tongue, throat or other parts of the body ; rash, itching or hives on the skin, wheezing or difficulty breathing. please tell your doctor if you develop any of these symptoms while being treated with prolia. very common side effects ( may affect more than 1 in
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the label and carton after exp . the expiry date refers to the last day of that month . store in a refrigerator ( 2 8 ). do not freeze . keep the container in the outer carton in order to protect from light . your pre - filled syringe may be left outside the refrigerator to reach room temperature ( up to 25 ) before injection . this will make the injection more comfortable . once your syringe has been left to reach room temperature ( up to 25 ), it must be used within 30 days . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help to protect the environment .
what prolia contains - the active substance is denosumab . each 1 ml pre - filled syringe contains 60 mg of denosumab ( 60 mg / ml ). - the other ingredients are acetic acid , glacial , sodium hydroxide , sorbitol ( e420 ), polysorbate 20 and water for injections . what prolia looks like and contents of the pack prolia is a clear , colourless to slightly yellow solution for injection provided in a ready to use pre - filled syringe . each pack contains one pre - filled syringe with a needle guard . each pack contains one pre - filled syringe . not all pack sizes may be marketed .
ambirix is a vaccine used in infants, children and young people from 1 year up to and including 15 years. it is used to prevent two diseases : hepatitis a and hepatitis b. hepatitis a : infection with the hepatitis a virus may cause the liver to become swollen ( inflamed ). the virus is usually caught from food or drink that contains the virus. however, it is sometimes caught in other ways, such as by swimming in water that has sewage in it or from another infected person. the virus is found in body fluids such as faeces, serum or saliva. symptoms begin 3 to 6 weeks after infection. some people can feel sick, have a fever and aches and pains. after a few days they may be very tired, and have dark urine, pale faeces, yellowish skin or eyes ( jaundice ). the severity and type of symptoms can vary. young children may not get all symptoms. most children recover completely but the illness is usually severe enough to make children ill for about a month. hepatitis b : infection with the hepatitis b virus may cause the liver to become swollen ( inflamed ). the virus is usually caught from another infected person. it is found in body fluids such as blood, semen, vaginal secretions, or saliva ( spit ). symptoms may not be seen for 6 weeks to 6 months after infection. not always people who have been infected look or feel ill. some people can feel sick, have a fever and aches and pains. however, others can become very ill. they may be very tired, and have dark urine, pale faeces, yellowish skin or eyes ( jaundice ). some people may need to go into hospital. most adults fully recover from the disease, but some people ( particularly children ) who may not have had symptoms can remain infected. they are called hepatitis b " carriers " and can still infect other people throughout their lives. carriers are also at
ambirix should not be given if : you are allergic to ambirix, or any of the other ingredients of this vaccine ( listed in section 6 ). signs of an allergic reaction may include itchy skin rash, shortness of breath and swelling of your face or tongue you have previously had an allergic reaction to any vaccine against hepatitis a or hepatitis b diseases you have a severe infection with a high temperature. the vaccine can be given after you have recovered. a minor infection such as a cold should not be a problem, but talk to your doctor first. ambirix should not be given if any of the above apply. if you are not sure, talk to your doctor, nurse or pharmacist before having ambirix. warnings and precautions talk to your doctor, nurse or pharmacist before having ambirix if : you need to be fully protected against hepatitis a and b infection within the next 6 months your doctor may recommend a different vaccine you have a bleeding problem or bruise easily - the injection may be given just under the skin instead of into a muscle to reduce the amount of bleeding or bruising you have immune system problems ( such as due to an illness, treatment or dialysis ) - the vaccine may not work fully. this means you may not be protected against one or both of the hepatitis a and b viruses. your doctor will run blood tests to see whether more injections are needed to help you be better protected you have fainted before or during a previous injection in case this happens again. fainting can occur ( mostly in adolescents ) following, or even before, any needle injection. if any of the above apply ( or you are not sure ), talk to your doctor, nurse or pharmacist before having ambirix. other medicines and ambirix tell your doctor if you are taking, have recently taken or might take any other medicines or vaccines. this includes medicines obtained without a prescription and herbal medicines. ask your doctor, nurse or pharmasist if you are not sure. if you are taking medicines that affect your body's immune response, you can still have ambirix if this is thought to be necessary
how the injection is given the doctor or nurse will give ambirix as an injection into a muscle . this is usually into the upper arm . they will take care that ambirix is not given into a vein . in very small children , the injection may be given into the thigh muscle . how much is given you will normally have a total of two injections . each is given on a separate visit . the injections will be given within 12 months : - the first injection on a date agreed with your doctor . - the second injection between 6 and 12 months after the first injection . your doctor will advise on the possible need for extra doses , and future booster dosing . missing a dose if you miss the second injection , talk to your doctor and arrange another visit as soon as possible . make sure you finish the complete course of two injections . if not , you may not be protected against the diseases .
like all medicines, this vaccine can cause side effects, although not everybody gets them. serious side effects tell your doctor straight away if you notice any of the following serious side effects you may need urgent medical treatment : allergic and anaphylactic reactions - the signs can include a rash that may be itchy or blistering, swelling of the eyes and face, difficulty in breathing or swallowing, a sudden drop in blood pressure and loss of consciousness. tell your doctor straight away if you notice any of the serious side effects listed above. side effects that occurred during clinical trials with ambirix were as follows : very common ( these may occur with more than 1 in 10 doses of the vaccine ) : headache loss of appetite feeling tired or irritable pain and redness where the injection was given common ( these may occur with up to 1 in 10 doses of the vaccine ) : fever feeling drowsy stomach and digestive problems swelling where the injection was given additional side effects that have been reported during clinical trials with very similar combined hepatitis a and hepatitis b vaccines, include : common ( these may occur with up to 1 in 10 doses of the vaccine ) : generally feeling unwell diarrhoea, feeling sick ( nausea ) reaction where the injection was given uncommon ( these may occur with up to 1 in 100 doses of the vaccine ) : feeling dizzy stomach pain being sick ( vomiting ) upper airway infections aching muscles ( myalgia ) rare ( these may occur with up to 1 in 1, 000 doses of the vaccine ) : low blood pressure joint pain ( arthralgia ) itching ( pruritus ), rash pins and needles ( paraesthesia ) swollen glands in the neck, armpit or groin ( lymphadenopathy ) flu - like symptoms, such as high temperature, sore throat, runny nose, cough and chills very rare ( these may occur with up to 1 in 10, 000 doses of the vaccine ): hives ( urticaria ) 25 please contact your doctor if you have similar side effects. side effects that occurred during routine use of ambirix were as
what ambirix contains 26 the active substances are : - hepatitis a virus ( inactivated ) 1 , 2 720 elisa units - hepatitis b surface antigen 3 , 4 20 micrograms 1produced on human diploid ( mrc - 5 ) cells 2adsorbed on aluminium hydroxide , hydrated 0 . 05 milligrams al3 + 3produced in yeast cells ( saccharomyces cerevisiae ) by recombinant dna technology 4adsorbed on aluminium phosphate , 0 . 4 milligrams al3 + the other ingredients in ambirix are : sodium chloride and water for injections . what ambirix looks like and contents of the pack suspension for injection in a pre - filled syringe . ambirix is a white , slightly milky liquid presented in a glass 1 ml pre - filled syringe . ambirix is available in packs of 1 and 10 pre - filled syringes ( with or without needles ) and in pack sizes of 50 pre - filled syringes without needles . not all pack sizes may be marketed .
bexsero is a meningococcal group b vaccine . bexsero contains four different components from the surface of the bacteria neisseria meningitidis group b . bexsero is given to individuals from 2 months of age and older to help protect against disease caused by the neisseria meningitidis group b bacteria . these bacteria can cause serious , and sometimes life - threatening , infections such as meningitis ( inflammation of the covering of the brain and spinal cord ) and sepsis ( blood poisoning ). the vaccine works by specifically stimulating the body ' s natural defense system of the vaccinated person . this results in protection against the disease .
do not use bexsero - if you or your child are allergic to the active substances or any of the other ingredients of this vaccine ( listed in section 6 ). warnings and precautions talk to your doctor or nurse before you or your child receive bexsero : - if you or your child have a severe infection with a high temperature. if this is the case, then vaccination will be postponed. the presence of a minor infection, such as a cold, should not require postponement of the vaccination, but talk to your doctor or nurse first. - if you or your child have haemophilia or any other problem that may stop your blood from clotting properly, such as treatment with blood thinners ( anticoagulants ). talk to your doctor or nurse first. - if you or your child receive treatment that blocks the part of the immune system known as complement activation, such as eculizumab. even if you or your child have been vaccinated with bexsero you or your child remain at increased risk of disease caused by the neisseria meningitidis group b bacteria. - if your child was born prematurely ( before or at 28 weeks of pregnancy ), particularly if they had breathing difficulties. stopping breathing or irregular breathing for a short time may be more common in the first three days following vaccination in these babies and they may need special monitoring. - if you or your child have an allergy to the antibiotic kanamycin. if present, the kanamycin level in the vaccine is low. if you or your child may have an allergy to kanamycin, talk to your doctor or nurse first. fainting, feeling faint or other stress - related reactions can occur as a response to any needle injection. tell your doctor or nurse if you have experienced this kind of reaction previously. tell your doctor or nurse if you know that you or your child is allergic to latex. the tip cap of the syringe may contain natural rubber latex. the risk for developing an allergic reaction is very small, but your doctor or nurse needs to be aware of your allergy when deciding if you
bexsero ( 0. 5 ml ) will be given to you or your child by a doctor or nurse. it will be injected into a muscle, usually the thigh for infants or the upper arm for children, adolescents and adults. it is important to follow the instructions from the doctor or nurse so that you or your child completes the course of injections. infants 2 months to 5 months of age at the time of first dose your child should receive an initial course of two or three injections of the vaccine followed by an additional injection ( booster ). - the first injection should be given no earlier than 2 months of age. - if three initial doses are given, the interval between injections should be at least 1 month. - if two initial doses are given, the interval between injections should be at least 2 months. - a booster will be given between 12 months and 15 months of age after an interval of at least 6 months from the last injection of the initial course. in case of delay, the booster should not be given later than 24 months of age. infants 6 months to 11 months of age at the time of first dose infants 6 months to 11 months of age should receive two injections of the vaccine followed by an additional injection ( booster ). - the interval between each injection should be at least 2 months. - a booster will be given in the second year of life after an interval of at least 2 months from the second injection. children 12 months to 23 months of age at the time of first dose children 12 months to 23 months of age should receive two injections of the vaccine followed by an additional injection ( booster ). - the interval between each injection should be at least 2 months. - a booster will be given after an interval of 12 to 23 months from the second injection. children 2 years to 10 years of age at the time of first dose children 2 years to 10 years of age should receive two injections of the vaccine. - the interval between each injection should be at least 1 month. your child may receive an additional injection ( booster ). adolescents and adults from 11 years of age at the time of first dose adolescents ( from 11 years of age ) and adults should receive two injections of the vaccine. - the interval between each injection
like all vaccines, this vaccine can cause side effects, although not everybody gets them. when bexsero is given to you or your child, the very common side effects ( may affect more than 1 in 10 people ) that you or your child may get ( reported in all age groups ) are : - pain / tenderness at the injection site, redness of the skin at the injection site, swelling of the skin at the injection site, hardness of the skin at the injection site. the following side effects may also occur after receiving this vaccine. infants and children ( up to 10 years of age ) very common ( these may affect more than 1 in 10 people ) - fever (<unk> 38oc ) - loss of appetite - tenderness at the injection site ( including severe injection site tenderness resulting in crying when injected limb is moved ) - painful joints - skin rash ( children aged 12 to 23 months ) ( uncommon after booster ) - sleepiness - feeling irritable - unusual crying - vomiting ( uncommon after booster ) - diarrhoea - headache common ( these may affect up to 1 in 10 people ) - skin rash ( infants and children 2 to 10 years of age ) uncommon ( these may affect up to 1 in 100 people ) - high fever (<unk> 40 ) - seizures ( including febrile seizures ) - dry skin - paleness ( rare after booster ) rare ( these may affect up to 1 in 1, 000 people ) - kawasaki disease which may include symptoms such as fever that lasts for more than five days, associated with a skin rash on the trunk of the body, and sometimes followed by a peeling of the skin on the hands and fingers, swollen glands in the neck, red eyes, lips, throat and tongue - itchy rash, skin rash adolescents ( from 11 years of age ) and adults very common ( these may affect more than 1 in 10 people ) - pain at the injection site resulting in inability to perform normal daily activity - painful muscles and joints - nausea - generally feeling unwell - headache side effects that have been reported during marketed use include :
what bexsero contains one dose ( 0 . 5 ml ) contains : active substances : recombinant neisseria meningitidis group b nhba fusion protein 1 , 2 , 3 50 micrograms recombinant neisseria meningitidis group b nada protein 1 , 2 , 3 50 micrograms recombinant neisseria meningitidis group b fhbp fusion protein 1 , 2 , 3 50 micrograms outer membrane vesicles ( omv ) from neisseria meningitidis group b strain nz98 / 254 measured as amount of total protein containing the pora p1 . 4 2 25 micrograms 1 produced in e . coli cells by recombinant dna technology 2 adsorbed on aluminium hydroxide ( 0 . 5 mg alÂ³ +) Â³ nhba ( neisserial heparin binding antigen ), nada ( neisseria adhesin a ), fhbp ( factor h binding protein ) other ingredients : sodium chloride , histidine , sucrose and water for injections ( see section 2 for further information on sodium and latex ). what bexsero looks like and contents of the pack bexsero is a suspension for injection in pre - filled syringe ( type i glass ) with a plunger stopper ( type i bromobutyl rubber ) and with a protective tip cap ( type i or type ii rubber ) with or without needles . pack sizes of 1 or 10 syringes . the suspension is white opalescent liquid . not all pack sizes may be marketed .
the active ingredient of nitisinone mdk is nitisinone . this medicine is used for treatment of a rare disease called hereditary tyrosinemia type 1 in adults , adolescents and children ( in any age range ). in this disease your body is unable to completely break down the amino acid tyrosine ( amino acids are building blocks of our proteins ), forming harmful substances . these substances are accumulated in your body . nitisinone mdk blocks the breakdown of tyrosine and the harmful substances are not formed . you must follow a special diet while you are taking this medicine , because tyrosine will remain in your body . this special diet is based on low tyrosine and phenylalanine ( another amino acid ) content .
do not take nitisinone mdk : - if you are allergic to nitisinone or any of the other ingredients of this medicine ( listed in section 6 ). do not breast - feed while taking this medicine, see section " pregnancy and breast - feeding ". warnings and precautions talk to your doctor or pharmacist before taking nitisinone mdk. - your eyes will be checked by an ophthalmologist before and regularly during nitisinone treatment. if you get red eyes or any other signs of effects on the eyes, contact your doctor immediately for an eye examination. eye problems could be a sign of inadequate dietary control ( see section 4 ). during the treatment, blood samples will be drawn in order for your doctor to check whether the treatment is adequate and to make sure that there are no possible side effects causing blood disorders. your liver will be checked at regular intervals because the disease affects the liver. follow - up by your doctor should be performed every 6 months. if you experience any side effects, shorter intervals are recommended. other medicines and nitisinone mdk tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. nitisinone mdk may interfere with the effect of other medicines, such as : - medicines for epilepsy ( such as phenytoin ) - medicines against blood clotting ( such as warfarin ) nitisinone mdk with food and drink if you start nitisinone mdk treatment by taking it with food, it is recommended that you carry on taking it with food throughout your course of treatment. pregnancy and breast - feeding the safety of this medicine has not been studied in pregnant and breast - feeding women. please contact your doctor if you plan to become pregnant. if you become pregnant you should contact your doctor immediately. do not breast - feed while taking this medicine, see section " do not take nitisinone mdk ". driving and using machines this medicine has minor influence on the ability to drive and use machines. however, if you experience side effects affecting your
always take this medicine exactly as your doctor has told you . check with your doctor or pharmacist if you are not sure . treatment with this medicine should be started and supervised by a doctor experienced in the treatment of the disease ( hereditary tyrosinemia type 1 ). the recommended total daily dose is 1 mg / kg body weight administered orally . your doctor will adjust the dose individually . it is recommended to administer the dose once daily . however , due to the limited data in patients with body weight < 20 kg , it is recommended to divide the total daily dose into two daily administrations in this patient population . if you have problems with swallowing the capsules , you may open the capsule and mix the powder with a small amount of water or formula diet just before you take it . if you take more nitisinone mdk than you should if you have taken more of this medicine than you should , contact your doctor or pharmacist as soon as possible . if you forget to take nitisinone mdk do not take a double dose to make up for a forgotten dose . if you forget to take a dose , contact your doctor or pharmacist . if you stop taking nitisinone mdk 20 if you have the impression that the medicine is not working properly , talk to your doctor . do not change the dose or stop the treatment without talking to your doctor . if you have any further questions on the use of this medicine , ask your doctor , pharmacist or nurse .
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the carton and the bottle after " exp ". the expiry date refers to the last day of that month . store in a refrigerator ( 2 - 8 ). store in the original bottle in order to protect from light . the medicine can be stored for a period of 2 months , after first opening the bottle , at a temperature not above 25 , after which it must be discarded . do not forget to mark the date on the bottle , when removed from the refrigerator . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what nitisinone mdk contains - the active substance is nitisinone . nitisinone mdk 2 mg : each capsule contains 2 mg nitisinone . nitisinone mdk 5 mg : each capsule contains 5 mg nitisinone . nitisinone mdk 10 mg : each capsule contains 10 mg nitisinone . - the other ingredients are : capsule content : pregelatinised maize starch capsule shell : gelatin , titanium dioxide ( e171 ) printing ink : black iron oxide ( e172 ), shellac glaze what nitisinone mdk looks like and contents of the pack nitisinone mdk capsules are 15 . 7 mm long , white , opaque , hard gelatin capsules , imprinted with " nitisinone " and the strength " 2 mg ", " 5 mg " or " 10 mg ", in black . the capsule contains a white to off - white powder . the capsules are packaged in plastic bottles . each bottle contains 60 capsules . each carton pack contains one bottle .
the name of this medicine is docetaxel accord . its common name is docetaxel . docetaxel is a substance derived from the needles of yew trees . docetaxel belongs to the group of anti - cancer medicines called taxoids . docetaxel accord has been prescribed by your doctor for the treatment of breast cancer , special forms of lung cancer ( non - small cell lung cancer ), prostate cancer , gastric cancer or head and neck cancer : - for the treatment of advanced breast cancer , docetaxel could be administered either alone or in combination with doxorubicin , or trastuzumab , or capecitabine . - for the treatment of early breast cancer with or without lymph node involvement , docetaxel could be administered in combination with doxorubicin and cyclophosphamide . - for the treatment of lung cancer , docetaxel could be administered either alone or in combination with cisplatin . - for the treatment of prostate cancer , docetaxel is administered in combination with prednisone or prednisolone . - for the treatment of metastatic gastric cancer , docetaxel is administered in combination with cisplatin and 5 - fluorouracil . - for the treatment of head and neck cancer , docetaxel is administered in combination with cisplatin and 5 - fluorouracil .
you must not be given docetaxel accord if you are allergic ( hypersensitive ) to docetaxel or any of the other ingredients of docetaxel accord ( listed in section 6 ). if the number of white blood cells is too low. if you have a severe liver disease. warnings and precautions before each treatment with docetaxel accord, you will have blood tests to check that you have enough blood cells and sufficient liver function to receive docetaxel accord. in case of white blood cells disturbances, you may experience associated fever or infections. tell your doctor, hospital pharmacist, or nurse immediately if you have abdominal pain or tenderness, diarrhoea, rectal haemorrhage, blood in stool or fever. these symptoms may be the first signs of a serious gastrointestinal toxicity, which could be fatal. your doctor should address them immediately. tell your doctor, hospital pharmacist or nurse if you have vision problems. in case of vision problems, in particular blurred vision, you should immediately have your eyes and vision examined. tell your doctor, hospital pharmacist or nurse if you have experienced an allergic reaction to previous paclitaxel therapy. tell your doctor, hospital pharmacist or nurse if you have heart problems. if you develop acute or worsening problems with your lungs ( fever, shortness of breath or cough ), please tell your doctor, hospital pharmacist or nurse immediately. your doctor may stop your treatment immediately. you will be asked to take premedication consisting of an oral corticosteroid such as dexamethasone, one day prior to docetaxel accord administration and to continue for one or two days after it in order to minimise certain undesirable effects which may occur after the infusion of docetaxel accord in particular allergic reactions and fluid retention ( swelling of the hands, feet, legs or weight gain ). during treatment, you may be given other medicines to maintain the number of your blood cells. severe skin problems such as stevens - johnson syndrome ( sjs ), toxic epidermal necrolysis ( ten ), acute generalized exanthematous pustulosis ( agep ) have been reported
docetaxel accord will be administered to you by a healthcare professional . recommended dose the dose will depend on your weight and your general condition . your doctor will calculate your body surface area in square meters ( mÂ² ) and will determine the dose you should receive . method and route of administration docetaxel accord will be given by infusion into one of your veins ( intravenous use ). the infusion will last approximately one hour during which you will be in the hospital . frequency of administration you should usually receive your infusion once every 3 weeks . your doctor may change the dose and frequency of dosing depending on your blood tests , your general condition and your response to docetaxel accord . in particular , please inform your doctor in case of diarrhoea , sores in the mouth , feeling of numbness or pins and needles , fever and give any results of 63 your blood tests to your doctor . such information will allow your doctor to decide whether a dose reduction is needed . if you have any further questions on the use of this medicine , ask your doctor , or hospital pharmacist .
like all medicines, this medicine can cause side effects, although not everybody gets them. your doctor will discuss these with you and will explain the potential risks and benefits of your treatment. the most commonly reported adverse reactions of docetaxel alone are : decrease in the number of red blood cells or white blood cells, alopecia, nausea, vomiting, sores in the mouth, diarrhoea and tiredness. the severity of adverse events of docetaxel may be increased when docetaxel is given in combination with other chemotherapeutic agents. during the infusion at the hospital the following allergic reactions may occur ( may affect more than 1 in 10 people ): flushing, skin reactions, itching chest tightness ; difficulty in breathing fever or chills back pain low blood pressure. more severe reactions may occur. if you had an allergic reaction to paclitaxel, you may also experience an allergic reaction to docetaxel, which may be more severe. the hospital staff will monitor your condition closely during treatment. tell them immediately if you notice any of these effects. between infusions of docetaxel the following may occur, and the frequency may vary with the combinations of medicines that are received very common ( may affect more than 1 in 10 people ): infections, decrease in the number of red ( anaemia ), or white blood cells ( which are important in fighting infection ) and platelets fever : if this happens you must tell your doctor immediately allergic reactions as described above loss of appetite ( anorexia ) insomnia feeling of numbness or pins and needles or pain in the joints or muscles headache alteration in sense of taste inflammation of the eye or increased tearing of the eyes swelling caused by faulty lymphatic drainage shortness of breath nasal drainage ; inflammation of the throat and nose ; cough bleeding from the nose sores in the mouth stomach upsets including nausea, vomiting and diarrhoea, constipation abdominal pain indigestion hair loss : in most cases normal hair growth should return. in some cases ( frequency not known ) permanent hair loss has been observed 64 redness and swelling of the palms of your hands or soles of your feet which may cause your skin to peel ( this may
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the outer carton and on the label of the vial after exp . the expiry date refers to the last day of that month . do not store above 25 . store in the original package in order to protect from light . use the vial immediately after its opening . if not used immediately , in - use storage times and conditions are the responsibility of the user . from a microbiological point of view , dilution must take place in controlled and aseptic conditions . use the medicine immediately after it is added into the infusion bag . if not used immediately , in - use storage times and conditions are the responsibility of the user and would normally not be longer than 6 hours below 25 including the one hour infusion . physical and chemical in - use stability of the infusion solution prepared as recommended has been demonstrated in non - pvc bags up to 48 hours when stored between 2 to 8 . prepare the infusion solution as recommended . do not couple the infusion solution to the infusion set for more than 6 hours when stored at 25 . docetaxel infusion solution is supersaturated , therefore may crystallise over time . if crystals appear , the solution must no longer be used and shall be discarded . do not throw away any medicines via wastewater . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what docetaxel accord contains - the active substance is docetaxel . each ml of concentrate for solution for infusion contains 20 mg docetaxel . one vial of 1 ml of concentrate contains 20 mg of docetaxel . one vial of 4 ml of concentrate contains 80 mg of docetaxel . one vial of 8 ml of concentrate contains 160 mg of docetaxel . - the other ingredients are polysorbate 80 , ethanol anhydrous ( see section 2 ) and citric acid anhydrous . what docetaxel accord looks like and contents of the pack docetaxel accord concentrate for solution for infusion is a clear pale yellow to brownish - yellow solution . docetaxel accord 20 mg / 1 ml is supplied in a 5 ml clear glass vial with fluorotec plus rubber stopper and aluminium seal and an orange flip - off cap . docetaxel accord 80 mg / 4 ml is supplied in a 5 ml clear glass vial with fluorotec plus rubber stopper and aluminium seal and a red flip - off cap . docetaxel accord 160 mg / 8 ml is supplied in a 10 ml clear glass vial with fluorotec plus rubber stopper and aluminium seal and a red flip - off cap . pack size : each box contains one vial of 1 ml concentrate . each box contains one vial of 4 ml concentrate . each box contains one vial of 8 ml concentrate .
what intuniv is intuniv contains the active substance guanfacine . this medicine belongs to a group of medicines which affects brain activity . this medicine can help improve your attention , concentration and make you less impulsive and hyperactive . what intuniv is used for this medicine is used to treat ' attention deficit hyperactivity disorder ' ( adhd ) in children and adolescents 6 - 17 years old for whom current stimulant medication is not appropriate and / or current medication does not adequately control adhd symptoms . the medicine is given as part of a treatment programme , which usually includes the following : psychological therapy educational therapy social therapy 38 about adhd people with adhd find it hard to : sit still concentrate . adhd can cause problems with everyday life . children and young people with adhd may have difficulty learning and doing homework . they can find it hard to behave well at home , at school or in other places .
do not take intuniv if : you are allergic to guanfacine or any of the other ingredients of this medicine ( listed in section 6 ). warnings and precautions talk to your doctor or pharmacist before taking this medicine if : you have low or high blood pressure, heart problems or have a family history of heart problems you have fainted recently you have thoughts or feelings of suicide you suffer from any other psychiatric conditions intuniv may affect your weight and height if taking for long periods, your doctor will therefore monitor your growth. do not stop taking intuniv without talking to your doctor. if you suddenly stop taking intuniv, you may develop withdrawal symptoms of increased heart rate and high blood pressure ( see section 4 ). if any of the above apply to you ( or you are not sure ), talk to your doctor or pharmacist before taking this medicine. this is because this medicine can make these problems worse. your doctor will routinely monitor you to see how this medicine affects you. children ( under 6 years old ) and adults ( 18 years and over ) this medicine should not be used in children under 6 years of age and adults 18 years and over because it is not known if it works or is safe. checks your doctor will do when you take intuniv before you start taking this medicine your doctor will check to make sure this medicine is safe for you and that it will help you. while you are taking this medicine your doctor will repeat these checks weekly during initial dosing, after dose adjustments, at least every 3 months for the first year and then at least twice a year. these checks may include : your blood pressure and heart rate and other checks on your heart if appropriate your response to treatment, in particular if it makes you sleepy or drowsy your height and weight you should talk to your doctor if you do not feel better or if you feel worse and very sleepy or drowsy after taking this medicine for around 6 weeks. your doctor may want to review your treatment 39 other medicines and intuniv tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. this is because intuniv and some other medicines can affect each other.
your treatment will start under the supervision of an appropriate specialist in childhood and / or adolescent behavioural disorders. always take this medicine exactly as your doctor or pharmacist has told you. check with your doctor or pharmacist if you are not sure. as part of your treatment your doctor will closely monitor how intuniv is affecting you during initial dosing and / or dose adjustments. how much to take your doctor will start you on 1 mg per day. your doctor may increase your dose based on your body weight and how intuniv is working for you but not by more than 1 mg per week. depending on how you respond to treatment your doctor may increase your dose more slowly. the recommended maintenance dose is between 0. 05 up to 0. 12 mg per kg of bodyweight per day. you may not notice an immediate effect upon starting treatment, some patients may notice an improvement after the first week but it could take longer. your daily dose will be between 1 and 7 mg depending on your age and how you respond to intuniv, but not more that 7 mg. how to take intuniv this medicine should be taken once a day either in the morning or evening. it can be taken with or without food, but do not take it with fatty foods ( e. g., high fat breakfast ). swallow the tablet whole with a drink of water or other liquid ( but not grapefruit juice ). do not break, crush or chew the tablet ; this will affect how the tablet works. tell your doctor if you cannot swallow the tablet whole. duration of treatment if you need to take intuniv for more than a year your doctor will monitor your response to treatment and your doctor may stop the medicine for a short time ; this may happen during a school holiday. this will show if you still need to take the medicine. if you take more intuniv than you should if you take more intuniv than you should, talk to a doctor or go to a hospital straight away. take the medicine pack with you and tell them how much you have taken. the following effects may happen : low or high blood pressure, slow heart rate, slow breathing rate,
like all medicines, this medicine can cause side effects, although not everybody gets them. if you are worried, speak to your doctor. if you feel unwell in any way while you are taking your medicine please tell an adult straight away. serious side effects the following serious side effects have been reported : feeling drowsy ( sedation ), feeling dizzy ( hypotension ), slow heart beat ( bradycardia ), feeling faint or loss of conciousness ( syncope ), a serious withdrawal side effect of high blood pressure after suddenly stopping intuniv ; symptoms may include headaches, feeling confused, nervousness, agitation, and tremors ( hypertensive encephalopathy ). some of these side effects are more likely to occur at the start of treatment and may disappear as you continue with your treatment, if you experience any of these side effects contact your doctor straight away. other side effects the following side effects have been reported. very common ( may affect more than 1 in 10 people ) feeling sleepy ( somnolence ) feeling tired ( fatigue ) headache tummy pain ( abdominal pain ). common ( may affect up to 1 in 10 people ) low heart rate blood pressure decreased feeling restless or irritable trouble sleeping ( insomnia ) or broken sleep ( middle insomnia ) or nightmares feeling depressed, worried ( anxiety ) or having mood swings ( affect lability ) lack of energy ( lethargy ) weight gain loss of appetite have a dry mouth wetting yourself ( enuresis ) feeling ( nausea ) or being sick ( vomiting ) diarrhoea, abdominal discomfort or constipation low blood pressure when standing up ( orthostatic hypotension ) rash. uncommon ( may affect up to 1 in 100 people ) allergic reaction ( hypersensitivity ) chest pain indigestion ( dyspepsia ) trouble breathing ( asthma ) feeling weak ( asthenia ) pale skin colour ( pallor ) fits or convulsions need to urinate frequently ( pollakiuria ) feeling agitated changes in liver blood test results ( increased alanine aminotransferase ) increase in blood pressure unusual heart rhythm ( sinus arrhythmi
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the carton and blister pack after exp . the expiry date refers to the last day of that month . this medicinal product does not require any special storage conditions . do not use this medicine if the tablets or blister pack look damaged . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what intuniv contains each 1 mg tablet contains guanfacine hydrochloride equivalent to 1 mg of guanfacine each 2 mg tablet contains guanfacine hydrochloride equivalent to 2 mg of guanfacine each 3 mg tablet contains guanfacine hydrochloride equivalent to 3 mg of guanfacine each 4 mg tablet contains guanfacine hydrochloride equivalent to 4 mg of guanfacine the other ingredients are hypromellose 2208 , methacrylic acid - ethyl acrylate copolymer , lactose monohydrate , povidone , crospovidone type a , microcrystalline cellulose , silica colloidal anhydrous , sodium laurilsulfate , polysorbate 80 , fumaric acid , glycerol dibehenate . the 3 mg and 4 mg tablets also contain indigo carmine aluminium lake ( e 132 ) and yellow iron oxide ( e 172 ) what intuniv looks like and contents of the pack intuniv is a prolonged - release tablet which means that the active substance is released from the tablet over a period of time . the tablets come in pack sizes of 7 , 28 or 84 but not all pack sizes may be available . the 1 mg prolonged - release tablets are round and white , hard tablets , debossed with 1mg on one side and 503 on the other side . the 2 mg prolonged - release tablets are oval and white , hard tablets , debossed with 2mg on one side and 503 on the other side . the 3 mg prolonged - release tablets are round and green , hard tablets , debossed with 3mg on one side and 503 on the other side . the 4 mg prolonged - release tablets are oval and green , hard tablets , debossed with 4mg on one side and 503 on the other side .
ecalta contains the active substance anidulafungin and is prescribed in adults and in paediatric patients aged 1 month to less than 18 years to treat a type of fungal infection of the blood or other internal organs called invasive candidiasis . the infection is caused by fungal cells ( yeasts ) called candida . ecalta belongs to a group of medicines called echinocandins . these medicines are used to treat serious fungal infections . ecalta prevents normal development of fungal cell walls . in the presence of ecalta , fungal cells have incomplete or defective cell walls , making them fragile or unable to grow .
do not use ecalta - if you are allergic to anidulafungin, other echinocandins ( e. g. caspofungin acetate ), or any of the other ingredients of this medicine ( listed in section 6 ). warnings and precautions talk to your doctor or pharmacist or nurse before using ecalta. your doctor may decide to monitor you - for liver function more closely if you develop liver problems during your treatment - if you are given anaesthetics during your treatment with ecalta for signs of an allergic reaction such as itching, wheezing, blotchy skin - for signs of an infusionrelated reaction which could include a rash, hives, itching, redness - for shortness of breath / breathing difficulties, dizziness or lightheadedness children and adolescents ecalta should not be given to patients under 1 month of age. other medicines and ecalta tell your doctor or pharmacist if you or your child are taking, have recently taken or might take any other medicines. pregnancy and breast - feeding the effect of ecalta in pregnant women is not known. therefore ecalta is not recommended during pregnancy. effective contraception should be used in women of childbearing age. contact your doctor immediately if you become pregnant while taking ecalta. the effect of ecalta in breast - feeding women is not known. ask your doctor or pharmacist for advice before taking ecalta while breast - feeding. ask your doctor or pharmacist for advice before taking any medicines. ecalta contains fructose this medicine contains fructose ( a type of sugar ). if you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. if you ( or your child ) have hereditary fructose intolerance ( hfi ), a rare genetic disorder, you ( or your child ) must not receive this medicine. patients with hfi cannot break down fructose in this medicine, which may cause serious side effects
ecalta will always be prepared and given to you or your child by a doctor or a healthcare professional ( there is more information about the method of preparation at the end of the leaflet in the section for medical and healthcare professionals only ). for use in adults, the treatment starts with 200 mg on the first day ( loading dose ). this will be followed by a daily dose of 100 mg ( maintenance dose ). for use in children and adolescents ( age from 1 month to less than 18 years ), the treatment starts with 3. 0 mg / kg ( not to exceed 200 mg ) on the first day ( loading dose ). this will be followed by a daily dose of 1. 5 mg / kg ( not to exceed 100 mg ) ( maintenance dose ). the dose that is given depends on the patient's weight. ecalta should be given to you once a day, by slow infusion ( a drip ) into your vein. for adults, this will take at least 1. 5 hours for the maintenance dose and 3 hours for the loading dose. for children and adolescents, the infusion may take less time depending on the patient's weight. your doctor will determine the duration of your treatment and how much ecalta you will receive each day and will monitor your response and condition. in general, your treatment should continue for at least 14 days after the last day candida was found in your blood. if you receive more ecalta than you should if you are concerned that you may have been given too much ecalta, tell your doctor or another healthcare professional immediately. if you forgot to use ecalta as you will be given this medicine under close medical supervision, it is unlikely that a dose would be missed. however tell your doctor or pharmacist if you think that a dose has been forgotten. you should not be given a double dose by doctor. if you stop using ecalta you should not experience any effects from ecalta if your doctor stops ecalta treatment. your doctor may prescribe another medicine following your treatment with ecalta to continue treating your fungal infection or prevent it from returning. if your original symptoms come back, tell your doctor
like all medicines , this medicine can cause side effects , although not everybody gets them . some of these side effects will be noted by your doctor while monitoring your response and condition . life - threatening allergic reactions that might include difficulty breathing with wheezing or worsening of an existing rash have been rarely reported during administration of ecalta . serious side effects tell your doctor or another healthcare professional immediately should any of the following occur : - convulsion ( seizure ) - flushing - rash , pruritis ( itching ) - hot flush - hives - sudden contraction of the muscles around the airways resulting in wheezing or coughing - difficulty of breathing other side effects very common side effects ( may affect more than 1 in 10 people ) are : - low blood potassium ( hypokalaemia ) - diarrhoea - nausea common side effects ( may affect up to 1 in 10 people ) are : - convulsion ( seizure ) - headache - vomiting - changes in blood tests of liver function - rash , pruritis ( itching ) 29 - changes in blood tests of kidney function - abnormal flow of bile from the gallbladder into the intestine ( cholestasis ) - high blood sugar - high blood pressure - low blood pressure - sudden contraction of the muscles around the airways resulting in wheezing or coughing - difficulty of breathing uncommon side effects ( may affect up to 1 in 100 people ) are : - disorder of blood clotting system - flushing - hot flush - stomach pain - hives - pain at injection site not known ( frequency cannot be estimated from the available data ) are : - life - threatening allergic reactions reporting of side effects if you get any side effects , talk to your doctor or , pharmacist or nurse . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the label . the expiry data refers to the last day of that month . store in a refrigerator ( 2c 8c ). the reconstituted solution may be stored up to 25c for up to 24 hours . the infusion solution may be stored at 25 ( room temperature ) for 48 hours ( do not freeze ) and should be administered at 25c ( room temperature ) within 48 hours . do not throw away any medicines via wastewater or household waste .
what ecalta contains - the active substance is anidulafungin . each vial of powder contains 100 mg anidulafungin . - the other ingredients are : fructose , mannitol , polysorbate 80 , tartaric acid , sodium hydroxide ( for ph - adjustment ), hydrochloric acid ( for ph - adjustment ) 30 what ecalta looks like and contents of the pack ecalta is supplied as a box containing 1 vial of 100 mg powder for concentrate for solution for infusion . the powder is white to off - white .
adynovi contains the active substance rurioctocog alfa pegol , pegylated human coagulation factor viii . the human coagulation factor viii has been modified to prolong its duration of action . factor viii is necessary for the blood to form clots and stop bleedings . in patients with haemophilia a ( inborn lack of factor viii ), it is missing or not working properly . adynovi is used for the treatment and prevention of bleeding in patients from 12 years of age with haemophilia a ( an inherited bleeding disorder caused by lack of factor viii ).
do not use adynovi : - if you are allergic to rurioctocog alfa pegol, octocog alfa or any of the other ingredients of this medicine ( listed in section 6 ) - if you are allergic to mouse or hamster proteins if you are unsure about this, ask your doctor. warnings and precautions talk to your doctor before using adynovi. there is a rare risk that you may experience an anaphylactic reaction ( a severe, sudden allergic reaction ) to adynovi. you should be aware of the early signs of allergic reactions such as rash, 95 hives, wheals, generalised itching, swelling of lips and tongue, difficulty in breathing, wheezing, tightness in the chest, general feeling of being unwell, and dizziness. these could be early symptoms of anaphylactic shock ; additional symptoms may include extreme dizziness, loss of consciousness, and extreme difficulty in breathing. if any of these symptoms occur, stop the injection immediately and contact your doctor. severe symptoms, including difficulty in breathing and ( near ) fainting, require prompt emergency treatment. if you suffer from cardiac disease, please inform your doctor, as there is an increased risk of blood clotting ( coagulation ) complications. patients developing factor viii inhibitors the formation of inhibitors ( antibodies ) is a known complication that can occur during treatment with all factor viii medicines. these inhibitors, especially at high levels, stop the treatment working properly and you or your child will be monitored carefully for the development of these inhibitors. if you or your child <unk> s bleeding is not being controlled with adynovi, tell your doctor immediately. catheter - related complications if you require a central venous access device ( cvad ), risk of cvad - related complications including local infections, presence of bacteria in the blood and catheter site thrombosis should be considered. children and adolescents adynovi can be used only in adolescents and adults ( 12 years and above ).
treatment with adynovi will be started and supervised by a doctor who is experienced in the care of patients with haemophilia a. your doctor will calculate your dose of adynovi depending on your condition and body weight, and on whether it is used for prevention or treatment of bleeding. the frequency of administration will depend on how well adynovi is working for you. usually, the replacement therapy with adynovi is a life - long treatment. always use this medicine exactly as your doctor has told you. check with your doctor if you are not sure. prevention of bleeding the usual dose of adynovi is 40 to 50 iu per kg body weight, administered 2 times per week. treatment of bleeding the dose of adynovi is calculated depending on your body weight and the factor viii levels to be achieved. the target factor viii levels will depend on the severity and location of the bleeding. if you think that the effect of adynovi is insufficient, talk to your doctor. your doctor will perform appropriate laboratory tests to make sure that you have adequate factor viii levels. this is particularly important if you are having major surgery. use in children and adolescents adynovi can be used only in adolescents and adults ( 12 years and above ). the dose in adolescents is also calculated to body weight and is the same dose as for adults. how adynovi is given adynovi is usually injected into a vein ( intravenously ) by your doctor or nurse. you or someone else might also administer adynovi as an injection, but only after receiving adequate training. detailed instructions for self - administration are given at the end of this package leaflet. if you use more adynovi than you should always use adynovi exactly as your doctor has told you. you should check with your doctor if you are not sure. if you inject more adynovi than recommended, tell your doctor as soon as possible. if you forget to use adynovi do not inject a double dose to make up for a forgotten dose. proceed with the
like all medicines , this medicine can cause side effects , although not everybody gets them . if severe , sudden allergic reactions ( anaphylactic ) occur , the injection must be stopped immediately . you must contact your doctor immediately if you have any of the following early symptoms of allergic reactions : - rash , hives , wheals , generalised itching , - swelling of lips and tongue , - difficulty in breathing , wheezing , tightness in the chest , - general feeling of being unwell , - dizziness and loss of consciousness . severe symptoms , including difficulty in breathing and ( nearly ) fainting , require prompt emergency treatment . for patients who have received previous treatment with factor viii ( more than 150 days of treatment ) inhibitor antibodies ( see section 2 ) may form uncommonly ( less than 1 in 100 patients ). if this happens your medicine may stop working properly and you may experience persistent bleeding . if this happens , you should contact your doctor immediately . common side effects ( may affect up to 1 in 10 people ) headache , nausea , diarrhoea , rash uncommon side effects ( may affect up to 1 in 100 people ) flushing , allergic reaction ( hypersensitivity ) 97 factor viii inhibitors ( for patients who have received previous treatment with factor viii ( more than 150 days of treatment )) additional side effects in children frequency , type and severity of adverse reactions in children are expected to be the same as in adults . reporting of side effects if you get any side effects , talk to your doctor . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date , which is stated on the label and carton after exp . the expiry date refers to the last day of that month . store in a refrigerator ( 2 8 ). do not freeze . keep the vial in the outer carton in order to protect from light . during the shelf life the powder vial may be kept at room temperature ( up to 30 ) for a single period not exceeding 3 months . in this case , this medicine expires at the end of this 3 - month period or the expiration date printed on the product vial , whichever is earlier . please record the end of the 3 - month storage at room temperature on the product carton . the product may not be returned to refrigerated storage after storage at room temperature . do not refrigerate the solution after preparation . use the product within 3 hours once the powder is completely dissolved . the product is for single use only . discard any unused solution appropriately . do not throw away any medicines via waste water or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what adynovi contains - the active substance is rurioctocog alfa pegol ( pegylated human coagulation factor viii produced by recombinant dna technology ). each powder vial contains nominally 250 , 500 , 1000 , or 2000 iu rurioctocog alfa pegol . - the solvent vial contains 5 ml of sterilised water for injections . - the other ingredients are mannitol , trehalose dihydrate , histidine , glutathion , sodium chloride , calcium chloride dihydrate , tris ( hydroxymethyl ) aminomethane , polysorbate 80 and sterilised water for injections . adynovi contains sodium , see section 2 . what adynovi looks like and contents of the pack adynovi is provided as a powder and solvent for solution for injection . the powder is a white to off - white crumbly powder . the solvent is a clear , colourless solution . after reconstitution , the solution is clear , colourless and free from foreign particles . each pack contains one powder vial , one solvent vial and a device for reconstitution ( baxject ii hi - flow ).
rekovelle contains follitropin delta , a follicle stimulating hormone which belongs to the family of hormones called gonadotropins . gonadotropins are involved in reproduction and fertility . rekovelle is used in the treatment of female infertility and in women undergoing assisted reproduction programmes such as in vitro fertilisation ( ivf ) and intracytoplasmic sperm injection ( icsi ). rekovelle stimulates the ovaries to grow and develop many egg sacs (' follicles '), from which eggs are collected and fertilised in the laboratory .
before starting treatment with this medicine, a doctor should check you and your partner for possible causes of your fertility problems. do not use rekovelle if : you are allergic to follicle stimulating hormone or any of the other ingredients of this medicine ( listed in section 6 ) you have a tumour of the uterus, ovaries, breasts, pituitary gland or hypothalamus you have enlarged ovaries or cysts on your ovaries ( unless caused by polycystic ovarian disease ) you suffer from bleeding from the vagina without any known cause you have had an early menopause you have malformations of the sexual organs which make a normal pregnancy impossible you have fibroids of the uterus which make a normal pregnancy impossible. warnings and precautions ovarian hyperstimulation syndrome gonadotropins like this medicine may cause ovarian hyperstimulation syndrome. this is when your follicles develop too much and become large cysts. talk to your doctor if you : have abdominal pain, discomfort or swelling have nausea are vomiting get diarrhoea gain weight have difficulty in breathing your doctor may ask you to stop using this medicine ( see section 4 ). if the recommended dose and schedule of administration are followed, ovarian hyperstimulation syndrome is less likely. blood clotting problems ( thromboembolic events ) clots in the blood vessels ( veins or arteries ) are more likely in women who are pregnant. infertility treatment can increase the risk of this happening, especially if you are overweight or you or someone in your family ( blood relative ) have a known blood clotting disease ( thrombophilia ). tell your doctor if you think this applies to you. twisting of ovaries there have been reports of twisting of ovaries ( ovarian torsion ) following assisted reproductive technology treatment. twisting of the ovary could cut off the blood flow to the ovary. multiple pregnancy and birth defects when undergoing assisted reproductive technology treatment the possibility of having a multiple pregnancy ( such as twins ) is mainly related to the number of embryos placed inside your womb, the
always use this medicine exactly as your doctor has told you and at the dose your doctor has told you. check with your doctor if you are not sure. the rekovelle dose for your first treatment cycle will be calculated by your doctor using the level of anti - mÃ¼llerian hormone ( amh, a marker of how your ovaries will respond to stimulation with gonadotropins ) in your blood and your body weight. therefore the amh result from a blood sample ( taken within the last 12 months ) should be available before you start treatment. your body weight will also be measured before you start treatment. the rekovelle dose is stated in micrograms. the rekovelle dose is fixed for the whole treatment period with no adjustments to increase or decrease your daily dose. your doctor will monitor the effect of rekovelle treatment, and treatment is stopped when an appropriate number of egg sacs are present. in general, you will be given a single injection of a medicine called human chorionic gonadotrophin ( hcg ) at a dose of 250 micrograms or 5, 000 iu for final development of the follicles. if your body <unk> s response to treatment is too weak or too strong, your doctor may decide to stop treatment with rekovelle. for the next treatment cycle, your doctor will in this case give you either a higher or a lower daily dose of rekovelle than before. how are injections given rekovelle is developed for use in the rekovelle injection pen. the instructions for using the injection pen supplied with the pen including loading the cartridge must be followed carefully. do not use the cartridge if the solution contains particles or if the solution does not look clear. the first injection of this medicine should be given under the supervision of a doctor or a nurse. your doctor will decide if you can give yourself further doses of this medicine at home, but only after receiving adequate training. this medicine is to be given by injection just under the skin ( subcutaneously ) usually in the abdomen. the cartridge may be used for several injections. if you use more rekovelle than you should the effects of taking too much of this medicine are unknown
like all medicines , this medicine can cause side effects , although not everybody gets them . serious side effects : hormones used in the treatment of infertility such as this medicine may cause a high level of activity in the ovaries ( ovarian hyperstimulation syndrome ). symptoms may include pain , discomfort or swelling of the abdomen , nausea , vomiting , diarrhoea , weight gain or difficulty breathing . if you have any of these symptoms you should contact a doctor immediately . the risk of having a side effect is described by the following categories : common ( may affect up to 1 in 10 people ): headache nausea ovarian hyperstimulation syndrome ( see above ) pelvic pain and discomfort , including of ovarian origin tiredness ( fatigue ) uncommon ( may affect up to 1 in 100 people ): mood swings sleepiness / drowsiness dizziness diarrhoea vomiting constipation discomfort of the abdomen vaginal bleeding breast complaints ( include breast pain , breast tenderness ) reporting of side effects if you get any side effects , talk to your doctor or pharmacist . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the cartridge label and carton after exp . the expiry date refers to the last day of that month . store in refrigerator ( 2 - 8 ). do not freeze . before first use , store in the original package in order to protect from light . rekovelle may be stored at or below 25 for up to 3 months including the period after first use . it must not be refrigerated again and must be discarded if it has not been used after 3 months . after first use : 28 days when stored at or below 25 . keep the cartidge in the rekovelle injection pen . at the end of the treatment any unused solution must be discarded . do not throw away any medicines via household waste . ask your pharmacist how to dispose of medicines you no longer use . these measures will help protect the environment .
what rekovelle contains - the active substance is follitropin delta . each multidose cartridge contains 12 micrograms of follitropin delta in 0 . 36 millilitre of solution . one millilitre of solution contains 33 . 3 micrograms of follitropin delta in each millilitre of solution . - the other ingredients are phenol , polysorbate 20 , l - methionine , sodium sulphate decahydrate , disodium phosphate dodecahydrate , concentrated phosphoric acid , sodium hydroxide and water for injections . what rekovelle looks like and contents of the pack rekovelle is a clear and colourless solution for injection ( injection ). it is available in packs of 1 cartridge and 3 pen injection needles .
revinty ellipta contains two active substances : fluticasone furoate and vilanterol. two different strengths of revinty ellipta are available : fluticasone furoate 92 micrograms / vilanterol 22 micrograms and fluticasone furoate 184 micrograms / vilanterol 22 micrograms. the 92 / 22 micrograms strength is used for the regular treatment of chronic obstructive pulmonary disease ( copd ) in adults, and asthma in adults and adolescents 12 years and over. the 184 / 22 micrograms strength is used to treat asthma in adults and adolescents aged 12 years and older. the 184 / 22 micrograms strength is not approved for the treatment of copd. revinty ellipta should be used every day and not only when you have breathing problems or other symptoms of copd and asthma. it should not be used to relieve a sudden attack of breathlessness or wheezing. if you get this sort of attack you must use a quick - acting inhaler ( such as salbutamol ). if you do not have a quick - acting inhaler contact your doctor. fluticasone furoate belongs to a group of medicines called corticosteroids, often simply called steroids. corticosteroids reduce inflammation. they reduce the swelling and irritation in the small air passages in the lungs and so gradually ease breathing problems. corticosteroids also help to prevent attacks of asthma and aggravation of copd. vilanterol belongs to a group of medicines called long acting bronchodilators. it relaxes the muscles of the small air passages in the lungs. this helps to open the airways and makes it easier for air to get in and out of the lungs. when it is taken regularly, it helps the small air passages to remain open. when you take these two active substances together regularly, they will help to control your breathing difficulties more than either medicine alone. asthma is a serious, long term lung disease where the muscles surrounding the smaller airways become tight ( bronchoconstriction ) and
do not use revinty ellipta - if you are allergic to fluticasone furoate, vilanterol or any other ingredients of this medicine ( listed in section 6 ). - if you think the above applies to you, don't use revinty ellipta until you have checked with your doctor. warnings and precautions talk to your doctor before you use revinty ellipta : - if you have liver disease, as you may be more likely to have side effects. if you have moderate or severe liver disease, your doctor will limit your dose to the lower strength of revinty ellipta ( 92 / 22 micrograms once daily ). - if you have heart problems or high blood pressure. - if you have tuberculosis ( tb ) of the lung, or any long standing or untreated infections. - if you have ever been told you have diabetes or high blood sugar. - if you have thyroid gland problems. - if you have low potassium in your blood. - if you experience blurred vision or other visual disturbances. check with your doctor before you use this medicine if you think any of these applies to you. while you're using revinty ellipta - contact your doctor if you experience blurred vision or other visual disturbances. - contact your doctor if you experience increased thirst, frequent urination or unexplained tiredness ( signs of high blood sugar ). immediate breathing difficulties if your breathing or wheezing gets worse straight after using revinty ellipta, stop using it and get medical help immediately. infection of the lung if you are using this medicine for copd you may be at an increased risk of developing an infection of the lungs known as pneumonia. see section 4 for information on symptoms to look out for while you are using this medicine. tell your doctor as soon as possible if you develop any of these symptoms. children and adolescents do not give this medicine to children under the age of 12 years for the treatment of asthma, or in children and adolescents of any age for the treatment of cop
always use this medicine exactly as your doctor has told you to. check with your doctor, nurse or pharmacist if you are not sure. how much to use asthma the recommended dose to treat asthma is one inhalation ( 92 micrograms of fluticasone furoate and 22 micrograms of vilanterol ) once daily at the same time each day. if you have severe asthma, your doctor may decide that you should use one inhalation of the higher strength inhaler ( 184 micrograms fluticasone furoate and 22 micrograms of vilanterol ). this dose is also used once daily at the same time each day. copd the recommended dose to treat copd is one inhalation ( 92 micrograms of fluticasone furoate and 22 micrograms of vilanterol ) once daily at the same time each day. the higher strength of revinty ellipta ( 184 micrograms fluticasone furoate and 22 micrograms of vilanterol ) is not suitable for the treatment of copd. revinty ellipta is for inhalation use. use revinty ellipta at the same time each day as it is effective over 24 hours it is very important that you use this medicine every day, as instructed by your doctor. this will help to keep you free of symptoms throughout the day and night. revinty ellipta should not be used to relieve a sudden attack of breathlessness or wheezing. if you get this sort of attack you must use a quick - acting inhaler ( such as salbutamol ). if you feel you are getting breathless or wheezy more often than normal, or if you are using your quick - acting inhaler more than usual, see your doctor. how to use revinty ellipta see'step - by - step instructions'after section 6 of this leaflet for full information. you do not need to prepare revinty ellipta in any special way, not even the first time you use it. if your symptoms do not improve if your symptoms ( breathlessness, wheez
like all medicines, this medicine can cause side effects, although not everybody gets them. allergic reactions allergic reactions to revinty ellipta are rare ( may affect up to 1 in 1, 000 people ). if you have any of the following symptoms after taking revinty ellipta stop taking this medicine and tell your doctor immediately. skin rash ( hives ) or redness swelling, sometimes of the face or mouth ( angioedema ) becoming very wheezy, coughing or having difficulty in breathing suddenly feeling weak or light headed ( which may lead to collapse or loss of consciousness ) immediate breathing difficulties immediate breathing difficulties after using revinty ellipta are rare. if your breathing or wheezing gets worse straight after using this medicine, stop using it and get medical help immediately. pneumonia ( infection of the lung ) ( common side effect, may affect up to 1 in 10 people ) tell your doctor if you have any of the following while taking revinty ellipta they could be symptoms of a lung infection : fever or chills increased mucus production, change in mucus colour increased cough or increased breathing difficulties other side effects include : very common side effects these may affect more than 1 in 10 people : headache common cold common side effects these may affect up to 1 in 10 people : sore, raised patches in the mouth or throat caused by a fungal infection ( candidiasis ). rinsing your mouth out with water immediately after using revinty ellipta may help stop this side effect developing. inflammation of the lungs ( bronchitis ) infection of the nose sinuses or throat flu ( influenza ) pain and irritation in the back of the mouth and throat inflammation of the sinuses itchy, runny or blocked nose cough voice disorders weakening of the bones, leading to fractures stomach pain back pain high temperature ( fever ) joint pain muscle spasms 68 uncommon side effects this may affect up to 1 in 100 people : irregular heartbeat blurred vision increase in blood sugar ( hyperglycaemia ) rare side effects these may affect up to 1 in 1, 000 people : heart beating faster ( tachycardia
what revinty ellipta contains - the active substances are fluticasone furoate and vilanterol . - for the 92 / 22mcg dose : each single inhalation provides a delivered dose ( the dose leaving the mouthpiece ) of 92 micrograms of fluticasone furoate and 22 micrograms of vilanterol ( as trifenatate ). - for the 184 / 22 dose : each single inhalation provides a delivered dose ( the dose leaving the mouthpiece ) of 184 micrograms of fluticasone furoate and 22 micrograms of vilanterol ( as trifenatate ). - the other ingredients are lactose monohydrate ( see section 2 ) and magnesium stearate . what revinty ellipta looks like and contents of the pack the ellipta device itself is a light grey inhaler with a yellow mouthpiece cover and a dose counter . it is packaged in a foil laminate tray with a peelable foil lid . the tray contains a desiccant sachet , to reduce 69 moisture in the packaging . once you have opened the lid of the tray , throw the desiccant away do not eat or inhale it . the device does not need to be stored in the foil laminate tray once it has been opened . the inhaler contains two aluminium foil laminate strips of 14 or 30 doses . multipacks contain 3 x 30 dose inhalers .
atripla contains three active substances that are used to treat human immunodeficiency virus ( hiv ) infection : - efavirenz is a non - nucleoside reverse transcriptase inhibitor ( nnrti ) - emtricitabine is a nucleoside reverse transcriptase inhibitor ( nrti ) - tenofovir is a nucleotide reverse transcriptase inhibitor ( ntrti ) each of these active substances , also known as antiretroviral medicines , work by interfering with an enzyme ( reverse transcriptase ) that is essential for the virus to multiply . atripla is a treatment for human immunodeficiency virus ( hiv ) infection in adults aged 18 years and over who have previously been treated with other antiretroviral medicines and have their hiv - 1 infection under control for at least three months . patients must not have experienced failure of a previous hiv therapy .
always take this medicine exactly as your doctor or pharmacist has told you. check with your doctor or pharmacist if you are not sure. the recommended dose is : one tablet taken each day by mouth. atripla should be taken on an empty stomach ( commonly defined as 1 hour before or 2 hours after a meal ) preferably at bedtime. this may make some side effects ( for example, dizziness, drowsiness ) less troublesome. swallow atripla whole with water. atripla must be taken every day. if your doctor decides to stop one of the components of atripla, you may be given efavirenz, emtricitabine and / or tenofovir disoproxil separately or with other medicines for the treatment of your hiv infection. if you take more atripla than you should if you accidentally take too many atripla tablets you may be at increased risk of experiencing possible side effects with this medicine ( see section 4, possible side effects ). contact your doctor or nearest emergency department for advice. keep the tablet bottle with you so that you can easily describe what you have taken. if you forget to take atripla it is important not to miss a dose of atripla. if you do miss a dose of atripla within 12 hours of when it is usually taken, take it as soon as you can, and then take your next dose at its regular time. if it is almost time ( less than 12 hours ) for your next dose anyway, do not take the missed dose. wait and take the next dose at the regular time. do not take a double dose to make up for a forgotten tablet. if you throw up the tablet ( within 1 hour after taking atripla ), you should take another tablet. do not wait until your next dose is due. you do not need to take another tablet if you were sick more than 1 hour after taking atripla. if you stop taking atripla don't stop taking atripla without talking to your doctor. stopping atripla can seriously affect your response to future treatment. if atripla is stopped, speak to your doctor before you restart taking atripla tablets. your
during hiv therapy there may be an increase in weight and in levels of blood lipids and glucose. this is partly linked to restored health and life style, and in the case of blood lipids sometimes to the hiv medicines themselves. your doctor will test for these changes. like all medicines, this medicine can cause side effects, although not everybody gets them. possible serious side effects : tell your doctor immediately - lactic acidosis ( excess lactic acid in the blood ) is a rare ( may affect up to 1 in every 1, 000 patients ) but serious side effect that can be fatal. the following side effects may be signs of lactic acidosis : - deep rapid breathing - drowsiness - feeling sick ( nausea ), being sick ( vomiting ) and stomach pain. if you think you may have lactic acidosis, contact your doctor immediately. other possible serious side effects the following side effects are uncommon ( these may affect up to 1 in every 100 patients ): allergic reaction ( hypersensitivity ) that may cause severe skin reactions ( stevens - johnson syndrome, erythema multiforme, see section 2 ) swelling of the face, lips, tongue or throat angry behaviour, suicidal thoughts, strange thoughts, paranoia, unable to think clearly, mood being affected, seeing or hearing things that are not really there ( hallucinations ), suicide 59 attempts, personality change ( psychosis ), catatonia ( a condition in which the patient is rendered motionless and speechless for a period ). pain in the abdomen ( stomach ), caused by inflammation of the pancreas forgetfulness, confusion, fitting ( seizures ), incoherent speech, tremor ( shaking ) yellow skin or eyes, itching, or pain in the abdomen ( stomach ) caused by inflammation of the liver damage to kidney tubules psychiatric side effects in addition to those listed above include delusions ( false beliefs ), neurosis. some patients have committed suicide. these problems tend to occur more often in those who have a history of mental illness. always notify your doctor immediately if you have these symptoms.
what atripla contains - the active substances are efavirenz , emtricitabine and tenofovir disoproxil . each atripla film - coated tablet contains 600 mg of efavirenz , 200 mg of emtricitabine and 245 mg of tenofovir disoproxil ( as fumarate ). - the other ingredients in the tablet are croscarmellose sodium , hyprolose , magnesium stearate , microcrystalline cellulose , sodium laurilsulfate . refer to section 2 " atripla contains sodium ". - the other ingredients in the tablet film coating are iron oxide black , iron oxide red , macrogol 3350 , poly ( vinyl alcohol ), talc , titanium dioxide . what atripla looks like and contents of the pack atripla film - coated tablets are pink , capsule shaped tablets , engraved on one side with the number " 123 " and plain on the other side . atripla comes in bottles of 30 tablets ( with a silica gel sachet that must be kept in the bottle to help protect your tablets ). the silica gel desiccant is contained in a separate sachet and should not be swallowed . the following pack sizes are available : outer cartons containing 1 bottle of 30 film - coated tablets and 90 ( 3 bottles of 30 ) film - coated tablets . not all pack sizes may be marketed .
orgalutran contains the active substance ganirelix and belongs to a group of medicines called " anti - gonadotrophin - releasing hormones " which act against the actions of the natural gonadotrophin releasing hormone ( gnrh ). gnrh regulates the release of gonadotrophins ( luteinising hormone ( lh ) and follicle stimulating hormone ( fsh )). gonadotrophins play an important role in human fertility and reproduction . in women , fsh is needed for the growth and development of follicles in the ovaries . follicles are small round sacs that contain the egg cells . lh is needed to release the mature egg cells from the follicles and ovaries ( i . e . ovulation ). orgalutran inhibits the action of gnrh , resulting in suppression of the release of especially lh . orgalutran is used for in women undergoing assisted reproduction techniques , including in vitro fertilisation ( ivf ) and other methods , occasionally ovulation may occur too early causing a significant reduction in the chance of getting pregnant . orgalutran is used to prevent the premature lh surge that might cause such a premature release of egg cells . in clinical studies orgalutran was used with recombinant follicle stimulating hormone ( fsh ) or corifollitropin alfa , a follicle stimulant with a long duration of action .
do not use orgalutran if you are allergic to ganirelix or any of the other ingredients of this medicine ( listed in section 6 ); if you are hypersensitive to gonadotrophin releasing hormone ( gnrh ) or a gnrh analogue ; if you have a moderate or severe kidney or liver disease ; if you are pregnant or breast - feeding. warnings and precautions talk to your doctor, pharmacist or nurse before using orgalutran allergic reactions if you have an active allergic condition, please tell your doctor. your doctor will decide, depending on the severity, if additional monitoring is required during treatment. cases of allergic reactions have been reported, as early as with the first dose. allergic reactions, both generalised and local, including hives ( urticaria ), swelling of the face, lips tongue and / or throat that may cause difficulty in breathing and / or swallowing ( angioedema and / or anaphylaxis ) have been reported. ( see also section 4.) if you have an allergic reaction, stop taking orgalutran and seek immediate medical assistance. latex allergy the needle cover contains dry natural rubber / latex which comes into contact with the needle and may cause allergic reactions. ovarian hyperstimulation syndrome ( ohss ) during or following hormonal stimulation of the ovaries, ovarian hyperstimulation syndrome may develop. this syndrome is related to the stimulation procedure with gonadotrophins. please refer to the package leaflet of the gonadotrophin - containing medicine prescribed for you. multiple births or birth defects the incidence of congenital malformations after assisted reproduction techniques may be slightly higher than after spontaneous conceptions. this slightly higher incidence is thought to be related to characteristics of the patients undergoing fertility treatment ( e. g. age of the woman, sperm characteristics ) and to the higher incidence of multiple gestations after assisted reproduction techniques. the incidence of congenital malformations after assisted reproduction techniques using orgalutran is not different from that after using other gnrh analogues in the course of assisted reproduction techniques. pregnancy complications there is
always use this medicine exactly as your doctor or pharmacist has told you. check with your doctor or pharmacist if you are not sure. orgalutran is used as part of the treatment for assisted reproduction techniques ( art ) including in vitro fertilisation ( ivf ). ovarian stimulation with follicle stimulating hormone ( fsh ) or corifollitropin may start at day 2 or 3 of your period. orgalutran ( 0. 25 mg ) should be injected just under the skin once daily, starting on day 5 or day 6 of stimulation. based on your ovarian response, your doctor may decide to start on another day. orgalutran and fsh should be administered approximately at the same time. however, the preparations should not be mixed and different injection sites are to be used. daily treatment with orgalutran should be continued up to the day that sufficient follicles of adequate size are present. final maturation of the egg cells in the follicles can be induced by administering human chorionic gonadotrophin ( hcg ). the time between two orgalutran injections as well as the time between the last orgalutran injection and hcg injection should not exceed 30 hours, as otherwise a premature ovulation ( i. e. release of egg cells ) may occur. therefore, when injecting orgalutran in the morning treatment with orgalutran should be continued throughout the gonadotrophin treatment period including the day of triggering ovulation. when injecting orgalutran in the afternoon the last orgalutran injection should be given in the afternoon prior to the day of triggering ovulation. instructions for use injection site orgalutran is supplied in pre - filled syringes and should be injected slowly, just under the skin, preferably in the upper leg. inspect the solution before use. do not use if the solution contains particles or is not clear. if you administer the injections yourself or have it done by your partner, follow the instructions below carefully. do not mix orgalutran with any other medicines. preparing the injection site wash your hands thoroughly
like all medicines , this medicine can cause side effects , although not everybody gets them . the chance of having a side effect is described by the following categories : very common : may affect more than 1 in 10 women local skin reactions at the site of injection ( predominantly redness , with or without swelling ). the local reaction normally disappears within 4 hours of administration . uncommon : may affect up to 1 in 100 women headache nausea malaise very rare : may affect up to 1 in 10 , 000 women allergic reactions have been observed , as early as with the first dose . rash facial swelling difficulty breathing ( dyspnoea ) swelling of face , lips , tongue , and / or throat that may cause difficulty in breathing and / or swallowing ( angioedema and / or anaphylaxis ) hives ( urticaria ) worsening of a pre - existing rash ( eczema ) has been reported in one subject after the first orgalutran dose . in addition , side effects are reported which are known to occur with controlled ovarian hyperstimulation treatment ( e . g . abdominal pain , ovarian hyperstimulation syndrome ( ohss ), ectopic pregnancy ( when the embryo develops outside the womb ) and miscarriage ( see the patient information leaflet of the fsh - containing preparation you are treated with )). reporting of side effects if you get any side effects , talk to your doctor , pharmacist or nurse . this includes any side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the carton and on the label after ' exp '. the expiry date refers to the last day of that month . do not freeze . store in the original package , in order to protect from light . inspect the syringe before use . use only syringes with clear , particle - free solutions and from undamaged containers . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what orgalutran contains - the active substance is ganirelix ( 0 . 25 mg in 0 . 5 ml solution ). - the other ingredients are acetic acid , mannitol , water for injections . the ph ( a measurement of the acidity ) may have been adjusted with sodium hydroxide and acetic acid . what orgalutran looks like and contents of the pack orgalutran is a clear and colourless aqueous solution for injection . the solution is ready for use and intended for subcutaneous administration . the needle cover contains dry natural rubber / latex which comes into contact with the needle . orgalutran is available in packs of 1 or 5 pre - filled syringes . not all pack sizes may be marketed .
what blitzima is blitzima contains the active substance " rituximab ". this is a type of protein called a " monoclonal antibody ". it sticks to the surface of a type of white blood cell called " b - lymphocyte ". when rituximab sticks to the surface of this cell, the cell dies. what blitzima is used for blitzima may be used for the treatment of several different conditions in adults and children. your doctor may prescribe blitzima for the treatment of : a ) non - hodgkin's lymphoma this is a disease of the lymph tissue ( part of the immune system ) that affects a type of white blood cell called b - lymphocytes. in adults, blitzima can be given alone or with other medicines called " chemotherapy ". in adult patients where the treatment is working, blitzima may be continued for 2 years after completing the initial treatment. in children and adolescents, blitzima is given in combination with " chemotherapy ". b ) chronic lymphocytic leukaemia chronic lymphocytic leukaemia ( cll ) is the most common form of adult leukaemia. cll affects a particular lymphocyte, the b cell, which originates from the bone marrow and develops in the lymph nodes. patients with cll have too many abnormal lymphocytes, which accumulate mainly in the bone marrow and blood. the proliferation of these abnormal b - lymphocytes is the cause of symptoms you may have. blitzima in combination with chemotherapy destroys these cells which are gradually removed from the body by biological processes. c ) granulomatosis with polyangiitis or microscopic polyangiitis blitzima is used for the treatment of adults and children 2 years of age and older with granulomatosis with polyangiitis ( formerly called wegener's granulomatosis ) or microscopic polyangiitis, taken in 71 combination with cor
do not take blitzima if : you are allergic to rituximab, other proteins which are like rituximab, or any of the other ingredients of this medicine ( listed in section 6 ) you have a severe active infection at the moment you have a weak immune system you have severe heart failure or severe uncontrolled heart disease and have granulomatosis with polyangiitis, microscopic polyangiitis or pemphigus vulgaris. do not have blitzima if any of the above apply to you. if you are not sure, talk to your doctor, pharmacist or nurse before you are given blitzima. warnings and precautions talk to your doctor, pharmacist or nurse before you are given blitzima if : you have ever had or might now have a hepatitis infection. this is because in a few cases, blitzima could cause hepatitis b to become active again, which can be fatal in very rare cases. patients who have ever had hepatitis b infection will be carefully checked by their doctor for signs of this infection. you have ever had heart problems ( such as angina, palpitations or heart failure ) or breathing problems. if any of the above apply to you ( or you are not sure ), talk to your doctor, pharmacist or nurse before you are given blitzima. your doctor may need to take special care of you during your treatment with blitzima. if you have granulomatosis with polyangiitis, microscopic polyangiitis or pemphigus vulgaris also tell your doctor if you think you may have an infection, even a mild one like a cold. the cells that are affected by blitzima help to fight infection and you should wait until the infection has passed before you are given blitzima. also please tell your doctor if you had a lot of infections in the past or suffer from severe infections. if you think you may need any vaccinations in the near future, including vaccinations needed to travel to other countries. some vaccines should not be
how it is given blitzima will be given to you by a doctor or nurse who is experienced in the use of this treatment. they will watch you closely while you are being given this medicine. this is in case you get any side effects. you will always be given blitzima as a drip ( intravenous infusion ). medicines given before each blitzima administration before you are given blitzima, you will be given other medicines ( pre - medication ) to prevent or reduce possible side effects. how much and how often you will receive your treatment a ) if you are being treated for non - hodgkin's lymphoma if you are having blitzima alone blitzima will be given to you once a week for 4 weeks. repeated treatment courses with blitzima are possible. if you are having blitzima with chemotherapy blitzima will be given to you on the same day as your chemotherapy. this is usually given every 3 weeks up to 8 times. if you respond well to treatment, you may be given blitzima every 2 or 3 months for two years. your doctor may change this, depending on how you respond to the medicine. if you are less than 18 years of age, you will be given blitzima with chemotherapy. you will receive blitzima up to 6 times over a 3. 5 5. 5 month period. b ) if you are being treated for chronic lymphocytic leukaemia when you are treated with blitzima in combination with chemotherapy, you will receive blitzima infusions on day 0 cycle 1 then day 1 of each cycle for 6 cycles in total. each cycle has a duration of 28 days. the chemotherapy should be given after the blitzima infusion. your doctor will decide if you should receive concomitant supportive therapy. c ) if you are being treated for granulomatosis with polyangiitis or microscopic polyangiitis treatment with blitzima uses four separate infusions given at weekly intervals. corticosteroids will usually be
like all medicines, this medicine can cause side effects, although not everybody gets them. most side effects are mild to moderate but some may be serious and require treatment. rarely, some of these reactions have been fatal. infusion reactions during or within the first 24 hours of the infusion you may develop fever, chills and shivering. less frequently, some patients may experience pain at the infusion site, blisters, itching, sickness ( nausea ), tiredness, headache, breathing difficulties, blood pressure raised, wheezing, throat discomfort, tongue or throat swelling, itchy or runny nose, vomiting, flushing or palpitations, heart attack or low number of platelets. if you have heart disease or angina, these reactions might get worse. tell the person giving you the infusion immediately if you or your child develops any of these symptoms, as the infusion may need to be slowed down or stopped. you may require additional treatment such as an antihistamine or paracetamol. when these symptoms go away, or improve, the infusion can be continued. these reactions are less likely to happen after the second infusion. your doctor may decide to stop your blitzima treatment if these reactions are serious. infections tell your doctor immediately if you or your child gets signs of an infection including : fever, cough, sore throat, burning pain when passing urine or feeling weak or generally unwell memory loss, trouble thinking, difficulty walking or sight loss these may be due to a very rare, serious brain infection, which has been fatal ( progressive multifocal leukoencephalopathy or pml ). you might get infections more easily during your treatment with blitzima. these are often colds, but there have been cases of pneumonia or urinary infections. these are listed below under " other side effects ". if you are being treated for granulomatosis with polyangiitis, microscopic polyangiitis or pemphigus vulgaris, you will also find this information in the patient alert card you have been given by your doctor. it is important that you keep this alert card and show it to your
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the carton and the vial after exp . the expiry date refers to the last day of that month . store in a refrigerator ( 2 8 ). keep the container in the outer carton in order to protect from light . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines that you no longer use . these measures will help protect the environment .
what blitzima contains the active ingredient in blitzima is called rituximab . the 10 ml vial contains 100 mg of rituximab ( 10 mg / ml ). the 50 ml vial contains 500 mg of rituximab ( 10 mg / ml ). the other ingredients are sodium chloride , tri - sodium citrate dihydrate , polysorbate 80 and water for injections . what blitzima looks like and contents of the pack blitzima is a clear , colourless solution , supplied as a concentrate for solution for infusion . ml vial pack of 2 vials 50 ml vial pack of 1 vial
roactemra contains the active substance tocilizumab, which is a protein made from specific immune cells ( monoclonal antibody ), that blocks the action of a specific protein ( cytokine ) called interleukin - 6. this protein is involved in inflammatory processes of the body, and blocking it can reduce the inflammation in your body. roactemra helps to reduce symptoms such as pain and swelling in your joints and can also improve your performance of daily tasks. roactemra has been shown to slow the damage to the cartilage and bone of the joints caused by the disease and to improve your ability to do normal daily activities. roactemra is used to treat adults with moderate to severe active rheumatoid arthritis ( ra ), an autoimmune disease, if previous therapies did not work well enough. roactemra is usually given in combination with methotrexate. however, roactemra can be given alone if your doctor determines that methotrexate is inappropriate. roactemra can also be used to treat adults who have not had previous methotrexate treatment if they have severe, active and progressive rheumatoid arthritis. roactemra is used to treat children with sjia. roactemra is used for children aged 2 years and over who have active systemic juvenile idiopathic arthritis ( sjia ), an inflammatory disease that causes pain and swelling in one or more joints as well as fever and rash. roactemra is used to improve the symptoms of sjia and can be given in combination with methotrexate or alone. roactemra is used to treat children with pjia. roactemra is used for children aged 2 years and over with active polyarticular juvenile idiopathic arthritis ( pjia ), an inflammatory disease that causes pain and swelling in one or more joints. roactemra is used to improve the
you are not to be given roactemra if you are allergic to tocilizumab or any of the other ingredients of this medicine ( listed in section 6 ). if you have an active, severe infection. if any of these applies to you, tell the doctor or nurse giving you the infusion. warnings and precautions talk to your doctor or nurse before you are given roactemra. if you experience allergic reactions such as chest tightness, wheezing, severe dizziness or light - headedness, swelling of the lips or skin rash during or after the infusion, then tell your doctor immediately. if you have any kind of infection, short - or long - term, or if you often get infections. tell your doctor immediately if you feel unwell. roactemra can reduce your body's ability to respond to infections and may make an existing infection worse or increase the chance of getting a new infection. if you have had tuberculosis, tell your doctor. your doctor will check for signs and symptoms of tuberculosis before starting roactemra. if symptoms of tuberculosis ( persistent cough, weight loss, listlessness, mild fever ), or any other infection appear during or after therapy tell your doctor immediately. if you have had intestinal ulcers or diverticulitis, tell your doctor. symptoms would include abdominal pain and unexplained changes in bowel habits with a fever. if you have liver disease, tell your doctor. before you use roactemra, your doctor may do a blood test to measure your liver function. if any patient has recently been vaccinated ( either adult or child ), or is planning a vaccination, tell your doctor. all patients, especially children, should be up - to - date with all their vaccinations before they start treatment with roactemra. certain types of vaccines should not be used while receiving roactemra. if you have cancer, tell your doctor. your doctor will have to decide
this medicine is subject to restricted medical prescription by your doctor. roactemra will be given to you as a drip into a vein, by a doctor or a nurse. they will dilute the solution, set up the intravenous infusion and monitor you during and after the treatment. adult patients with ra the usual dose of roactemra is 8 mg per kg of body weight. depending on your response, your doctor may decrease your dose to 4 mg / kg then increase back to 8 mg / kg when appropriate. adults will be given roactemra once every 4 weeks through a drip in the vein ( intravenous infusion ) over one hour. children with sjia ( aged 2 and over ) the usual dose of roactemra depends on your weight. if you weigh less than 30 kg : the dose is 12 mg for every kilogram of body weight if you weigh 30 kg or more, the dose is 8 mg for every kilogram of body weight the dose is calculated based on your body weight at each administration. children with sjia will be given roactemra once every 2 weeks through a drip in the vein ( intravenous infusion ) over one hour. children with pjia ( aged 2 and over ) the usual dose of roactemra depends on your weight. if you weigh less than 30 kg : the dose is 10mg for every kilogram of body weight if you weigh 30 kg or more : the dose is 8 mg for every kilogram of body weight the dose is calculated based on your body weight at each administration. children with pjia will be given roactemra once every 4 weeks through a drip in the vein ( intravenous infusion ) over one hour. patients with crs the usual dose of roactemra is 8 mg for every kg of body weight if you weigh 30 kg or more. the dose is 12 mg for every kg of body weight if you weigh less than 30 kg. roactemra can be given alone or in combination with corticosteroids. if you
like all medicines, roactemra can cause side effects, although not everybody gets them. side effects could occur at least up to 3 months after your last dose of roactemra. possible serious side effects : tell a doctor straight away. these are common : they may affect up to 1 in every 10 users allergic reactions during or after infusion : difficulty with breathing, chest tightness or light - headedness rash, itching, hives, swelling of the lips, tongue or face if you notice any of these, tell your doctor immediately. signs of serious infections fever and chills mouth or skin blisters stomach ache signs and symptoms of liver toxicity these may affect up to 1 in every 1000 users tiredness, abdominal pain, jaundice ( yellow discoloration of skin or eyes ) if you notice any of these, tell your doctor as soon as possible. very common side effects : these may affect more than 1 in every 10 users upper respiratory tract infections with typical symptoms such as cough, blocked nose, runny nose, sore throat and headache high blood fat ( cholesterol ) levels. common side effects : these may affect up to 1 in every 10 users lung infection ( pneumonia ) shingles ( herpes zoster ) cold sores ( oral herpes simplex ), blisters skin infection ( cellulitis ) sometimes with fever and chills rash and itching, hives allergic ( hypersensitivity ) reactions eye infection ( conjunctivitis ) headache, dizziness, high blood pressure mouth ulcers, stomach pain fluid retention ( oedema ) in the lower legs, weight increase cough, shortness of breath low white blood cell counts shown by blood tests ( neutropenia, leucopenia ) abnormal liver function tests ( increased transaminases ) increased bilirubin shown by blood tests low fibrinogen levels in the blood ( a protein involved in blood clotting ). uncommon side effects : these may affect up to 1 in every 100 users diverticulitis ( fever, nausea, diarrhoea, constipation, stomach pain ) red swolle
keep roactemra out of the sight and reach of children . store in a refrigerator ( 2 - 8 ). do not freeze . keep the vial in the outer carton in order to protect from light . do not use this medicine after the expiry date which is stated on the carton .
what roactemra contains the active substance is tocilizumab . each 4 ml vial contains 80 mg tocilizumab ( 20 mg / ml ). each 10 ml vial contains 200 mg tocilizumab ( 20 mg / ml ). each 20 ml vial contains 400 mg tocilizumab ( 20 mg / ml ). the other ingredients are sucrose , polysorbate 80 , disodium phosphate dodecahydrate , sodium dihydrogen phosphate dihydrate and water for injections . what roactemra looks like and contents of the pack roactemra is a concentrate for solution for infusion . the concentrate is a clear to opalescent , colourless to pale yellow liquid . roactemra is supplied as vials containing 4 ml , 10 ml and 20 ml concentrate for solution for infusion . pack size of 1 and 4 vials . not all pack sizes may be marketed .
what onbrez breezhaler is onbrez breezhaler contains the active substance indacaterol which belongs to a group of medicines called bronchodilators . when you inhale it , it relaxes the muscles in the walls of the small air passages in the lungs . this helps open up the airways , making it easier to get air in and out . what onbrez breezhaler is used for onbrez breezhaler is used to make breathing easier for adult patients who have breathing difficulties due to a lung disease called chronic obstructive pulmonary disease ( copd ). in copd the muscles around the airways tighten . this makes breathing difficult . this medicine relaxes these muscles in the lungs , making it easier for air to get in and out of the lungs .
do not use onbrez breezhaler - if you are allergic to indacaterol or any of the other ingredients of this medicine ( listed in section 6 ). warnings and precautions talk to your doctor or pharmacist before using onbrez breezhaler if you have asthma ( in this case you should not use onbrez breezhaler ). if you have heart problems. if you have epilepsy. if you have thyroid gland problems ( thyrotoxicosis ). if you have diabetes. during treatment with onbrez breezhaler, stop using the medicine and tell your doctor immediately if you get tightness of the chest, coughing, wheezing or breathlessness immediately after using the medicine. these may be signs of a condition called bronchospasm. tell your doctor immediately if your copd symptoms ( breathlessness, wheezing, cough ) do not improve or get worse. children and adolescents onbrez breezhaler should not be given to children or adolescents below the age of 18 years. other medicines and onbrez breezhaler tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. in particular, please tell your doctor if you are using : medicines for breathing problems that are similar to onbrez breezhaler ( i. e. medicines such as salmeterol and formoterol ). you may be more likely to get side effects. medicines called beta blockers that are used for high blood pressure or other heart problems ( such as propranolol ), or for the eye problem called glaucoma ( such as timolol ). medicines that lower the amount of potassium in your blood. these include : o steroids ( e. g. prednisolone ), o diuretics ( water tablets ) used for high blood pressure such as hydrochlorothiazide, o medicines for breathing problems such as theophylline. pregnancy and breast - feeding if you are pregnant or breast - feeding, think you may be pregnant or are planning to have a baby
always use this medicine exactly as your doctor has told you. check with your doctor or pharmacist if you are not sure. how much onbrez breezhaler to use the usual dose is to inhale the content of one capsule each day. your doctor may tell you to use the 150 microgram capsule or the 300 microgram capsule depending on your condition and on how you respond to the treatment. do not use more than your doctor tells you to use. use your inhaler at the same time each day, the effects last for 24 hours. this ensures that there is always enough medicine in your body to help you breathe more easily throughout the day and night. it will also help you to remember to use it. how to use onbrez breezhaler in this pack, you will find an inhaler and capsules ( in blisters ) that contain the medicine as inhalation powder. the onbrez breezhaler inhaler enables you to inhale the medicine contained in a capsule. only use the capsules with the inhaler provided in this pack ( onbrez breezhaler inhaler ). the capsules should remain in the blister until you need to use them. when you start a new pack, use the new onbrez breezhaler inhaler that is supplied in the pack. dispose of each inhaler after all capsules have been used. do not swallow the capsules. please read the instructions at the end of this leaflet for more information about how to use the inhaler. if you use more onbrez breezhaler than you should if you have inhaled too much onbrez breezhaler or if someone else uses your capsules, tell your doctor immediately or go to the nearest emergency unit. show the pack of onbrez breezhaler. medical attention may be needed. you may notice that your heart is beating faster than usual, or you may have a headache, feel drowsy, feel nauseous or have to vomit. if you forget to use onbrez breezhaler if you forget to inhale a dose, inhale just one dose at the usual time the
what onbrez breezhaler contains - each onbrez breezhaler 150 microgram capsule contains 150 microgram indacaterol as indacaterol maleate . the other ingredients include lactose and the capsule is made of gelatin . - each onbrez breezhaler 300 microgram capsule contains 300 microgram indacaterol as indacaterol maleate . the other ingredients include lactose and the capsule is made of gelatin . what onbrez breezhaler looks like and content of the pack in this pack , you will find an inhaler , together with capsules in blisters . the capsules are transparent ( uncoloured ) and contain a white powder . onbrez breezhaler 150 microgram capsules have a black product code " idl 150 " printed above a black bar and a black company logo ( ) printed below the black bar . onbrez breezhaler 300 microgram capsules have a blue product code " idl 300 " printed above a blue bar and a blue company logo ( ) printed below the blue bar . the following pack sizes are available : carton containing 10 capsules and 1 inhaler . carton containing 30 capsules and 1 inhaler . multipack comprising 2 packs ( each containing 30 capsules and 1 inhaler ). multipack comprising 3 packs ( each containing 30 capsules and 1 inhaler ). multipack comprising 30 packs ( each containing 10 capsules and 1 inhaler ). not all pack sizes or strengths may be available in your country .
clopidogrel hcs contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products. platelets are very small structures in the blood, which clump together during blood clotting. by preventing this clumping, antiplatelet medicinal products reduce the chances of blood clots forming ( a process called thrombosis ). clopidogrel hcs is taken by adults to prevent blood clots ( thrombi ) forming in hardened blood vessels ( arteries ), a process known as atherothrombosis, which can lead to atherothrombotic events ( such as stroke, heart attack, or death ). you have been prescribed clopidogrel hcs to help prevent blood clots and reduce the risk of these severe events because : - you have a condition of hardening of arteries ( also known as atherosclerosis ), and - you have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease, or - you have experienced a severe type of chest pain known as'unstable angina'or'myocardial infarction'( heart attack ). for the treatment of this condition your doctor may have placed a stent in the blocked or narrowed artery to restore effective blood flow. you should also be given acetylsalicylic acid ( a substance present in many medicines used to relieve pain and lower fever as well as to prevent blood clotting ) by your doctor. - you have an irregular heartbeat, a condition called'atrial fibrillation ', and you cannot take medicines known as'oral anticoagulants'( vitamin k antagonists ) which prevent new clots from forming and prevent existing clots from growing. you should have been told that'oral anticoagulants'are more effective than acetylsalicylic acid or the combined use of clopidogrel hcs and acetylsalicylic acid for this condition. your doctor should have prescribed clopidogrel h
do not take clopidogrel hcs if you are allergic to clopidogrel or any of the other ingredients of this medicine ( listed in section 6 ). if you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain, if you suffer from severe liver disease. if you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking clopidogrel hcs. warnings and precautions if any of the situations mentioned below apply to you, you should tell your doctor before taking clopidogrel hcs : if you have a risk of bleeding such as - a medical condition that puts you at risk of internal bleeding ( such as a stomach ulcer ). - a blood disorder that makes you prone to internal bleeding ( bleeding inside any tissues, organs or joints of your body ). - a recent serious injury. - a recent surgery ( including dental ). - a planned surgery ( including dental ) in the next seven days. if you have had a clot in an artery of your brain ( ischaemic stroke ) which occurred within the last seven days. if you have kidney or liver disease. if you have had an allergy or reaction to any medicine used to treat your disease. while you are taking clopidogrel hcs : you should tell your doctor if a surgery ( including dental ) is planned. you should also tell your doctor immediately if you develop a medical condition ( also known as thrombotic thrombocytopenic purpura or ttp ) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes ( jaundice ) ( see section 4'possible side effects '). if you cut or injure yourself, it may take longer than usual for bleeding to stop. this is linked to the way your medicine works as it prevents the ability of blood clots to form. for minor cuts and injuries e.
always take this medicine exactly as your doctor or pharmacist has told you . you should check with your doctor or pharmacist if you are not sure . the recommended dose , including for patients with a condition called ' atrial fibrillation ' ( an irregular heartbeat ), is one 75 mg tablet of clopidogrel hcs per day to be taken orally with or without food , and at the same time each day . if you have experienced severe chest pain ( unstable angina or heart attack ), your doctor may give you 300 mg of clopidogrel hcs ( 4 tablets of 75 mg ) once at the start of treatment . then , the recommended dose is one 75 mg tablet of clopidogrel hcs per day as described above . you should take clopidogrel hcs for as long as your doctor continues to prescribe it . if you take more clopidogrel hcs than you should contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding . if you forget to take clopidogrel hcs if you forget to take a dose of clopidogrel hcs , but remember within 12 hours of your usual time , take your tablet straightaway and then take your next tablet at the usual time . if you forget for more than 12 hours , simply take the next single dose at the usual time . do not take a double dose to make up for a forgotten tablet . for the 28x1 tablets pack size , you can check the day on which you last took a tablet of clopidogrel hcs by referring to the calendar printed on the blister . if you stop taking clopidogrel hcs do not stop the treatment unless your doctor tells you so . contact your doctor or pharmacist before stopping . if you have any further questions on the use of this medicine , ask your doctor or pharmacist .
like all medicines, this medicine can cause side effects, although not everybody gets them. contact your doctor immediately if you experience : - fever, signs of infection or extreme tiredness. these may be due to rare decrease of some blood cells. - signs of liver problems such as yellowing of the skin and / or the eyes ( jaundice ), whether or not associated with bleeding which appears under the skin as red pinpoint dots and / or confusion ( see section 2'warnings and precautions '). - swelling in the mouth or skin disorders such as rashes and itching, blisters of the skin. these may be the signs of an allergic reaction. the most common side effect reported with clopidogrel hcs is bleeding. bleeding may occur as bleeding in the stomach or bowels, bruising, haematoma ( unusual bleeding or bruising under the skin ), nose bleed, blood in the urine. in a small number of cases, bleeding in the eye, inside the head, the lung or the joints has also been reported. if you experience prolonged bleeding when taking clopidogrel hcs if you cut or injure yourself, it may take slightly longer than usual for bleeding to stop. this is linked to the way your medicine works as it prevents the ability of blood clots to form. for minor cuts and injuries e. g., cutting yourself, shaving, this is usually of no concern. however, if you are concerned by your bleeding, you should contact your doctor straightaway ( see section 2'warnings and precautions '). other side effects include : common side effects ( may affect up to 1 in 10 people ): diarrhoea, abdominal pain, indigestion or heartburn. uncommon side effects ( may affect up to 1 in 100 people ): headache, stomach ulcer, vomiting, nausea, constipation, excessive gas in stomach or intestines, rashes, itching, dizziness, sensation of tingling and numbness. rare side effect ( may affect up to 1 in 1000 people ): vertigo
what clopidogrel hcs contains the active substance is clopidogrel . each film - coated tablet contains 75 mg of clopidogrel ( as hydrochloride ). the other ingredients are ( see section 2 ' clopidogrel hcs contains hydrogenated castor oil '): tablet core : microcrystalline cellulose , colloidal anhydrous silica , crospovidone ( type a ), macrogol 6000 and hydrogenated castor oil . tablet coating : polyvinyl alcohol , titanium dioxide ( e171 ), red iron oxide ( e172 ), yellow iron oxide ( e172 ), talc and macrogol 3000 . what clopidogrel hcs looks like and contents of the pack the film - coated tablets are pink , round and slightly convex . boxes of 28 , 30 , 50 , 56 , 84 , 90 or 100 film - coated tablets in blisters or boxes of 28x1 , 28x1 ( calendar pack ), 30x1 , 50x1 , 56x1 , 84x1 , 90x1 and 100x1 film - coated tablets in perforated unit dose blisters are available . not all pack sizes may be marketed .
fetcroja contains the active substance cefiderocol . it is an antibiotic medicine that belongs to a group of antibiotics called cephalosporins . antibiotics help to fight bacteria that cause infections . fetcroja is used in adults to treat infections caused by certain types of bacteria when other antibiotics cannot be used .
do not use fetcroja if you are allergic to cefiderocol or any of the other ingredients of this medicine ( listed in section 6 ); if you are allergic to other antibiotics known as cephalosporins ; if you have had a severe allergic reaction to certain antibiotics, such as penicillins or carbapenems. this can include severe skin peeling, swelling of the hands, face, feet, lips, tongue or throat ; or difficulty swallowing or breathing. tell your doctor if any of these apply to you. warnings and precautions talk to your doctor or nurse before you are given fetcroja : if you have ever had any allergic reaction to other antibiotics. see also section above, " do not use fetcroja "; if you have kidney problems. your doctor will adjust your dose to ensure you don't get too much or too little medicine ; if you suffer from diarrhoea during your treatment ; if you are on a low sodium diet ; if you have ever had seizures. talk to your doctor or nurse before you are given fetcroja. new infection although fetcroja can fight certain bacteria, there is a possibility that you may get a different infection caused by another organism during or after your treatment. your doctor will monitor you closely for any new infections and give you another treatment if necessary. blood / laboratory tests tell your doctor that you are taking fetcroja if you are going to have any blood / laboratory tests. this is because you may get an abnormal result. with something called a " coombs test " this looks for the presence of antibodies that can destroy red blood cells or may be affected by the response of your immune system to fetcroja. fetcroja may also result in false - positive results in urine dipstick tests ( urine protein or diabetes markers ). children and adolescents fetcroja should not be given to children and adolescents under the age of 18. this is because it is not known if the medicine is safe to use in these age groups. other medicines and fetcroja tell your doctor or nurse
your doctor or nurse will give you this medicine as an infusion ( a drip ) into your vein over 3 hours , three times a day . the usual recommended dose is 2 g . the number of days you will be given fetcroja treatment depends on the type of infection you have and how well your infection is clearing . if you get any pain where the fetcroja infusion goes into your vein , tell your doctor or nurse . people with kidney problems if you have kidney problems , talk to your doctor before you are given fetcroja . the doctor will adjust your dose of fetcroja . if you are given more fetcroja than you should fetcroja will be given to you by a doctor or nurse , so it is unlikely you will be given the wrong dose . tell your doctor or nurse straight away if you think you have been given more fetcroja than you should have . if you miss a dose of fetcroja if you think you have not been given a dose of fetcroja , tell your doctor or nurse straight away . if you have any further questions on the use of this medicine , ask your doctor or nurse .
like all medicines , this medicine can cause side effects , although not everybody gets them . serious side effects tell your doctor straight away if you notice any of the following serious side effects you may need urgent medical treatment : severe allergic reaction signs include sudden swelling of your lips , face , throat or tongue ; a severe rash or other severe skin reactions ; difficulty swallowing or breathing . this reaction may be life - threatening . diarrhoea that gets worse or does not go away , or stools that contain blood or mucus . this may happen during treatment , or after it has been stopped . if this happens , do not take medicines that stop or slow bowel movement . tell your doctor straight away if you notice any of the serious side effects above . other side effects tell your doctor or nurse if you notice any of the following side effects . common ( may affect up to 1 in 10 people ) feeling sick ( nausea ) or being sick ( vomiting ) swelling , redness and / or pain around the needle where the medicine is given into a vein yeast infections e . g . thrush increase in levels of liver enzymes , shown in blood tests cough rash , with small raised bumps severe gut infection known as clostridioides difficile colitis . symptoms include watery diarrhoea , abdominal pain , fever , etc . uncommon ( may affect up to 1 in 100 people ) allergy to fetcroja reporting of side effects if you get any side effects , talk to your doctor or nurse . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects , you can help provide more information on the safety of this medicine .
what fetcroja contains - the active substance is cefiderocol sulfate tosylate , equivalent to 1 g cefiderocol . - the other excipients are sucrose , sodium chloride and sodium hydroxide . what fetcroja looks like and contents of the pack fetcroja is a white to off - white powder for concentrate for solution for infusion in a vial . it is available in packs containing 10 vials .
depocyte is used to treat lymphomatous meningitis . lymphomatous meningitis is a condition in which tumour cells have invaded the fluid or membranes that surround the brain and spinal cord . depocyte is used in adults to kill lymphoma tumour cells .
depocyte should not be given â if you are allergic to cytarabine or any of the other ingredients of this medicine ( listed in section 6 ). â if you have a meningeal infection . warnings and precautions severe neurological side effects have been reported with the use of depocyte . symptoms have included effects on the nervous system ( e . g . convulsions , pain , numbness or tingling , blindness or visual disturbances ). your doctor will check for these symptoms regularly . make sure you take as directed any dexamethasone tablets that you may have been prescribed , as they reduce the risk of unwanted effects caused by depocyte . if your side effects get worse or you notice any new side effects , tell your doctor . other medicines and depocyte please tell your doctor if you are taking or have recently taken any other medicines , including medicines obtained without a prescription . pregnancy , breast - feeding and fertility depocyte should not be given to pregnant women as it may harm an unborn child . women of childbearing potential should use a reliable contraceptive method to avoid pregnancy whilst being treated with depocyte . male patients undergoing depocyte treatment should use a reliable contraceptive method . women should not breast - feed during treatment as depocyte may enter breast milk . driving and using machines do not drive during treatment . do not operate any tools or machines during treatment .
a qualified and experienced doctor or physician in the treatment of cancer will inject depocyte in the spinal fluid or lumber sac. depocyte must not be administered by any other way. injections are given slowly over 1 - 5 minutes and you may be asked to lie flat for one hour afterwards. you will also be given dexamethasone, usually as tablets but possibly by intravenous injection for 5 days after you receive each depocyte dose to help reduce any side effects which might occur. before depocyte is used the vial should be warmed to room temperature ( 18 22 ) for at least 30 minutes. just before withdrawing depocyte, the vial should be gently inverted to mix the particles evenly. it should not be shaken vigorously. proper precautions should be taken for the handling and administration of a cytotoxic drug ( proper handling technique, use of a suitable designated area, protective clothing, procedures to address risk of contamination ). staff who are pregnant or trying to conceive ( male and female ) should not work with depocyte. in the event of accidental contact with the mucous membranes, treat immediately by copious washing with water ; medical attention should be sought. depocyte should be withdrawn from the vial immediately before administration ; the medicinal product should be used within 4 hours of withdrawal from the vial. unused medicinal product must be discarded and not used subsequently. depocyte must not be mixed with any other medicinal products. in - line filters must not be used when administering depocyte. depocyte must be used as supplied without further dilution. the dose for adults is 50 mg ( one vial of depocyte ). for the treatment of lymphomatous meningitis, depocyte is given according to the following schedules : start - up treatment : one vial of depocyte ( 50 mg ) administered every 14 days for 2 doses ( weeks 1 and 3 ). follow - up treatment : one vial of depocyte ( 50 mg ) administered every 14 days for 3 doses ( weeks 5, 7 and 9 ) followed by an additional dose at week 13. maintenance treatment : one vial of depocyte ( 50 mg ) administered every 28
like all medicines , this medicine can cause side effects , although not everybody gets them . side effects may occur after each injection , usually within the first five days . your doctor will discuss these with you and will explain the potential risks and benefits of your treatment . the frequency of possible side effects listed below is defined using the following convention : very common ( affects more than 1 user in 10 ); common ( affects 1 to 10 users in 100 ); uncommon ( affects 1 to 10 users in 1 , 000 ); rare ( affects 1 to 10 users in 10 , 000 ); very rare ( affects less than 1 user in 10 , 000 ); not known ( frequency cannot be estimated from the available data ). the severity of adverse events of depocyte may be increased when depocyte is given in combination with other chemotherapeutic agents . tell the medical staff monitoring you during this time , if you suffer from : very common ( experienced in more than 1 in 10 patients ) nausea and / or vomiting weakness confusion fever headaches dizziness shaking common ( experienced in less than 1 in 10 but more than 1 in 100 patients ) back pain convulsion neck pain a stiff or rigid neck infection of the meninges fatigue pain , numbness or tingling ( feeling of sensation of pins and needles ) blindness and other visual disturbances hearing loss persistent or extreme sleepiness partial paralysis if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please inform the medical staff looking after you . reporting of side effects if you get any side effects , talk to your doctor or nurse . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the carton and on the vial after exp . the expiry date refers to the last day of that month . store in a refrigerator ( 2 8 ). do not freeze . depocyte should be used as soon as possible after first opening , and should normally be used within 4 hours ( stored at 18 - 22Âºc ). depocyte is a sterile white to off - white - suspension . do not use this medicine if you notice severe discolouration , a changed appearance or a defective container . do not throw away any medicines via wastewater . depocyte contains cytarabine , and should be disposed of in a manner consistent with local requirements .
what depocyte contains â the active substance is cytarabine . one ml of suspension contains 10 mg cytarabine . each 5 ml vial contains 50 mg cytarabine â the other ingredients are cholesterol , triolein , dioleoylphosphatidylcholine , dipalmitoylphosphatidylglycerol , sodium chloride , and water for injections . what depocyte looks like and contents of the pack depocyte is a white to off - white - suspension for injection supplied in a glass vial . each vial contains 5 ml of suspension for a single injection . each pack contains a single vial .
what bemrist breezhaler is and how it works bemrist breezhaler contains two active substances called indacaterol and mometasone furoate . indacaterol belongs to a group of medicines called bronchodilators . it relaxes the muscles of the small airways in the lungs . this helps to open the airways and makes it easier for air to get in and out of the lungs . when it is taken regularly , it helps the small airways to remain open . mometasone furoate belongs to a group of medicines called corticosteroids ( or steroids ). corticosteroids reduce the swelling and irritation ( inflammation ) in the small airways in the lungs and so gradually ease breathing problems . corticosteroids also help to prevent attacks of asthma . what bemrist breezhaler is used for bemrist breezhaler is used regularly as treatment for asthma in adults and adolescents ( 12 years of age and older ). asthma is a serious , long - term lung disease where the muscles surrounding the smaller airways become tight ( bronchoconstriction ) and inflamed . symptoms come and go and include shortness of breath , wheezing , chest tightness and cough . you should use bemrist breezhaler every day and not only when you have breathing problems or other symptoms of asthma . this will ensure that it controls your asthma properly . do not use this medicine to relieve a sudden attack of breathlessness or wheezing . if you have any questions about how bemrist breezhaler works or why this medicine has been prescribed for you , ask your doctor .
follow all the doctor's instructions carefully. do not use bemrist breezhaler - if you are allergic to indacaterol, mometasone furoate or any of the other ingredients of this medicine ( listed in section 6 ). if you think you may be allergic, ask your doctor for advice. warnings and precautions talk to your doctor, pharmacist or nurse before using bemrist breezhaler if any of the following applies to you : - if you have heart problems, including an irregular or fast heartbeat. - if you have thyroid gland problems. - if you have ever been told you have diabetes or high blood sugar. - if you suffer from seizures or fits. - if you have a low level of potassium in your blood. - if you have severe liver problems. - if you have tuberculosis ( tb ) of the lung, or any long - standing or untreated infections. during treatment with bemrist breezhaler stop using this medicine and get medical help immediately if you have any of the following : - tightness of the chest, coughing, wheezing or breathlessness immediately after using bemrist breezhaler ( signs the medicine is unexpectedly tightening the airways, known as paradoxical bronchospasm ). - difficulty breathing or swallowing, swelling of the tongue, lips or face, skin rash, itching and hives ( signs of allergic reaction ). children and adolescents do not give this medicine to children below 12 years of age because it has not been studied in this age group. other medicines and bemrist breezhaler tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. in particular, tell your doctor or pharmacist if you are using : - medicines that decrease the level of potassium in your blood. these include diuretics ( which increase urine production and can be used to treat high blood pressure, e. g. hydrochlorothiazide ), other bronchodilators such as methylxan
always use this medicine exactly as your doctor or pharmacist has told you. check with your doctor or pharmacist if you are not sure. how much bemrist breezhaler to inhale there are three different strengths of bemrist breezhaler capsules. your doctor will decide which is best for you. the usual dose is to inhale the content of one capsule each day. you only need to use the medicine once a day. do not use more than your doctor tells you to use. you should use bemrist breezhaler every day, even when your asthma is not troubling you. when to inhale bemrist breezhaler inhale bemrist breezhaler at the same time each day. this will help control your symptoms throughout the day and night. it will also help you to remember to use it. how to inhale bemrist breezhaler - bemrist breezhaler is for inhalation use. - in this pack, you will find an inhaler and capsules that contain the medicine. the inhaler enables you to inhale the medicine in the capsule. only use the capsules with the inhaler provided in this pack. the capsules should remain in the blister until you need to use them. - peel the backing away from the blister to open it, do not push the capsule through the foil. - when you start a new pack, use the new inhaler supplied in this new pack. - dispose of the inhaler in each pack after all capsules in that pack have been used. - do not swallow the capsules. - please read the instructions for use on the other side of this leaflet for more information on how to use the inhaler. if your symptoms do not improve if your asthma is not getting better or if it gets worse after you have started using bemrist breezhaler, talk to your doctor. if you use more bemrist breezhaler than you should if you accidently inhale too much of this medicine, contact your doctor or hospital for advice immediately. you may need medical attention.
like all medicines , this medicine can cause side effects , although not everybody gets them . some side effects could be serious stop using bemrist breezhaler and get medical help immediately if you have any of the following : common : may affect up to 1 in every 10 people - difficulty breathing or swallowing , swelling of the tongue , lips , or face , skin rash , itching and hives ( signs of allergic reaction ). uncommon : may affect up to 1 in every 100 people - swelling mainly of the tongue , lips , face or throat ( possible signs of angioedema ). other side effects other side effects include the following listed below . if these side effects become severe , please tell your doctor , pharmacist or nurse . very common : may affect more than 1 in 10 people - sore throat - runny nose - sudden difficulty breathing and feeling of tightness in chest with wheezing or coughing common : may affect up to 1 in every 10 people - voice alteration ( hoarseness ) - blocked nose - sneezing , cough - headache - pain in muscles , bones or joints ( signs of musculoskeletal pain ) uncommon : may affect up to 1 in every 100 people - fast heart beat - oral thrush ( sign of candidiasis ) - high level of sugar in the blood - muscle spasm - skin itching - rash - clouding of the lens of your eyes ( signs of cataract ) - blurred vision reporting of side effects if you get any side effects , talk to your doctor , pharmacist or nurse . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
- keep this medicine out of the sight and reach of children . - do not use this medicine after the expiry date which is stated on the carton and blister after " exp ". the expiry date refers to the last day of that month . - this medicinal product does not require any special temperature storage conditions . - store the capsules in the original blister in order to protect from light and moisture , and do not remove until immediately before use . - do not throw away any medicines via wastewater . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what bemrist breezhaler contains - the active substances are indacaterol ( as acetate ) and mometasone furoate. bemrist breezhaler 125 micrograms / 62. 5 micrograms each capsule contains 173 micrograms of indacaterol acetate ( equivalent to 150 micrograms of indacaterol ) and 80 micrograms of mometasone furoate. the delivered dose ( the dose that leaves the mouthpiece of the inhaler ) is equivalent to 125 micrograms of indacaterol and 62. 5 micrograms of mometasone furoate. bemrist breezhaler 125 micrograms / 127. 5 micrograms each capsule contains 173 micrograms of indacaterol acetate ( equivalent to 150 micrograms of indacaterol ) and 160 micrograms of mometasone furoate. the delivered dose ( the dose that leaves the mouthpiece of the inhaler ) is equivalent to 125 micrograms of indacaterol and 127. 5 micrograms of mometasone furoate. bemrist breezhaler 125 micrograms / 260 micrograms each capsule contains 173 micrograms of indacaterol acetate ( equivalent to 150 micrograms of indacaterol ) and 320 micrograms of mometasone furoate. the delivered dose ( the dose that leaves the mouthpiece of the inhaler ) is equivalent to 125 micrograms of indacaterol and 260 micrograms of mometasone furoate. - the other ingredient is lactose monohydrate ( see " bemrist breezhaler contains lactose " in section 2 ). what bemrist breezhaler looks like and content of the pack in this pack, you will find an inhaler together with capsules in blisters. the capsules are transparent and contain a white powder. - bemrist breezhaler
zyllt contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products. platelets are very small structures in the blood, which clump together during blood clotting. by preventing this clumping, antiplatelet medicinal products reduce the chances of blood clots forming ( a process called thrombosis ). zyllt is taken by adults to prevent blood clots ( thrombi ) forming in hardened blood vessels ( arteries ), a process known as atherothrombosis, which can lead to atherothrombotic events ( such as stroke, heart attack, or death ). you have been prescribed zyllt to help prevent blood clots and reduce the risk of these severe events because : - you have a condition of hardening of arteries ( also known as atherosclerosis ), and - you have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease, or - you have experienced a severe type of chest pain known as'unstable angina'or'myocardial infarction'( heart attack ). for the treatment of this condition your doctor may have placed a stent in the blocked or narrowed artery to restore effective blood flow. you should also be given acetylsalicylic acid ( a substance present in many medicines used to relieve pain and lower fever as well as to prevent blood clotting ) by your doctor. - you have an irregular heartbeat, a condition called'atrial fibrillation ', and you cannot take medicines known as'oral anticoagulants'( vitamin k antagonists ) which prevent new clots from forming and prevent existing clots from growing. you should have been told that'oral anticoagulants'are more effective than acetylsalicylic acid or the combined use of zyllt and acetylsalicylic acid for this condition. your doctor should have prescribed zyllt plus acetylsalicylic acid if you cannot take'oral anticoagulants'and you do not
do not take zyllt if you are allergic to clopidogrel or any of the other ingredients of this medicine ( listed in section 6 ). if you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain. if you suffer from severe liver disease. if you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking zyllt. warnings and precautions if any of the situations mentioned below apply to you, you should tell your doctor before taking zyllt : if you have a risk of bleeding such as - a medical condition that puts you at risk of internal bleeding ( such as a stomach ulcer ) - a blood disorder that makes you prone to internal bleeding ( bleeding inside any tissues, organs or joints of your body ). - a recent serious injury - a recent surgery ( including dental ) - a planned surgery ( including dental ) in the next seven days if you have had a clot in an artery of your brain ( ischaemic stroke ) which occurred within the last seven days if you have kidney or liver disease if you have had an allergy or reaction to any medicine used to treat your disease. while you are taking zyllt : you should tell your doctor if a surgery ( including dental ) is planned. you should also tell your doctor immediately if you develop a medical condition ( also known as thrombotic thrombocytopenic purpura or ttp ) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes ( jaundice ) ( see section 4'possible side effects '). if you cut or injure yourself, it may take longer than usual for bleeding to stop. this is linked to the way your medicine works as it prevents the ability of blood clots to form. for minor cuts and injuries e. g., cutting yourself, shaving, this is usually of no concern. however, if you are concerned by your bleeding
always take this medicine exactly as your doctor or pharmacist has told you . check with your doctor or pharmacist if you are not sure . the recommended dose , including for patients with a condition called ' atrial fibrillation ' ( an irregular heartbeat ), is one 75 mg tablet of zyllt per day to be taken orally with or without food , and at the same time each day . if you have experienced severe chest pain ( unstable angina or heart attack ), your doctor may give you 300 mg of zyllt ( 4 tablets of 75 mg ) once at the start of treatment . then , the recommended dose is one 75 mg tablet of zyllt per day as described above . you should take zyllt for as long as your doctor continues to prescribe it . if you take more zyllt than you should contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding . if you forget to take zyllt 32 if you forget to take a dose of zyllt , but remember within 12 hours of your usual time , take your tablet straightaway and then take your next tablet at the usual time . if you forget for more than 12 hours , simply take the next single dose at the usual time . do not take a double dose to make up for a forgotten tablet . if you stop taking zyllt do not stop the treatment unless your doctor tells you so . contact your doctor or pharmacist before stopping . if you have any further questions on the use of this medicine , ask your doctor or pharmacist .
like all medicines, this medicine can cause side effects, although not everybody gets them. contact your doctor immediately if you experience : - fever, signs of infection or extreme tiredness. these may be due to rare decrease of some blood cells. - signs of liver problems such as yellowing of the skin and / or the eyes ( jaundice ), whether or not associated with bleeding which appears under the skin as red pinpoint dots and / or confusion ( see section 2'warnings and precautions '). - swelling in the mouth or skin disorders such as rashes and itching, blisters of the skin. these may be the signs of an allergic reaction. the most common side effect is bleeding. bleeding may occur as bleeding in the stomach or bowels, bruising, haematoma ( unusual bleeding or bruising under the skin ), nose bleed, blood in the urine. in a small number of cases, bleeding in the eye, inside the head, the lung or the joints has also been reported. if you experience prolonged bleeding when taking zyllt if you cut or injure yourself, it may take longer than usual for bleeding to stop. this is linked to the way your medicine works as it prevents the ability of blood clots to form. for minor cuts and injuries e. g., cutting yourself, shaving, this is usually of no concern. however, if you are concerned by your bleeding, you should contact your doctor straightaway ( see section 2'warnings and precautions '). other side effects include : common side effects ( may affect up to 1 in 10 people ): diarrhoea, abdominal pain, indigestion or heartburn. uncommon side effects ( may affect up to 1 in 100 people ): headache, stomach ulcer, vomiting, nausea, constipation, excessive gas in stomach or intestines, rashes, itching, dizziness, sensation of tingling and numbness. rare side effects ( may affect up to 1 in 1000 people ): vertigo, enlarged breasts in males. very rare side effects ( may affect up
what zyllt contains - the active substance is clopidogrel . each film - coated tablet contains 75 mg of clopidogrel ( as hydrogen sulphate ). - the other ingredients are lactose ( see section 2 ' zyllt contains lactose '), microcrystalline cellulose , pregelatinised maize starch , macrogol 6000 and hydrogenated castor oil in the tablet core and hypromellose ( e464 ), titanium dioxide ( e171 ), red iron oxide ( e172 ), talc and propylene glycol in the film - coating . what zyllt looks like and contents of the pack the film - coated tablets are pink , round and slightly convex . boxes of 7 , 14 , 28 , 30 , 50 , 56 , 60 , 84 , 90 and 100 film - coated tablets in blisters are available . not all pack sizes may be marketed .
the active ingredient in lamivudine teva is lamivudine . lamivudine teva is used to treat long term ( chronic ) hepatitis b infection in adults . lamivudine teva is an antiviral medicine that suppresses the hepatitis b virus and belongs to a group of medicines called nucleoside analogue reverse transcriptase inhibitors ( nrtis ). hepatitis b is a virus that infects the liver causes long term ( chronic ) infection , and can lead to liver damage . lamivudine teva can be used in people whose liver is damaged but still functions normally ( compensated liver disease ). treatment with lamivudine teva can reduce the amount of hepatitis b virus in your body . this should lead to a reduction in liver damage and an improvement in your liver function . not everyone responds to treatment with lamivudine teva in the same way . your doctor will monitor the effectiveness of your treatment with regular blood tests .
do not take lamivudine teva if you are allergic to lamivudine or any of the other ingredients of this medicine ( listed in section 6 ). check with your doctor if you think this applies to you. warnings and precautions 28 some people taking lamivudine teva or other similar medicines are more at risk of serious side effects. you need to be aware of the extra risks : if you have ever had other types of liver disease, such as hepatitis c. if you are seriously overweight ( especially if you are a woman ). talk to your doctor if any of these apply to you. you may need extra check - ups, including blood tests, while you are taking your medication. see section 4 for more information about the risks. do not stop taking lamivudine teva without your doctor's advice, as there is a risk of your hepatitis getting worse. when you stop taking lamivudine teva your doctor will monitor you for at least four months to check for any problems. this will mean taking blood samples to check for any raised liver enzyme levels, which may indicate liver damage. see section 3 for more information about how to take lamivudine teva. look out for important symptoms some people taking medicines for hepatitis b infection develop other conditions, which can be serious. you need to know about important signs and symptoms to look out for while you are taking lamivudine teva. read the information'other possible side effects of therapy for hepatitis b'in section 4 of this leaflet. protect other people hepatitis b infection is spread by sexual contact with someone who has the infection, or by transfer of infected blood ( for example, by sharing injection needles ). lamivudine teva will not stop you passing hepatitis b infection on to other people. to protect other people from becoming infected with hepatitis b : use a condom when you have oral or penetrative sex. do not risk blood transfer
always take this medicine exactly as your doctor has told you to. check with your doctor or pharmacist if you are not sure. stay in regular contact with your doctor lamivudine teva helps to control your hepatitis b infection. you need to keep taking it every day to control your infection and stop your illness getting worse. keep in touch with your doctor, and do not stop taking lamivudine teva without your doctor's advice. how much to take the usual dose of lamivudine teva is one tablet ( 100 mg lamivudine ) once a day. your doctor may prescribe a lower dose if you have problems with your kidneys. an oral solution of lamivudine is available for people who need a lower than usual dose, or who can't take tablets. talk to your doctor if this applies to you. if you are already taking another medicine that contains lamivudine for hiv infection, your doctor will continue to treat you with the higher dose, ( usually 150 mg twice a day ), because the dose of lamivudine in lamivudine teva ( 100 mg ) is not enough to treat hiv infection. if you are planning to change your hiv treatment, discuss this change with your doctor first. swallow the tablet whole, with some water. lamivudine teva can be taken with or without food. if you take more lamivudine teva than you should accidentally taking too much lamivudine teva is unlikely to cause any serious problems. if you accidentally take too much, tell your doctor or pharmacist, or contact your nearest hospital emergency department for further advice. if you forget to take lamivudine teva if you forget to take a dose, take it as soon as you remember. then continue your treatment as before. do not take a double dose to make up for a missed dose. do not stop taking lamivudine teva you must not stop taking lamivudine teva
like all medicines, this medicine can cause side effects, but not everyone gets them. as well as the side effects listed below for lamivudine teva, other conditions can develop during therapy for hepatitis b. it is important to read the information under'other possible side effects of therapy for hepatitis b '. side effects that were commonly reported in lamivudine clinical trials were tiredness, respiratory tract infections, throat discomfort, headache, stomach discomfort and pain, nausea, vomiting and diarrhoea, increases in liver enzymes and enzymes produced in the muscles ( see below ). allergic reaction these are rare ( may affect up to 1 in 1, 000 people ). signs include : swelling of eyelids, face or lips difficulty swallowing or breathing contact a doctor immediately if you get these symptoms. stop taking lamivudine teva. side effects thought to be caused by lamivudine teva a very common side effect ( these may affect more than 1 in 10 people ) which may show up in blood tests is : an increase in the level of some liver enzymes ( transaminases ), which may be a sign of inflammation or damage in the liver. a common side effect ( these may affect up to 1 in 10 people ) is : cramps and muscle pains skin rash or'hives'anywhere on the body. a common side effect which may show up in blood tests is : an increase in the level of an enzyme produced in the muscles ( creatine phosphokinase ) which may be a sign that body tissue is damaged. other side effects other side effects have occurred in a very small number of people but their exact frequency is unknown breakdown of muscle tissue a worsening of liver disease after lamivudine teva is stopped or during treatment if the hepatitis b virus becomes resistant to lamivudine teva. this can be fatal in some people. lactic acidosis ( see the next section,'other possible side effects of therapy for hepatitis b '). a side effect
keep this medicine out of the sight and reach of children . do not take this medicine after the expiry date shown on the container or carton and blister pack after exp . the expiry date refers to the last day of that month . this medicinal product does not require any special storage conditions do not use lamivudine teva if you notice any change in the appearance of the tablet . do not throw away any medicines in your wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help to protect the environment .
what lamivudine teva contains - the active substance is lamivudine . each film - coated tablet contains 100 mg of lamivudine . - the other ingredients are ; tablet core : microcrystalline cellulose , sodium starch glycolate , magnesium stearate . tablet film coat : hypromellose , titanium dioxide ( e171 ), macrogol , polysorbate 80 , iron oxide yellow ( e172 ), iron oxide red ( e172 ). what lamivudine teva looks like and contents of the pack orange , capsule shaped , biconvex film - coated tablet engraved with " l100 " on one side and plain on the other 32 lamivudine teva is available in aluminium blisters containing 28 , 30 , 84 or 100 tablets or hdpe containers containing 60 tablets . not all pack sizes may beavailable in your country .
your doctor has given you nespo ( an anti - anaemic ) to treat your anaemia . anaemia is when your blood does not contain enough red blood cells and the symptoms may be fatigue , weakness and shortness of breath . nespo works in exactly the same way as the natural hormone erythropoietin . erythropoietin is produced in your kidneys and encourages your bone marrow to produce more red blood cells . the active substance of nespo is darbepoetin alfa produced by gene - technology in chinese hamster ovary cells ( cho - k1 ). if you have chronic renal failure nespo is used to treat symptomatic anaemia that is associated with chronic renal failure ( kidney failure ) in adults and children . in kidney failure , the kidney does not produce enough of the natural hormone erythropoietin which can often cause anaemia . because it will take your body some time to make more red blood cells , it will be about four weeks before you notice any effect . your normal dialysis routine will not affect the ability of nespo to treat your anaemia . if you are receiving chemotherapy nespo is used to treat symptomatic anaemia in adult cancer patients with non - bone marrow cancers ( non - myeloid malignancies ) who are receiving chemotherapy . one of the main side effects of chemotherapy is that it stops the bone marrow producing enough blood cells . at first , only white blood cells seem to be affected . this is because the red blood cells have a much longer life span in the circulating blood . towards the end of your chemotherapy course , particularly if you have had a lot of chemotherapy , your red blood cell count may fall making you anaemic .
do not use nespo : if you have been diagnosed with high blood pressure which is not being controlled with other medicines prescribed by your doctor ; or if you are allergic to nespo ( darbepoetin alfa ), r - huepo or to any of the other ingredients in nespo. take special care with nespo please tell your doctor if you are suffering or have suffered from : high blood pressure which is being controlled with medicines prescribed by your doctor ; sickle cell anaemia ; epileptic fits ( seizures ); convulsions ( fits or seizures ); liver disease ; significant lack of response to drugs used to treat anaemia ; or an allergy to latex ( the needle cover on the pre - filled syinge contains a derivative of latex ). special warnings if you have symptoms which include unusual tiredness and a lack of energy this could mean you have pure red cell aplasia ( prca ), which has been reported in patients. prca means that the body has stopped or reduced the production of red blood cells which causes severe anaemia. if you experience these symptoms you should contact your doctor who will determine the best course of action to treat your anaemia. your doctor should try to keep your haemoglobin between 10 and 12 g / dl. if you have chronic renal failure there is an increased risk of serious problems with your heart or blood vessels ( cardiovascular events ) if your haemoglobin is kept too high. if you are a cancer patient you should be aware that nespo may act as a blood cell growth factor and in some circumstances may have a negative impact on your cancer. depending on your individual situation a blood transfusion may be preferable. please discuss this with your doctor. misuse by healthy people can cause life - threatening problems with the heart or blood vessels. using other medicines cyclosporin and tacrolimus may be affected by the number of red cells in your blood. it is important to tell your doctor if you are taking either of these drugs. please tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. using n
following blood tests, your doctor has decided you need nespo as your haemoglobin level is 10 g / dl or less. your doctor will tell you how much and how often you must take nespoin order to maintain a haemoglobin level between 10 and 12 g / dl. this may vary depending on whether you are an adult or a child. injecting nespo yourself your doctor may decide that it is best for you or a carer to inject nespo. your doctor, nurse or pharmacist will show you how to inject yourself with the pre - filled syringe. do not try to inject yourself if you have not been trained. never inject nespo into a vein yourself. if you have chronic renal failure nespo is given as a single injection, either once a week, once every two weeks, or once every month either under your skin ( subcutaneous ) or into a vein ( intravenous ). in order to correct your anaemia, your initial dose of nespo per kilogram of your body weight will be either : 0. 75 micrograms once every two weeks, or 0. 45 micrograms once weekly your doctor will take regular blood samples to measure how your anaemia is responding and may adjust your dose once every four weeks as necessary. once your anaemia is corrected, your doctor will continue to regularly check your blood and your dose may be adjusted further in order to maintain long - term control of your anaemia. your doctor will inform you if your dose changes. your blood pressure will also be checked regularly, particularly at the beginning of your treatment. in some cases, your doctor may recommend that you take iron supplements. your doctor may decide to change the way that your injection is given ( either under the skin or into a vein ). if this changes you will start on the same dose as you have been receiving and your doctor will take blood samples to make sure that your anaemia is still being managed correctly. if your doctor has decided to change your treatment from r - huepo ( erythropoietin produced by gene - technology ) to ne
like all medicines , nespo may cause side effects , although not everybody gets them . the following side effects have been experienced by some patients taking nespo : 471 very common ( seen in more than 10 in 100 people ) high blood pressure ( hypertension ) fluid retention ( oedema ) common ( seen in more than 1 in 100 people ) blood clots ( thrombosis ) pain around the area injected rash and / or redness of the skin rare ( seen in more than 1 in 10 , 000 people ) serious allergic reactions which may include : sudden life - threatening allergic reactions ( anaphylaxis ) swelling of the face , lips , mouth , tongue or throat which may cause difficulty in swallowing or breathing ( angioedema ) shortness of breath ( dyspnoea ) skin rash hives ( urticaria ) very rare ( seen in less than 1 in 10 , 000 people ) pure red cell aplasia ( prca ) ( anaemia , unusual tiredness , lack of energy ) convulsions ( fits and seizures ) have been reported in patients treated with nespo . if you have any of these symptoms or you notice any side effects that are not mentioned in this leaflet , please tell your doctor , nurse or pharmacist .
keep out of the reach and sight of children . keep in the original package in order to protect from light . store in a refrigerator ( 2 8 ). do not freeze . do not use nespo if you think it has been frozen . when your syringe has been removed from the refrigerator and left at room temperature for approximately 30 minutes before injection it must either be used within 7 days or disposed of . do not use nespo after the expiry date which is stated on the carton and on the pre - filled pen label after exp . the expiry date refers to the last day of that month . medicines should not be disposed of via wastewater or household waste . ask your pharmacist how to dispose of medicines no longer required . these measures will help to protect the environment .
what nespo contains nespo comes in a pre - filled syringe that contains either 10 , 15 , 20 , 30 , 40 , 50 , 60 , 80 , 100 , 130 , 150 , 300 or 500 micrograms of the active substance darbepoetin alfa . nespo also contains sodium phosphate monobasic , sodium phosphate dibasic , sodium chloride , polysorbate 80 and water for injections . what nespo looks like and contents of the pack nespo is a clear , colourless or slightly pearly liquid . if it is cloudy or there are particles in it , you must not use it . nespo is available in packs of 1 or 4 pre - filled syringes ( not all pack sizes may be marketed ). the syringes are provided either with ( 1 -& 4 - pack ) or without ( 1 - pack ) a blister - wrapping .
macugen is a solution which is injected into the eye . pegaptanib , the active substance of this medicine , inhibits the activity of the factor involved in the abnormal formation of new blood vessels in the eye , known as vascular endothelial growth factor165 ( vegf165 ). macugen is used for the treatment of the wet form of age - related macular degeneration ( amd ). this disease leads to vision loss resulting from damage to the central part of the retina ( called the macula ), at the back of the eye . the macula enables the eye to provide the fine central vision that is needed for activities such as driving a car , reading fine print and other similar tasks . in the wet form of amd , abnormal blood vessels grow under the retina and macula . these new blood vessels may bleed and leak fluid , causing the macula to bulge or lift up , thus distorting or destroying central vision . under these circumstances vision loss may be rapid and severe . macugen works by inhibiting the growth of these abnormal blood vessels and by stemming the bleeding and leakage . the medicine is used for the treatment of all types of abnormal blood vessels growth in adult amd patients .
you must not be given macugen : if you are allergic to pegaptanib or any of the other ingredients of this medicine ( listed in section 6 ). if you have an active or suspected infection in or around the eye. warnings and precautions talk to your doctor before you are given macugen. occasionally, an infection or bleeding in the eye can occur after macugen injection ( in the next two weeks ). it is important to identify and treat these types of conditions as soon as possible. please tell your doctor immediately if you notice any of the following symptoms : eye pain or increased discomfort, worsening eye redness, blurred or decreased vision, increased sensitivity to light, increased number of small particles in your vision. if your doctor cannot be reached for any reason, an alternate doctor should be contacted immediately. in some patients the pressure inside the treated eye may increase for a short period directly after the injection. your doctor may monitor this after each injection. soon after the injection serious allergic reactions may occur. the symptoms you might experience and the instruction what to do in such cases are described in section 4 of this leaflet. children and adolescents macugen should not be used in children and adolescents under 18 years old. other medicines and macugen tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. pregnancy and breast - feeding if you are pregnant or breast - feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before macugen treatment. there is no experience of using macugen in pregnant women. macugen should not be used during pregnancy unless the potential benefit outweighs the potential risk to the unborn child. if you are pregnant discuss this with your doctor before treatment with macugen. macugen is not recommended during breastfeeding as it is not known whether macugen passes into human milk. ask your doctor or pharmacist for advice before starting macugen treatment. driving and using machines you may experience temporary visual blurring after receiving macugen. if you are affected, do not drive or use machines until this resolves. important information about some of the ingredients of macugen this medicine contains less than 1 mmol sodium ( 23 mg
all injections of macugen will be administered by your doctor . macugen is administered as a single injection ( 0 . 3 mg ) into your eye at intervals of 6 weeks ( i . e . 9 times per year ). the injection is given into the vitreous of the eye , which is the jelly - like substance inside the eye . your doctor will monitor your condition and recommend how long you should be treated with macugen . before the treatment is given your doctor may ask you to use antibiotic eye drops , or to wash your eyes carefully . your doctor will also give you some local anaesthetic ( numbing medicine ). this will reduce or prevent any pain you might have with the injection . please do not forget to tell your doctor if you are known to be allergic to any substance . after each injection you might be asked to use antibiotic eye drops ( or another type of antibiotic treatment ) to guard against eye infection . if you have been given more macugen than you should have in the case excess macugen volume is injected , serious increase in intraocular pressure may occur . whenever you ' ll experience vision disturbances , eye discomfort / pain , eye redness or nausea and vomiting , immediately refer to your doctor and tell about your symptoms . if you have any further questions on the use of this medicine , ask your doctor or pharmacist .
like all medicines, this medicine can cause side effects, although not everybody gets them. cases of serious allergic reaction, including anaphylactic reaction and angioedema of which symptoms are described below, has been reported soon after the injection. please seek immediate medical help if you experience any of the following soon after the injection : sudden onset of breathing difficulty or wheezing, swollen mouth, face, hands or feet, itching skin, fainting, rapid pulse, stomach cramps, nausea, vomiting or diarrhoea. frequency of these side effects cannot be estimated from the data available. uncommonly, an infection in the internal portion of the eye can occur after two weeks following macugen treatment. the symptoms you might experience are described in section 2 of this leaflet (" warnings and precautions "). please read section 2. it tells you what to do if you have any of these symptoms. other possible side effects are as follows : very common ( may affect more than 1 in 10 people ) these side effects are most probably caused by the injection procedure rather than the medicine, and include : eye inflammation eye pain increased pressure inside the eye small marks on the eye surface ( punctate keratitis ) small particles or spots in your vision ( vitreous floaters or opacities ). common ( may affect up to 1 in 10 people ) other common eye side effects reported to be possibly caused by the medicine or by the injection procedure include : blurred vision visual disturbance eye discomfort decreased vision increased sensitivity to light, appearance of flashing lights bleeding that occurs around the eye ( periorbital bleeding ) bloodshot eye ( conjunctival haemorrhage ) disorder of the jelly portion inside the eye ( vitreous disorder ), such as displacement or tear ( vitreous detachment ) clouding of the lens ( cataract ) disorder of the surface of the eye ( cornea ) swelling or inflammation of the eyelid, swelling of the area on the inside of the eyelid or the outer surface of the eye ( conjunctiva ) eye inflammation, tears, inflammation of the conjunctiva ( conjunctivitis ), dryness, eye discharge, eye
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the label and carton after exp . the expiry date refers to the last day of that month . store in a refrigerator ( 2Âºc - 8Âºc ). do not freeze . the medicine must be discarded if kept at room temperature for more than two weeks . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what macugen contains - the active substance is pegaptanib . each single dose pre - filled syringe delivers a dose of 0 . 3 mg pegaptanib in 90 microlitres . - the other ingredients are sodium chloride , monobasic sodium phosphate monohydrate , dibasic sodium phosphate heptahydrate , sodium hydroxide and hydrochloric acid ( for ph adjustment ) and water for injections . for additional information regarding sodium content of macugen , see section 2 . what macugen looks like and contents of the pack macugen solution for injection is supplied in a single dose pack . each pack contains a pouch in a carton , containing a pre - filled syringe , type i glass , filled with 0 . 25 - 0 . 27 ml of solution , sealed with an elastomeric plunger stopper and a pre - attached plunger rod , held by a plastic clip . the syringe has a pre - attached polycarbonate plastic luer lock adaptor and the tip is sealed with an elastomeric tip cap . the pack is supplied without a needle .
kepivance contains the active substance palifermin which is a protein produced by biotechnology in a bacteria called escherichia coli . palifermin stimulates the growth of specific cells called epithelial cells that form the tissue lining of your mouth and digestive tract , as well as other tissues such as skin . palifermin works in the same way as keratinocyte growth factor ( kgf ) which is made naturally by your body in small amounts . kepivance is used to treat oral mucositis ( soreness , dryness and inflammation of the mouth ) which has occurred as a side effect of treatments for your blood cancer . to treat your blood cancer you may be receiving chemotherapy , radiotherapy and autologous hematopoietic stem cell transplantation ( cells from your own body that produce blood cells ). one of the side effects of these treatments is oral mucositis . kepivance is used to reduce the frequency , duration and severity of oral mucositis symptoms . kepivance should only be used in adults over the age of 18 years .
do not use kepivance : - if you are allergic to palifermin , escherichia coli derived proteins or any other ingredients of this medicine ( listed in section 6 ). children kepivance is not recommended in children ( 0 to 18 years ). other medicines and kepivance tell your doctor or pharmacist if you are taking , have recently taken or might take any other medicines . kepivance might interact with a medicine called heparin . please inform your doctor if you are receiving or have recently received heparin . pregnancy and breast - feeding kepivance has not been tested in pregnant women . it is important to tell your doctor if you : - are pregnant ; - think you may be pregnant ; or - plan to have a baby . if you are pregnant you should not use kepivance unless clearly necessary . it is not known whether kepivance is present in human milk . do not use kepivance if you are breast - feeding . ask your doctor or pharmacist for advice before taking this medicine .
kepivance will be given to you by a doctor or nurse with experience in cancer treatment . the usual dose of kepivance is 60 micrograms of kepivance per kilogram of bodyweight per day . this dose will be given to you as an intravenous injection ( into a vein ). when you will be given kepivance you will be given kepivance for three days in a row before chemotherapy and radiotherapy and for three days in a row after chemotherapy and radiotherapy for a total of six doses . the last of the three doses given before chemotherapy andradiotherapy , must be given at least 24 to 48 hours before the chemotherapy and radiotherapy starts . the first of the three doses given after the chemotherapy and radiotherapy must be given at least 7 days after the most recent kepivance administration . for information on preparation and administration of kepivance , please see information for healthcare professionals at the end of this leaflet .
like all medicines , this medicine can cause side effects , although not everybody gets them . very common ( affects more than 1 user in 10 ) side effects are : skin rash , itching and redness ( pruritus and erythaema ); an increase in the thickness in the mouth or tongue ; change in colour of the mouth or tongue ; generalised swelling ( oedema ); swelling of hands , ankles or feet ; pain ; fever ; aching joints ( arthralgia ); altered taste ; increase in lipase and amylase levels ( digestive enzymes ) in the blood ( which do not require treatment and usually return to normal after stopping treatment with kepivance ). common ( affects 1 to 10 users in 100 ) side effects are : tingling of the mouth ; darkening of an area of skin ( hyperpigmentation ); eyelid swelling ; lip swelling . not known ( frequency cannot be estimated from available data ): redness , bumps or swelling of the tongue ; swelling ( oedema ) of the face or mouth ; swelling or redness of the vagina ; hand - and - foot skin - reaction ( palms of the hands or soles of the feet tingle , become numb , painful , swollen or red ); allergic reactions . if you get any side effects , talk to your doctor or pharmacist . this includes any possible side effects not listed in this leaflet . reporting of side effects if you get any side effects , talk to your doctor or pharmacist . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
what kepivance contains - the active substance is palifermin . each vial contains 6 . 25 mg of palifermin . - the other ingredients are mannitol , sucrose , l - histidine , polysorbate 20 and diluted hydrochloric acid . what kepivance looks like and contents of the pack kepivance is a white powder supplied in vials . each pack contains 6 vials .
cinacalcet accordpharma contains the active ingredient cinacalcet , which works by controlling the levels of parathyroid hormone ( pth ), calcium and phosphorous in your body . it is used to treat problems with organs called parathyroid glands . the parathyroids are four small glands in the neck , near the thyroid gland , that produce parathyroid hormone ( pth ). cinacalcet accordpharma is used in adults : - to treat secondary hyperparathyroidism in adults with serious kidney disease who need dialysis to clear their blood of waste products . - to reduce high levels of calcium in the blood ( hypercalcaemia ) in adult patients with parathyroid cancer . - to reduce high levels of calcium in the blood ( hypercalcaemia ) in adult patients with primary hyperparathyroidism when removal of the gland is not possible . cinacalcet accordpharma is used in children aged 3 years to less than 18 years of age to treat secondary hyperparathyroidism in patients with serious kidney disease who need dialysis to clear their blood of waste products , whose condition is not controlled with other treatments . in primary and secondary hyperparathyroidism too much pth is produced by the parathyroid glands . " primary " means that the hyperparathyroidism is not caused by any other condition and " secondary " means that the hyperparathyroidism is caused by another condition , e . g . kidney disease . both primary and secondary hyperparathyroidism can cause the loss of calcium in the bones , which can lead to bone pain and fractures , problems with blood and heart vessels , kidney stones , mental illness and coma .
do not take cinacalcet accordpharma : - if you are allergic to cinacalcet or any of the other ingredients of this medicine ( listed in section 6 ). - if you have low levels of calcium in your blood. your doctor will monitor your blood calcium levels. warnings and precautions talk to your doctor, pharmacist or nurse before taking cinacalcet accordpharma. before you start taking cinacalcet accordpharma, tell your doctor if you have or have ever had : - seizures ( fits or convulsions ). the risk of having seizures is higher if you have had them before ; - liver problems ; - heart failure. cinacalcet accordpharma reduces calcium levels. life threatening events and fatal outcomes associated with low calcium levels ( hypocalcaemia ) have been reported in adults and children treated with cinacalcet accordpharma. please tell your doctor if you experience any of the following which may be signs of low calcium levels : spasms, twitches, or cramps in your muscles, or numbness or tingling in your fingers, toes or around your mouth or seizures, confusion or loss of consciousness while being treated with cinacalcet accordpharma. low calcium levels can have an effect on your heart rhythm. tell your doctor if you experience an unusually fast or pounding heartbeat, if you have heart rhythm problems, or if you take medicines known to cause heart rhythm problems, while taking cinacalcet accordpharma. for additional information see section 4. during treatment with cinacalcet accordpharma, tell your doctor : - if you start or stop smoking, as this may affect the way cinacalcet accordpharma works. children and adolescents children under the age of 18 with parathyroid cancer or primary hyperparathyroidism must not take cinacalcet accordpharma. if you are being treated for secondary hyperparathyroidism, your doctor should monitor your calcium levels before starting treatment with cinacalcet accordpharma and during treatment with cinacalcet accordpharma. you should inform your doctor if you experience any of the signs of low calcium levels as described above. cinacalcet accordpharma is only available as film
always take this medicine exactly as your doctor or pharmacist has told you . check with your doctor or pharmacist if you are unsure . your doctor will tell you how much cinacalcet accordpharma you must take . cinacalcet accordpharma must be taken orally , with or shortly after food . the tablets must be taken whole and are not to be chewed , crushed or divided . your doctor will take regular blood samples during treatment to monitor your progress and will adjust your dose if necessary . if you are being treated for secondary hyperparathyroidism the usual starting dose for cinacalcet accordpharma in adults is 30 mg ( one tablet ) once per day . the usual starting dose of cinacalcet accordpharma for children aged 3 years to less than 18 years of age is no more than 0 . 20 mg / kg of body weight daily . cinacalcet accordpharma is only available as film - coated tablet . thus , it is not possible to administer cinacalcet accordpharma to paediatric patients who require doses lower than 30 mg , or who are unable to swallow tablets . if an alternate dose or form of this medicine is required , other cinacalcet medicines offering such an option should be used ; ask your doctor or pharmacist . if you are being treated for parathyroid cancer or primary hyperparathyroidism the usual starting dose for cinacalcet accordpharma in adults is 30 mg ( one tablet ) twice per day . if you take more cinacalcet accordpharma than you should if you took more cinacalcet accordpharma than you should you must contact your doctor immediately . possible signs of overdose include numbness or tingling around the mouth , muscle aches or cramps and seizures . if you forget to take cinacalcet accordpharma 49 do not take a double dose to make up for a forgotten dose . if you have forgotten a dose of cinacalcet accordpharma , you should take your next dose as normal . if you have any further questions on the use of this medicine , ask your doctor , pharmacist or nurse .
like all medicines, this medicine can cause side effects, although not everybody gets them. please tell your doctor immediately : - if you start to get numbness or tingling around the mouth, muscle aches or cramps and seizures these may be signs that your calcium levels are too low ( hypocalcaemia ). - if you experience swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing ( angioedema ). very common : may affect more than 1 in 10 people - nausea and vomiting, these side effects are normally quite mild and do not last for long. common : may affect up to 1 in 10 people - dizziness - numbness or tingling sensation ( paraesthesia ) - loss ( anorexia ) or decrease of appetite - muscle pain ( myalgia ) - weakness ( asthenia ) - rash - reduced testosterone levels - high potassium levels in the blood ( hyperkalaemia ) - allergic reactions ( hypersensitivity ) - headache - seizures ( convulsions or fits ) - low blood pressure ( hypotension ) - upper respiratory infection - breathing difficulties ( dyspnoea ) - cough - indigestion ( dyspepsia ) - diarrhoea - abdominal pain, abdominal pain upper - constipation - muscle spasms - back pain - low calcium levels in the blood ( hypocalcaemia ). not known : frequency cannot be estimated from available data - hives ( urticaria ) - swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing ( angioedema ) - unusually fast or pounding heart beat which may be associated with low levels of calcium in your blood ( qt prolongation and ventricular arrhythmia secondary to hypocalcaemia ). after taking cinacalcet accordpharma a very small number of patients with heart failure had worsening of their condition and / or low blood pressure ( hypotension ). reporting of side effects if you get any side effects, talk to your doctor or pharmacist
what cinacalcet accordpharma contains - the active substance is cinacalcet. each film - coated tablet contains 30 mg, 60 mg or 90 mg of cinacalcet ( as hydrochloride ). - the other ingredients are : - cellulose, microcrystalline - crospovidone - magnesium stearate - the tablets are coated with : - hypromellose ( e464 ), - titanium dioxide ( e171 ), - triacetin, - indigo carmine aluminum lake ( e132 ), - iron oxide yellow ( e172 ) what cinacalcet accordpharma looks like and contents of the pack cinacalcet accordpharma 30 mg film - coated tablets ( tablet ) light green colored, oval shaped ( approximately 9. 65 mm long and 6. 00 mm wide ), biconvex, film - coated tablets debossed with " hb1 " on one side and plain on other side. cinacalcet accordpharma 60 mg film - coated tablets ( tablet ) light green colored, oval shaped ( approximately 12. 20 mm long and 7. 60 mm wide ), biconvex, film - coated tablets debossed with " hb2 " on one side and plain on other side. cinacalcet accordpharma 90 mg film - coated tablets ( tablet ) light green colored, oval shaped ( approximately 14. 00 mm long and 8. 70 mm wide ), biconvex, film - coated tablets debossed with " hb3 " on one side and plain on other side. cinacalcet accordpharma is available in blisters of 30 mg, 60 mg or 90 mg film - coated tablets. cinacalcet accordpharma is provided in pvc / alu blister packs containing 14, 28 or 84 tablets and unit dose blister containing 14 x 1, 28 x 1 or 84 x 1 tablet. cinacalcet accordpharma is available in bottles of 30 mg, 60 mg or 90 mg film - coated tablets. each bottle holds 30 film - coated tablets. not all pack
the name of your tablet is jentadueto . it contains two different active substances linagliptin and metformin . - linagliptin belongs to a class of medicines called dpp - 4 inhibitors ( dipeptidyl peptidase - 4 inhibitors ). - metformin belongs to a class of medicines called biguanides . how jentadueto works the two active substances work together to control blood sugar levels in adult patients with a form of diabetes called ' type 2 diabetes mellitus '. along with diet and exercise , this medicine helps to improve the levels and effects of insulin after a meal and lowers the amount of sugar made by your body . this medicine can be used alone or with certain other medicines for diabetes like sulphonylureas , empagliflozin , or insulin . what is type 2 diabetes ? type 2 diabetes is a condition in which your body does not make enough insulin , and the insulin that your body produces does not work as well as it should . your body can also make too much sugar . when this happens , sugar ( glucose ) builds up in the blood . this can lead to serious medical problems like heart disease , kidney disease , blindness , and amputation .
do not take jentadueto - if you are allergic to linagliptin or metformin or any of the other ingredients of this medicine ( listed in section 6 ). - if you have severely reduced kidney function. if you have uncontrolled diabetes, with, for example, severe hyperglycaemia ( high blood glucose ), nausea, vomiting, diarrhoea, rapid weight loss, lactic acidosis ( see " risk of lactic acidosis " below ) or ketoacidosis. ketoacidosis is a condition in which substances called'ketone bodies'accumulate in the blood and which can lead to diabetic pre - coma. symptoms include stomach pain, fast and deep breathing, sleepiness or your breath developing an unusual fruity smell. - if you ever had a diabetic pre - coma. - if you have a severe infection such as an infection affecting your lung or bronchial system or your kidney. severe infections may lead to kidney problems, which can put you at risk for lactic acidosis ( see'warnings and precautions '). - if you have lost a lot of water from your body ( dehydration ), e. g. due to long - lasting or severe diarrhoea, or if you have vomited several times in a row. dehydration may lead to kidney problems, which can put you at risk for lactic acidosis ( see'warnings and precautions '). - if you are treated for acute heart failure or have recently had a heart attack, have severe problems with your circulation ( such as shock ) or have breathing difficulties. this may lead to a lack in oxygen supply to tissue which can put you at risk for lactic acidosis ( see'warnings and precautions '). - if you have liver problems. - if you drink alcohol to excess, either every day or only from time to time ( see section'jentadueto with alcohol '). do not take jentadueto if
always take this medicine exactly as your doctor or pharmacist has told you. check with your doctor or pharmacist if you are not sure. how much to take the amount of jentadueto that you will take varies depending on your condition and the doses you currently take of metformin and / or individual tablets of linagliptin and metformin. your doctor will tell you exactly the dose of this medicine to take. how to take this medicine - one tablet twice daily by mouth in the dose prescribed by your doctor. - with meals to lower your chance of an upset stomach. you should not exceed the maximum recommended daily dose of 5 mg linagliptin and 2, 000 mg metformin hydrochloride. continue to take jentadueto as long as your doctor prescribes it so you can continue to help control your blood sugar. your doctor may prescribe this medicine together with another oral anti - diabetic medicine or insulin. remember to take all medicines as directed by your doctor to achieve the best results for your health. you should continue your diet during treatment with jentadueto and take care that your carbohydrate intake is equally distributed over the day. if you are overweight, continue your energy - restricted diet as instructed. this medicine alone is unlikely to cause abnormally low blood sugar ( hypoglycaemia ). when jentadueto is used with a sulphonylurea medicine or with insulin, low blood sugar can occur and your doctor may reduce the dose of your sulphonylurea or insulin. if you take more jentadueto than you should if you take more jentadueto tablets than you should have, you may experience lactic acidosis. symptoms of lactic acidosis are non - specific such as feeling or being very sick, vomiting, stomach ache with muscle cramps, a general feeling of not being well with severe tiredness, and difficulty in breathing. further symptoms are reduced body temperature and heartbeat. if this happens to you, you may need immediate hospital treatment, as lactic acidosis can lead to coma. stop taking this medicine immediately and contact a doctor or
like all medicines, this medicine can cause side effects, although not everybody gets them. some symptoms need immediate medical attention you should stop taking jentadueto and see your doctor straight away if you experience the following symptoms of low blood sugar ( hypoglycaemia ): trembling, sweating, anxiety, blurred vision, tingling lips, paleness, mood change, or confusion. hypoglycaemia ( frequency very common ( may affect more than 1 in 10 people )) is an identified side effect for the combination of jentadueto plus sulphonylurea and for the combination jentadueto plus insulin. jentadueto may cause a very rare ( may affect up to 1 user in 10, 000 ), but very serious side effect called lactic acidosis ( see section'warnings and precautions '). if this happens you must stop taking jentadueto and contact a doctor or the nearest hospital immediately, as lactic acidosis may lead to coma. some patients have experienced inflammation of the pancreas ( pancreatitis ; frequency rare, may affect up to 1 in 1000 people ). stop taking jentadueto and contact a doctor immediately if you notice any of the following serious side effects : - severe and persistent pain in the abdomen ( stomach area ) which might reach through to your back, as well as nausea and vomiting, as it could be a sign of an inflamed pancreas ( pancreatitis ). other side effects of jentadueto include : some patients have experienced allergic reactions ( frequency rare ), which may be serious, including wheezing and shortness of breath ( bronchial hyperreactivity ; frequency uncommon ( may affect up to 1 in 100 people )). some patients experienced rash ( frequency uncommon ), hives ( urticaria ; frequency rare ), and swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing ( angioedema ; frequency rare ). if you experience any of the signs of illness mentioned above, stop taking
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the blister , bottle and carton after exp . the expiry date refers to the last day of that month . this medicine does not require any special temperature storage conditions . blister : store in the original package in order to protect from moisture . bottle : keep the bottle tightly closed in order to protect from moisture . do not use this medicine if the package is damaged or shows signs of tampering . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what jentadueto contains - the active substances are linagliptin and metformin hydrochloride. - each jentadueto 2. 5 mg / 850 mg film - coated tablet contains 2. 5 mg of linagliptin and 850 mg of metformin hydrochloride. - each jentadueto 2. 5 mg / 1, 000 mg film - coated tablet contains 2. 5 mg of linagliptin and 1, 000 mg of metformin hydrochloride. - the other ingredients are : - tablet core : arginine, copovidone, magnesium stearate, maize starch, silica, colloidal anhydrous. - film coating : hypromellose, titanium dioxide ( e171 ), talc, propylene glycol. jentadueto 2. 5 mg / 850 mg film - coated tablets also contains iron oxide red ( e172 ) and iron oxide yellow ( e172 ). jentadueto 2. 5 mg / 1, 000 mg film - coated tablets also contains iron oxide red ( e172 ). what jentadueto looks like and contents of the pack jentadueto 2. 5 mg / 850 mg are oval, biconvex, light orange, film - coated tablets ( tablets ). they have " d2 / 850 " debossed on one side and the boehringer ingelheim logo debossed on the other. jentadueto 2. 5 mg / 1, 000 mg are oval, biconvex light pink film - coated tablets ( tablets ). they have " d2 / 1000 " debossed on one side and the boehringer ingelheim logo debossed on the other. jentadueto is available in perforated unit dose blisters with 10 x 1, 14 x 1, 28 x 1, 30 x 1, 56 x 1
edurant contains rilpivirine that is used for the treatment of human immunodeficiency virus ( hiv ) infection . it belongs to a group of hiv medicines called non - nucleoside reverse transcriptase inhibitors ( nnrtis ). edurant works by reducing the amount of hiv in your body . edurant is used in combination with other hiv medicines to treat adolescents and adults 12 years of age and older who are infected with hiv and who have never been treated before with hiv medicines . your doctor will discuss with you which combination of medicines is best for you .
do not take edurant if you are allergic to rilpivirine or any of the other ingredients of this medicine ( listed in section 6 ). do not take edurant in combination with any of the following medicines as they may affect the way edurant or the other medicine works : - carbamazepine, oxcarbazepine, phenobarbital, phenytoin ( medicines to treat epilepsy and prevent seizures ) - rifampicin, rifapentine ( medicines to treat some bacterial infections such as tuberculosis ) - omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole, ( proton pump inhibitors that are medicines to prevent and treat stomach ulcers, heartburn or acid reflux disease ) - dexamethasone ( a corticosteroid used in a variety of conditions such as inflammation and allergic reactions ) when taken by mouth or injected, except as a single dose treatment - products that contain st john's wort ( hypericum perforatum ) ( a herbal product used for depression ). if you are taking any of the above, ask your doctor about alternatives. warnings and precautions talk to your doctor or pharmacist before taking edurant. edurant is not a cure for hiv infection. it is part of a treatment reducing the amount of virus in the blood. you can still pass on hiv when taking this medicine, although the risk is lowered by effective antiretroviral therapy. discuss with your physician the precautions needed to avoid infecting other people. edurant has only been used in a limited number of patients of 65 years or older. if you belong to this age group, please discuss the use of edurant with your doctor. tell your doctor about your situation make sure that you check the following points and tell your doctor if any of these apply to you. - tell your doctor if you have or have had problems with your liver, including hepatitis b and / or c
always take this medicine exactly as your doctor or pharmacist has told you. check with your doctor or pharmacist if you are not sure. instructions for proper use in adults and adolescents ( 12 to less than 18 years of age ) the recommended dose of edurant is one tablet once a day. edurant must be taken with a meal. a meal is important to get the right levels of active substance in your body. a nutritional drink ( e. g. protein - rich ) alone does not replace a meal. there are four situations that require special attention : 1. if you take rifabutin ( a medicine to treat some bacterial infections ), take two tablets of edurant once a day. when you stop taking rifabutin, take one tablet of edurant once a day. talk to your doctor or pharmacist if you are not sure. 2. if you take an antacid ( a medicine to treat diseases related to the acid in the stomach such as aluminium / magnesium hydroxide, calcium carbonate ). take the antacid either at least 2 hours before or at least 4 hours after edurant ( see section 2 " other medicines and edurant "). 3. if you take an h2 - receptor antagonist ( medicines used to treat stomach or intestinal ulcers or used to relieve heartburn due to acid reflux ( such as cimetidine, famotidine, nizatidine or ranitidine ). take the h2 - receptor antagonist at least 12 hours before or at least 4 hours after edurant ( see section 2 " other medicines and edurant "). h2 - receptor antagonists should not be taken in a twice a day regimen. talk to your doctor about an alternative regimen. 4. if you take didanosine ( a medicine to treat hiv infection ), no dose adjustment is required. didanosine should be administered on an empty stomach at least two hours before or at least four hours after edurant ( which must be taken with a meal ). removing the child resistant cap the bottle comes with a child resistant cap. it can be opened by pushing the screw cap down while turning it anti
like all medicines , this medicine can cause side effects , although not everybody gets them . very common : - headache - nausea - difficulty falling asleep ( insomnia ) - dizziness - changes in one of your routine liver tests ( transaminase ) - increase in cholesterol and / or pancreatic amylase in your blood common : - abnormal dreams - rash - stomach pain - depression - tiredness - vomiting - drowsiness - decreased appetite - sleep disorders - stomach discomfort - depressed mood - dry mouth 36 - low white blood cell and / or platelet count , decrease in haemoglobin in your blood , increase in triglycerides , lipase and / or bilirubin in your blood uncommon : - signs or symptoms of inflammation or infection , for example fever , chills , sweats ( immune reactivation syndrome ) reporting of side effects if you get any side effects , talk to your doctor or pharmacist . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
what edurant contains - the active substance is rilpivirine in the form of rilpivirine hydrochloride . each tablet of edurant contains rilpivirine hydrochloride equivalent to 25 mg rilpivirine . - the other ingredients of the film - coated tablet core are lactose monohydrate , croscarmellose sodium , povidone k30 , polysorbate 20 , silicified microcrystalline cellulose and magnesium stearate . the film - coating contains lactose monohydrate , hypromellose 2910 6 mpa . s , titanium dioxide e171 , macrogol 3000 and triacetin . what edurant looks like and contents of the pack white to off - white , film - coated , round , biconvex tablet , with " tmc " on one side and " 25 " on the other side . a bottle with child resistant closure containing 30 film - coated tablets .
avandamet tablets are a combination of two different medicines called rosiglitazone and metformin . these two medicines are used to treat type 2 diabetes . people with type 2 diabetes either don ' t make enough insulin ( a hormone that controls blood sugar levels ), or don ' t respond normally to the insulin their body makes . rosiglitazone and metformin work together so your body makes better use of the insulin it produces , and this helps reduce your blood sugar to a normal level . avandamet can be used alone or with a sulphonylurea , another medicine for diabetes .
to help manage your diabetes, it is important that you follow any diet and lifestyle advice from your doctor as well as taking avandamet. don't take avandamet : if you are allergic ( hypersensitive ) to rosiglitazone or metformin or any of the other ingredients of avandamet ( listed in section 6 ) if you have had a heart attack or severe angina, that's being treated in hospital if you have heart failure, or have had heart failure in the past if you have severe breathing difficulties if you have liver disease if you are a heavy drinker of alcohol if you regularly drink a lot, or if you have occasional sessions of heavy drinking ( binge drinking ) if you have had diabetic ketoacidosis ( a complication of diabetes causing rapid weight loss, nausea or vomiting ) if you have kidney disease 107 if you are very dehydrated or have a severe infection ( see'while you take avandamet your doctor needs to know'later in section 2 ) if you are going to have an x - ray using an injected dye ( see'while you take avandamet your doctor needs to know'later in section 2 ) if you are breast - feeding ( see'pregnancy and breast - feeding'later in section 2 ). check with your doctor if you think any of these apply to you. don't take avandamet. take special care with avandamet avandamet is not recommended for people aged under 18, as the safety and effectiveness are not known. if you have been diagnosed with angina ( chest pain ), or peripheral arterial disease ( reduced blood flow to the legs ): check with your doctor, as avandamet may not be suitable for you. conditions to look out for avandamet and other medicines for diabetes can make some existing conditions worse, or cause serious side effects. you must look out for certain symptoms while you are taking avandamet, to reduce the risk of any problems. see'conditions you need to look out for'in section 4. ovulation may restart women who are infertile due to
always take avandamet tablets exactly as your doctor has told you . do not take more than the recommended dose . check with your doctor or pharmacist if you are not sure . how much to take the usual starting dose is one combined tablet ( 2 mg rosiglitazone and 1000 mg metformin ), taken twice a day , morning and evening . ( you can also take this dose as two 1 mg / 500 mg tablets , twice a day .) after about 8 weeks your doctor may need to increase your dose . the maximum dose is 4 mg rosiglitazone and 1000 mg metformin , taken twice a day . ( you can also take this dose as two 2 mg / 500 mg tablets , twice a day .) how to take swallow the tablets with some water . it is best to take avandamet with food , or just after food . this helps to reduce any problems with your stomach ( including indigestion , nausea , vomiting and diarrhoea ). take your tablets around the same time every day and follow any dietary advice that your doctor has given you . if you take more avandamet than you should 109 if you accidentally take too many tablets , contact your doctor or pharmacist for advice . if you forget to take avandamet don ' t take extra tablets to make up for a missed dose . just take your next dose at the usual time . don ' t stop taking avandamet take avandamet for as long as your doctor recommends . if you stop taking avandamet , your blood sugar will not be controlled , and you may become unwell . talk to your doctor if you want to stop .
like all medicines, avandamet can cause side effects, but not everybody gets them. conditions you need to look out for allergic reactions : these are very rare in people taking avandamet. signs include : raised and itchy rash ( hives ) swelling, sometimes of the face or mouth ( angioedema ), causing difficulty in breathing collapse. contact a doctor immediately if you get any of these symptoms. stop taking avandamet. lactic acidosis : an increase in the amount of lactic acid in the blood ( lactic acidosis ) is a very rare side effect of metformin. this most often affects people who have severe kidney disease. symptoms of lactic acidosis include : rapid breathing feeling cold stomach pain, nausea and vomiting. contact a doctor immediately if you get these symptoms. stop taking avandamet. fluid retention and heart failure : avandamet can cause you to retain water ( fluid retention ) which leads to swelling and weight gain. extra body fluid can make some existing heart problems worse or lead to heart failure. this is more likely if you are also taking other medicines for your diabetes ( like insulin ), if you have kidney problems, or if you are over 65. check your weight regularly ; if it goes up rapidly, tell your doctor. symptoms of heart failure include : shortness of breath, waking up short of breath at night getting tired easily after light physical activity such as walking rapid increase in your weight swollen ankles or feet. tell your doctor as soon as possible if you get any of these symptoms - either for the first time or if they get worse. low blood sugar ( hypoglycaemia ): if you are taking avandamet with other medicines for diabetes, it is more likely that your blood sugar could fall below the normal level. early symptoms of low blood sugar are : shaking, sweating, faintness nervousness, palpitations hunger. the severity can increase, leading to confusion and loss of consciousness. tell your doctor as soon as possible if you get any of these symptoms. the dose of your medicines may need to be reduced. liver problems : before you
keep out of the reach and sight of children . do not use avandamet after the expiry date shown on the pack . this medicine does not require any special storage conditions . if you have any unwanted tablets , don ' t put them in waste water or household rubbish . ask your pharmacist how to dispose of tablets you don ' t need . this will help to protect the environment .
what avandamet contains the active substances are rosiglitazone and metformin . avandamet tablets come in different strengths . each tablet contains either : 1 mg rosiglitazone and 500 mg metformin ; 2 mg rosiglitazone and 500 mg metformin ; 2 mg rosiglitazone and 1000 mg metformin or 4 mg rosiglitazone and 1000 mg metformin . the other ingredients are : sodium starch glycollate , hypromellose ( e464 ), microcrystalline cellulose ( e460 ), lactose monohydrate , povidone ( e1201 ), magnesium stearate , titanium dioxide ( e171 ), macrogol , iron oxide yellow or red ( e172 ). what avandamet looks like and contents of the pack avandamet 1 mg / 500 mg tablets are yellow and marked " gsk " on one side and " 1 / 500 " on the other . avandamet 2 mg / 500 mg tablets are pale pink , marked " gsk " on one side and " 2 / 500 " on the other . these strengths are supplied in blister packs containing 28 , 56 , 112 , 3x112 or 360 film - coated tablets . avandamet 2 mg / 1000 mg tablets are yellow , marked " gsk " on one side and " 2 / 1000 " on the other . avandamet 4 mg / 1000 mg tablets are pink , marked " gsk " on one side and " 4 / 1000 " on the other . these strengths are supplied in blister packs containing 14 , 28 , 56 , 2x56 , 3x56 or 180 film - coated tablets . not all pack sizes or tablet strengths may be available in your country .
clopidogrel mylan contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products. platelets are very small structures in the blood, which clump together during blood clotting. by preventing this clumping, antiplatelet medicinal products reduce the chances of blood clots forming ( a process called thrombosis ). clopidogrel mylan is taken by adults to prevent blood clots ( thrombi ) forming in hardened blood vessels ( arteries ), a process known as atherothrombosis, which can lead to atherothrombotic events ( such as stroke, heart attack, or death ). you have been prescribed clopidogrel mylan to help prevent blood clots and reduce the risk of these severe events because : - you have a condition of hardening of arteries ( also known as atherosclerosis ), and - you have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease, or - you have experienced a severe type of chest pain known as'unstable angina'or'myocardial infarction'( heart attack ). for the treatment of this condition your doctor may have placed a stent in the blocked or narrowed artery to restore effective blood flow. you should also be given acetylsalicylic acid ( a substance present in many medicines used to relieve pain and lower fever as well as to prevent blood clotting ) by your doctor. - you have an irregular heartbeat, a condition called'atrial fibrillation ', and you cannot take medicines known as'oral anticoagulants'( vitamin k antagonists ) which prevent new clots from forming and prevent existing clots from growing. you should have been told that'oral anticoagulants'are more effective than acetylsalicylic acid or the combined use of clopidogrel mylan and acetylsalicylic acid for this condition. your doctor should have prescribed clopidogrel mylan plus acetylsal
do not take clopidogrel mylan 31 if you are allergic to clopidogrel or any of the other ingredients of this medicine ( listed in section 6 ); if you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain ; if you suffer from severe liver disease ; if you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking clopidogrel mylan. warnings and precautions talk to your doctor before taking clopidogrel mylan if any of the situations mentioned below apply to you : if you have a risk of bleeding such as - a medical condition that puts you at risk of internal bleeding ( such as a stomach ulcer ) - a blood disorder that makes you prone to internal bleeding ( bleeding inside any tissues, organs or joints of your body ). - a recent serious injury - a recent surgery ( including dental ). - a planned surgery ( including dental ) in the next seven days. if you have had a clot in an artery of your brain ( ischaemic stroke ) which occurred within the last seven days. if you have kidney or liver disease. if you have had an allergy or reaction to any medicine used to treat your disease. while you are taking clopidogrel mylan : you should tell your doctor if a surgery ( including dental ) is planned. you should also tell your doctor immediately if you develop a medical condition ( also known as thrombotic thrombocytopenic purpura or ttp ) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes ( jaundice ) ( see section 4'possible side effects '). if you cut or injure yourself, it may take longer than usual for bleeding to stop. this is linked to the way your medicine works as it prevents the ability of blood clots to form. for minor cuts and injuries e. g., cutting yourself, shaving,
always take this medicine exactly as your doctor or pharmacist has told you . check with your doctor or pharmacist if you are not sure . the recommended dose , including for patients with a condition called ' atrial fibrillation ' ( an irregular heartbeat ), is one 75 mg tablet of clopidogrel mylan per day to be taken orally with or without food , and at the same time each day . if you have experienced severe chest pain ( unstable angina or heart attack ), your doctor may give you 300 mg of clopidogrel mylan ( 4 tablets of 75 mg ) once at the start of treatment . then , the recommended dose is one 75 mg tablet of clopidogrel mylan per day as described above . you should take clopidogrel mylan for as long as your doctor continues to prescribe it . if you take more clopidogrel mylan than you should contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding . if you forget to take clopidogrel mylan if you forget to take a dose of clopidogrel mylan , but remember within 12 hours of your usual time , take your tablet straightaway and then take your next tablet at the usual time . if you forget for more than 12 hours , simply take the next single dose at the usual time . do not take a double dose to make up for a forgotten tablet . for the 7 , 14 , 28 , 56 , 84 tablets ( calendar blister ) pack sizes , you can check the day on which you last took a tablet of clopidogrel mylan by referring to the calendar printed on the blister if you stop taking clopidogrel mylan do not stop the treatment unless your doctor tells you so . contact your doctor or pharmacist before stopping . if you have any further questions on the use of this medicine , ask your doctor or pharmacist .
like all medicines, this medicine can cause side effects, although not everybody gets them. contact your doctor immediately if you experience : - fever, signs of infection or extreme tiredness. these may be due to rare decrease of some blood cells. - signs of liver problems such as yellowing of the skin and / or the eyes ( jaundice ), whether or not associated with bleeding which appears under the skin as red pinpoint dots and / or confusion ( see section 2'warnings and precautions '). - swelling in the mouth or skin disorders such as rashes and itching, blisters of the skin. these may be the signs of an allergic reaction. the most common side effect reported with clopidogrel mylan is bleeding. bleeding may occur as bleeding in the stomach or bowels, bruising, haematoma ( unusual bleeding or bruising under the skin ), nose bleed, blood in the urine. in a small number of cases, bleeding in the eye, inside the head, the lung or the joints has also been reported. if you experience prolonged bleeding when taking clopidogrel mylan if you cut or injure yourself, it may take longer than usual for bleeding to stop. this is linked to the way your medicine works as it prevents the ability of blood clots to form. for minor cuts and injuries e. g., cutting yourself, shaving, this is usually of no concern. however, if you are concerned by your bleeding, you should contact your doctor straightaway ( see section 2'warnings and precautions '). other side effects include : common side effects ( may affect up to 1 in 10 people ): diarrhoea, abdominal pain, indigestion or heartburn. uncommon side effects ( may affect up to 1 in 100 people ): headache, stomach ulcer, vomiting, nausea, constipation, excessive gas in stomach or intestines, rashes, itching, dizziness, sensation of tingling and numbness. rare side effect ( may affect up to 1 in 1000 people ): vertigo, enlarged breast
what clopidogrel mylan contains the active substance is clopidogrel . each film - coated tablet contains 75 mg of clopidogrel ( as hydrochloride ). the other ingredients are : - tablet core : microcrystalline cellulose , colloidal anhydrous silica , crospovidone ( type a ), macrogol 6000 , hydrogenated castor oil ( see section 2 ' clopidogrel mylan contains hydrogenated castor oil ') - film - coating : polyvinyl alcohol , titanium dioxide ( e171 ), red iron oxide ( e172 ), yellow iron oxide ( e172 ), talc and macrogol 3000 . what clopidogrel mylan looks like and contents of the pack the film - coated tablets are pink , round and biconvex . boxes of 7 , 14 , 28 , 30 , 50 , 56 , 84 , 90 and 100 film - coated tablets in blisters are available . boxes of 7 , 14 , 28 , 56 , 84 film - coated tablets in calendar blisters are available . boxes of 30x1 and 50x1 film - coated tablets in perforated unit dose blisters are available . not all pack sizes may be marketed .
doptelet contains an active substance called avatrombopag . it belongs to a group of medicines called thrombopoietin receptor agonists . doptelet is used in adults with chronic liver disease to treat low platelet count ( called thrombocytopenia ) before having a medical procedure where there is a risk of bleeding . doptelet works by helping to increase the number of platelets in the blood . platelets are blood cells that help the blood to clot and so reduce or prevent bleeding .
do not take doptelet if : - you are allergic to avatrombopag or any of the other ingredients of this medicine ( listed in section 6 ). if you are not sure, talk to your doctor or pharmacist before taking doptelet. warnings and precautions talk to your doctor or pharmacist before taking doptelet if : - you are at risk of blood clots in your veins or arteries, or members of your family have had blood clots. you may be at higher risk of blood clots as you get older or if : - you have had to stay in bed for a long time - you have cancer - you are taking the contraceptive birth control pill or hormone replacement therapy - you have recently had surgery or been injured 23 - you are very overweight - you smoke - you have advanced chronic liver disease. if any of the above applies to you, or you are not sure, talk to your doctor or pharmacist before taking doptelet. children and adolescents do not give doptelet to people less than 18 years old. the safety and effectiveness of this medicine in this age group is not known. other medicines and doptelet tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. pregnancy and breast - feeding if you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. doptelet is not recommended in pregnancy and in women who are able to have children and are not using contraception. if you are breast - feeding, ask your doctor or pharmacist for advice before taking doptelet. this medicine can pass into breast milk. your doctor will help you decide whether the benefit of breast - feeding outweighs any possible risks to your baby while you are breast - feeding. driving and using machines doptelet is not expected to affect you being able to drive, cycle or use tools or machines. doptelet contains lactose doptelet contains lactose ( a type of sugar ). if you have been told by your doctor that you have an intolerance to some sugars
always take this medicine exactly as your doctor or pharmacist has told you . check with your doctor or pharmacist if you are not sure . you should be scheduled to undergo your procedure 5 to 8 days after the last dose of doptelet . how much to take doptelet is available in 20 mg tablets . the usual recommended dose is either 40 mg ( 2 tablets ) or 60 mg ( 3 tablets ) every day for 5 days in a row . your dose will depend on your platelet counts . your doctor or pharmacist will tell you how many tablets to take and when to take them . taking this medicine start taking doptelet 10 to 13 days before your planned medical procedure . swallow the tablets whole , once daily with food . if you take more doptelet than you should talk to a doctor or pharmacist straight away . if you forget to take doptelet take your missed dose as soon as you remember , then take your next dose at the usual time . do not take a double dose to make up for a forgotten dose . if you stop taking doptelet take doptelet for as long as your doctor tells you . do not stop taking doptelet unless your doctor tells you to . if you have any questions on the use of this medicine , ask your doctor or pharmacist .
like all medicines , this medicine can cause side effects , although not everybody gets them . tell your doctor or pharmacist if you notice any of the following side effects : common ( may affect up to 1 in 10 people ) feeling tired uncommon ( may affect up to 1 in 100 people ) low red blood cell count ( anaemia ) blood clot in the portal vein ( blood vessel that carries blood to the liver from the intestines ) which may result in upper abdominal pain or swelling bone pain muscle aches fever reporting of side effects if you get any side effects , talk to your doctor or pharmacist . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
what doptelet contains - the active substance is avatrombopag . each film - coated tablet contains avatrombopag maleate equivalent to 20 mg of avatrombopag . - the other ingredients are : tablet core : lactose monohydrate ( see section 2 " doptelet contains lactose "); microcrystalline cellulose [ e460 ( i )]; crospovidone type b [ e1202 ]; silica , colloidal anhydrous [ e551 ]; magnesium stearate [ e470b ]. film coating : poly ( vinyl alcohol ) [ e1203 ]; talc [ e553b ]; macrogol 3350 [ e1521 ]; titanium dioxide [ e171 ]; iron oxide yellow [ e172 ]. what doptelet looks like and contents of the pack doptelet 20 mg film - coated tablets are pale yellow , round , rounded on the upper and lower side , marked with " ava " imprinted on one side and " 20 " on the other . the tablets are supplied in cartons containing one aluminium blister . each blister contains either 10 or 15 tablets .
rapiscan contains the active substance regadenoson . this belongs to a group of medicines called ' coronary vasodilators '. it makes the heart arteries expand and heart rate increase . this makes more blood flow to the muscles of the heart . this medicine is for diagnostic use only . rapiscan is used in a type of heart scan in adults called ' myocardial perfusion imaging '. the scan uses a radioactive substance called a ' radiopharmaceutical ' to create images . these images show how well blood flows to the muscles of the heart . usually , exercise on a treadmill is used to put the heart under stress before a scan . during the exercise , a small amount of radiopharmaceutical is injected into the body , often into a vein in the hand . images are then taken of the heart . the doctor can then see if the heart muscles are getting enough blood flow when it is under stress . if you are unable to exercise enough to reach sufficient stress to the heart , rapiscan will be injected to provide a stress of similar amplitude to the heart to increase the blood flow . rapiscan is also used during catheterisation and imaging arteries of the heart ( invasive coronary angiography ) to expand the arteries of the heart to measure the difference in pressure , caused by a narrowing within one or more arteries . during cardiac catheterisation , a long thin tube called a catheter is inserted either through your femoral or radial artery and threaded through your blood vessels to your heart . the doctor performing the catheterisation may also want to measure the difference in pressure ( fractional flow reserve ) due to a narrowing detected in one or more arteries of the heart .
do not take rapiscan : if you have slow heart rate ( high degree heart block or sinus node disease ), and don't have a pacemaker fitted. if you have chest pain that occurs unpredictably ( unstable angina ) and that has not improved after treatment. if you have low blood pressure ( hypotension ). if you have heart failure. if you are allergic to regadenoson or any of the other ingredients of rapiscan listed in section 6 of this leaflet. talk to your doctor or nurse before taking rapiscan your doctor needs to know before you are given rapiscan : if you have had a recent serious heart problem ( for example a heart attack or abnormal heart rhythms ). if you have a heart rhythm where your heartbeat is very fast or uneven ( atrial fibrillation or atrial flutter ) if you have high blood pressure that is not controlled, especially if this has been accompanied by recent episodes of nose bleed, headache or blurred or double vision. if you have had episodes of mini strokes ( called transient ischaemic attacks ) if you have a heart rhythm disorder called long qt syndrome. if you have episodes of heart block ( which can slow the heart down ) or a very slow heart rate. if you have any heart or blood vessel condition, particularly one that gets worse when your blood pressure decreases. these include low blood volume ( caused, for example, by severe diarrhoea or dehydration or taking water pills ), inflammation around the heart ( pericarditis ) and some forms of heart valve or artery disease ( for example, aortic or mitral stenosis ). if you have a condition that causes fits ( seizures ), such as epilepsy, or if you have ever had fits. if you have asthma or lung disease. if any of these apply to you, tell your doctor before you are given the injection. children and adolescents rapiscan should not be used in children and adolescents below the age of 18 years. other medicines and rapiscan please tell your doctor if you are taking or have recently taken any other
rapiscan is injected by a healthcare professional ( a doctor , nurse or medical technician ) in a medical facility where your heart and blood pressure can be monitored . it is injected directly into a vein , as a single dose of 400 micrograms in a 5 ml solution the injection will take about 10 seconds to complete . the dose injected does not depend on your weight . you will also be given an injection of sodium chloride 9 mg / ml ( 0 . 9 %) solution ( 5 ml ), and an injection of a small amount of a radioactive substance ( radiopharmaceutical ). when you are given rapiscan , your heart rate will increase quickly . your heart rate and blood pressure will be monitored . after the rapiscan injection you will need to sit or lie down until your heart rate and blood pressure return to your normal levels . the doctor , nurse or medical technician will let you know when you can stand up . a scan of your heart will be made after enough time has passed to allow the radiopharmaceutical to reach the heart muscle . during catheterisation of the arteries of the heart , your doctor may measure the pressure difference ( also known as fractional flow reserve ffr ) due to a narrowing in one or more arteries of the heart . if deemed necessary , a second dose of 400 micrograms can be injected at least 10 minutes after the first dose for such pressure difference measurement during the same catheterization procedure . heart rate and blood pressure will be monitored during the entire procedure . if you are given more rapiscan than you should some people have had flushing , dizziness and increased heart rate when they have been given too much rapiscan . if your doctor thinks that you are having severe side effects , or the effects of rapiscan are lasting too long , they may give you an injection of a medicine called aminophylline that reduces these effects .
like all medicines, rapiscan can cause side effects, although not everybody gets them. the side effects are usually mild. they normally start soon after the rapiscan injection and are usually over within 30 minutes. they don't usually need any treatment. more serious side effects include : sudden stopping of the heart or damage to the heart, heart block ( a disorder of the heart's electrical signal, where the signal cannot pass from the upper to the lower chambers ), rapid heart beat low blood pressure which may result in fainting or mini strokes ( including weakness of the face or an inability to speak ). rarely, rapiscan can cause a stroke ( also known as a cerebrovascular accident ). an allergic reaction which can cause rash, wheals / weals, swelling under the skin near the eyes or throat, throat tightness, and difficulty in breathing may occur immediately or have delayed onset after rapiscan injection tell your doctor straight away if you think you are having severe side effects. your doctor may then 28 give you an injection of a medicine called aminophylline that reduces these effects. very common side effects ( affects more than 1 user in 10 ) headache, dizziness shortness of breath chest pain changes in heart tracing tests ( electrocardiogram ) flushing discomfort in the stomach common side effects ( affects 1 to 10 users in 100 ) heart pain ( angina ), abnormal heart rhythms, rapid heart beat, feeling the heart skipping a beat, fluttering, or beating too hard or fast ( palpitations ) low blood pressure throat tightness, throat irritation, cough being sick ( vomiting ), feeling sick ( nausea ) feeling unwell or weak excessive sweating pain in the back, arms, legs, neck or jaw discomfort in the bones and muscles pins and needles, reduced sensation, taste changes discomfort in the mouth uncommon side effects ( affects 1 to 10 users in 1, 000 ) sudden stopping of the heart or damage to the heart, heart block ( a disorder of the heart's electrical signal, where the signal cannot pass from the upper to the lower chambers ), slow heart beat fits, fainting, mini stroke
viagra contains the active substance sildenafil which belongs to a group of medicines called phosphodiesterase type 5 ( pde5 ) inhibitors . it works by helping to relax the blood vessels in your penis , allowing blood to flow into your penis when you get sexually excited . viagra will only help you to get an erection if you are sexually stimulated . viagra is a treatment for adult men with erectile dysfunction , sometimes known as impotence . this is when a man cannot get , or keep a hard , erect penis suitable for sexual activity .
do not take viagra <unk> if you are allergic to sildenafil or any of the other ingredients of this medicine ( listed in section 6 ). <unk> if you are taking medicines called nitrates, as the combination may lead to a dangerous fall in your blood pressure. tell your doctor if you are taking any of these medicines which are often given for relief of angina pectoris ( or " chest pain "). if you are not certain, ask your doctor or pharmacist. <unk> if you are using any of the medicines known as nitric oxide donors such as amyl nitrite (" poppers "), as the combination may also lead to a dangerous fall in your blood pressure. <unk> if you are taking riociguat. this drug is used to treat pulmonary arterial hypertension ( i. e., high blood pressure in the lungs ) and chronic thromboembolic pulmonary hypertension ( i. e., high blood pressure in the lungs secondary to blood clots ). pde5 inhibitors, such as viagra 56 have been shown to increase the hypotensive effects of this medicine. if you are taking riociguat or are unsure tell your doctor. <unk> if you have a severe heart or liver problem. <unk> if you have recently had a stroke or a heart attack, or if you have low blood pressure. <unk> if you have certain rare inherited eye diseases ( such as retinitis pigmentosa ). <unk> if you have ever had loss of vision due to non - arteritic anterior ischaemic optic neuropathy ( naion ). warnings and precautions talk to your doctor, pharmacist or nurse before taking viagra <unk> if you have sickle cell anaemia ( an abnormality of red blood cells ), leukaemia ( cancer of blood cells ), multiple myeloma ( cancer of bone marrow ). <unk> if you have a deformity of your penis or peyronie's disease. <unk> if you have problems with your heart. your doctor should carefully check whether
always take this medicine exactly as your doctor or pharmacist has told you . check with your doctor or pharmacist if you are not sure . the recommended starting dose is 50 mg . you should not take viagra more than once a day . do not take viagra film - coated tablets in combination with viagra orodispersible tablets . you should take viagra about one hour before you plan to have sex . swallow the tablet whole with a glass of water . if you feel that the effect of viagra is too strong or too weak , talk to your doctor or pharmacist . viagra will only help you to get an erection if you are sexually stimulated . the amount of time viagra takes to work varies from person to person , but it normally takes between half an hour and one hour . you may find that viagra takes longer to work if you take it with a heavy meal . if viagra does not help you to get an erection , or if your erection does not last long enough for you to complete sexual intercourse you should tell your doctor . if you take more viagra than you should : you may experience an increase in side effects and their severity . doses above 100 mg do not increase the efficacy . you should not take more tablets than your doctor tells you to . contact your doctor if you take more tablets than you should . if you have any further questions on the use of this medicine , ask your doctor , pharmacist or nurse .
like all medicines, this medicine can cause side effects although not everybody gets them. the side effects reported in association with the use of viagra are usually mild to moderate and of a short duration. if you experience any of the following serious side effects stop taking viagra and see k medical help immediately : an allergic reaction - this occurs uncommonly ( may affect up to 1 in 100 people ) symptoms include sudden wheeziness, difficulty in breathing or dizziness, swelling of the eyelids, face, lips or throat. chest pains - this occurs uncommonly if this occurs during or after intercourse - get in a semi - sitting position and try to relax. - do not use nitrates to treat your chest pain. prolonged and sometimes painful erections - this occurs rarely ( may affect up to 1 in 1, 000 people ) if you have an erection which lasts for more than 4 hours, you should contact a doctor immediately. a sudden decrease or loss of vision - this occurs rarely serious skin reactions - this occurs rarely symptoms may include severe peeling and swelling of the skin, blistering of the mouth, genitals and around the eyes, fever. seizures or fits - this occurs rarely other side effects : very common ( may affect more than 1 in 10 people ): headache. common ( may affect up to 1 in 10 people ): nausea, facial flushing, hot flush ( symptoms include a sudden feeling of heat in your upper body ), indigestion, colour tinge to vision, blurred vision, visual disturbance, stuffy nose and dizziness. uncommon ( may affect up to 1 in 100 people ): vomiting, skin rash, eye irritation, bloodshot eyes / red eyes, eye pain, seeing flashes of light, visual brightness, light sensitivity, watery eyes, pounding heartbeat, rapid heartbeat, high blood pressure, low blood pressure, muscle pain, feeling sleepy, reduced sense of touch, vertigo, ringing in the ears, dry mouth, blocked or stuffy sinuses, inflammation of the lining of the nose (
what viagra contains â the active substance is sildenafil . each tablet contains 25 mg of sildenafil ( as the citrate salt ). â the other ingredients are : â tablet core : microcrystalline cellulose , calcium hydrogen phosphate ( anhydrous ), croscarmellose sodium , magnesium stearate , â film coat : hypromellose , titanium dioxide ( e171 ), lactose monohydrate , triacetin , indigo carmine aluminium lake ( e132 ) what viagra looks like and contents of the pack viagra film - coated tablets are blue , with a rounded - diamond shape . they are marked " pfizer " on one side and " vgr 25 " on the other side . the tablets are provided in blister packs containing 2 , 4 , 8 or 12 tablets . some pack sizes may not be marketed in your country .
sifrol contains the active substance pramipexole and belongs to a group of medicines known as dopamine agonists , which stimulate dopamine receptors in the brain . stimulation of the dopamine receptors triggers nerve impulses in the brain that help to control body movements . sifrol is used to : - treat the symptoms of primary parkinson ' s disease in adults . it can be used alone or in combination with levodopa ( another medicine for parkinson ' s disease ). - treat the symptoms of moderate to severe primary restless legs syndrome in adults .
do not take sifrol : - if you are allergic to pramipexole or to any of the other ingredients of this medicine ( listed in section 6 ). warnings and precautions talk to your doctor before taking sifrol. tell your doctor if you have ( had ) or develop any medical conditions or symptoms, especially any of the following : - kidney disease. - hallucinations ( seeing, hearing or feeling things that are not there ). most hallucinations are visual. - dyskinesia ( e. g. abnormal, uncontrolled movements of the limbs ). if you have advanced parkinson's disease and are also taking levodopa, you might develop dyskinesia during the up - titration of sifrol. - dystonia ( inability of keeping your body and neck straight and upright ( axial dystonia )). in particular, you may experience forward flexion of the head and neck ( also called antecollis ), forward bending of the lower back ( also called camptocormia ) or sidewards bending of the back ( also called pleurothotonus or pisa syndrome ). - sleepiness and episodes of suddenly falling asleep. - psychosis ( e. g. comparable with symptoms of schizophrenia ). - vision impairment. you should have regular eye examinations during treatment with sifrol. - severe heart or blood vessels disease. you will need to have your blood pressure checked regularly, especially at the beginning of treatment. this is to avoid postural hypotension ( a fall in blood pressure on standing up ). - augmentation. you may experience that symptoms start earlier than usual, be more intense and involve other limbs. tell your doctor if you or your family / carer notices that you are developing urges or cravings to behave in ways that are unusual for you and you cannot resist the impulse, drive or temptation to carry out certain activities that could harm yourself or others. these are called impulse control disorders and can include behaviours such as addictive gambling, excessive eating or spending, an abnormally high sex drive
always take this medicine exactly as your doctor has told you. check with your doctor if you are not sure. the doctor will advise you on the right dosing. you can take sifrol with or without food. swallow the tablets with water. parkinson's disease the daily dose is to be taken divided into 3 equal doses. during the first week, the usual dose is 1 tablet sifrol 0. 088 mg three times a day ( equivalent to 0. 264 mg daily ): 1st week number of tablets 1 tablet sifrol 0. 088 mg three times a day total daily dose ( mg ) 0. 264 this will be increased every 5 - 7 days as directed by your doctor until your symptoms are controlled ( maintenance dose ). 2nd week 3rd week number of tablets 1 tablet sifrol 0. 18 mg three times a day or 2 tablets sifrol 0. 088 mg three times a day 1 tablet sifrol 0. 35 mg three times a day or 2 tablets sifrol 0. 18 mg three times a day total daily dose ( mg ) 0. 54 1. 1 the usual maintenance dose is 1. 1 mg per day. however, your dose may have to be increased even further. if necessary, your doctor may increase your tablet dose up to a maximum of 3. 3 mg of pramipexole a day. a lower maintenance dose of three sifrol 0. 088 mg tablets a day is also possible. lowest maintenance dose highest maintenance dose number of tablets 1 tablet sifrol 0. 088 mg three times a day 1 tablet sifrol 0. 7 mg and 1 tablet sifrol 0. 35 mg three times a day total daily dose ( mg ) 0. 264 3. 15 patients with kidney disease if you have moderate or severe kidney disease, your doctor will prescribe a lower dose. in this case, you will have to take the tablets only once or twice a day. if you have moderate kidney disease, the usual starting dose is 1 tablet sif
like all medicines, this medicine can cause side effects, although not everybody gets them. evaluation of these side effects is based on the following frequencies : very common may affect more than 1 in 10 people common may affect up to 1 in 10 people uncommon may affect up to 1 in 100 people rare may affect up to 1 in 1, 000 people very rare may affect up to 1 in 10, 000 people not known frequency cannot be estimated from the available data if you suffer from parkinson's disease, you may experience the following side effects : very common : - dyskinesia ( e. g. abnormal, uncontrolled movements of the limbs ) - sleepiness - dizziness - nausea ( sickness ) common : - urge to behave in an unusual way - hallucinations ( seeing, hearing or feeling things that are not there ) - confusion - tiredness ( fatigue ) - sleeplessness ( insomnia ) - excess of fluid, usually in the legs ( peripheral oedema ) - headache - hypotension ( low blood pressure ) - abnormal dreams - constipation 73 - visual impairment - vomiting ( being sick ) - weight loss including decreased appetite uncommon : - paranoia ( e. g. excessive fear for one's own well - being ) - delusion - excessive daytime sleepiness and suddenly falling asleep - amnesia ( memory disturbance ) - hyperkinesia ( increased movements and inability to keep still ) - weight increase - allergic reactions ( e. g. rash, itching, hypersensitivity ) - fainting - cardiac failure ( heart problems which can cause shortness of breath or ankle swelling )* - inappropriate antidiuretic hormone secretion * - restlessness - dyspnoea ( difficulties to breathe ) - hiccups - pneumonia ( infection of the lungs ) - inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include : - strong impulse to gamble excessively despite serious personal or family consequences.
what sifrol contains the active substance is pramipexole . each tablet contains 0 . 088 mg , 0 . 18 mg , 0 . 35 mg , or 0 . 7 mg pramipexole as 0 . 125 mg , 0 . 25 mg , 0 . 5 mg , or 1 mg pramipexole dihydrochloride monohydrate , respectively . the other ingredients are mannitol , maize starch , anhydrous colloidal silica , povidone k 25 and magnesium stearate . what sifrol looks like and contents of the pack sifrol 0 . 088 mg tablets are white , of round shape , flat , and without scoring . sifrol 0 . 18 mg tablets and sifrol 0 . 35 mg tablets are white , of oval shape , and flat . tablets are scored on both sides and breakable in halves . sifrol 0 . 7 mg tablets are white , of round shape , and flat . tablets are scored on both sides and breakable in halves . all tablets have the boehringer ingelheim company symbol embossed on one side and the codes p6 , p7 , p8 , or p9 on the other side , representing the tablet strengths 0 . 088 mg , 0 . 18 mg , 0 . 35 mg , and 0 . 7 mg , respectively . all strengths of sifrol are available in aluminium blister strips of 10 tablets per strip , in cartons containing 3 or 10 blister strips ( 30 or 100 tablets ). not all pack sizes may be marketed .
emadine is a medicine for the treatment of seasonal allergic conjunctivitis of the eye ( allergic conditions of the eye ). it works by reducing the intensity of the allergic reaction . allergic conjunctivitis . some materials ( allergens ) like pollens , house dust or animal fur may cause allergic reactions resulting in itching , redness as well as swelling of the surface of your eye . you must talk to a doctor if you do not feel better or if you feel worse .
do not use emadine if you are allergic to emedastine or any of the other ingredients of this medicine listed in section 6 . ask your doctor for advice . warning and precautions do not use emadine in children under the age of 3 years . if you wear contact lenses please see section ' emadine contains benzalkonium chloride below '. emadine is not recommended for use in patients over 65 years of age , as it has not been studied in clinical trials in this age group . emadine is not recommended for use in patients with kidney or liver problems . talk to your doctor or pharmacist before using emadine . other medicines and emadine tell your doctor or pharmacist if you are using , have recently used or might use any other medicines . if you are using other eye drops at the same time as emadine , follow the advice at the end of section 3 " how to use emadine ". pregnancy , breast feeding and fertility if you are pregnant or breast - feeding , think you may be pregnant or are planning to have a baby , ask your doctor or pharmacist for advice before taking this medicine . driving and using machines you may find that your vision is blurred for a time just after you use emadine . do not drive or use machines until your vision is clear . emadine contains benzalkonium chloride this medicine contains 0 . 5 mg or 1 mg benzalkonium chloride in each 5 or 10 ml , which are equivalent to 0 . 1 mg / ml . the preservative in emadine , benzalkonium chloride , may be absorbed by soft contact lenses and may change the colour of the contact lenses . you should remove contact lenses before using this medicine and put them back 15 minutes afterwards . benzalkonium chloride may also cause eye irritation , especially if you have dry eyes or disorders of the cornea ( the clear layer at the front of the eye ). if you feel abnormal eye sensation , stinging or pain in the eye after using this medicine , talk to your doctor .
always use emadine exactly as your doctor has told you. you should check with your doctor or pharmacist if you are not sure. the recommended dose is in adults and children over 3 years : one drop in the eye, twice a day. always use this medicine exactly as described in this leaflet or as your doctor has told you. check with your doctor or pharmacist if you are not sure. only use the drops in your eyes. turn the page for more advice now turn over > 3. how to use emadine ( continued ) 1 2 the recommended dose <unk> see side 1 get the emadine bottle and a mirror. wash your hands. take the bottle and twist off the cap. after cap is removed, if tamper evident snap collar is loose, remove before using product. hold the bottle, pointing down, between your thumb and middle finger. tilt your head back. pull down your eyelid with a clean finger, until there is a'pocket'between the eyelid and your eye. the drop will go in here ( picture 1 ). bring the bottle tip close to the eye. use the mirror if it helps. don't touch your eye or eyelid, surrounding areas or other surfaces with the dropper. it could infect the drops left in the bottle. gently press on the base of the bottle to release one drop of emadine at a time. don't squeeze the bottle, it is designed so that just a gentle press on the bottom is needed ( picture 2 ). if you use drops in both eyes, repeat the steps for your other eye. put the bottle cap back on firmly immediately after use. if you accidentally swallow emadine or inject it contact a doctor immediately. it may affect your heart rhythm. if a drop misses your eye, try again. if you get too much in your eyes, rinse it all out preferably with sterile saline or, if not available, with warm water. don't put in any more drops until it's time for your next regular dose. if you forget to use emadine, use
like all medicines , this medicine can cause side effects , although not everybody gets them . you can carry on taking the drops , unless the effects are serious , if you are worried , talk to your doctor or pharmacist . common side effects ( may affect up to 1in 10 people ) effects in the eye : eye pain , itchy eye , eye redness uncommon side effects ( may affect up to 1 in 100 people ) effects in the eye : corneal disorder , abnormal eye sensation , increased tear production , tired eyes , eye irritation , blurred vision , corneal staining , dry eye . general side effects : headache , difficulty sleeping , sinus headache , bad taste , rash not known ( frequency cannot be estimated from the available data ) general side effects : increased heart rate reporting of side effects if you get any side effects , talk to your doctor or pharmacist . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
keep out of the sight and reach of children . do not use emadine after the expiry date which is stated on the bottle and box after " exp ". the expiry date refers to the last day of the month . do not store above 25 . you must throw away the bottle four weeks after you first opened it , to prevent infections . write down the date you opened each bottle in the space below and in the space on the bottle label and box . opened : do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what emadine contains - the active substance is emadastine 0 . 5 mg / ml as difumarate . - the other ingredients are benzalkonium chloride , trometamol ; sodium chloride ; hypromellose ; purified water . tiny amounts of hydrochloric acid or sodium hydroxide are sometimes added to keep acidity levels ( ph levels ) normal what emadine looks like and the contents of the pack emadine is a liquid ( a solution ) supplied in a pack containing a 5 ml or 10 ml plastic ( drop - tainer ) bottle with a screw cap . not all pack sizes may be marketed .
levetiracetam is an antiepileptic medicine ( a medicine used to treat seizures in epilepsy ). levetiracetam actavis is used : on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy , to treat a certain form of epilepsy . epilepsy is a condition where the patients have repeated fits ( seizures ). levetiracetam is used for the epilepsy form in which the fits initially affect only one side of the brain , but could thereafter extend to larger areas on both sides of the brain ( partial onset seizure with or without secondary generalisation ). levetiracetam has been given to you by your doctor to reduce the number of fits . as an add - on to other antiepileptic medicines to treat : partial onset seizures with or without generalisation in adults , adolescents , children and infants from one month of age ; myoclonic seizures ( short , shock - like jerks of a muscle or group of muscles ) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy ; primary generalised tonic - clonic seizures ( major fits , including loss of consciousness ) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy ( the type of epilepsy that is thought to have a genetic cause ).
do not take levetiracetam actavis if you are allergic to levetiracetam, pyrrolidone derivatives or any of the other ingredients of this medicine ( listed in section 6 ). warnings and precautions talk to your doctor before taking levetiracetam actavis if you suffer from kidney problems, follow your doctor's instructions. he / she may decide if your dose should be adjusted. if you notice any slow down in the growth or unexpected puberty development of your child, please contact your doctor. a small number of people being treated with anti - epileptics such as levetiracetam actavis have had thoughts of harming or killing themselves. if you have any symptoms of depression and / or suicidal ideation, please contact your doctor. tell your doctor or pharmacist if any of the following side effects gets serious or last longer than a few days : abnormal thoughts, feeling irritable or reacting more aggressively than usually, or if you or your family and friends notice important changes in mood or behaviour. children and adolescents levetiracetam actavis is not indicated in children and adolescents below 16 years on its own ( monotherapy ). other medicines and levetiracetam actavis tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. do not take macrogol ( a drug used as laxative ) for one hour before and one hour after taking levetiracetam as this may result in a loss of its effect. pregnancy and breast - feeding if you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. levetiracetam can be used during pregnancy, only if after careful assessment it is considered necessary by your doctor. you should not stop your treatment without discussing this with your doctor. a risk of birth defects for your unborn child cannot be completely excluded. breast - feeding is not recommended during treatment. driving and using machines levetiracetam actavis may impair your ability to drive or operate any tools or machinery, as it may make you feel sleepy. this is more likely at the
always take this medicine exactly as your doctor or pharmacist has told you. check with your doctor or pharmacist if you are not sure. take the number of tablets following your doctor <unk> s instructions. levetiracetam actavis must be taken twice a day, once in the morning and once in the evening, at about the same time each day. monotherapy dose in adults and adolescents ( from 16 years of age ): general dose : between 1, 000 mg and 3, 000 mg each day. when you will first start taking levetiracetam actavis, your doctor will prescribe you a lower dose ( 500 mg each day ) during 2 weeks before giving you the lowest general dose of 1, 000 mg. add - on therapy dose in adults and adolescents ( 12 to 17 years ) weighing 50 kg or more : general dose : between 1, 000 mg and 3, 000 mg each day. example : if your daily dose is 1, 000 mg, you might take 2 tablets of 250 mg in the morning and 2 tablets of 250 mg in the evening. dose in infants ( 1 month to 23 months ), children ( 2 to 11 years ) and adolescents ( 12 to 17 years ) weighing less than 50 kg : your doctor will prescribe the most appropriate pharmaceutical form of levetiracetam according to the age, weight and dose. an oral solution is a formulation more appropriate to infants and children under the age of 6 years and to children and adolescents ( from 6 to 17 years ) weighing less than 50 kg and when tablets do not allow accurate dosage. method of administration swallow levetiracetam actavis tablets with a sufficient quantity of liquid ( e. g. a glass of water ). you may take levetiracetam actavis with or without food. after oral administration the bitter taste of levetiracetam may be experienced. duration of treatment levetiracetam actavis is used as a chronic treatment. you should continue levetiracetam actavis treatment for as long as your doctor has told you. do not stop your treatment without your doctor's advice as this could increase your seizures. if you take more levetiracetam actavis than you should
like all medicines, this medicine can cause side effects, although not everybody gets them. tell your doctor immediately, or go to your nearest emergency department, if you experience : weakness, feel light - headed or dizzy or have difficulty breathing, as these may be signs of a serious allergic ( anaphylactic ) reaction ; swelling of the face, lips, tongue and throat ( quincke's oedema ); flu - like symptoms and a rash on the face followed by an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell 56 ( eosinophilia ) and enlarged lymph nodes ( drug reaction with eosinophilia and systemic symptoms [ dress ]); symptoms such as low urine volume, tiredness, nausea, vomiting, confusion and swelling in the legs, ankles or feet, as this may be a sign of sudden decrease of kidney function ; a skin rash which may form blisters and look like small targets ( central dark spots surrounded by a paler area, with a dark ring around the edge ) ( erythema multiforme ); a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals ( stevens - johnson syndrome ); a more severe form of rash causing skin peeling in more than 30 % of the body surface ( toxic epidermal necrolysis ); signs of serious mental changes or if someone around you notices signs of confusion, somnolence ( sleepiness ), amnesia ( loss of memory ), memory impairment ( forgetfulness ), abnormal behaviour or other neurological signs including involuntary or uncontrolled movements. these could be symptoms of an encephalopathy. the most frequently reported side effects are nasopharyngitis, somnolence ( sleepiness ), headache, fatigue and dizziness. at the beginning of the treatment or at dose increase side effects like sleepiness, tiredness and dizziness may be more common. these effects should however decrease over time
what levetiracetam actavis contains the active substance is called levetiracetam. one tablet of levetiracetam actavis 250 mg contains 250 mg of levetiracetam. one tablet of levetiracetam actavis 500 mg contains 500 mg of levetiracetam. one tablet of levetiracetam actavis 750 mg contains 750 mg of levetiracetam. one tablet of levetiracetam actavis 1, 000 mg contains 1, 000 mg of levetiracetam. the other ingredients are : crospovidon, povidone, silica colloidal anhydrous, magnesium stearate, polyvinyl alcoholpart. hydrolyzed, macrogol 4000, talc, titanium dioxide ( e171 ), colourants *. * the colourants are : 250 mg tablet : indigo carmine ( e132 ). 500 mg tablet : iron oxide yellow ( e172 ), indigo carmine ( e132 ). 750 mg tablet : indigo carmine ( e132 ), sunset yellow ( e110 ), iron oxide red ( e172 ). what levetiracetam actavis looks like and contents of the pack 58 levetiracetam actavis 250 mg film - coated tablets are oval, light blue, 13. 6 x 6. 4 mm marked with " l " on one side and " 250 " on the other side. levetiracetam actavis 500 mg tablets are oval, yellow, 17. 1 x 8. 1 mm marked with " l " on one side and " 500 " on the other side. levetiracetam actavis 750 mg tablets are oval, orange, 19. 0 x 9. 3 mm marked with " l " on one side and " 750 " on the other side. levetiracetam actavis 1, 000 mg tablets are oval, white, 19. 0 x 10. 0 mm marked with " l " on one side and " 1000 " on the other side. pack sizes blisters
what incruse ellipta is incruse ellipta contains the active substance umeclidinium bromide , which belongs to a group of medicines called bronchodilators . what incruse ellipta is used for this medicine is used to treat chronic obstructive pulmonary disease ( copd ) in adults . copd is a long - term condition in which the airways and air - sacs in the lungs gradually become blocked or damaged , leading to breathing difficulties that slowly get worse . difficulties in breathing is added to by tightening of the muscles around the airways , which narrows the airways and so restricts the flow of air . this medicine blocks the tightening of these muscles , making it easier for air to get in and out of the lungs . when used regularly , it can help control your breathing difficulties and reduce the effects of copd on your everyday life . incruse ellipta should not be used to relieve a sudden attack of breathlessness or wheezing . if you get this sort of attack you must use a quick - acting reliever inhaler ( such as salbutamol ). if you do not have a quick - acting inhaler contact your doctor .
do not use incruse ellipta : 27 - if you are allergic to umeclidinium or any of the other ingredients of this medicine ( listed in section 6 ). if you think the above applies to you, don't use this medicine until you have checked with your doctor. warnings and precautions talk to your doctor before using this medicine : - if you have asthma ( don't use incruse ellipta to treat asthma ) - if you have heart problems - if you have an eye problem called narrow - angle glaucoma - if you have an enlarged prostate, difficulty passing urine or a blockage in your bladder - if you have severe liver problems check with your doctor if you think any of these may apply to you. immediate breathing difficulties if you get tightness of the chest, coughing, wheezing or breathlessness immediately after using your incruse ellipta inhaler : stop using this medicine and seek medical help immediately, as you may have a serious condition called paradoxical bronchospasm. eye problems during treatment with incruse ellipta if you get eye pain or discomfort, temporary blurring of vision, visual halos or coloured images in association with red eyes during treatment with incruse ellipta : stop using this medicine and seek medical help immediately, these may be signs of an acute attack of narrow - angle glaucoma. children and adolescents do not give this medicine to children or adolescents below the age of 18 years. other medicines and incruse ellipta tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. if you are not sure what your medicine contains talk to your doctor or pharmacist. in particular, tell your doctor or pharmacist if you are taking other long - acting medicines similar to this medicine for breathing problems, e. g. tiotropium. don't use incruse ellipta as well as these other medicines. if you are not sure what your medicine contains talk to your doctor or pharmacist. pregnancy
always use this medicine exactly as your doctor has told you. check with your doctor or pharmacist if you are not sure. the recommended dose is one inhalation every day at the same time of day. you only need to inhale once a day because the effect of this medicine lasts for 24 hours. don't use more than your doctor tells you to use. use incruse ellipta regularly it is very important that you use incruse ellipta every day, as instructed by your doctor. this will help to keep you free of symptoms throughout the day and night. do not use this medicine to relieve a sudden attack of breathlessness or wheezing. if you get this sort of attack you must use a quick - acting reliever inhaler ( such as salbutamol ). how to use the inhaler see'step - by - step instructions for use'in this leaflet for full information. incruse ellipta is for inhalation use. to use incruse ellipta, you breathe it into your lungs through your mouth using the ellipta inhaler. if your symptoms do not improve if your copd symptoms ( breathlessness, wheezing, cough ) do not improve or get worse, or if you are using your quick - acting inhaler more often : contact your doctor as soon as possible. if you use more incruse ellipta than you should if you accidentally use too much of this medicine, contact your doctor or pharmacist for advice immediately as you may need medical attention. if possible, show them the inhaler, the package or this leaflet. you may notice that your heart is beating faster than usual, you have visual disturbances or have a dry mouth. if you forget to use incruse ellipta don't inhale an extra dose to make up for a forgotten dose. just inhale your next dose at the usual time. if you become wheezy or breathless, use your quick - acting inhaler ( such as salbutamol ), then seek medical advice
like all medicines , this medicine can cause side effects , although not everybody gets them . allergic reactions allergic reactions are uncommon ( may affect up to 1 in 100 people ). if you have any of the following symptoms after taking incruse ellipta , stop using this medicine and tell your doctor immediately : itching skin rash ( hives ) or redness 29 common side effects these may affect up to 1 in 10 people : faster heart beat painful and frequent urination ( may be signs of a urinary tract infection ) common cold infection of nose and throat cough feeling of pressure or pain in the cheeks and forehead ( may be signs of inflammation of the sinuses called sinusitis ) headache constipation . uncommon side effects these may affect up to 1 in 100 people : irregular heart beat sore throat dry mouth rash taste disturbance . rare side effects these may affect up to 1 in 1 , 000 people : eye pain other side effects other side effects have occurred in a very small number of people but their exact frequency is unknown ( cannot be estimated from the available data ): decrease in vision or pain in your eyes due to high pressure ( possible signs of glaucoma ). blurred vision increase of the measured eye pressure difficulty and pain when passing urine these may be signs of a bladder obstruction or urinary retention dizziness reporting of side effects if you get any side effects , talk to your doctor , pharmacist or nurse . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the carton , tray and inhaler after ' exp '. the expiry date refers to the last day of that month . keep the inhaler inside the sealed tray in order to protect from moisture and only remove immediately before first use . once the tray is opened , the inhaler can be used for up to 6 weeks , starting from the date of opening the tray . write the date the inhaler should be thrown away on the label in the space provided . the date should be added as soon as the inhaler has been removed from the tray . do not store above 30 . if stored in a refrigerator , allow the inhaler to return to room temperature for at least an hour before use . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to dispose of medicines no longer required . this will help to protect the environment .
what incruse ellipta contains the active substance is umeclidinium bromide . each single inhalation provides a delivered dose ( the dose leaving the mouthpiece ) of 55 micrograms umeclidinium ( equivalent to 65 micrograms of umeclidinium bromide ). the other ingredients are lactose monohydrate ( see section 2 under ' incruse ellipta contains lactose ') and magnesium stearate . what incruse ellipta looks like and contents of the pack incruse ellipta is an inhalation powder , pre - dispensed . the ellipta inhaler consists of a grey plastic body , a light green mouthpiece cover and a dose counter . it is packaged in a foil laminate tray with a peelable foil lid . the tray contains a desiccant packet , to reduce moisture in the packaging . the active substance is present as a white powder in a blister inside the inhaler . each inhaler contains either 7 or 30 doses . multipacks containing 90 ( 3 inhalers of 30 ) doses are also available . not all pack sizes may be marketed .
nucala contains the active substance mepolizumab , a monoclonal antibody , a type of protein designed to recognise a specific target substance in the body . it is used to treat severe asthma in adults , adolescents and children aged 6 years and older . some people with severe asthma have too many eosinophils ( a type of white blood cell ) in the blood and lungs . this condition is called eosinophilic asthma the type of asthma nucala can treat . nucala can reduce your number of asthma attacks , if you or your child are already using medicines such as high dose inhalers , but your asthma is not well controlled by these medicines . if you are taking medicines called oral corticosteroids , nucala can also help reduce the daily dose you need to control your asthma . mepolizumab , the active substance in nucala , blocks a protein called interleukin - 5 . by blocking the action of this protein , it limits the production of more eosinophils from the bone marrow and lowers the number of eosinophils in the bloodstream and the lungs .
do not use nucala : - if you are allergic to mepolizumab or any of the other ingredients of this medicine ( listed in section 6 ). check with your doctor if you think this applies to you. warnings and precautions talk to your doctor before using this medicine. worsening asthma 58 some people get asthma - related side effects, or their asthma may become worse, during treatment with nucala. tell your doctor or nurse if your asthma remains uncontrolled, or gets worse, after you start nucala treatment. allergic and injection site reactions medicines of this type ( monoclonal antibodies ) can cause severe allergic reactions when injected into the body ( see section 4,'possible side effects '). if you may have had a similar reaction to any injection or medicine : tell your doctor before you are given nucala. parasitic infections nucala may weaken your resistance to infections caused by parasites. if you already have a parasitic infection ; it should be treated before you start treatment with nucala. if you live in a region where these infections are common or if you are travelling to such a region : check with your doctor if you think any of these may apply to you. children and adolescents the pre - filled pen is not intended for use in children below 12 years of age. for children aged 6 - 11 years, contact your doctor who will prescribe the recommended dose of nucala which will be administered by a nurse or doctor. other medicines and nucala tell your doctor if you are taking, have recently taken or might take any other medicines. other medicines for asthma don't suddenly stop taking your preventer medicines for your asthma once you have started nucala. these medicines ( especially ones called corticosteroids ) must be stopped gradually, under the direct supervision of your doctor and dependant on your response to nucala. pregnancy and breast - feeding if you are pregnant, if you think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. it is not known whether the ingredients of nucala can pass into breast milk. if you are breast - feeding, you must check with
nucala is given by injection just under the skin ( subcutaneous injection ). your doctor or nurse will decide if you or your caregiver can inject nucala . if appropriate , they will then provide training to show you or your caregiver the correct way to use nucala . the recommended dose for adults and adolescents aged 12 years and older is 100 mg . you will have 1 injection every four weeks . instructions for using the pre - filled pen are given on the other side of this leaflet . if you use more nucala than you should if you think you have injected too much nucala , contact your doctor for advice . if a dose of nucala is missed you or your caregiver should inject the next dose of nucala as soon as you remember . if you do not notice that you have missed a dose until it is already time for your next dose , then just inject the next dose as planned . if you are not sure what to do , ask your doctor , pharmacist or nurse . stopping treatment with nucala do not stop injections of nucala unless your doctor advises you to . interrupting or stopping the treatment with nucala may cause your asthma symptoms and attacks to come back . if your asthma symptoms get worse while receiving injections of nucala call your doctor . if you have any further questions on the use of this medicine , ask your doctor , pharmacist or nurse .
like all medicines , this medicine can cause side effects , although not everybody gets them . the side effects caused by nucala are usually mild to moderate but can occasionally be serious . allergic reactions some people may have allergic or allergic - like reactions . these reactions may be common ( they can affect up to 1 in 10 people ). they usually occur within minutes to hours after the injection , but sometimes symptoms can start up to several days later . symptoms can include : chest tightness , cough , difficulty breathing fainting , dizziness , feeling lightheaded ( due to a drop in blood pressure ) swelling of eyelids , face , lips , tongue or mouth hives rash seek medical attention immediately if you think you or your child may be having a reaction . if you may have had a similar reaction to any injection or medicine : tell your doctor before you or your child are given nucala . other side effects include : very common side effects these may affect more than 1 in 10 people : headache common side effects these may affect up to 1 in 10 people : chest infection - symptoms of which may include cough and fever ( high temperature ) urinary tract infection ( blood in urine , painful and frequent urination , fever , pain in lower back ) upper abdominal pain ( stomach pain or discomfort in the upper area of the stomach ) fever ( high temperature ) eczema ( itchy red patches on the skin ) injection - site reaction ( pain , redness , swelling , itching , and burning sensation of the skin near where the injection was given ) 60 back pain pharyngitis ( sore throat ) nasal congestion ( stuffy nose ) rare side effects these may affect up to 1 in 1 , 000 people : severe allergic reactions ( anaphylaxis ) tell your doctor or a nurse immediately if you get any of these symptoms . reporting of side effects if you get any side effects , talk to your doctor or nurse . this includes any possible side effects not listed in this leaflet . you can also report side effects directly via the national reporting system listed in appendix v . by reporting side effects you can help provide more information on the safety of this medicine .
keep this medicine out of the sight and reach of children . do not use nucala after the expiry date which is stated on the label and carton after exp . the expiry date refers to the last day of that month . store in a refrigerator ( 2 to 8 ). do not freeze . store in the original package in order to protect from light . the nucala pre - filled pen can be removed from the refrigerator and kept in its unopened carton for up to 7 days at room temperature ( up to 30 ), when protected from light . discard if left out of the refrigerator for more than 7 days .
what nucala contains the active substance is mepolizumab . each 1 ml pre - filled pen contains 100 mg of mepolizumab . the other ingredients are sucrose , sodium phosphate dibasic heptahydrate , citric acid monohydrate , polysorbate 80 , edta disodium dihydrate , water for injections . what nucala looks like and contents of the pack nucala is supplied as a 1 ml clear to opalescent , colourless to pale yellow to pale brown solution in a single use pre - filled pen . nucala is available in a pack containing 1 pre - filled pen , or in a multipack comprised of 3 x 1 pre - filled pen .
what ninlaro is ninlaro is a cancer medicine that contains ixazomib , a ' proteasome inhibitor '. ninlaro is used to treat a cancer of the bone marrow called multiple myeloma . its active substance ixazomib works by blocking the action of proteasomes . these are structures inside the cell that digest proteins and are important for cell survival . because myeloma cells produce a lot of proteins , blocking the action of proteasomes can kill the cancerous cells . what ninlaro is used for ninlaro is used to treat adults with multiple myeloma . ninlaro will be given to you together with lenalidomide and dexamethasone , which are other medicines used to treat multiple myeloma . what multiple myeloma is multiple myeloma is a cancer of the blood which affects a type of cell , called the plasma cell . a plasma cell is a blood cell that normally produces proteins to fight infections . people with multiple myeloma have cancerous plasma cells , also called myeloma cells , which can damage the bones . protein produced by myeloma cells can damage the kidneys . treatment for multiple myeloma involves killing myeloma cells and reducing the symptoms of the disease . javascript : void ( 0 ); 49
do not take ninlaro - if you are allergic to ixazomib or to any of the other any of the other ingredients of this medicine ( listed in section 6 ). if you are uncertain whether the condition above applies to you, talk to your doctor, pharmacist or nurse before taking ninlaro. warnings and precautions talk to your doctor, pharmacist or nurse before taking ninlaro if : you have a history of bleeding you have persistent nausea, vomiting or diarrhoea you have a history of nerve problems, to include tingling and numbness you have a history of swelling you have a persistent rash you have or have had liver or kidney problems as your dose may have to be adjusted. your doctor will examine you and you will be monitored closely during treatment. before starting ninlaro and during treatment, you will have blood tests to check that you have enough blood cells. children and adolescents ninlaro is not recommended for use in children and adolescents aged under 18 years. other medicines and ninlaro tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. this includes any medicines obtained without a prescription, such as vitamins or herbal remedies. this is because other medicines can affect the way ninlaro works. in particular, tell your doctor, pharmacist or nurse if you are taking any of the following medicines : carbamazepine, phenytoin, rifampicin and st. john's wort ( hypericum perforatum ). these medicines should be avoided as they may reduce the effectiveness of ninlaro. pregnancy and breast - feeding ninlaro is not recommended during pregnancy as it may harm your unborn baby. breast - feeding should be stopped when taking ninlaro. avoid becoming pregnant or breast - feeding while being treated with ninlaro. if you are pregnant or breast - feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. if
ninlaro must be prescribed to you by a doctor with experience of treating multiple myeloma. always take this medicine exactly as your doctor or pharmacist has told you. ninlaro is used with lenalidomide ( a medicine which affects how your immune system works ) and dexamethasone ( an anti - inflammatory medicine ). ninlaro, lenalidomide and dexamethasone are taken in 4 - week treatment cycles. ninlaro is taken once a week ( on the same day of the week ) for the first 3 weeks of this cycle. the recommended dose is one 4 mg capsule taken by mouth. the recommended dose of lenalidomide is 25 mg taken every day for the first 3 weeks of the cycle. the recommended dose of dexamethasone is 40 mg taken once a week on the same day for all 4 weeks of the cycle. you should read the package leaflets of these other medicines for further information on their use and effects. if you have liver or kidney problems, your doctor may prescribe ninlaro capsules containing 3 mg. if you have side effects, your doctor may prescribe ninlaro capsules containing 3 mg or 2. 3 mg. the doctor may also adjust the doses of the other medicines. how and when to take ninlaro take ninlaro at least one hour before or at least two hours after food. swallow the capsule whole with water. do not crush, chew or open the capsule. do not let the contents of the capsule come into contact with your skin. if the powder accidentally comes into contact with your skin, wash it off thoroughly with soap and water. if the capsule breaks, clean up the powder, taking care that it does not cause dust in the air. if you take more ninlaro than you should if you take more ninlaro than you should, talk to a doctor or go to a hospital straight away. take the medicine pack with you. duration of the treatment with ninlaro you should continue treatment until your doctor tells you to stop. if
like all medicines, this medicine can cause side effects, although not everybody gets them. tell your doctor or pharmacist straight away if you notice any of these following very common serious side effects which may affect more than 1 in 10 people : low platelet counts ( thrombocytopenia ) which may increase the risk of nose bleeds and you may easily bruise nausea, vomiting and diarrhoea numbness, tingling or burning of the hands or feet ( peripheral neuropathy ) swelling of the legs or feet ( peripheral oedema ) skin rash that may be itchy and in a few areas or all over the body additionally, tell a doctor immediately if you notice any of these following rare side effects which may affect up to 1 in 1, 000 people : severe skin rashes such as red to purple bumps ( sweet's syndrome ) or rash with skin peeling and mouth sores ( stevens - johnson syndrome ) muscle weakness, loss of feelings of the toes and feet or loss of leg movement ( transverse myelitis ) changes in vision, changes in mental status, or seizures ( posterior reversible encephalopathy syndrome ) rapid death of cancer cells that may cause dizziness, decreased urination, confusion, vomiting, nausea, swelling, shortness of breath, or heart rhythm disturbances ( tumour lysis syndrome ) rare blood condition resulting from blood clots that may cause fatigue, fever, bruising, nose bleeds, decreased urination ( thrombotic thrombocytopenic purpura ) other possible side effects tell your doctor or pharmacist if any of the side effects below become severe. very common side effects may affect more than 1 in 10 people : constipation back pain cold - like symptoms ( upper respiratory tract infection ) feeling tired or weak ( fatigue ) lowered white blood cells called neutrophils ( neutropenia ) that may increase the risk of infection not feeling like eating ( decreased appetite ) irregular heart rate ( arrhythmia ) vision conditions including blurred vision, dry eye and pink eye ( conjunctivitis ) common side effects may affect up to
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the blister , wallet and carton after exp . the expiry date refers to the last day of that month . do not store above 30 . do not freeze . store in the original package in order to protect from moisture . do not remove the capsule until you need to take a dose . do not use this medicine if you notice any damage or signs of tampering to medicine packaging . do not throw away any medicines via wastewater or household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what ninlaro contains ninlaro 2. 3 mg hard capsule : - the active substance is ixazomib. each capsule contains 2. 3 mg of ixazomib ( as 3. 3 mg of ixazomib citrate ). - the other ingredients are : in the capsule : microcrystalline cellulose, magnesium stearate and talc. the capsule shell contains : gelatin, titanium dioxide ( e171 ) and red iron oxide ( e172 ) the printing ink contains : shellac, propylene glycol, potassium hydroxide, and black iron oxide ( e172 ). ninlaro 3 mg hard capsule : - the active substance is ixazomib. each capsule contains 3 mg of ixazomib ( as 4. 3 mg of ixazomib citrate ). - the other ingredients are : in the capsule : microcrystalline cellulose, magnesium stearate and talc. the capsule shell contains : gelatin, titanium dioxide ( e171 ) and black iron oxide ( e172 ) the printing ink contains : shellac, propylene glycol, potassium hydroxide, and black iron oxide ( e172 ). ninlaro 4 mg hard capsule : - the active substance is ixazomib. each capsule contains 4 mg of ixazomib ( as 5. 7 mg of ixazomib citrate ). - the other ingredients are in the capsule : microcrystalline cellulose, magnesium stearate and talc. the capsule shell contains : gelatin, titanium dioxide ( e171 ), yellow iron oxide ( e172 ) and red iron oxide ( e172 ) the printing ink contains : shellac, propylene glycol, potassium hydroxide, and black iron oxide ( e172 ). what ninlaro looks like and contents of the pack ninlaro 2. 3 mg hard capsule : light pink, size 4, marked " taked
palforzia contains peanut protein from defatted powder of peanut seed . it is a treatment for people who are allergic to peanuts ( arachis hypogaea l .). palforzia is intended for children and young people aged from 4 to 17 years and those who become adults whilst on treatment . palforzia works in people with peanut allergy by gradually increasing the body ' s ability to tolerate small amounts of peanut ( desensitisation ). palforzia can help reduce the severity of allergic reactions after coming into contact with peanut . palforzia is not effective against any other nut or food allergies . you must continue to strictly avoid eating peanuts while taking palforzia .
do not take palforzia - if you are allergic to any of the excipients ( other ingredients ) in this medicine ( listed in section 6 ). - if you have severe asthma or if your asthma is not under control ( as assessed by a doctor ). - if you have ever had a problem swallowing or long term problems with your digestive system. - if you have ever had a severe mast cell disorder ( as assessed by a doctor ). - if you had severe or life - threatening anaphylaxis within 60 days before starting treatment. warnings and precautions talk to your doctor before taking palforzia and tell your doctor about any medical conditions that you have. you must not take any peanut or peanut containing food in your diet whilst taking palforzia. it is important to keep a record of the batch number of your palforzia. so, every time you get a new package of palforzia, note down the date and the batch number ( which is on the packaging after " lot ") and keep this information in a safe place. palforzia does not treat the symptoms of peanut allergy and you must not take palforzia during an allergic reaction. your doctor will advise the best time to start treatment depending on any medical conditions that you have. palforzia contains the substance that patients with peanut allergy react to. allergic reactions to palforzia may occur during treatment. these reactions mostly occur during the first two hours after taking a palforzia dose and are usually mild or moderate but ocasionally can be severe. stop taking palforzia and get medical treatment straight away if you have any of the following symptoms : - trouble breathing - throat tightness or feeling of fulness in throat - trouble swallowing - change in voice - dizziness or fainting or feeling of impending doom - severe stomach cramps or pain, vomiting or diarrhoea - severe flushing or itching of the skin - worsening of asthma or of any other breathing condition - heartburn, difficult swallowing, pain with swallowing, stomach pain or chest pain that does not go away or worsens certain conditions or factors can increase
always take this medicine exactly as your doctor has told you. check with your doctor if you are not sure. palforzia is prescribed by doctors who are experienced in the diagnosis and treatment of allergy and allergic reactions, including anaphylaxis. how should i take palforzia? dosing there are 3 phases of treatment with palforzia : initial dose escalation, up - dosing, and maintenance. you must complete these treatment phases in the order that your doctor has prescribed. during the initial dose escalation and up - dosing phases, the dose of palforzia is increased in a precise way. during the maintenance phase, you take the same dose of palforzia each day. you should take palforzia every day to maintain your level of desensitisation to peanuts. tell your doctor on the day of each clinic visit if you are feeling unwell or if you feel your asthma is less controlled. initial dose escalation you will be treated with the first doses ( initial dose escalation ) of palforzia over about 4 to 5 hours in your doctor's clinic. on the first day you will be treated with 0. 5 mg, 1 mg, 1. 5 mg, 3 mg, and 6 mg of palforzia. up - dosing if you tolerate the initial dose - escalation phase, you will be asked to return to your doctor's clinic on another day ( usually the next day ) to start the up - dosing phase. there are 11 different dose levels of up - dosing, starting with palforzia 3 mg ( level 1 ) and increasing to palforzia 300 mg ( level 11 ). the up - dosing levels are shown in the table below : daily dose dose level presentation of dose 3 mg level 1 3 <unk> 1 mg capsules ( red ) 6 mg level 2 6 <unk> 1 mg capsules ( red ) 12 mg level 3 2 <unk> 1 mg capsules ( red ) and 1 <unk> 10 mg capsule ( blue ) 20 mg level 4 1 <unk> 20 mg capsule ( white ) 40 mg level 5 2
like all medicines, this medicine can cause side effects, although not everybody gets them. important side effects palforzia can cause severe allergic reactions that may be life - threatening. if you get any of the following symptoms, stop taking palforzia, treat the reaction according to any instructions previously provided by your doctor, and then contact a doctor immediately. - trouble breathing - throat tightness or or feeling of fulness in throat - trouble swallowing or speaking - changes in voice - dizziness or fainting - severe stomach cramps or pain, vomiting, or diarrhoea - severe flushing or itching of the skin palforzia can cause problems with the stomach and digestive system including eosinophilic oesophagitis. this is a condition that affects the passage between the mouth and the stomach and affects up to 1 in 1, 000 people. symptoms of eosinophilic oesophagitis can include : - trouble swallowing - food stuck in throat - burning in chest, mouth, or throat - regurgitation if you have these symptoms persistently, contact a doctor. other side effects very common ( may affect up to 1 in 10 people ) - throat tightness - vomiting - stomach discomfort or ache - feeling sick - allergic reactions ( mild or moderate ) - cough - sneezing - throat irritation - stomach pain - tingling of mouth or itching in and around the mouth - hives - itchy skin common ( may affect up to 1 in 100 people ) - difficulty breathing - allergic reactions ( severe ) - wheezing allergic reactions may affect different parts of the body as follows : - skin related : hives, flushing or itching of the skin, face swelling, rash - breathing related : difficulty breathing, wheezing, cough, throat tightness, runny nose, throat irritation - stomach related : stomach pain, feeling sick, vomiting reporting of side effects if you get any side effects, talk to your doctor or pharmacist or nurse. this includes any possible side effects
keep this medicine out of the sight and reach of children . do not use this medicine after the expiry date which is stated on the carton and the blister or sachet after exp . the expiry date refers to the last day of that month . store below 25 . do not use this medicine if you notice any hard lumps of powder that do not easily fall apart or if the powder is discoloured . do not throw away any medicines via household waste . ask your pharmacist how to throw away medicines you no longer use . these measures will help protect the environment .
what palforzia contains the active substance is peanut protein from defatted powder of peanut ( arachis hypogaea l.) seed. the other ingredients are : palforzia 0. 5 mg, 1 mg, 10 mg, 20 mg oral powder in capsules for opening partially pregelatinised maize starch, microcrystalline cellulose, colloidal anhydrous silica, magnesium stearate palforzia 100 mg oral powder in capsules for opening microcrystalline cellulose, colloidal anhydrous silica, magnesium stearate palforzia 300 mg oral powder in sachet microcrystalline cellulose, colloidal anhydrous silica, magnesium stearate what palforzia looks like and contents of the pack white to beige oral powder in capsule for opening or sachet. initial dose escalation ( see section 3 ) each carton contains 13 capsules in 5 single - dose blisters : - 0. 5 mg ( 1 <unk> 0. 5 mg capsule ) - 1 mg ( 1 <unk> 1 mg capsule ) - 1. 5 mg ( 1 <unk> 0. 5 mg capsule and 1 <unk> 1 mg capsule ) - 3 mg ( 3 <unk> 1 mg capsules ) - 6 mg ( 6 <unk> 1 mg capsules ) 72 up - dosing phase ( see section 3 ) name / capsule or sachet strength pack contents by dose level ( daily dose ) palforzia 1 mg oral powder in capsules for opening level 1 ( 3 mg daily ): 48 capsules in blisters 16 doses ( each blister - well contains 3 capsules of 1 mg ) level 2 ( 6 mg daily ): 96 capsules in blisters 16 doses ( each blister - well contains 6 capsules of 1 mg ) palforzia 10 mg palforzia 1 mg oral powder in capsules for opening level 3 ( 12 mg daily ): 48 capsules in blisters 16 doses ( each blister - well contains 1 capsule of 10 mg + 2 capsules of 1 mg ) palforzia 20 mg oral powder in capsules for opening level 4 ( 20 mg daily ): 16
zerene belongs to a class of substances called benzodiazepine - related medicinal products , which consists of preparations with hypnotic actions . zerene will help you to sleep . sleeping problems do not usually last long , and most people only need a short course of treatment . the duration of treatment should usually vary from a few days to two weeks . if you still have problems sleeping after you have finished your capsules , contact your doctor again .
do not take zerene if you have hypersensitivity ( an allergy ) to zaleplon or to any other ingredients of zerene sleep apnoea syndrome ( stopping breathing for short periods while asleep ) severe kidney or liver problems myasthenia gravis ( very weak or tired muscles ) severe breathing or chest problems if you are in any doubt about whether you have any of these conditions, do ask your doctor. children under 18 years of age must not take zerene. take special care with zerene never drink alcohol while you are being treated with zerene. alcohol can increase the undesirable effects of any medicine taken to help you sleep. use with extreme caution if you have ever been addicted to medicines or alcohol. if you are taking any medicines belonging to the sleep inducing group, including zerene, there is a possibility that you may become dependent on them. once physical dependence has developed, abrupt termination of treatment may be accompanied by withdrawal symptoms. these may consist of headaches, muscle pain, extreme anxiety, tension, restlessness, confusion and irritability. do not use zerene or any other sleeping medicine for longer than your doctor tells you to. do not use a second dose of zerene within a single night. if your sleeplessness persists or worsens after a short course of zerene treatment contact your doctor. there is a chance that you may experience a certain type of temporary memory loss ( amnesia ) and lack of coordination when taking sleep medicines. this can usually be avoided if you remain inactive for at least 4 hours after taking zerene. there is a chance that you may experience somnambulism ( sleepwalking ), including eating or driving while not fully awake with no memory of the event. if you experience these events, contact your doctor immediately. reactions like restlessness, agitation, irritability, aggressiveness, abnormal thinking, delusion, rages, nightmares, depersonalisation, hallucinations, psychoses, inappropriate behaviour, extroversion that seems out of character and other behavioural effects have been
always take zerene exactly as your doctor has told you . you should check with your doctor if you are not sure . the usual dose for adults is 10 mg just before going to bed , or after you have gone to bed and you are having difficulty falling asleep . you should not take a second dose within a single night . there are different doses for people who are 65 or older , and those who have mild to moderate liver problems : 65 or older : take one 5 mg capsule mild to moderate liver problems : take one 5 mg capsule zerene has been designed , so that if the contents of the capsule are dissolved in liquid , the liquid will change colour and become cloudy . if you take more zerene than you should contact a doctor immediately and say how many capsules you have taken . do not go unaccompanied to seek medical help . if an overdose has been taken you may become increasingly drowsy very quickly , with high doses probably leading to a coma . if you forget to take zerene just take your next capsule at the usual time , then go on as before . do not try and catch up on the doses you have missed . if you stop taking zerene on stopping treatment , your original sleeplessness may return and you may experience symptoms such as mood changes , anxiety , and restlessness . if you suffer from these symptoms , ask your doctor for advice . if you have any further questions on the use of this product , ask your doctor or pharmacist .
like all medicines, zerene can cause side effects, although not everybody gets them. if you notice any of the following, or any other changes in your health, do tell your doctor as soon as possible. the frequency of possible side effects listed below is defined using the following convertion : 36 very common ( affects more than 1 user in 10 ) common ( affects 1 to 10 users in 100 ) uncommon ( affects 1 to 10 users in 1, 000 ) rare ( affects 1 to 10 users in 10, 000 ) very rare ( affects less than 1 user in 10, 000 ) not known ( frequency cannot be estimated from the available data ) like all medicines, zerene can cause side effects, although not everybody gets them. if you notice any of the following, or any other changes in your health, do tell your doctor as soon as possible. side effects that may occur commonly : drowsiness ; memory difficulties ; sensations like tingling, e. g. in the extremities ( paraesthesia ); painful menstruation. uncommon side effects include : dizziness ; weakness ; reduced coordination of movements ; unsteadiness and / or falls ( ataxia ); decreased concentration ; apathy ; restlessness ; depression ; agitation ; irritability ; confusion, abnormal thinking and behaviour ( extroversion that seems out of character, decreased inhibition, aggressiveness, rages, delusion, depersonalisation, psychosis ); nightmares ; hallucinations ; double vision or other sight problems ; increased sensitivity to noise ( hyperacusis ); smell disorder ( parosmia ); speech disorders, including slurred speech ; numbness, e. g. in the extremities ( hypoaesthesia ); nausea ; decreased appetite ; increased sensitivity to light ( sunlight, uv light ); feeling vaguely ill ( malaise ). in very rare cases, allergic reactions, some severe, sometimes with difficulty in breathing, have been reported and may require immediate medical care. an allergic reaction may also
what zerene contains the active substance in each zerene hard capsule is zaleplon 5 mg . the other ingredients are microcrystalline cellulose , pregelatinised starch , silicon dioxide , sodium lauryl sulphate , magnesium stearate , lactose monohydrate , indigo carmine ( e132 ), titanium dioxide ( e171 ). ingredients of the capsule shell : gelatin , titanium dioxide ( e171 ), red iron oxide ( e172 ), yellow iron oxide ( e172 ), black iron oxide ( e172 ), sodium lauryl sulphate and silicon dioxide . printing inks on the shell contain the following ( gold ink s - 13050 ): shellac , lecithin , simethicone , yellow iron oxide ( e172 ). what zerene looks like and contents of the pack zerene 5 mg hard capsules , which contain an intensely dark blue powder , have a light brown cap , with gold imprint " w ", and white body , with gold imprint " 5 mg ". they are packed in blisters . each pack contains 7 , 10 or 14 hard capsules . not all pack sizes may be marketed .
